

AUTHOR INDEX*

Volume 53

A

Aaltonen, L. A., 5849, 5853
 Abbi, R., 2758
 Abboud, C. N., 5274
 Abe, S., 1982
 Abecassis, J., 165
 Abe-Hashimoto, J., 2534
 Abel, G., 2581
 Abel, P., 5365
 Abonyi, M., 5982
 Abraham, G. N., 5274
 Abraham, I., 1354
 Abraham, R. T., 1862
 Abrahamsson, P.-A., 1724, 1967
 Abrams, J. T., 5501
 Acetoso, M., 5429
 Adachi, E., 2884
 Adachi, S., 4153
 Adachi, Y., 1706
 Adams, E. G., 1354
 Adams, G. P., 94, 3217, 4026
 Adamson, P. C., 472
 Adkins, D. A., 4243
 Adolf, G. R., 4754
 Afshari, C. A., 1777
 Agarwal, M. L., 5897
 Agarwal, R., 5409
 Agrawal, A., 1348
 Ahern, J., 266
 Aherne, G. W., 3321
 Ahluwalia, G., 5714
 Ahmad, I., 1484
 Ahmann, G. J., 5320
 Ahmed, F. E., 2249
 Ahn, M.-C., 3362
 Aida, Y., 429
 Aiello, A., 6036
 Akazawa, K., 5000
 Akerkar, S., 721
 Akeson, W., 4890
 Akimoto, H., 4658
 Akita, R., 4960
 Akiyama, M., 2940
 Akiyama, S.-i., 5680
 Akman, S. A., 1269
 Alaoui-Jamali, M. A., 4900,
 5370
 Alavaikko, M., 4486
 Al-Baker, S., 4567, 4913
 Albeck, M., 1838, 5962
 Albertini, M., 1286
 Alberto, R., 5727
 Alberts, D. S., 550
 Albin, N., 3541, 4608
 Albino, A. P., 3327
 Albright, K. D., 1571
 Aldaz, C. M., 5339
 Alder, H., 5624
 Alexander, D. B., 1808, 1816
 Alexander, J. P., 1380
 Alexander, R. B., 2358
 Alfieri, A. A., 3518
 Alimena, G., 3800
 Ali-Osman, F., 4143, 5663
 Allalunis-Turner, M. J., 3674
 Allan, L. A., 2128
 Allegra, C. J., 4828
 Allen, B. J., 1770

Allen, H. J., 2667
 Allen, T. M., 1484
 Allred, D. C., 3369
 Almquist, K. C., 4866
 Alonso, T. R., 3964
 Alpert, E., 2803
 Alt, E., 2020
 Altas, I., 4322
 Altavilla, G., 5569
 Altomonte, M., 3343
 Alvord, W. G., 2204
 Amadori, D., 2614
 Aman, E., 5475
 Amanuma, H., 429
 Ames, M. M., 1032
 Amiel, D., 4890
 Amin, S., 4182
 Amlot, P., 3015
 Amox, D., 1098
 Amstad, P. A., 38
 Ananthaswamy, H. N., 2961
 Andersen, T. I., 5849
 Anderson, L. M., 3874
 Anderson, M. S., 806
 Anderson, M. W., 410
 Anderson, P., 2300
 Anderson, P., 5610
 Anderson, R., 318
 Andersson, B. S., 3603
 Andl, T., 4189
 Andrade, S. P., 3000
 Andreassen, A., 468
 Andreeff, M., 2100
 Andreola, S., 5864
 Angeletti, C. A., 2846
 Anglard, P., 3092
 Angstwurm, M., 1027
 Angus, B., 2697
 Ankrap, D. P., 3399
 Annino, L., 3800
 Antignac, C., 2888
 Anttila, S., 5643
 Anver, M. R., 4329
 Anzano, M. A., 1480, 4461
 Aoike, A., 1328
 Aoki, D., 3643
 Aoki, M., 5038
 Aragaki, C. C., 212
 Arai, H., 4466, 5127
 Arakawa, H., 490
 Arand, G., 1416
 Araujo, D., 6011
 Arbuck, S. G., 4828
 Areeci, R. J., 310
 Archer, G. E., 2338
 Ardel, B., 3186, 4613
 Ardouin, P., 1550
 Ariazi, E. A., 3849
 Ariyoshi, K., 5475
 Arkel, Y. S., 221
 Arlett, C. F., 609
 Armour, E. P., 2740
 Armstrong, B., 4337
 Armstrong, E., 2603
 Arnsmeier, S. L., 6058
 Asano, Y., 3638
 Aschele, C., 3677
 Ask, A., 5262

Asplund, T., 388
 Aston, C., 2858
 Atchison, L., 3118
 Atkinson, E. N., 5188
 Atsumi, S., 4896
 Attal, M., 4850
 Au, J. L.-S., 3314
 Audette, M., 826
 Audrézet, M. P., 5745
 Aukerman, S. L., 4273
 Austin, C. A., 3591
 Austin, E. A., 4619
 Austin, V. N., 1929
 Austruy, E., 2888
 Auzannet, V., 523
 Avila, M. A., 4474
 Azhari, R., 5841

B

Baak, J. P. A., 5413
 Baas, F., 310, 1747
 Baba, K., 1706
 Baba, T., 1871
 Bachelot, T., 4715
 Bäckström, T., 2309, 4550
 Bacus, S. S., 5251
 Badalament, R. A., 3314
 Bader, S., 2410
 Baeckström, D., 755
 Baek, J.-H., 4811
 Bagaglio, D. M., 2260
 Baggs, R. B., 2522
 Baglioni, C., 348
 Bail, J. P., 5745
 Bailey, D., 3574
 Baiery, M. Q., 3308
 Baiocchi, G., 1297
 Baird, S., 1122
 Baker, M. A., 3052
 Balcerzak, S. P., 4843
 Baldus, S. E., 4367
 Baldwin, R. L., 2704
 Balis, F. M., 472, 725, 1032,
 1596, 2587, 4828
 Balkwill, F. R., 2087, 5365
 Balla, G., 5308
 Balla, J., 5308
 Balmain, A., 6022
 Balosso, J., 2105
 Bamberger, U., 1974
 Banerjee, S., 717
 Bankert, R. B., 3964
 Banks, S., 810
 Bannasch, P., 4204, 5447
 Bara, J., 4367
 Barbanti-Brodano, G., 5569
 Barbany, G., 2044
 Barber, J. L., 5071
 Barcellos-Hoff, M. H., 3880
 Bardi, G., 1895
 Bargetzi, M. J., 4010
 Barker, E., 362
 Barnard, G. F., 4048
 Barnathan, E. S., 3109
 Barnea, G., 3118
 Barnes, L., 5654
 Barnett, T., 27
 Barra, Y., 5121

Barrett, J. C., 1777, 3098, 3475
 Barrios, E., 5750
 Barry, M. A., 2349
 Barth, R. F., 3308
 Bartke, L., 4424
 Bartolucci, M., 5429
 Bartram, C. R., 4053
 Bartram, H.-P., 3283
 Barzan, L., 5775
 Barzi, A., 19
 Baselga, J., 2379, 4637
 Baserga, R., 1102
 Basler, J. W., 5597
 Basolo, F., 2957
 Basrur, V. S., 1091
 Bassett, P., 165, 4096
 Bassioukas, P., 2374
 Bast, A., 4603
 Bast, R. C., Jr., 1218, 1939,
 3839
 Bastian, N. R., 5507
 Bastin, A. M., 1286
 Basu, H. S., 3948
 Basu-Modak, S., 4505
 Batist, G., 4900
 Baudoin, C., 1175
 Bauer, K. D., 681
 Baumgartner, K. J., 46
 Baxter, L. T., 2466
 Baylin, S. B., 1684, 2715, 2719
 Beamer, W. G., 1059, 3741
 Beaney, R. P., 2300
 Bear, H. D., 833
 Beauchage, S. L., 868
 Beauchemin, N., 4938
 Bechhofer, R., 1286
 Beck, W. T., 1373, 5946
 Becker, M., 1602
 Becker, M., 5439
 Beckett, M. A., 1978, 3667,
 5542
 Beelen, R. H. J., 4399
 Beems, D. B., 4603
 Beere, H. M., 3034
 Beger, H. G., 2704, 5289
 Bei, M., 3229
 Bei, R., 2154
 Beijnen, J. H., 2061
 Beittenmiller, H., 2272
 Belaguli, N. S., 4432
 Belanger, A. J., 4803
 Belardelli, F., 569, 1107
 Belehradek, J., Jr., 5462
 Belinsky, S. A., 410
 Bell, C., 1788
 Bell, D. A., 1489
 Bell, R. H., Jr., 3925
 Bell, W. N., 500
 Bellocq, J.-P., 4096
 Belotti, D., 3812
 Benabid, A. L., 4715
 Ben-Baruch, N., 5251
 Bendig, M. M., 851
 Benedetti, P., 1297
 Benedetti, P., 4343
 Bengoufa, D., 5872
 Benjamin, W. H., Jr., 2810
 Bennett, E. P., 5494

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Bennett, J. A., 3149
 Bennett, W. P., 2035, 4817
 Benning, C. M., 1724
 Beran, M., 3603
 Berchuck, A., 1218, 1906, 1939,
 5100
 Berdel, W. E., 3747
 Berezin, F., 1293, 2304
 Berg, R. J. W., 1642, 4212
 Berg, S. L., 2587
 Berger, F. R., 4715
 Berger, M. S., 3416, 5663
 Bergeron, R. J., 581, 2071
 Berggren, M. I., 4297
 Berggren, M. M., 1862
 Bergstraesser, L. M., 2644
 Bergstresser, P. R., 4014
 Berhane, K., 4257
 Berkow, R. L., 2810
 Berkowitz, R. S., 1489
 Berlin, O., 4890
 Bernacki, R. J., 581, 2667
 Bernerd, F., 1175
 Bernstein, M., 5269
 Béroud, C., 2888
 Berse, B., 4727
 Berthold, F., 4053
 Bertino, J. R., 3677
 Bertola, G., 3343
 Bertoni, G., 1456
 Berzofsky, J. A., 3257
 Best, L. L., 2265
 Bettelheim, P., 3638
 Bevan, D. R., 3399
 Beyaert, R., 2623
 Bhachech, N., 3294
 Bhardwaj, G., 3221
 Bhat, H. K., 5447
 Bhatia, K., 4776
 Bhimani, R. S., 1255, 4528
 Bhuyan, B. K., 1354
 Bi, N., 884
 Bicher, A., 3694
 Bickers, D. R., 3439
 Bicknell, R., 4161
 Bièche, I., 1990
 Biedermann, K. A., 1244, 6011
 Biedler, J. L., 4978
 Biersack, A., 4268
 Biesma, B., 5915
 Biggar, S., 2112
 Bigger, C. A. H., 1273
 Bignami, M., 1149
 Bigner, D. D., 120, 2338, 3217
 Bignozzi, F., 5569
 Billingham, M. E., 4658
 Billström, A., 4573
 Binder, B. R., 1788
 Binelli, G., 209
 Björklund, A., 2140
 Birchmeier, W., 1690
 Bird, R. P., 4499
 Birrer, M. J., 3103
 Birt, D. F., 27
 Bisagni, E., 5987
 Bishop, J. E., 3935
 Bissery, M-C., 2823, 5987
 Bissett, D., 523
 Bistocchi, M., 2846, 4665
 Biswas, C., 3154
 Bivins, H. M., 1777
 Bizanek, R., 5127
 Bizzì, B., 1297
 Bjarnason, G., 4837
 Bjerkvig, R., 5158
 Black, P. M., 1312
 Blaese, R. M., 83
 Blaevenstein, P., 5727
 Blair, A., 2421
 Blair, D. G., 2976
 Blake, N. J., 2976
 Blanckaert, V. D., 4075
 Blanco, G., 4486
 Blaney, S. M., 725, 1032
 Blank, M., 4082
 Blankenstein, M. A., 4563
 Blankenstein, T., 714, 4134
 Blanz, J., 5135
 Blättler, W. A., 1360
 Blazar, B. R., 4273
 Bleehen, N. M., 4680
 Blichert-Toft, M., 2513
 Blick, M., 1630
 Blickensderfer, D. B., 5401
 Bliss, D. P., Jr., 67
 Block, N. L., 4493, 4855
 Bloemena, E., 456
 Bloemers, H. P. J., 6061
 Blommaert, F. A., 5669
 Blood, C. H., 2661
 Bloom, L. B., 4582
 Bloomfield, C. D., 1670
 Blot, W. J., 795, 1317
 Blumberg, P. M., 2507
 Boccardo, F., 4769
 Boddy, A. V., 3758
 Bode, P., 4860
 Bodley, A., 1332
 Bodner, E., 260
 Boghosian-Sell, L., 3118
 Bognel, C., 1550
 Bohlen, H., 4310
 Böhml, J., 5797
 Bohr, V. A., 5377
 Boiocchi, M., 5775
 Bokun, N., 5022
 Boland, I., 1534
 Boldt, D. H., 3930
 Bols, B. L. M. C., 4797
 Bolton, E. S., 2358
 Bolton, M. G., 3499
 Boman, B. M., 1630
 Bomme, L., 1895
 Bonaiti-Pellié, C., 452
 Bonardi, M. A., 3015
 Bonavida, B., 2591
 Bonin, G., 3655
 Bonkhoff, H., 4035
 Bonsing, B. A., 3804
 Boobis, A. R., 6076
 Bookman, M. A., 4026
 Bookstein, R., 3369
 Boone, E., 2623
 Borchard, F., 4791
 Borchert, A. A., 1286
 Borden, E. C., 4109, 5176
 Borg, A., 5882
 Borgatti, P., 4481
 Borisch, B., 921
 Borkowski, A., 4817
 Børresen, A-L., 468, 1637, 5849,
 5853
 Borst, P., 1747
 Bortell, R., 2399
 Borup-Christensen, P., 5920
 Bos, E., 456
 Bosch, F. X., 4189
 Bosl, G. J., 3730
 Bossenmaier, B., 4424
 Bostick, R. M., 4230
 Bostick-Bruton, F., 242, 3694
 Bottero, F., 5791
 Botti, G., 3198
 Boucher, Y., 2466, 4764
 Bouillon, M., 826
 Bouizar, Z., 5076
 Boulay, V., 283
 Bourguignon, A., 3536
 Bourret, L. A., 1360
 Bova, G. S., 3869
 Bowden, G. T., 417
 Bowen, K. J., 5929
 Bowen, P. E., 3723
 Bowman, E. D., 3486
 Bowman, W. P., 2954
 Boyd, D., 3109, 4143
 Boyd, J., 1906, 5100
 Boyd, M. R., 1794
 Boyer, C. M., 1939
 Boyer, J. C., 3270
 Boylan, J. F., 472
 Boyle, J. O., 4477
 Boynton, R. F., 1889
 Brabant, G., 4987
 Brach, M. A., 3638
 Brachman, D. G., 3667
 Bradley, L. M., 3149
 Bradner, R. C., 2460
 Brakkee, J. H., 544
 Bramson, J., 3237, 5370
 Branda, R. F., 5401
 Bras, J., 310
 Brattain, M. G., 4041
 Braun, D. P., 3362
 Braun, S., 1027
 Braunbeck, T. A., 3700
 Braunschweiger, P. G., 1091
 Breccia, M., 3800
 Brechbiel, M. W., 2834, 5683
 Bréchet, C., 235
 Bredehorst, R., 592, 2368
 Breier, G., 5822
 Breitkreuz, T., 4035
 Breitman, M. L., 615
 Brem, H., 329
 Brennan, J., 67
 Brennan, M. F., 5483
 Brenner, D. A., 2279
 Brenner, D. E., 2796
 Brent, T. P., 1731
 Bressac, B., 5872
 Bridges, A. J., 2553
 Brigati, D. J., 937
 Briggs, S. L., 3956
 Bright, R. K., 5734
 Brightman, B. K., 3433
 Bringuer, P. P., 3241
 Brisson, L., 5269
 Brocklehurst, C., 2840
 Brockmöller, J., 1004
 Broder, S., 477
 Brodeur, G. M., 2715, 5269
 Brodie, C., 3968
 Broek, D., 1867
 Broekhoven, M. G., 4399
 Brøgger, A., 5849, 5853
 Brondyk, W. H., 2162
 Bronner, G., 165
 Brooks, J., 2719
 Brossard, J., 5269
 Brown, G. A., 5885
 Brown, J., 2803
 Brown, J. M., 1244, 4633, 6011
 Brown, J. P., 334
 Brown, L. F., 4727
 Brown, L. M., 2421
 Brown, P. D., 2087
 Brown, R. R., 1286
 Brown, T. J., 1304
 Brown, T. R., 1751
 Brownell, A. L., 5867
 Brownell, G. L., 5867
 Broxterman, H. J., 1475, 1747
 Bruce, J. L., 12
 Brugières, L., 452, 2888
 Bruland, O. S., 468
 Brunet, J-F. M., 4715
 Brunner, N., 283, 1911, 2513,
 3229
 Bruno, N. A., 4658
 Bruno, R., 1037
 Bruno, S., 401
 Brunson, K. W., 1921
 Bryant, J., 5654
 Brylawski, B. P., 3865
 Bu, D., 5386
 Bucana, C. D., 937
 Buchanan, J., 3574
 Buchberg, A. M., 1498
 Buchhagen, D. L., 1098, 2410
 Büchler, M., 2704, 5289
 Budach, W., 5012, 5018
 Budding, M., 977
 Budillon, A., 868
 Buettner, G. R., 711, 3670
 Bugat, R., 4850
 Bugg, B. Y., 1373
 Bühring, H-J., 4424
 Buist, M. R., 5413
 Bukowski, R. M., 1380, 5613
 Bulbul, M., 3574
 Bult, A., 2061
 Bunch, R. T., 3547
 Bunting, P., 4837
 Buras, R. R., 3712
 Burger, C. W., 5413
 Burkart, W., 1507
 Burke, T. G., 1583
 Burmeister, L. F., 2421
 Burns, C. P., 711, 3670
 Burns, L. A., 1862
 Burrell, M., 2231
 Burris, H. A., 5929
 Burt, M., 2858, 5483
 Busch, F. W., 4424
 Busquets, X., 5554
 Bussemakers, M. J. G., 3869
 Butcher, R. D., 3405
 Butel, J. S., 1646, 3374
 Butler, R. N., 3455
 Buttitta, F., 2846, 4665
 Byers, S. W., 1233
 Byrd, J. C., 1437

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

C
 Cabanillas, F., 2118
 Cabral, F., 4573
 Cai, D. W., 4129
 Caillou, B., 5314
 Cairns, P., 1230
 Calcagnile, A., 1149
 Calderwood, S. K., 12, 2212
 Califano, D., 5523
 Callahan, R., 1990, 2846, 4665,
 5617
 Calle, E. E., 1322
 Callery, P. S., 766
 Calorini, L., 1952, 3349
 Calvo, S., 2957
 Camera, L., 2834
 Cameron, M. J., 1043
 Campagnoni, A. T., 170
 Campani, D., 4665
 Campbell, C., 2697
 Canaani, E., 2147, 3800, 4489,
 5624
 Canaani, O., 9044
 Canal, P., 4850
 Candreva, E. C., 5750
 Caneveri, S., 5791
 Canman, C. E., 5219
 Cannistra, S. A., 3830
 Cannizzaro, L. A., 3118
 Cansado, J., 4474
 Cantor, K. P., 2421
 Cantoreggi, S., 3505
 Canzian, F., 209
 Cao, X. R., 6051
 Capeau, J., 2762
 Capitani, S., 4481
 Capuani, L., 4343
 Carbone, A., 3343
 Carbone, D. P., 3257
 Carboni, J. M., 4041
 Carcelain, G., 3569
 Cardiff, R. D., 3233
 Cardona, H., 3536
 Carlsen, S. A., 2906
 Carlson, P., 4337
 Carmeli, S., 1343
 Carmella, S. G., 721
 Carmichael, J., 5649
 CarMichael, M. J., 744
 Carmichael, P. L., 944
 Caron de Fromental, C., 5872
 Carr, I., 4499
 Carrasquillo, J. A., 2834
 Carriero, M. V., 3198
 Carroll, P., 2199
 Carroll, R. S., 1312
 Carson, D. A., 1098
 Carter, B. S., 3869
 Cascinu, S., 5429
 Casero, R. A., Jr., 2071
 Casey, G., 2712
 Casey, L., 3362
 Cassidy, J., 523
 Casson, A., 1676
 Castagnetta, L., 741
 Castello, M. A., 2044
 Castles, C. G., 5934
 Castonguay, A., 2498
 Catalano, G., 5429
 Catchpoole, D. R., 4287
 Catlett, J., 4337
 Catsafados, E., 4769
 Cattaneo, M. G., 5566
 Cavalletti, E., 544
 Cavallo, F., 5067
 Cavanaugh, P. G., 4418
 Cavenue, W. K., 957, 2386,
 2715, 4486
 Cazals-Hatem, D., 4978
 Cecchetti, D., 4665
 Celli, G., 2287
 Center, M. S., 3658
 Cermak, J., 5308
 Cerra, M., 3198
 Cerutti, P. A., 38
 Cesnjaj, M., 5214
 Cetin, Y., 4987
 Cha, C., 16
 Chabot, G. G., 1550, 3541, 4608
 Chace, D., 334
 Chadwick, G. A., 523
 Chae, H. P., 447
 Chae, Y.-H., 2028, 3719
 Chaganti, R. S. K., 2732
 Challine, D., 1534
 Chamberlin, H., 1142
 Chambers, A. F., 701
 Champon, P., 165, 4096
 Champépé, M.-H., 1990, 5617
 Chandan-Langlie, M., 1431
 Chaney, S. G., 799
 Chang, A. E., 1043, 4315
 Chang, C., 1244
 Chang, C., 4648
 Chang, E. H., 1889, 4452
 Chang, H.-C., 1653
 Chang, H.-L., 4391
 Chang, H. R., 1122
 Chang, K.-S., 4449
 Chang, K.-T., 1079
 Chang, P.-L., 2217
 Chang, R. L., 3294
 Chang, S., 1122
 Chang, T. K. H., 2490, 5629
 Chang, Y.-M., 3677
 Chang, Y.-s., 1317
 Chang, Z.-F., 3253
 Charles, J. F., 5745
 Chasin, M., 329
 Chastre, E., 2762
 Chatelut, E., 4850
 Chazin, V. R., 2715, 4960
 Chella, A., 2846
 Chen, A., 5339
 Chen, A. P., 4828
 Chen, A. Y., 1332
 Chen, B.-X., 1388
 Chen, C. H., 1511
 Chen, C.-J., 790
 Chen, C.-S., 3853
 Chen, D.-S., 1653
 Chen, G., 2544
 Chen, H.-C., 717
 Chen, H.-x., 1974
 Chen, J., 6028
 Chen, K., 221
 Chen, L. B., 1916, 4048, 5808
 Chen, M., 5946
 Chen, P.-J., 1653
 Chen, R., 3394
 Chen, R. S., 3233
 Chen, S.-H., 4648
 Chen, T.-H., 4720
 Chen, T.-M., 1167
 Chen, W.-T., 3159
 Chen, Y. Q., 2723
 Chen, Z. J., 112
 Chen, Z. Y., 9
 Chenard, M.-P., 4096
 Cheng, E. H. C., 2260
 Cheng, J. Q., 4761
 Cheng, L. Z., 2527
 Cheng, S.-M., 3253
 Cheng, X., 5592
 Cheng, Y.-c., 1974
 Cheong, N., 1213, 5592
 Cherian, M. G., 922, 1829
 Cherqui, G., 2762
 Cherrick, H. M., 4811
 Cherwitz, D. L., 641
 Cheshire, P. J., 2823
 Chew, K., 2199
 Chiang, Y., 6017
 Chiappetta, G., 5523
 Chin, D., 5251
 Chin, J. L., 1829
 Chiocca, E. A., 3125
 Chirivi, R. G. S., 5051
 Chisena, T., 4828
 Chiu, M. L., 977
 Cho-Chung, Y. S., 868
 Chokshi, S., 3028
 Chompret, A., 452
 Choudhury, S., 3394
 Chowdary, D., 5127
 Christen, R. D., 1571
 Christensen, I. J., 2513
 Christian, M. C., 1794
 Christman, J. K., 5033
 Christou, M., 968
 Chu, E., 3362
 Chung, K. Y., 1676
 Chung, L. W. K., 2852, 5300
 Chung, Y.-s., 884
 Ciardiello, F., 5548
 Cimino, G., 3800
 Cincotta, A. H., 2571
 Cincotta, L., 2571
 Cines, D. B., 3109
 Cirafici, A. M., 5548
 Clark, G. M., 3736, 5929
 Clark, S. H., 6058
 Clarke, C. L., 5940
 Clarke, R., 283, 3229
 Clarkson, B., 401
 Clausen, H., 5494
 Clavel, M., 1037
 Cleary, K. R., 937
 Clément, F., 1182
 Clementi, F., 5566
 Clerget, M., 1421
 Cleris, L., 5374
 Cleton-Jansen, A.-M., 3804
 Clezardin, P., 1421, 4695
 Cliby, W., 2393
 Cliby, W. A., 4456
 Clift, S., 2221
 Cline, J. M., 101
 Cockett, A. T. K., 1724, 1967
 Coderre, J. A., 3308
 Codignola, A., 5566
 Coffey, D. S., 744, 1995, 4720
 Coffey, R. J., 1630

Coggins, D. L., 1403
 Cohen, L. K., 2221
 Cohen, R. J., 1899
 Cohen-Salmon, M., 2888
 Colby, T. V., 4817
 Cole, C., 53
 Cole, D. E., 725, 1032
 Cole, J., 609
 Cole, M., 4881
 Cole, S. P. C., 3221, 4156, 4866
 Coleman, C. N., 12, 2212
 Coleman, K., 4041
 Coletta, K. A., 777
 Colletta, G., 5548
 Collins, D. C., 533
 Collins, V. P., 2475, 2736, 3674
 Colnaghi, M. I., 5791, 5864
 Colofiore, J. R., 3518
 Colombo, E., 681
 Colvin, O. M., 2338
 Comeau, L. D., 3865
 Comstock, G. W., 795
 Conaldi, P. G., 2957
 Conney, A. H., 1255, 3294
 Connolly, J. M., 4686
 Conrad, F., 260
 Cook, J. A., 2066
 Cooke, T. G., 4161
 Cooney, D. A., 5714
 Coons, S. W., 5605
 Coppes, M. J., 2712
 Corallini, A., 5569
 Cordeiro-Stone, M., 3865
 Cordon-Cardo, C., 2379, 5780
 Cork, A., 3603, 4449
 Cornelisse, C. J., 3804
 Correa, P., 1317
 Correia, R., 4477
 Corry, P. M., 2740
 Cortessis, V. K., 212, 5083
 Cosand, W. L., 2560
 Cossman, J., 4251
 Costa, A., 4769, 6036
 Costa, M., 460
 Cotelingam, J. D., 5181
 Couderc, B., 1182
 Cowan, J. M., 5542
 Cowan, K. H., 2587
 Cowens, J. W., 2796
 Cowser, L. M., 2330
 Cragoe, E. J., Jr., 1599
 Craig, C., 1032
 Craig, F. E., 3930
 Creaven, P. J., 2796, 5970
 Crechet, F., 3246
 Creek, K. E., 905
 Crespi, C. L., 5629
 Cressman, D. E., 3789
 Crimmin, M. J., 2087
 Croce, C. M., 2954, 3118, 3800,
 4489, 5624
 Crompton, N. E. A., 1507
 Crone, T. M., 4750
 Croop, J. M., 310, 977
 Cropp, C. S., 1990, 5617
 Cruz, P. D., Jr., 4014
 Cui, X. X., 3294
 Culver, K. W., 83
 Cummings, K. K., 2961
 Curti, B. D., 2204
 Cushing, M., 477

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Cutler, D. S., 3149
Cysyk, R., 4828

D

Da, D., 3765
Dabelsteen, E., 5494
Dabholkar, M., 3694
Daburon, F., 3246
Dahiya, R., 641, 1437
Dahlöf, B., 4573
D'Aiuto, G., 3198
D'Alessio, A., 5523
Dalla-Favera, R., 2732
Dalton, W. S., 1475
Damani, M. T., 271
Dämmrich, J., 4197
Dandona, P., 5104
Danforth, D. N., Jr., 1538
Danks, M. K., 1373
Danø, K., 1911, 2513
Danyluk, J., 4960
Darwiche, N., 2287
Darzynkiewicz, R. J., 4613
Darzynkiewicz, Z., 401, 1945,
3186, 4613, 5096
Das Gupta, T. K., 5740
Dashner, K., 1312
Daurès, J.-P., 61
Daver, A., 61
David, L., 5494, 5853
Davidson, N. E., 291, 2071,
3976, 5424
Davies, B., 2087, 5365
Davies, D. S., 6076
Davies, R. E., 53
Davies, S. M., 4781
Davis, J., 5424
Davis, R. L., 2386
Davoodi, F., 3712
Dawson, B. V., 550
Dawson, G., 170
Day, M. L., 5597
Day, N. K., 1188
Day, R. S., III, 3674
Daya-Grosjean, L., 1625
Dean, P. A., 4652
DeAngelis, C., 4837
Debinski, W., 4588
de Boer, C. J., 4148
DeBruyne, F. M. J., 3241, 5512
DeCarvalho, M., 4828
DeCastro, R., 3154
Decensi, A., 4769
De Clerck, Y. A., 693
deConinck, E. C., 3472
Dedrick, R. L., 2092, 3752
Deeley, R. G., 3221, 4156
Deen, D. F., 3948
Defendi, V., 1167
de Francisics, V., 5523
de Frankrijker, E., 4563
DeFranco, B., 3830
DeFreitas, E., 5501
Deftos, L. J., 1724
DeGraff, W., 5845
de Gruyl, F. R., 53, 4212
Deguchi, T., 5350
Deguchi, Y., 373
de Haas, M., 1747
Deisseroth, A., 4772
Dejana, E., 3812

de Jong, B., 5707
de Jong, J., 4603
de Jong, S., 1064
Dekkers, J. A. J. M., 1642
DeLacey, K. A., 4456
de la Chapelle, A., 5849, 5853
Delage, S., 2762
de la Monte, S. M., 3823
De Leo, A. B., 1602
Del Ferro, E., 5429
Delia, D., 6036
Della Porta, G., 209
Delmas, P. D., 1421, 4695
Delsite, R., 1416
De Luca, L. M., 2287
Del Vecchio, S., 3198
Demarchez, M., 1175
Demple, B., 3250
den Engelse, L., 5669
den Hollander, W., 5413
Denial, T. M., 1665
Denicoff, A. M., 2587
Dennert, G., 6001
Dennis, I., 5649
Den Otter, W., 5754
Denyn, M.-M., 5512
Derbyshire, E. J., 3000
de Rijk, D., 3611
Deroussent, A., 1534
Deryckx, R., 4391
Desai, D., 4182
Desgrandchamps, F., 5872
Desnoyers, S., 3976, 5370
de Trobolet, N., 957, 5345
Deutsch, T. F., 5954
Dev, I. K., 810
De Valk, D., 2623
de Verneuil, M. C., 5076
Devilee, P., 3804
Devine, P. L., 4082
Devitt, M. L., 3518
de Vos, S., 3638
de Vries, E. G. E., 248, 1064,
1475, 1747, 5707, 5915
De Vries, H. T., 248, 784
Dew, S. E., 2965
Dewey, W. C., 1239
Dewhurst, M. W., 3765
Deytieux, S., 5076
Diamantstein, T., 714, 4134
Diamond, E. L., 795
Diasio, R. B., 2816, 5433
Diaz, M. O., 2410
Dickerson, S. H., 810
Dickson, R. B., 873, 1409, 2168,
2178
DiCunto, F., 5517
Diehl, V., 4310
Diella, F., 2846, 4665
Diep, A., 5083
Dietel, M., 2683
Dietrich, D. R., 3505
Dietzelbinger, H. F., 3747
Diffey, B. L., 609
Di Gregorio, C., 3726
Di Lorenzo, T. P., 910
DiMassimo, B. I., 1195
Dimitroff, K., 27
Dinnen, R. D., 1877
Di Pierro, F., 5067
Dipple, A., 1273

di Sant'Agnone, P. A., 1724,
1967
Discher, H., 4189
Diserens, A.-C., 5345
Ditzel, H., 5920
Dive, C., 1735, 2133, 3321
Diwan, B. A., 3874
Dixit, V. M., 378
Dizdaroglu, M., 1269
Djakiew, D., 1416
Dmitrovsky, E., 2379
Doan, V. T., 3486
Dobbs, D., 5683
Dobrovic, A., 3455
Dodson, M. K., 2393, 4456
Dodson, R., 2810
Dogliotti, E., 1149
Dohi, K., 2940
Doi, T., 5350
Doki, Y., 3421
Dolan, M. E., 4281
Doll, M. A., 509
Dominici, C., 2044
Donehower, R. C., 1794
Dong, L., 4542, 5554
Donis-Keller, H. R., 2947
Donker, T. H., 4563
Donohue, J. H., 4652
Donthinen-Rao, R., 4890
Dorant, E., 75, 4860
Dorie, M. J., 4633
Dörken, B., 4310
Doroshow, J. H., 1269
Dorr, R. T., 550
Dorsch, M., 714
Dosescu, J., 2618
Dos Santos, B., 3386
Dotto, G. P., 5517
Dou, Q.-P., 1493
Downing, J. R., 5108
Dowsett, M., 266
Drach, J., 2100
Dragani, T. A., 209
Drake, J., 4828
Drakoulis, N., 1004
Dralle, H., 4987
Dranoff, G., 2221
Drechsler, K., 4082
Drees, M., 3058
Dressler, L. A., 4297
Dreyfus, F., 235
Dritschilo, A., 4474
Droller, M. J., 4971
Drouard, C., 1625
Drouin, J., 4695
Druck, T., 1498, 3118
Drucker, D. J., 2980
Dube, D. K., 6067
Dube, S., 6067
Dubeau, L., 4138
Duch, D. S., 810
Duffy, F. A., 5915
Duh, F.-M., 861
Dumenco, L. L., 997
Duncan, L., 298
Dunne, A. D., 176
Durand, R. E., 733
Durr, F. E., 3336
Durrani, F. A., 1560
Dusel, G., 3283
Dutcher, J. P., 3509

Du Vignaud, P., 4595
Dvorak, H. F., 2631, 2912, 4727
Dvorak, J. M., 2631

E

Early, J. A., 1577
East, N., 2087
Eastman, A., 2349
Eaton, D. L., 9, 2313
Eber, M., 165
Ebert, E. C., 1608
Ebina, M., 3103
Ebisuzaki, K., 1877
Eby, Y. J., 4477
Eccles, D. M., 2128
Eccles, M. R., 5166
Eckhardt, J. R., 5929
Eckhardt, J. N., 5071
Edinger, M. G., 1380
Edwards, C. C., 1731
Edwards, C. L., 5188
Eggenperger, D., 600
Egorin, M. J., 766
Egyházi, S., 4257
Ehara, H., 5350
Ehninger, G., 5135
Eijdem, E. W. H. M., 1747
Eisenberg, S. P., 4010
Eisenbrand, G., 3058
Eklöv, S., 3193
El-Bayoumy, K., 2028, 3719
El-Beltagi, H. M., 3008
Eliason, J. F., 2319
Eliyahu, S., 5
el Kouni, M. H., 3687
el Kouni, M. M., 3687
Elledge, S. J., 1986
Ellis, L. M., 937
Elmore, E., 3475
Elmore, L. W., 254
Elstad, C. A., 4075
Emerman, J. T., 4224
Emi, M., 857, 1172, 3869
Emons, G., 5439
Empereur, S., 2762
Enders, C., 4189
Endlich, B., 1511
Endo, Y., 1397
Endo, Y., 5419
Engelman, R. W., 1188
Engelmann, A., 165
Enomoto, M., 5079
Enomoto, T., 1883
Enright, H., 5308
Epner, D. E., 1995
Epstein, J. I., 329, 744, 3869
Erb, K., 5920
Erdos, G. W., 1899
Erickson, L. C., 4281
Ericson, L. E., 4987
Erlanger, B. F., 1388
Erlichman, C., 4837
Ermler, D., 1788
Escot, C., 2901
Esheric, J. S., 5517
Esposito, G., 3198
Esselman, W. J., 2272
Esteban, E. F., 3233
Estival, A., 1182
Estroff, Z., 3289
Esumi, H., 2786

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Ethier, S. P., 627
 Eto, S., 4643
 Ettinger, D. S., 1794
 Evans, C. A., 1735
 Evans, C. D., 4866
 Evans, D. L., 2133
 Evans, M. K., 5377
 Evans, S. R. T., 3712
 Everett, G., 2421
 Ewers, T. G., 3416
 Ewing, C. M., 3585
 Extra, J.-M., 1037
 Eyfjord, J. E., 1637

F
 Fabbro, D., 4542
 Faggarasan, M., 5214
 Fahl, W. E., 2162, 4900
 Fair, K., 2947
 Fair, W. R., 227, 5780
 Falcone, V., 2957
 Falvella, F. S., 209
 Fan, H., 3433
 Fan, Z., 4322, 4637
 Fand, I., 4026
 Fante, R., 3726
 Farbstein, H., 5251
 Fardel, O., 231
 Farmer, B., 3455
 Farr, P. M., 2697
 Faure, F., 3569
 Favaudon, V., 2105
 Fecarotta, E., 741
 Fedeli, A., 5429
 Federici, F., 19
 Fedida, D., 4156
 Fee, F., 6022
 Feist, H., 1956
 Feix, J. B., 806
 Felgner, J., 1956
 Felix, C. A., 2954, 4489
 Fell, H. P., 2123
 Fenaux, P., 5872
 Fenger, C., 1895, 5920
 Fenton, W., 4701
 Férec, C., 5745
 Ferguson, R. J., 509
 Ferguson-Smith, M., 861
 Fernig, D. G., 4627
 Ferone, R., 810
 Ferradini, L., 3569
 Ferrantini, M., 1107
 Ferrara, G. B., 5581
 Ferraro, T., 1255
 Ferris, C. A., 1360
 Ferrone, S., 112, 2830, 3343,
 3349, 4303, 4927
 Fesseler, B., 5797
 Feuerstein, B. G., 3948
 Feunteun, J., 452
 Fey, M. F., 921
 Fidler, A. E., 5166
 Fidler, I. J., 937
 Fields, S. M., 5929
 Fiers, W., 2623
 Figari, I., 4391
 Finch, M. D., 3355
 Fingert, H. J., 3028
 Finke, J. H., 1380, 5613
 Finley, G. G., 2919
 Finn, O. J., 5386

Fiorani, P., 4343
 Fiore, L., 2957
 Firestone, G. L., 1808, 1816
 Fischer, L., 1956
 Fish, E. N., 5148
 Fishbaugh, P. M., 1489
 Fisher, C. J., 515
 Fisher, H., 5458
 Fisher, L. M., 3591
 Fisher, P. B., 1929
 Fisher, T. C., 3321
 Fishman, E. K., 1794
 FitzGerald, D. J. P., 340, 819,
 4588
 Flam, F., 2927
 Flamant, F., 452
 Flanders, K. C., 5517
 Flanders, W. D., 1322
 Fleischer, D., 4938
 Fletcher, R. G., 2279
 Fleuren, G. J., 3804
 Flørenes, V. A., 468
 Flotte, T. J., 5954
 Foddai, M. L., 1297
 Fodde, R., 2614
 Fodstad, Ø., 468, 3784
 Foglietti, G., 5429
 Fojo, A., 283
 Foley, J. W., 2571
 Folkman, J., 5297
 Folsom, A. R., 536, 4230
 Fontana, J. A., 3226
 Fontenot, J. D., 5386
 Fonti, R., 3198
 Forbes, P. D., 53
 Ford, H. Jr., 5714
 Ford, J., 3262
 Formelli, F., 5374, 6036
 Fornari, F. A., 3547
 Forni, G., 5067
 Forni, M., 5067
 Fortini, P., 1149
 Fosså, S. D., 5849
 Fosse, P., 5987
 Foster, T. H., 1249
 Fournier, G., 5872
 Fowler, J. F., 4413
 Fox, S. B., 4161
 Fox, T. R., 2265
 Franchetti, P., 19
 Frandsen, T. L., 3229
 Frank, T. S., 627
 Frappart, L., 1421
 Frati, L., 2457
 Fraumeni, J. F., Jr., 1317
 Friedman, P., 120
 Freeman, J., 5012, 5018
 Freeman, S. M., 5274
 Freireich, E. J., 4449
 Frelinger, J. G., 2112
 French, J. E., 2750
 French, R. R., 3015
 Frenkel, K., 1255, 4528
 Fresstedt, J., 3853
 Freter, C. E., 283
 Frey, C. M., 1079
 Friche, E., 1373
 Friedman, H. S., 120, 2338
 Friedman, P. N., 334
 Friess, H., 2704, 4741, 5289
 Frisolí, J. K., 5954

Frixen, U. H., 3618
 From, L., 2235
 Frostesjö, L., 5262
 Fry, M., 2895
 Fu, X., 1204
 Fuchs, H. E., 2338
 Fudge, K., 3073
 Fujihiro, S., 5350
 Fujii, D. K., 158
 Fujii, N., 4466
 Fujii, T., 1136
 Fujiki, H., 239, 992, 1012, 1777,
 1982, 3462
 Fujimoto, K., 1136
 Fujita, H., 1156
 Fujita, J., 3795
 Fujita, K., 2566
 Fujita, M., 1883
 Fujita, N., 5022
 Fujita, S., 464
 Fujita, T., 4262, 5233
 Fujita, Y., 4823
 Fujita-Yamaguchi, Y., 3736
 Fujiwara, T., 4129
 Fujiwara, Y., 857, 1172, 3869
 Fujiwara, Y., 3302
 Fuks, A., 3817
 Fuks, Z., 2987
 Fukuda, Y., 368
 Fukumura, D., 2676
 Fukushima, K., 2970
 Fukushima, M., 4004
 Fukushima, S., 32, 4218
 Fuller, G. N., 120
 Funai, K., 3193, 4550
 Funke, I., 1690
 Fuqua, S. A. W., 4443, 5882,
 5934
 Furuhata, M., 4823
 Furitsu, T., 675
 Furlanetto, R. W., 2522
 Furmanski, P., 5055
 Furukawa, H., 3632
 Furukawa, K., 5395
 Furukawa, K., 5395
 Furukawa, T., 1204, 3070
 Furukawa, T., 5680
 Furusato, M., 1906
 Fusamoto, H., 3899
 Futakuchi, M., 32
 Futreal, P. A., 1218
 Futscher, B. W., 1373

G
 Gabbianelli, M., 569
 Gabriele, L., 569, 1107
 Gagliardi, A., 533
 Gale, R. P., 5624
 Galivan, J., 2227
 Gall, H., 456
 Gallagher, H. S., 5188
 Gallegos, A., 4297
 Gallick, G. E., 1630
 Gallie, B. L., 3574
 Gallinger, S., 271
 Gallion, H. H., 3839
 Gamarra, F., 1590
 Gamson, J., 5845
 Ganapathi, R., 3262
 Ganesan, T., 5649
 Gansbacher, B., 4020

Gansow, O. A., 2834, 5683
 Gao, H., 1783
 Gao, X., 2723
 Garcia de Palazzo, I. E., 94,
 3217
 Gardes, M., 452
 Gardner, G. R., 2976
 Garewal, H., 1469
 Gariboldi, M., 209
 Garin-Chesa, P., 3327
 Garmestani, K., 2834
 Garofalo, A., 5051
 Gasa, S., 2484, 5638
 Gasdaska, P. Y., 1338, 5458
 Gasparollo, A., 3343
 Gasparotto, D., 5775
 Gatter, K. C., 4161
 Gatti, R. A., 438, 5083
 Gattoni-Celli, S., 1952, 3349
 Gaut, Z. N., 6074
 Gawlak, S. L., 334
 Gazdar, A. F., 1079, 2410, 5181
 Gazitt, Y., 1899
 Gebhardt, R., 5135
 Gehani, S. K., 3394
 Gehring, U., 3513
 Geil, L., 861
 Gelfand, E., 3968
 Gelman, I. H., 915
 Gelös, U., 5750
 Georges, E., 5994
 Georges, R. N., 1743
 Gerdes, H., 279
 Gerretsen, M., 3524
 Gerson, S. L., 997
 Gerwin, B. I., 985, 2035
 Gespach, C., 2762
 Getzenberg, R. H., 744
 Gewirtz, D. A., 3547
 Gharebaghi, K., 2344
 Ghetti, C. A., 2457
 Ghislain, J., 5148
 Ghosh, B. C., 5181
 Ghosh, L., 717
 Ghosh, R., 38
 Ghosh, S. K., 5501
 Giavazzi, R., 3812, 5051
 Gibbs, C. J., Jr., 6067
 Gibellini, D., 4481
 Gibson, D. F. C., 4413
 Gierthy, J. F., 3149
 Gilissen, M. J., 2548
 Gill, I., 3694
 Gill, N. S., 2700
 Gill, T. J., III, 4089
 Gillett, N., 4391
 Gillin, J. S., 279
 Gillis, K. C. P. M., 4797
 Gilmore, K. S., 231
 Ginsberg, R., 2796
 Ginya, H., 5559
 Giocanti, N., 2105
 Gioioso, D., 5012, 5018
 Giovannella, B. C., 1577
 Giovarelli, M., 5067
 Gismondi, V., 5581
 Gispen, W. H., 544
 Gleave, M. E., 2852, 5300
 Glennie, M. J., 3015
 Glick, A. B., 4803
 Gliozzo, B., 3736

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Gloghini, A., 3343
 Gloudemans, T., 5754
 Glover, M. T., 5328
 Glowacka, D., 1312
 Gnarra, J. R., 861, 2719, 3092
 Godal, A., 3784
 Goddard, P. M., 2581
 Godolphin, W., 4960
 Godwin, A. K., 3662, 3771, 5225
 Godwin, K. A., 472, 725
 Godwin, T. A., 762
 Goepfert, H., 1676
 Goetz, A. E., 1590
 Going, J. J., 4161
 Goldbohm, R. A., 75, 4860
 Goldenberg, D. M., 819
 Goldenberg, G. J., 3530, 5885
 Goldfine, I. D., 3736
 Goldin, E., 2374
 Goldmacher, V. S., 1360
 Goldspiel, B., 4828
 Goldstein, A. L., 5214
 Goldstein, L., 4828
 Goldstein, S. M., 762
 Goldsworthy, S. M., 2265
 Goldsworthy, T. L., 2265
 Gollahan, L. S., 5339
 Golumbek, P. T., 5841
 Gomella, L., 1102
 Gong, J., 1945, 3186, 4613,
 5096
 Gonzalez-Zulueta, M., 4066,
 5620
 Good, R. A., 1188
 Good, S. S., 4619
 Gooderham, N., 6076
 Goodgame, R., 2803
 Goodin, S., 5382
 Goodman, M. F., 4582
 Goodman, P., 4837
 Goonetilleke, R., 3919
 Gorczyca, W., 1945, 3186
 Gordon, J. N., 4971
 Gorelick, F. S., 2260
 Goris, M. L., 3022
 Goshorn, S. C., 2123
 Gosland, M., 5382
 Goss, P. E., 3574
 Gottesman, M. M., 747
 Gouérou, H., 5745
 Gould, M. N., 2272, 3849, 5766
 Gouyette, A., 1534, 1550, 3541,
 4608
 Goya, L., 1808, 1816
 Grabowski, D., 3262
 Graem, N., 1911
 Graham, M. A., 523
 Gramacho, C., 1222
 Grandis, J. R., 3579
 Grand-Perret, T., 4595
 Grant, T. D., 2700
 Granzen, B., 1373
 Graves, D., 3667
 Gray, G. D., 577
 Gray, K., 509
 Gray, R., 4108
 Gray, R. D., 1998
 Greaves, P., 3919
 Greco, G., 569
 Greco, W. R., 2796
 Green, M. H. L., 609

Greenall, M., 3597
 Greenfield, L., 3752
 Greenhalgh, D. A., 5071
 Gregory, C. D., 3321
 Greiner, J. W., 600
 Greipp, P. R., 5320
 Grekin, R. C., 762
 Grem, J. L., 4828
 Grenier, J., 61
 Gresser, I., 1107
 Grani, C., 5429
 Griffin, R. J., 1599
 Griffith, O. W., 3207
 Grignani, F., 6036
 Grignani, F., 6036
 Grignon, D., 2723
 Grimm, E. A., 2597, 4129
 Grisham, J. W., 500
 Grizzel, W. E., 4555
 Grobholz, R., 4204
 Groce, A., 2479, 5676
 Groden, J., 5581
 Groff, J. M., 1761
 Grogan, T. M., 417
 Gromo, G., 3015
 Grond, M. P., 2279
 Grøndahl-Hansen, J., 2513
 Grondard, L., 5987
 Groopman, J. D., 3499
 Gros, P., 1657, 5269
 Gross, A. J., 67
 Grossberg, S. E., 5176
 Grover, P. L., 944
 Grunberger, D., 1255, 4528
 Grune, T., 5143
 Grunewald, D., 4608
 Gruss, H.-J., 3638
 Gu, J., 3899
 Gu, J. R., 4817
 Gu, X., 3046
 Gu, Y., 5624
 Gualandi, F., 5569
 Gudas, L. J., 472
 Gudat, F., 2199
 Gudkov, A. V., 5251
 Guengerich, F. P., 2028
 Guglielmi, C., 3800
 Guichard, S., 4850
 Guillaudeux, J., 3536
 Guillaume, T., 3139
 Guillouzo, A., 231
 Gulati, S. C., 3730
 Gulino, A., 5067
 Gullick, W. J., 627
 Gum, E. T., 641
 Gunja-Smith, Z., 4493
 Günthert, U., 1516
 Guo, H.-Y., 2479, 5676
 Guo, X., 1974
 Guo, Z., 3276
 Gusella, J. F., 3465
 Gustafson, D. L., 5470
 Gustin, T., 4715
 Guthrie, P. D., 5300
 Guzman, R. C., 1816

H

Haag, J. D., 3849
 Haber, D. A., 4757
 Habuchi, T., 3795
 Hacker, H.-J., 4204, 5447

Hadi, A., 5043
 Haegeman, G., 2623
 Hagenbeek, A., 3008
 Haghayegh, S., 1444
 Hagiwara, A., 687
 Hahn, H. A., 291
 Hahn, S. M., 2066
 Haile, R. W., 212, 5083
 Hain, J., 1507
 Hainaut, P., 1739, 4469
 Hait, W. N., 2260
 Haites, N. E., 2128
 Hajek, R. A., 5188
 Hajnal, A., 4670
 Hakim, J., 4477
 Haldorsen, T., 5849
 Hall, E. J., 1368
 Hall, W. A., 2092
 Halling, K. C., 2393
 Hallman, J. C., 2823
 Halloran, P. M., 1360
 Halpin, J., 6006
 Hamada, H., 2538
 Hamada, J.-i., 4418
 Hamaguchi, K., 3771, 5225
 Hamann, P. R., 3336
 Hamanoue, M., 1281
 Hamazaki, S., 3795
 Hamburger, A. W., 557
 Hamdan, O., 3139
 Hamers, F. P. T., 544
 Hamilton, J. M., 4828
 Hamilton, T. A., 1380
 Hamilton, T. C., 3662, 3771,
 5225
 Hamlin, H. A., Jr., 3172
 Hammond, D., 1032
 Hamou, M.-F., 5345
 Han, H.-J., 5087
 Han, I., 4913
 Han, Z.-x., 1317
 Hanada, M., 4978
 Hanada, R., 5284
 Hanafusa, H., 915
 Hanauske, A. R., 3747
 Hanby, A., 5365
 Hancock, S. L., 3857
 Handel, L. M., 3771
 Hanisch, F.-G., 4082, 4367, 4791
 Hank, J., 1286
 Hanna, M. G., Jr., 456, 2368
 Hansen, H. J., 819
 Hanski, C., 4082
 Hanski, M.-L., 4082
 Hanss, M., 4695
 Hansson, G. C., 755, 4987
 Hansson, J., 4257
 Hao, W., 1921
 Hao, X.-Y., 4257
 Hao, Z.-M., 4452
 Hara, A., 772, 3903
 Harada, M., 106
 Haraf, D., 3667
 Haraguchi, M., 5680
 Haraguchi, T., 1808
 Haran-Ghera, N., 2147, 3433
 Harcourt, S. A., 609
 Hard, G. C., 4534
 Hardingham, J. E., 3455
 Hardy, E., 5745
 Harel, W., 1113

Harker, W. G., 1373
 Häkkinen, P. L., 5199
 Harlow, S. P., 681
 Harmon, J. M., 4059
 Harms, D., 4053
 Haroun, E. A., 3008
 Harpalani, A. D., 766
 Harrap, K. R., 2581
 Harrington, A. M., 3486
 Harrington, T., 1218
 Harris, A. L., 3597, 4161, 5649
 Harris, C. C., 985, 1684, 2035,
 4817, 5377
 Harris, J. E., 3362
 Harris, L. C., 1731
 Hart, A. A. M., 5669
 Hart, I. R., 962, 3860
 Hartley, D. F., 1249
 Hartley, J. A., 3321
 Hartley-Asp, B., 1833, 4573
 Hartmann, L. C., 2393, 4456
 Hartmann, O., 1534
 Harwell, L., 5721
 Harwell, S. E., 2522
 Hasan, T., 153, 5954
 Hasegawa, A., 354
 Hasegawa, T., 1555
 Hashimoto, H., 4823
 Hassan, F., 3314
 Hata, H., 495
 Hata, Y., 5982
 Hatala, M. A., 4686
 Hatano, T., 4238
 Hattori, Y., 1136
 Hauda, K. M., 2221
 Haugen, A., 5853
 Hauser, S. H., 1952
 Hawkins, G. A., 2368
 Hay, K., 271
 Hayashi, H., 1871
 Hayashi, K., 5284
 Hayashi, N., 3899
 Hayashi, S.-i., 2994
 Hayashi, T., 2940
 Hayashi, Y., 4218
 Hayashi, Y., 5284
 Hayashido, Y., 147
 Hayes, J. D., 3887, 5643
 He, J., 3674
 Healey, J. H., 16, 3327
 Heath, C. W., Jr., 1322
 Heath, L. S., 810
 Heaton, K. M., 2597
 Hebel, D., 577
 Heby, O., 5262
 Hecht, S. S., 721, 2189, 2780,
 3719
 Heckel, A., 1974
 Hefta, L. J. F., 1612
 Hei, T. K., 1368
 Heider, K.-H., 1262, 4197, 4754
 Heidorn, K., 1956
 Heike, Y., 5022
 Heim, S., 1895, 2140
 Heimbüchel, G., 4367
 Heimdal, K., 5849
 Hein, D. W., 509
 Hein, G., 4134
 Heiss, M. M., 1690
 Heitjan, D. F., 6042
 Heldin, P., 388

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Helmerhorst, T. J. M., 5413
 Hemler, M., 2192
 Hendrix, M. J. C., 550, 3411
 Hennequin, C., 2105
 Hennet, T., 1456
 Hennig, E., 3294
 Hennings, H., 4803
 Henriksen, R., 4550
 Henry, D. L., 4041
 Henry, I., 2888
 Henry, J. L., 1403
 Henry, M., 3103
 Henttu, P., 1051
 Herait, P., 1550
 Herberman, R. B., 1461, 5654
 Herbst, R., 4424
 Herbergers, A., 3262
 Hercend, T., 3569
 Herget, T., 5208
 Herlyn, M., 1450
 Herman, C. J., 5055
 Hermann, G. G., 1162, 5620
 Hermus, R. J. J., 75, 4860
 Hernandez, O. M., 577
 Herold-Mende, C., 4189
 Herrera, H., 2479, 5676
 Herrlich, P., 1262, 1516, 4197,
 4754
 Herrmann, F., 3638
 Hertel, L. W., 4582
 Herzberg, K. T., 2631
 Heston, W. D. W., 227
 Heynink, K., 2623
 Hiasa, Y., 4408
 Hibbs, J. B., Jr., 5507
 Hibi, K., 1
 Hickman, J. A., 3034, 3321
 Hida, T., 1709
 Hidaka, H., 2051
 Hiipakka, R. A., 1967
 Hilden, J. M., 3853
 Hilf, R., 1249
 Hill, D. E., 2231, 2728
 Hill, S. M., 5934
 Hillig, M., 2587
 Hillmann, A. G., 4059
 Hilsenbeck, S. G., 3369, 4443
 Hinman, L. M., 3336
 Hino, O., 5856
 Hinton, D. E., 1761, 3700
 Hintz, R., 2858
 Hinz, H. R., 1577
 Hirabayashi, H., 1461, 5654
 Hirai, H., 5419
 Hirai, K., 4175
 Hirai, S., 112
 Hiramatsu, K., 4175
 Hirano, H., 3643
 Hirano, S., 1696
 Hirata, T., 1833
 Hirohashi, S., 2005, 5903
 Hirohata, S., 4175
 Hirose, M., 32
 Hirsch, A., 5872
 Hirvonen, A., 5643
 Hitomi, Y., 5759
 Hittelman, W. N., 2874
 Ho, C., 5386
 Ho, J. J. L., 884
 Ho, J. P., 3221
 Ho, S. B., 641, 1437
 Ho, S.-m., 528
 Hoang-Vu, C., 4987
 Hock, H., 714
 Hockenberry, D., 1853
 Hoda, S., 2379
 Hodgson, C. P., 1630
 Hodnick, W. F., 4907
 Hoerl, B. J., 1338
 Hoffman, R. M., 1204, 2479,
 3070, 5676
 Hoffman, T., 5382
 Hoffmann, D., 2758
 Hoffmann, J.-S., 2895
 Höfler, H., 5797
 Hofmann, A., 3283
 Hofmann, M., 1262, 1516, 5345
 Hogg, D., 3574
 Høie, J., 468
 Holder, J. W., 3475
 Hollande, E., 1182
 Holm, I., 5853
 Holm, R., 468, 5853
 Holmes, M., 94
 Holmgren, L., 2927
 Holst-Hansen, C., 3229
 Holt, M., 2947
 Holt, P. R., 2745
 Hözel, F., 5439
 Homann, N., 4189
 Hong, J.-Y., 1783
 Hong, S.-J., 5300
 Hong, W. K., 1676, 2874, 5113
 Hongo, T., 5284
 Honig, S. F., 2168
 Honke, K., 2484, 5638
 Honn, K. V., 2723
 Honoki, K., 5038
 Hoogewerf, A. J., 2912
 Hoon, D. S. B., 949, 5244
 Horak, E., 3597
 Horan, P. K., 2358
 Hori, K., 5528
 Hori, M., 953
 Horie, M., 5350
 Horikoshi, I., 3046
 Horikoshi, T., 2830
 Horio, Y., 1
 Horn, T., 1162, 5620
 Hornung, S. K., 2313
 Hosick, H. L., 2655
 Hosono, M., 4218
 Hota, C., 701
 Houde, P. V., 1091
 Houghton, J. A., 2823, 4243
 Houghton, P. J., 2823
 Houin, G., 4850
 Houston, L. L., 4026
 Hovig, E., 468
 Howarth, N. M., 298
 Howell, S. B., 1571, 1596
 Höyer-Hansen, G., 1911
 Hrabie, J. A., 564
 Hruban, R. H., 4477
 Hsiao, S.-H., 1079
 Hsieh, J.-T., 2852, 5300
 Hsieh, L.-L., 1278
 Hsieh, T.-T., 1278
 Hsiung, Y., 89
 Hsu, H.-C., 4691
 Hsu, J.-C., 3789
 Hsu, L.-C., 5766
 Hu, C.-p., 4648
 Hu, M.-C., 2865
 Hu, P., 4920
 Hu, X.-z., 4303
 Huang, G.-T., 1653
 Huang, M.-T., 1255
 Huang, P. C., 922
 Huang, Y., 1889
 Huang, Y.-W., 1392
 Huber, B. E., 4619
 Huber, J., 1788
 Hubert, S. L., 3776
 Huebner, K., 1498, 3118, 5624
 Huelskamp, A. M., 5424
 Huff, T., 4337
 Hughes, C. S., 5127
 Huguet, F., 4850
 Hui, F., Jr., 2035
 Hull, J. E., 9
 Hüls, C., 4134
 Humphreys, J., 810
 Hung, G., 4960
 Hung, M.-C., 891, 5784
 Hurkadi, K. S., 4855
 Hursting, S. D., 2750
 Husgafvel-Pursiainen, K., 5643
 Hussain, A., 3226
 Huston, J. S., 4026
 Hutter, E. K., 2112
 Huvos, A. G., 16
 Huynh, H. T., 1727, 5585
 Hyafil, F., 4595
 Hyman, P., 5458

J

Iannone, R., 6067
 Iatropoulos, M. J., 4534
 Iavarone, A., 304
 Ichimura, K., 2736
 Ida, N., 737
 Idle, J. R., 3758
 Ihara, Y., 3899
 Ihde, D. C., 67, 5181
 Iihara, K., 3421
 Inuma, H., 4896
 Ikebe, M., 1706
 Ikeda, H., 675
 Ikeda, H., 3078
 Ikeda, K., 2534
 Ikeda, Y., 1706
 Ikenaga, M., 368, 846
 Ikeyama, S., 4262, 5233
 Iliakis, G., 1213, 5592
 Imai, K., 2994
 Imai, K., 4927
 Imai, S., 5638
 Imam, S. A., 3233
 Imamura, J., 4053
 Imamura, M., 846
 Imaoka, S., 3632, 4071
 Imondi, A. R., 4534
 Imura, H., 368
 Imura, N., 1829, 4767
 Inada, K., 464
 Inaji, H., 4071
 Inazawa, J., 3382
 Inge, T. H., 833
 Ingles, S., 212, 5083
 Inoko, K., 1555
 Inoue, K., 4823
 Inoue, M., 1696, 3421
 Jackman, A. L., 3321
 Jackman, J., 4776
 Jackman, R. W., 4727
 Jackson, R. C., 3998
 Jackson, S. M., 733
 Jacob, H. S., 5308
 Jacob, L. S., 3052
 Jacobs, I. J., 1218
 Jacobs, S. C., 3869
 Jacobsen, J., 1755
 Jacobson, L. P., 3499
 Jaffee, E. M., 2221, 5841
 Jagirdar, J., 2858
 Jain, R., 2771
 Jain, R. K., 2466, 4764, 5867
 Jaken, S., 4542
 Jalal, S. M., 5320
 James, C. D., 3674
 Jameson, B. A., 1102
 Janik, J. E., 2204
 Janin, N., 5872
 Janisch, L., 1293, 2304
 Jansson, S., 4987
 Jarvis, L. J., 447
 Jaspers, N. G. J., 438
 Jaszcza, W., 1431
 Jauch, K. W., 1690
 Jauferally, R., 5345
 Jaussi, R., 1507
 Jayaram, H. N., 2344
 Jeanpierre, C., 2888
 Jefcoate, C. R., 968
 Jeffers, M., 5355
 Jelinek, D. F., 5320
 Jenkins, G. R., 905
 Jenkins, R. B., 2393, 4456
 Jensen, R. T., 3165

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Jensenius, J. C., 5920
 Jerina, D. M., 1273, 3294
 Jerry, D. J., 1646, 3374
 Jessup, M. J., 4048
 Jewett, M., 3574
 Jhanwar, S. C., 16, 4349, 4761,
 5780
 Ji, J., 2895
 Jiang, H., 1929
 Jiang, Y., 4224
 Jin, M.-I., 1317
 Jin, Y., 2140
 Jirsch, J., 4156
 Jirtle, R. L., 3849
 Joh, K., 4238
 Johns, D. G., 5714
 Johnson, B. E., 67, 3165, 4169,
 5181
 Johnson, J. P., 1690
 Johnson, J. T., 1461, 5654
 Johnson, K. A., 2728
 Johnson, M. D., 873, 2178
 Johnson, P. A., 2092
 Johnson, R. T., 2012
 Jonczyk, P., 3098
 Jondle, D., 4776
 Jones, A. L., 819
 Jones, D., 2118
 Jones, J. A., 1571
 Jones, L. A., 5188
 Jones, M., 2581
 Jones, N. J., 1522
 Jones, P. A., 1162, 4066, 5620
 Jones, R. T., 4817
 Jones-Blackett, S., 5090
 Jordan, E., 4828
 Jordan, K., 4534
 Jordan, V. C., 4413
 Jorgensen, T. J., 4251
 Jorquer, R., 2498
 Joshi, S. S., 1921
 Jothy, S., 957, 4938
 Ju, G., 2597
 Judah, D. J., 3887
 Juell, S., 3784
 Juhlin, C., 5610
 Jullienne, A., 5076
 Junghans, R. P., 5683
 Jungheim, L. N., 3956
 Junien, C., 2888

K
 Kaaijk, P., 1475
 Kabuto, T., 3632
 Kaddurah-Daouk, R., 3172
 Kadhim, S. A., 1829
 Kadlec, J. V., 592
 Kadlubar, F. F., 2028
 Kadmon, D., 4461
 Kadomatsu, K., 1281
 Kadomatsu, K., 1480
 Kadowaki, T., 3421
 Kageshita, T., 2830, 3349, 4927
 Kahn, H. J., 2235
 Kaido, T., 1107
 Kaji, H., 5350
 Kajita, S., 1555
 Kakehi, Y., 3795
 Kalbacher, H., 4424
 Kalechman, Y., 1838, 5962
 Kaltenberg, O. P., 4534

Kalyanaraman, B., 806
 Kamada, T., 3899
 Kamesaki, H., 4251
 Kamesaki, S., 4251
 Kameyama, M., 3632
 Kameyama, S., 5172
 Kaminski, M. J., 4014
 Kamiyama, M., 221
 Kamoshita, S., 5284
 Kanakura, Y., 675
 Kanayama, Y., 675
 Kanda, H., 5244
 Kane, T. D., 6067
 Kaneda, Y., 949
 Kaneko, S., 5000
 Kaneko, T., 2326
 Kaneko, Y., 5284
 Kang, Y., 3040
 Kanjilal, S., 2961
 Kannagi, R., 354, 5559
 Kansas, G. S., 3830
 Kantarjian, H. M., 3289, 3603
 Kantor, J. D., 1971
 Kanzaki, T., 3193
 Kaplan, C., 4695
 Kappler, F., 1751
 Kapuscinski, J., 4613
 Karakousis, C. P., 1670
 Karg, O., 1027
 Kari, F. W., 2750
 Karikó, K., 3109
 Karthaus, H. F. M., 3241, 5512
 Kasai, M., 4466, 5127
 Kashima, T., 170
 Kashmiri, S. V. S., 3355
 Kasper, H., 3283
 Kastan, M. B., 4164
 Kastury, K., 3118
 Kasumi, F., 3382
 Kataoka, H., 3154
 Kataoka, S., 5022
 Katiwala, M., 2502
 Katiyar, S. K., 5409
 Kato, Y., 953, 1172, 5087
 Katoh, O., 1136
 Katzmann, J. A., 5320
 Kaufman, D. C., 2066
 Kaufman, D. G., 3865
 Kaufmann, S. H., 3976
 Kaupila, A., 5028
 Kaur, G., 2081
 Kawada, Y., 5350
 Kawai, K., 5172
 Kawai, M., 2051
 Kawai, S., 2472
 Kawai, T., 5419
 Kawajiri, K., 2994
 Kawakami, H., 3643
 Kawakami, Y., 5
 Kawamata, H., 5172
 Kawamori, T., 2775, 3903
 Kawamura, K., 4153
 Kawamura, M., 5284
 Kawamura, T., 5350
 Kaye, S. B., 523
 Ke, Y., 985
 Keating, A., 1304
 Keefer, L. K., 564, 5845
 Keeney, G. L., 2393, 4456
 Kehrel, B., 4695
 Kehrl, J. H., 373

Keith, I. M., 968
 Kelfkens, G., 53
 Kelland, L. R., 2581
 Keller, S. M., 4349
 Kelley, E. E., 3670
 Kellogg, G. J., 2502, 3493
 Kelly, K. F., 2128
 Kelly, R. C., 1354
 Kelly, T., 3159
 Kemp, C. J., 6022
 Kemperman, H., 3611
 Kenemans, P., 5413
 Kennedy, M. J., 5424
 Kennedy, R. C., 5734
 Kensler, T. W., 231, 3499
 Kerb, R., 1004
 Kerbel, R. S., 2708
 Kern, F. G., 1816, 2168, 2178
 Kerr, D. E., 2123
 Kerr, D. J., 523
 Kerr, I. G., 4837
 Kerschmann, R., 2199
 Kersey, J. H., 3853
 Keszenman, D. J., 5750
 Ketterer, B., 231, 5643
 Khan, M. A., 905
 Khan, P. M., 2614
 Khanuja, P. S., 3394
 Khatib, Z. A., 5535
 Khatibi, S., 1596
 Khazaeli, M. B., 4555
 Khokhar, A. R., 4567, 4913
 Kibbey, M. C., 423
 Kido, Y., 4567
 Kickback, D. G., 5188
 Kiefe, C., 2803
 Kiessling, R., 5610
 Kiguchi, K., 5903
 Kikendall, J. W., 3723
 Kikkawa, F., 2051
 Kikuchi, K., 1702, 3078
 Kikuchi, T., 2534
 Kikuchi-Yanoshita, R., 5079
 Kikuchi, T., 957
 Killary, A. M., 5043
 Kim, C.-H., 2368
 Kim, J., 1676
 Kim, M. S., 4811
 Kim, S., 1596
 Kim, Y., 3830
 Kim, Y. S., 641, 884, 1437
 Kimel, N., 158
 Kimura, T., 3349, 4927
 King, C. R., 1403
 King, S., 3000
 Kinuya, S., 2834
 Kinzler, K. W., 1986, 2231,
 2728
 Kirchgessner, C. U., 6011
 Kirchheimer, J. C., 1788
 Kirkwood, J. M., 4745, 5654
 Kirsh, J. C., 271
 Kishimoto, T., 851
 Kiso, M., 354
 Kitadai, Y., 4102
 Kitagawa, K., 5589
 Kitagawa, T., 953
 Kitahori, Y., 4408
 Kitajima, M., 1204, 3070
 Kitayama, H., 675
 Kitchener, H. C., 2128

Kittelson, J., 417
 Kittrell, F. S., 663, 668, 1646,
 3374
 Kiviniemi, H., 4486
 Klaassen, C. D., 922
 Klaus, M., 2319
 Kleibeuker, J. H., 248
 Klein, E., 1380, 5613
 Klein, E., 2416
 Kleinman, H. K., 423, 3459
 Klemenz, R., 4670
 Klominek, J., 4376
 Klooth, D. M., 1829
 Klotz, D. M., 5934
 Kluin, P. M., 4148
 Kluin-Nelemans, H. C., 4148
 Klussmann, E., 4082
 Knapp, R. C., 1489
 Kneller, R., 1317
 Knick, V. C., 810, 4619
 Knight, R. A., 926
 Knock, D., 4268
 Knowles, M. A., 133, 1230
 Knowles, P. P., 3000
 Knox, J. D., 417
 Knox, S. J., 3022, 3857
 Knudson, A. G., 5856
 Kobayashi, E., 5038
 Kobayashi, H., 2708
 Kobayashi, K., 1696
 Kobayashi, N., 106
 Kobayashi, T., 1696
 Kobayashi, T., 2484, 5638
 Kobrin, M. S., 2704, 4741, 5289
 Koch, C. J., 3992, 5721
 Koch, K. S., 2279
 Koch, W., 4477
 Koda, K., 1122
 Kodama, S., 1777
 Kodama, S., 2566
 Koefller, H. P., 4053
 Koeman, J. H., 784
 Koeplin, D. S., 5274
 Kogner, P., 2044
 Kohler, M. F., 1906, 5100
 Kohli, V., 3603
 Kohn, K. W., 1853, 4776
 Kohno, K., 1085
 Koi, S., 3382
 Koishihara, Y., 851
 Koji, T., 5419
 Kojima, T., 772, 2775, 3903,
 3908
 Kojiri, K., 490
 Kokkinakis, D. M., 2790
 Kokura, S., 2326
 Kokuryu, H., 368
 Kolachana, P., 1023
 Koldovsky, U., 4791
 Komatsu, N., 1156
 Komeda, H., 5350
 Komori, A., 239, 992, 1982,
 3462
 Komuro, H., 5284
 Kondo, M., 2326
 Kondo, Y., 4767
 Konishi, F., 5079
 Konishi, M., 5079
 Konishi, N., 4408
 Konishi, Y., 5038
 Kooistra, A. J., 1064

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Korc, M., 636, 2704, 4741, 5289
 Kormeyer, S. J., 1853
 Kortes, V., 5669
 Koscielny, S., 1534
 Koski, R. A., 2919
 Kostenuik, P. J., 5452
 Koster, J. F., 2548
 Kostka, G., 4424
 Kotasek, D., 3455
 Koutcher, J. A., 3518
 Kovacs, M., 6011
 Kovarik, J. M., 5915
 Koyama, H., 4071
 Koyama, M., 1555
 Kozielski, A. J., 1577
 Kraft, A., 652
 Kraft, A. S., 2810
 Kraiem, Z., 3943
 Kralio, M., 1032
 Krajewski, S., 4701, 4978
 Kramer, B. S., 1079
 Kramer, R., 2950
 Kramer, R. A., 977
 Krausz, T., 5365
 Kraut, E. H., 4843
 Kreipe, H., 1956
 Kreitman, R. J., 340, 819
 Krepinsky, J. J., 2906
 Krett, N. L., 3877
 Krinock, R. A., 4315
 Kripke, M. L., 2961
 Krishan, A., 2544
 Krishna, M. C., 5845
 Krishnamachary, N., 3658
 Krishnan, V., 1802
 Krishnaswamy, G., 1239
 Kristjansen, P. E. G., 4764
 Kroes, R. A., 4281
 Kroin, J. S., 4582
 Kronauge, J. F., 977
 Kronberger, P., 260
 Kronborg, O., 1895, 5920
 Kropshofer, H., 4424
 Krsmannovic, L., 2507
 Kruger-Krasagakes, S., 4134
 Kruithof, E. K. O., 6051
 Krystal, G., 4337
 Ku, C.-K., 1653
 Kubota, T., 1204, 3070, 5676
 Kudo, R., 3382
 Kudoh, S., 1380, 5613
 Kühn, D., 3747
 Kuhn, J. G., 5929
 Kuhne, G. E. H., 1590
 Kuipers-Dijkshoorn, N., 3804
 Kujoth, G. C., 2162
 Kulkarni, N., 4182
 Kumar, S., 348
 Kumar, S. P., 2745
 Kunitomo, T., 737
 Kunkel, T. A., 3270
 Kunz, H. W., 4089
 Kunzendorf, U., 714
 Kuo, A., 3109
 Kurebayashi, J., 2168, 2178
 Kurie, J., 2379
 Kurimoto, I., 728
 Kuriya, N., 2830, 4927
 Kuriyama, K., 5624
 Kuroishi, T., 1
 Kurosawa, S., 106

Kurose, I., 2676
 Kurth, L. A., 1546
 Kurz, E. U., 3221
 Kurzman, I. D., 3986
 Kurzrock, R., 2118, 3289, 3603
 Kushii, L. H., 4230
 Kuwano, H., 1706
 Kuwano, M., 1085
 Kuzmin, I., 861, 3118
 Kwak, K.-S., 1437
 Kwon, H., 1017
 Kyle, R. A., 5320
 Kyo, E., 4102
 Kyrianou, N., 3869

L

Labrecque, S., 3468
 LaCreta, F., 94
 Ladanyi, M., 16
 Laderoute, K. R., 2700
 Laerum, O. D., 3129
 LaForgia, S., 1498, 3118
 Lahat, N., 3943
 Lai, M.-Y., 1653
 Lai, P.-L., 4691
 Lambek, C., 401
 Lampson, L. A., 176
 Lampson, M. A., 176
 Lan, M. S., 4169
 Lancillotti, F., 2287
 Lane, D. P., 3374, 4817
 Lane, L. B., 2304
 Langdon, S., 1802
 Lange, B. J., 2954, 4489
 Lange-Carter, C. A., 393
 Langenhuijsen, M. M. A. C., 4399
 Langley, K. E., 693
 Langmark, F., 5849
 Langmuir, V. K., 3022
 Langouet, S., 231
 Lantz, M., 4010
 La Placa, M., 4481
 Lapré, J. A., 248, 784
 Larkin, H. E., 5897
 Larsen, A. K., 5987
 Larsson, C., 3707, 4356
 Larsson, E., 2927
 Lasic, D. D., 3964
 Lasorella, A., 304
 Lasota, J., 3118
 Lassam, N. J., 2235
 Lassen, E., 5920
 Last, T. J., 2399
 Latif, F., 861, 3118
 Laug, W. E., 6051
 Laun, R., 5439
 Laurent, G., 4850
 Laurent, T. C., 388
 Laurent-Puig, P., 5872
 Lavelle, F., 4784, 5987
 Law, K. L., 3956
 Law, L. W., 1602
 Lawrence, T. S., 5219
 Lawson, S., 4555
 Lazebny, A., 5841
 Lazzareschi, D., 5548
 Le, P. T., 67, 3165
 Leach, F. S., 1986, 2231
 Le Bail, N., 523, 1037
 Lechner, J. F., 985

Leclerc, J.-M., 5269
 Lecoq, S., 944
 Ledbetter, S. R., 2912
 Le Duc, A., 5872
 Leduy, L., 957
 Lee, A., 2553
 Lee, A., 6001
 Lee, C.-K., 4648
 Lee, I., 2466
 Lee, J. S., 2874
 Lee, M.-S., 4449
 Lee, P.-H., 1653, 4691
 Lee, T. C., 2858
 Leech, V., 1218
 Leek, R., 3597
 Lefaxa, J.-L., 3246
 Leffert, H. L., 2279
 Leftwich, J., 4337
 Le Gal, J.-M., 3681
 Lehman, N. L., 5697
 Lehmann, H.-P., 2840
 Lehr, J. E., 224, 3394
 Leigh, B. R., 3857
 Leigh, I. M., 5328
 Leitao, D., 5494
 Leith, J. T., 2188
 Leitl, F., 1690
 LeJeune, S., 3597
 Lelieveld, P., 3008
 Lelièvre, E., 3536
 LeMaistre, C. F., 3930
 Lemerle, J., 452, 1534
 Leng, L., 5554
 Leng, Z.-T., 2313
 Leon, J. A., 1929
 Leonard, R. C. F., 2128
 Leong, K., 5841
 Lepage, P., 1657
 Le Paslier, D., 861
 Le Riche, J., 733
 Lerman, M. I., 861, 3118
 Lerner, S. P., 4066
 Lester, S. C., 4676
 Lester, S. M., 3700
 Letessier, E., 5654
 Leu, J.-G., 1388
 Levens, D., 4109
 Lévi, F., 1534
 Levin, A. H., 1493
 Levine, A. J., 929
 Levine, B. A., 1360
 Levitsky, H. I., 5841
 Lewis, R., 16
 Leyshon-Sørland, K., 4874
 Li, B., 5108
 Li, C., 3276
 Li, H., 861
 Li, H., 5345
 Li, H.-C., 5528
 Li, H.-P., 1653
 Li, J.-y., 1317
 Li, P. Y., 3198
 Li, X., 2980
 Lian, J. B., 2399
 Liao, S., 1967
 Lichtner, R. B., 1516
 Lidereau, R., 1990, 5617
 Liebes, L., 3509
 Liebmann, J. E., 2066
 Liefers, G. J., 2712
 Liehr, J. G., 5447

Lillie, J. W., 3172
 Lin, C.-S., 2950
 Lin, C.-Y., 3159
 Lin, J.-C., 324, 2076
 Lin, J.-C., 4408
 Lin, J.-G., 2865
 Lin, P.-F. M., 4041
 Lin, S., 3730
 Lindblom, A., 3707, 4356
 Lindholm, L., 755
 Lindstrom, M. J., 4413
 Linehan, M., 2719
 Linehan, W. M., 861, 3092
 Ling, C. C., 1511, 2987
 Ling, V., 5994
 Ling, Y.-H., 1583, 1845, 4913
 Lingwood, C. A., 5314
 Linnoila, R. I., 3103, 5181
 Lints, T., 3405
 Liotta, L. A., 2208
 Lipinski, M., 3655
 Lipkin, M., 279, 2745
 Lippman, M. E., 283, 873, 1409, 2168, 2178, 3229
 Lippman, S. M., 5113
 Lips, C. J. M., 5754
 Lipschultz, C., 2066
 Lishko, V. K., 5676
 Little, J. B., 2188
 Littlefield, B. A., 2553
 Liu, A. Y., 2460
 Liu, B. C.-S., 4971
 Liu, C. C., 112
 Liu, L., 2736
 Liu, L. F., 1332, 5908
 Liu, S., 3092
 Liu, T., 2816, 4555
 Liu, W.-d., 1317
 Liu, X.-K., 2780
 Liu, Y.-J., 663
 Liu, Y.-P., 922
 Liu, Y.-X., 89
 Liu, Z., 5994
 Livanos, E. M., 4946
 Livingston, R. B., 5663
 Lloyd, K. O., 5395
 LoBuglio, A. F., 4555
 Lo Coco, F., 3800
 Loeb, L. A., 2895, 4172
 Logan, T. F., 4745
 Lohman, P. H. M., 1642, 4797
 Lohmann, D. R., 5797
 Lokeshwar, B. L., 4493, 4855
 Lokic, F., 3536
 Lombardi, L., 6036
 Longee, D. C., 120
 Longenecker, M., 1484
 Longfellow, D. G., 922
 Longnecker, D. S., 3925
 Longo, D. L., 2204, 5613
 Look, A. T., 5535
 Lopaczynska, J., 5977
 Lopez, A. R., 4391
 Lopez, M. E., 4741
 Lopez-Berestein, G., 2100
 Lord, E. M., 2112, 5721
 Lorio, A., 5487
 Lotan, R., 4109
 Lote, K., 3129
 Lothe, R. A., 5849, 5853
 Lou, Z., 1498

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Louis, D. N., 3465
 Louvel, D., 1182
 Love, J. L., 6067
 Lowe, J. B., 5559
 Lowe, J. E., 609
 Lowis, S. P., 4881
 Lyson, S., 4148
 Lozac'h, P., 5745
 Lu, C., 2708
 Lu, D., 4089
 Lu, J., 4169
 Lu, L., 1602
 Lu, X. P., 2279
 Lu, Y. Y., 4761
 Lu, Z., 2816, 5433
 Lubejko, B. G., 1794
 Lubin, R., 5872
 Lucas, C., 3536
 Lucas, J., 3968
 Ludwig, W-D., 3638
 Luk, G. D., 2618, 3723
 Lum, K., 3098
 Lungarotti, F., 5429
 Lupu, R., 2035, 5251
 Lust, J. A., 5320
 Lutz, S., 4035
 Lutz, W. K., 3505
 Lyftogt, C., 641
 Lyn, P., 3730
 Lynch, A. M., 6076
 Lynch, D. H., 1565
 Lynch, H. T., 5100
 Lynch, J., 221
 Lynch, J. H., 1416
 Lynch, M. J., 4041
 Lynch, T. H., 2300
 Lyons, J. C., 324, 1599
 Lysik, R. M., 140, 1195
 Lyubsky, S., 1195

M

Macchiarini, P., 2846
 MacEwen, E. G., 3986
 MacGrogan, D., 3369
 Machino, S., 4218
 Mackensen, A., 3569
 Mackensen, D. G., 3956
 Mackenzie, P. I., 1529
 MacMillan, D. L., 46
 Madara, K., 2204
 Madhuizen, H. T., 4603
 Maduakor, E. C., 2553
 Maecke, H. R., 5727
 Maeda, O., 2051
 Maestro, R., 5775
 Mafune, K-i., 1916
 Magnuson, B. A., 4499
 Magnusson, I., 5610
 Magrath, I. T., 127, 4776
 Mahacek, M. L., 627
 Maher, E., 861
 Maher, V. M., 3270
 Mählik, C. G., 2309
 Mahler, M., 2105
 Mai, M., 1397
 Maio, M., 3343
 Makepeace, C. M., 1599
 Makino, S., 4218
 Makita, A., 2484, 5638
 Makos, M., 2715, 2719
 Malapetsa, A., 5370

Malik, K., 2410
 Malkin, D., 3574
 Malmkin, A. M., 393
 Malm, C., 191
 Maloy, W. L., 3052
 Malspeis, L., 3062
 Mancini, M., 5
 Mancuso, S., 1297, 2457
 Mandahl, N., 2140
 Mandel, U., 5494
 Mandelli, F., 3800
 Manenti, G., 209
 Manfai, M., 3681, 4784
 Mangeney, M., 5314
 Mangin, P., 5872
 Mank, A. R., 2071
 Mannermaa, A., 4486
 Mannervik, B., 4257
 Mannhart, M., 2840
 Manni, A., 6042
 Manning, D. L., 5940
 Manseau, E. J., 4727
 Mansfield, P. J., 378
 Manske, M., 4082
 Mantovani, A., 3812, 5051
 Manzke, O., 4310
 Manzo, G., 5523
 Maragos, C. M., 564
 Marathi, U. K., 4281
 Marchetti, A., 2846, 4665
 Marie, J. P., 235
 Marienhagen, K., 5158
 Marino, P. A., 1719
 Markoe, A. M., 1091
 Markowicz, M., 4960
 Markowitz, S., 1986
 Marks, P. A., 5554
 Marmonti, L., 544
 Marshall, F. F., 2221
 Marshall, G. M., 615, 622
 Marshall, J. D., 1665
 Martell, L. A., 1348
 Martens, A. C. M., 3008
 Martikainen, P. M., 5199
 Martin, A., 452
 Martin, C., 4489
 Martin, D. S., 3518
 Martin, F. J., 3964
 Martin, M., 3246
 Martinez, A., 2740
 Marton, L. J., 3948
 Martucci, R., 1297
 Martuzza, R. L., 3125
 Marty, M., 1037
 Marui, N., 1328
 Maruyama, F., 4449
 Masaki, T., 4262
 Masci, A. M., 3355
 Mashal, R. D., 4676
 Massa, O., 3198
 Massaad, L., 3541, 4608
 Masse, E. M., 2912
 Mastrangelo, R., 304
 Masui, H., 4322, 4637
 Matalka, K. Z., 3308
 Mathieu, M-C., 3541
 Mathieu-Boué, A., 2823
 Matifas, F., 1990
 Matlashewski, G., 3468
 Matsubara, S., 1281
 Matsuda, M., 4238

Matsuda, M., 5610
 Matsukawa, Y., 1328
 Matsumata, T., 2884
 Matsumoto, K., 1328
 Matsumoto, T., 2534
 Matsumura, T., 4315
 Matsunaga, T., 495
 Matsunaga, T., 3179
 Matsuno, S., 183
 Matsuo, K-i., 1085
 Matsuo, S., 464
 Matsushime, H., 5535
 Matsushita, Y., 3632
 Matsuura, A., 3078
 Matsuura, S., 5419
 Matsuura, T., 147
 Matsuyoshi, N., 1696
 Matsuzaki, G., 106
 Matsuzawa, Y., 675
 Mattei, M-G., 4096
 Matthews, J., 6006
 Matushima, T., 1706
 Maudelonde, T., 2901
 Maurel, P., 5121
 Maxuitenko, Y. Y., 3499
 Maxwell, S. A., 5361
 May, W. T., 3865
 Maybaum, J., 5219
 Maydonovich, C., 3723
 Mayer, B., 1690
 Mayhew, E., 3964, 5877
 Maytin, E. V., 4952
 Mazumdar, M., 3730, 5780
 Mazzoni, M., 4481
 McAdam, A. J., 2112
 McAndrew, S. J., 334
 McAtee, N., 4828
 McAliffe, T. L., 5176
 McBride, T. J., 4172
 McCabe, R. P., 2368
 McCamant, S. K., 5188
 McCartney, J. E., 4026
 McClain, K. L., 3289
 McClay, E. F., 1571
 McCormick, B., 1971
 McCormick, J. J., 3270
 McCrady, C. W., 833
 McCullers, G. A., 2368
 McCully, C., 1596
 McCutcheon, I., 4143
 McDaniel, T., 1889
 McDonald, T. L., 1921
 McEachern, D., 2740
 McGregor, A. D., 1522
 McGuire, W. L., 3736
 McIntosh, J., 2379
 McKeage, M. J., 2581
 McKenna, W. G., 1128
 McKenzie, D. R., 4230
 McKenzie, I. F. C., 4082
 McLendon, R. E., 120, 2338
 McLeskey, S. W., 2168, 2178
 McMullin, B., 3930
 McPherson, J. P., 5885
 McQueen, T., 2100
 Meadows, G. G., 4075
 Medema, J. P., 728
 Medina, D., 663, 668, 1646,
 3374
 Mehta, K., 2100
 Meijer, C. J. L. M., 456, 1475,

3524, 4383, 5707
 Meisler, A. I., 2919
 Meissner, S., 868
 Melby, E. L., 1755
 Melder, R. J., 5867
 Melera, P. W., 6031
 Melhem, M. F., 2919, 4089
 Meling, G. I., 5849
 Melino, G., 926
 Melle, J., 235
 Mellstedt, H., 5610
 Melsop, K. A., 1380
 Meltzer, P., 2231
 Meltzer, S. J., 1889
 Ménard, S., 5791, 5864, 6036
 Mendelsohn, J., 4322, 4637
 Mendonca, H. L., 3022
 Mendoza, J. T., 1577
 Meneghetti, C., 3930
 Meneguzzi, G., 1175
 Menendez, A. T., 3336
 Menendez-Botet, C., 3730
 Menichella, G., 1297
 Menrad, A., 1450
 Mentzel, M., 4268
 Mercier, B., 5745
 Meredith, R., 4555
 Meresse, V., 452
 Merkl, K. A., 3294
 Merlino, G., 1719, 4329
 Merlo, G., 2846
 Merrill, J. E., 170
 Merrill, M. A., 4952
 Mertens, F., 2140
 Merwin, J., 4041
 Metcalf, R. A., 4817
 Methlin, G., 165
 Mettler, L., 1956
 Meunier, B., 231
 Mewes, K., 5135
 Meyer, D. J., 231
 Meyer, D. L., 3956
 Meyer, F., 1107
 Meyer, K. B., 1023
 Meyers, S. M., 4518
 Mezzina, M., 1244
 Mi, J-X., 3455
 Michael, C., 5669
 Michel, F-B., 61
 Mick, R., 1293, 2304
 Mihatsch, M. J., 2199
 Mihich, E., 2192
 Mii, Y., 5038
 Miki, K., 868
 Miki, K., 4418
 Mikolajczyk, S. D., 3956
 Milani, D., 4481
 Milenic, D. E., 3776
 Millauer, B., 5822
 Miller, J., 581
 Miller, L. A., 2527
 Miller, M. R., 3700
 Miller, R. E., 1565
 Miller, W. R., 1802
 Millikan, R., 212, 5083
 Millon, R., 165
 Mills, G. B., 1304
 Mills, J. J., 2265
 Milner, A. E., 3321
 Milner, B. J., 2128
 Milner, J., 1739, 4469

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Milton, J. D., 4627
 Minamoto, T., 2786
 Mincione, G., 5548
 Mineo, A., 5523
 Minna, J. D., 2410, 3257, 5181
 Minnick, D. T., 997
 Miotti, S., 5791
 Mir, L. M., 5462
 Mirkin, B. L., 6058
 Mirski, S. E. L., 4866
 Mirzadeh, S., 5683
 Mishra, S., 557
 Missero, C., 5517
 Mita, M., 4767
 Mitaka, T., 3145
 Mitani, H., 5856
 Mitchell, J. B., 2066, 5845
 Mitchell, K., 5649
 Mitchell, M. A., 5690
 Mitchell, M. S., 1113
 Mitelman, F., 2140
 Mitsui, H., 675
 Mitsui, K.-i., 2260
 Miura, S., 2676
 Miura, S., 5038
 Miyaki, M., 5079
 Miyamoto, K.-i., 1555
 Miyao, N., 4066, 5620
 Miyuchi, Y., 5038
 Miyazaki, T., 2484, 5638
 Miyazaki, Y., 5624
 Miyazawa, M., 183
 Miyazono, K., 183, 3193
 Miyoshi, E., 3899
 Mizoguchi, H., 5613
 Mizoi, T., 183
 Mizuno, K., 2051
 Mizuno, T., 2940
 Moalli, P. A., 3877
 Moch, H., 2199
 Mochizuki, Y., 3145
 Modena, D., 3015
 Modest, E. J., 4297
 Modest, A., 5067
 Modi, W., 861, 3118
 Moeschberger, M. L., 3308
 Mohanam, S., 2208, 4143
 Mok, S. C.-H., 1489
 Moldenhauer, G., 4310
 Molin, L. F., 4715
 Moll, U., 140
 Møller, P., 5849
 Mølne, J., 4987
 Molthoff, C. J. M., 5413
 Molyneux, A., 1218
 Monaco, C., 5523
 Monden, M., 857
 Monroe, T. J., 5690
 Monsky, W. L., 3159
 Montelaro, R. C., 5386
 Montgomery, A. M. P., 693
 Moody, T. W., 5214
 Moolten, F. L., 5274
 Moore, D., 2199
 Moore, D., 3736
 Moore, K. H., 1286
 Moore, M., 4837
 Moore, R., 3853
 Moore, R. E., 1343
 Moorehead, R., 4994
 Moran, R. G., 5697
 Morel, F., 231
 Morel-Kopp, M.-C., 4695
 Morgan, J., 4680
 Mori, H., 772, 2775, 3903, 3908
 Mori, M., 1706, 4048
 Mori, N., 4643
 Mori, R., 2884
 Mori, S., 4218
 Mori, S., 5475
 Mori, T., 495, 609
 Mori, T., 857, 1172, 1696, 3421
 Mori, T., 5079
 Morikage, T., 3302
 Morimoto, H., 2591
 Morimoto, R. I., 3034
 Morisaki, T., 949
 Morishita, T., 5038
 Moriyama, K., 737
 Morizet, J., 3541, 4608
 Morjani, H., 3681, 4784
 Mørk, S., 5158
 Mørkrid, L., 4874
 Morris, J. S., 795
 Morrison, S. L., 5244
 Morton, C. L., 4243
 Morton, D. L., 949, 5244
 Morton, R. A., 3585
 Moshier, J. A., 2618
 Mosseri, M., 3028
 Motomura, K., 4071
 Motulsky, A. G., 2313
 Motzer, R. J., 3730
 Mouridens, H. T., 2513
 Moutou, C., 452
 Moynes, R. A., 1967
 Mrózek, K., 1670
 Mueller, B. A., 3416
 Mueller, B. M., 693
 Mueller, S. C., 3159
 Muggia, F. M., 3694, 5669
 Muindi, J. F., 1226
 Muirhead, K. A., 2358
 Mukhopadhyay, T., 1676, 1743,
 4129, 4362
 Mukhtar, H., 3439, 5409, 5897
 Mulcahy, R. T., 4413
 Mulder, N. H., 1064, 1747,
 5707, 5915
 Mulholland, G., 1102
 Mullenders, L. H. F., 1642
 Muller, C., 4850
 Müller, C. A., 4424
 Muller, D., 165
 Müller-Hermelink, H.-K., 4197
 Mulligan, L., 957
 Mulligan, R. C., 2221
 Mulshine, J. L., 67, 5181
 Munck, J.-N., 1550
 Mundy, G. R., 737
 Munn, D. H., 2603
 Muñoz, A., 3499
 Murai, T., 4218
 Murakami, H., 1719
 Murakami, M., 2035
 Murakami, S., 4643
 Muramatsu, T., 1281
 Muraoka, M., 5079
 Muraszko, K., 3752
 Muraszko, K. M., 1348
 Murphy, B. J., 2700
 Murphy, J. R., 3723
 Murphy, L. A., 4952
 Murphy, R. F., 472, 4828
 Murphy, S. E., 777
 Murray, J. H., 456
 Murray, S., 6076
 Murrer, B. A., 2581
 Muschel, R. J., 1128
 Muto, M. G., 1489
 Myers, E., 5654
 Myklebost, O., 468
 Myklebust, A. T., 3784
 Myseros, J. S., 329

N

Naaktgeboren, J. M., 4797
 Nabiev, I., 4784
 Nachman, J., 1978
 Naeve, C. W., 5108
 Nagafuchi, A., 3585
 Nagai, Y., 5903
 Nagamine, Y., 3618
 Naganuma, A., 1829, 4767
 Nagasawa, H., 2188
 Nagle, R. B., 417
 Naguib, F. N. M., 3687
 Nagura, H., 183
 Nagy, J. A., 2631, 2912
 Nagy, P., 1719
 Nair, M. G., 2227
 Nairn, A. C., 2260
 Naito, M., 5022
 Naito, Y., 1871
 Naito, Y., 2326
 Nakachi, K., 2994
 Nakada, S. Y., 1967
 Nakagawa, I., 4767
 Nakagawara, A., 1281
 Nakagomi, H., 5610
 Nakashishi, K., 4408
 Nakai, M., 737
 Nakajima, M., 5022, 5802
 Nakajima, R., 1883
 Nakajima, T., 1172
 Nakamori, S., 3632
 Nakamura, H., 4053
 Nakamura, N., 2940
 Nakamura, T., 1233
 Nakamura, T., 4489, 5624
 Nakamura, Y., 1, 857, 1172,
 3382, 5087
 Nakano, H., 4466
 Nakashima, Y., 464
 Namboodiri, M. M., 1322
 Nandi, S., 1816
 Nangia-Makker, P., 5033
 Naor, N., 3468
 Narayan, S., 2256
 Nash, J. D., 3103
 Nath, K., 5308
 Nau, M. M., 2410
 Nauta, R. J., 3712
 Navre, M., 417
 Nazar-Stewart, V., 2313
 Neal, D., 5365
 Neal, G. E., 3887
 Neckers, L. M., 127
 Nédellec, P., 4938
 Needham, D., 3765
 Nees, M., 4189
 Negrini, M., 2954, 4489, 5569
 Neijt, J. P., 544

Nelkin, B. D., 2715, 2719
 Nelson, H., 4652
 Nelson, W. G., 4164
 Nepveu, A., 1657
 Nesbitt, J. C., 5181
 Nesland, J. M., 468
 Neufeld, G., 158
 Neuringer, L. J., 5808
 Nevalainen, M. T., 5199
 Newell, D. R., 4881
 Newsham, I., 4486
 Ng, B., 5483
 Nguyen, C. H., 5987
 Nguyen, M., 5297
 Nguyen, N. M., 224
 Nichols, M. G., 1249
 Nichols, P. W., 1162, 4066,
 5620
 Nicholson, R. I., 5940
 Nicolson, G. L., 4418, 5802
 Nicotera, T., 5104
 Niehans, G. A., 641
 Niericker, M., 4797
 Nieroda, C., 600
 Nihei, T., 1702
 Niimi, T., 1
 Nikai, H., 4102
 Nikaido, O., 495, 609
 Niloff, J., 3830
 Nilsson, M., 4987
 Nilsson, O., 755
 Nilsson, S., 3193
 Ning, S. M., 3276
 Nisen, P. D., 4757, 6028
 Nishi, S., 2970
 Nishida, K., 1709
 Nishida, N., 368
 Nishigori, C., 2944
 Nishii, H., 1906
 Nishii, Y., 2534
 Nishikawa, A., 3899
 Nishino, H., 1328
 Nishino, Y., 5350
 Nishio, K., 3302
 Nishioka, H., 4408
 Nishioka, K., 2689
 Nitiss, J. L., 89
 Nitz, M., 1004
 Nobori, T., 1098, 2410
 Nocentini, G., 19
 Noda, K., 3382
 Noë, A. J., 5370
 Noe, D. A., 1794
 Noga, S. J., 5424
 Noguchi, K., 2538
 Noguchi, M., 2035
 Noguchi, S., 4071
 Nomizu, M., 3459
 Nomoto, K., 106
 Nomura, K., 464
 Nomura, K., 490
 Nomura, T., 1883
 Nooijen, W. J., 2061
 Nord, L. D., 3518
 Nordenskjöld, M., 3707, 4356
 Nordgren, H., 3193
 Norioka, K.-i., 3145
 Norkus, E. P., 795
 Norman, A. W., 3935
 North, S. M., 1630
 Nortier, H. W. R., 4563

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Norton, L., 2987
 Nosaka, C., 4896
 Notario, V., 4474
 Notkins, A. L., 4169
 Noto, A. C., 3394
 Nousbaum, J. B., 5745
 Novak-Hofer, I., 5727
 Nowell, P. C., 5624
 Nozawa, S., 3643
 Nozawa, S., 5903
 Numata, M., 495
 Numoto, M., 5815
 Nunes, E., 5750
 Nunn, G., 3919
 Nunoshiba, T., 3250
 Nurmi, M., 5199
 Nurse, P., 1867
 Nuti, M., 2457
 Nyamuswa, G., 5908
 Nyström-Lahti, M., 5849, 5853

O

Oakley, C., 2272
 Öberg, K., 4550
 Oborn, C. J., 668
 O'Brien, S., 3603
 Obuz, V., 1431
 Ochi, Y., 4896
 Ochieng, J., 5033
 Ochoa, A. C., 5613
 O'Connell, S. M., 1608
 O'Connor, P. M., 1853, 4776
 Oda, S., 4643
 Ødum, L., 1823
 O'Dwyer, P. J., 3662, 5225
 Odze, R. D., 271
 Oesch, F., 944
 Oesterreich, S., 4443
 Offerhaus, G. J. A., 4754
 Ogasawara, M., 3561
 Ogata, E., 2534
 Ogawa, M., 464
 Ogawa, O., 3795
 Ogorek, D., 4082
 Oguchi, H., 2051
 Ogura, K., 3795
 O'Hara, C. J., 2840
 Ohara, T., 4218
 Ohashi, K., 953
 Ohata, H., 1172
 Ohi, Y., 1281
 Ohkawa, K., 4238
 Ohkura, T., 2970
 Ohlsson, R., 2927
 Ohly, K., 5424
 Ohmori, K., 354, 5559
 Ohmori, T., 3302
 Ohnesoit, P. F., 1162
 Ohnishi, T., 4408
 Ohno, T., 5859
 Ohnuki, Y., 985
 Ohnuna, N., 3179
 Ohsaki, Y., 3165
 Ohshima, M., 4408
 Oh sugi, Y., 851
 Ohta, K., 4175
 Ohta, M., 3118
 Ohta, T., 239, 992
 Ohtake, K., 953
 Ohtani, H., 183
 Ohto, M., 2472

Ohtoshi, T., 4175
 Ohtsuki, Y., 4823
 Oie, H. K., 5181
 Oikawa, A., 495
 Oikawa, T., 5759
 Oka, H., 1696, 3421
 Okabe, S., 1012, 1982, 3462
 Okada, K., 429
 Okada, S. S., 3109
 Okada, Y., 1397
 Okai, Y., 1612
 Okaiichi, K., 4408
 Okamura, W. H., 3935
 Okano, S., 687
 Okayasu, R., 5592
 O'Keefe, M., 3172
 Okihiro, M. S., 1761
 Okochi, E., 5475
 Okuma, M., 5559
 Okura, A., 490
 Old, L. J., 3327
 Oldfield, E. H., 83, 3752
 Olegård, C., 2140
 Oleinick, N. L., 5897
 Oliner, J. D., 2231
 Olinski, R., 1269
 Olive, M., 1630
 Olive, P. L., 733
 Olivieri, Q., 5429
 Olivotto, I. A., 733
 Ollert, M. W., 592
 Olofsson, A., 3193
 Olopade, O. I., 1098, 2410
 Olsons, S., 1755
 Olsson, I., 4010
 Olumi, A. F., 1162, 4066
 Omata, M., 2472
 Onda, M., 5289
 Ong, D. E., 2965
 Ono, K., 5475
 Ono, T., 2830, 3349, 4927
 Onoda, M., 1416
 Onozaki, K., 1871
 Oosterhuis, J. W., 5707
 Oppenheim, J. J., 564
 Oppermann, H., 4026
 Orazem, J., 2379
 Orcutt, M. L., 861
 Orengo, C. C., 5071
 Orengo, M. A., 4769
 Ormandy, C. J., 5940
 Orr, F. W., 5452
 Orr, M. S., 3547
 Ortmann, O., 5439
 Orton, T., 3919
 Ortonne, J. P., 1175
 Osada, S.-i., 5554
 Osaki, K., 687
 Osborne, C. K., 4443
 Osborne, R. J., 1218
 O'Shaughnessy, J. A., 2587
 O'Shea, J. P., 5613
 Oshima, M., 5589
 Oskarsson, M., 5355
 Ossenkoppele, G. J., 4399
 Ostro, M., 2796
 Otero, G., 4474
 O'Toole, S. M., 3895
 Ottaviano, Y., 3976
 Ottensmeier, C., 3830
 Otter, G. M., 587

Owen-Lynch, P. J., 1735
 Owen-Schaub, L. B., 4129
 Oyama, F., 2005
 Oyamada, H., 2326
 Oyasu, R., 5172
 Øyjord, T., 468
 Ozburn, M. A., 1646, 3374
 Ozer, H. L., 3327
 Ozols, R. F., 3662, 5225

P
 Pääkkö, P., 4817
 Packman, C. H., 5274
 Padarathsingh, M., 5055
 Padura, I. M., 5051
 Paganini-Hill, A., 212, 5083
 Page, R. L., 101
 Pai, L. H., 2834, 4588
 Paik, C. H., 2834
 Pak, A. S., 6006
 Palladino, M. A., 4391
 Paller, A. S., 6058
 Palmer, L. D., 2358
 Pals, S. T., 4754
 Panasci, L. C., 3237, 5370
 Pandis, N., 1895
 Pang, H., 2906
 Panici, P. B., 2457
 Pantazis, P., 1577
 Pantel, K., 1027
 Pantelias, G. E., 5592
 Papa, V., 3736
 Papadopoulou, L. C., 1072
 Papavassiliou, E. D., 2374
 Pardee, A. B., 1493
 Pardoll, D. M., 2221, 5841
 Parise, O., Jr., 3541, 4608
 Park, J.-G., 5087
 Park, N.-H., 4811
 Park, R. C., 3103
 Park, S., 4757
 Park, S. H., 4461
 Parker, B., 1098
 Parker, K., 3930
 Parker, R. J., 242, 3694
 Parker, S., 1906
 Parkin, D. E., 2128
 Partin, A. W., 744, 1995
 Parwarsch, R., 1956
 Pass, H. I., 5181
 Passaniti, A., 1833
 Passlick, B., 1027
 Passos-Coelho, J., 5424
 Pastan, I., 340, 819, 2834, 4588
 Pasternack, G. R., 4720
 Patel, B., 4310
 Patel, U., 717
 Pater, A., 4432
 Pater, M. M., 4432
 Paterlini, P., 235
 Paterson, M. C., 4960
 Patterson, G. M. L., 1343
 Paxton, R. J., 1612
 Payne, C., 3386
 Pearson, A. D. J., 3758, 4881
 Pechoux, C., 1421
 Pecoraro, G., 1167
 Pedersen, P.-H., 5158
 Pedroni, M., 3726
 Pegg, A. E., 3895, 4750
 Pekarek, L. A., 1978

Peled, A., 2147, 3433
 Peles, E., 5251
 Pellicci, P. G., 6036
 Pellarin, M., 3948
 Pellegata, N. S., 2614
 Pellegrini, S., 2846, 4665
 Pelletier, G., 5872
 Pelletier, J., 5269
 Pelosi, E., 569
 Pelosi, L., 4041
 Peltomäki, P., 5849, 5853
 Pendergast, W., 810
 Pendleton, C. D., 3257
 Pendyala, L., 5970
 Peng, H.-Q., 3574
 Peng, L. F., 1332
 Peng, S.-Y., 4691
 Pensa, F., 4769
 Pepe, S., 2846, 5548
 Peretti, M., 1107
 Peretz, D., 158
 Perez, A., 401
 Perez, R. P., 3771
 Perez-Soler, R., 1583, 1845,
 3046, 4913
 Perle, M. A., 2858
 Perng, R.-P., 1079
 Perry, R. R., 3040
 Perry-Lalley, D., 2358
 Pershouse, M. A., 5043
 Persson, H., 2044
 Persson, L., 5262
 Peschle, C., 569, 1297
 Peterhans, E., 1456
 Peter-Katalinic, J., 4367
 Peters, B. P., 101
 Peterson, L. A., 2780
 Peterson, M., 5610
 Peto, R., 4108
 Petrella, E. C., 592
 Petrelli, N., 2796
 Petti, M. C., 3800
 Pettit, G. R., 2810
 Peyrat, J. P., 5872
 Pezzino, V., 3736
 Pezzoni, G., 544
 Pfeffer, U., 741
 Pflug, B. R., 1416
 Pfreundschuh, M., 4367
 Phan, A., 27
 Phang, J. M., 5977
 Pharo, A., 3784
 Phelps, R., 67, 5181
 Philip, P. A., 5649
 Phillips, D. H., 944
 Phillips, R. W., 3723
 Phipps, M., 861
 Pickett, C. B., 3207
 Pienta, K. J., 224, 3394
 Pierceall, W. E., 2961
 Pierelli, L., 1297
 Pierotti, M. A., 209, 6036
 Pietrzkowski, Z., 1102
 Pike, M. C., 4960
 Pilkiewicz, F., 2796
 Pillay, S., 3877
 Pimenov, A. M., 5143
 Pinch, H. J., 27
 Pinedo, H. M., 1475
 Ping, W., 5199
 Pinton, P., 3246

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Pipas, J. M., 2919
 Pirisi, L., 905
 Pisa, P., 3603
 Pisani, A., 1175
 Pitot, H. C., 3145
 Pittman, S. M., 1222
 Pivik, C., 762
 Piwnica-Worms, D., 977
 Pizzo, S. V., 1998
 Placidi, M., 5121
 Plate, K. H., 5822
 Platko, J. D., 3085
 Platt, K. L., 944
 Plavec, I., 1107
 Plowman, G., 3597
 Plummer, H., III, 4337
 Podratz, K. C., 2393, 4456
 Poiesz, B. J., 6067
 Poirier, G. G., 3976, 5370
 Poisson, N., 452
 Pokorny, R., 5915
 Polihronis, J., 271
 Pollak, M. N., 1727, 5193, 5585
 Pomato, N., 456, 2368
 Pommier, Y., 1583, 4251
 Ponder, B. A. J., 1218
 Ponta, H., 1262, 1516, 4197,
 4754
 Ponzani, P., 4769
 Ponz de Leon, M., 3726
 Poole, D. J., 2154
 Poore, C. M., 5977
 Poplack, D. G., 472, 725, 1032,
 1596, 2587
 Portella, G., 5523
 Porter, C. W., 581
 Portier, M. M., 1175
 Pospiech, I., 5754
 Potten, C. S., 2057
 Potter, B. V. L., 298
 Potter, J. D., 536, 4230
 Potter, P. M., 1731
 Povirk, L. F., 3547
 Povoski, S. P., 3925
 Powell, C. T., 227
 Powell, W. C., 417
 Powers, J. H., 4059
 Powis, G., 1338, 1862, 4297,
 5458
 Pow-Sang, J. M., 577
 Pozzi, L., 5523, 5569
 Prajda, N., 5982
 Prasad, R., 5624
 Prats, H., 1182
 Pratt, S. E., 5193
 Präuer, H., 5797
 Prehn, R. T., 3266
 Press, M. F., 4960, 5188
 Press, N., 3000
 Presti, J. C., Jr., 5780
 Prestigiacomo, L. J., 291, 2071
 Preston, S. R., 5090
 Preudhomme, C., 5872
 Prévost, J., 5370
 Price, B. D., 12, 2212
 Price, J. E., 891
 Price, L., 3758
 Price, M. R., 755
 Priebe, W., 1583, 1845
 Prieto, E., 728
 Primrose, J. N., 5090
 Primus, F. J., 3355
 Prince, C. W., 701, 2217
 Pritsos, C. A., 5470
 Proby, C. M., 5328
 Proietti, E., 569, 1107
 Pron, G., 5462
 Puder, M., 4048
 Puech, C., 2901
 Puistola, U., 5028
 Pujol, H., 61
 Pujol, J.-L., 61
 Pulaski, B. A., 2112
 Pupa, S. M., 5864
 Purdie, K. J., 5328
 Purohit, A., 298
 Pütz, B., 5797
 Pyke, C., 1911
 Pykkänen, L., 5849, 5853
 Pytel, B. A., 348
 Q
 Qi, C.-F., 600
 Qin, Z., 714
 Qiu, M., 4443
 Qiu, S.-L., 1783
 Quak, J. J., 4383
 Quinn, A. G., 2697
 Quintanilla, M. I., 5071
 R
 Rackley, R., 2712
 Radda, G. K., 5649
 Rademaker, A., 5172
 Radford, D. M., 2947
 Radi, L., 4534
 Radinsky, R., 937
 Raff, H. V., 2560
 Rahman, A., 4243
 Rahmani, R., 5121
 Raitano, A. B., 636
 Rajagopal, S., 5663
 Rajagopalan, B., 5649
 Rak, J. W., 2708
 Ralfkiaer, E., 1911
 Ralph, R., 3405
 Ram, T. G., 2655
 Ram, Z., 83
 Ramachandran, C., 2544
 Ramirez, L. H., 1550
 Ramsey, P. S., 4652
 Randolph, J. K., 3547
 Ransom, J. H., 456
 Ranzani, G. N., 2614
 Rao, C. V., 2502, 3493, 4182
 Rao, J. S., 2208, 4143
 Rao, P. H., 2732
 Rao, V. N., 215, 3449, 5859
 Rao-Betté, M., 3000
 Rappa, G., 5487
 Raschellá, G., 2044
 Rasmussen, J. W., 5920
 Rasmussen, U. B., 4096
 Rastetter, J. W., 3747
 Ratain, M. J., 1293, 2304
 Raubitschek, A. A., 5683
 Ravichander, P., 1142
 Ravikumar, T. S., 1916
 Rayburn, J., 4686
 Raymond, M., 1657
 Raz, A., 5033
 Rea, D., 5649
 Reaman, G., 1032
 Reddel, R. R., 985
 Reddy, B. S., 2502, 2745, 3493,
 3914, 4182
 Reddy, E. S. P., 215, 3449, 5859
 Reding, D., 5176
 Redman, J., 2118
 Reed, E., 242, 3694
 Reed, J. C., 4701, 4978
 Reed, M. J., 298
 Rees, J. L., 2697
 Reeve, A. E., 5166
 Reeve, J. G., 4680
 Reeves, R., 2655
 Rehfeld, J. F., 1823
 Rehm, S., 3874
 Rehnholm, A., 5262
 Reibneger, G., 260
 Reich, U., 5797
 Reichert, A., 2498
 Reid, J. M., 1032
 Reid, L. M., 652
 Reid, T. M., 4172
 Reifenberger, G., 2736
 Reilly, J. G., 67
 Reilly, R. M., 271
 Reinecke, M., 2475
 Reisfeld, R. A., 362, 693, 4933
 Reiss, M., 899
 Reiter, R. E., 2719, 3092
 Reiter, Z., 3555
 Remack, J. S., 1731
 Rempel, S. A., 957, 2386
 Renault, B., 2614
 Renkonen, O., 5600
 Resau, J. H., 5355
 Rettig, W. J., 3327
 Reuben, J., 3930
 Reuter, V. E., 5780
 Reynolds, J. E., 2349
 Rhee, M. S., 2227
 Rhodes, J. M., 4627
 Riccardi, R., 304
 Rice, J. M., 1883, 3874
 Richards, C. A., 4619
 Richards, F., 861
 Richardson, F. C., 4582
 Richardson, J. A., 1392
 Richardson, L., 212, 5083
 Richon, V. M., 5554
 Richter, A., 3283
 Richter, C., 1456
 Richter, F., 3283
 Richter, G., 4134
 Ridderheim, M., 2309, 4550
 Rideout, W. M., III, 1162
 Rieber, M. S., 2469
 Rieber, M. S., 2469
 Riebow, J., 1338
 Riecken, E.-O., 4082
 Riethmüller, G., 1027
 Rifkind, R. A., 5554
 Rigas, B., 762, 2374
 Rigg, M., 1550
 Rimessi, P., 5569
 Rinaldi, D. A., 5929
 Ringborg, U., 4257
 Rio, M.-C., 165, 4096
 Riou, J.-F., 4784, 5987
 Risau, W., 5822
 Risinger, J. I., 5100
 Risteli, J., 5028
 Risteli, L., 5028
 Ritch, P. S., 5176
 Ritke, M. K., 3547
 Ritland, S. R., 2393, 4456
 Ritter, J. H., 2947
 Rivenson, A., 2502, 2758, 3493,
 3719, 3914
 Rivers, E. N., 1916
 Riviere, J. E., 101
 Rizos, S., 2374
 Ro, J. Y., 1676, 2874
 Roa, R. A., 4477
 Robaszkiewicz, M., 5745
 Robbins, P. F., 2154
 Robert, C., 1625
 Robér, K.-H., 4376
 Robert, N. J., 3509
 Roberts, A. I., 1608
 Roberts, W. G., 153
 Robertson, M., 5581
 Robinow, C. F., 1877
 Robinson, J. C., 3869
 Rochefort, H., 2901
 Rockwell, S., 5127
 Rodbourn, L., 1529
 Roebuck, B. D., 46, 3499, 3925
 Rofstad, E. K., 3308
 Rogler, C. E., 2020
 Rognum, T. O., 5849
 Rom, W. N., 2858
 Roman, S. D., 5940
 Romanakis, K., 4035
 Roncucci, G., 2457
 Roncucci, L., 3726
 Rong, S., 5355
 Rønne, E., 1911
 Roop, D. R., 5071
 Roos, E., 3611
 Roos, J. C., 5413
 Root, M., 577
 Roots, I., 1004
 Rorke, E. A., 4511
 Rosati, R., 5523
 Rose, D. P., 4686
 Rose, E., 2803
 Rosen, S. T., 3877
 Rosenberg, M., 4938
 Rosenberg, S. A., 5, 3561
 Rosenblum, M., 3930
 Rosenblum, M. L., 2386
 Rosenquist, C., 2513
 Rosner, A., 2147
 Ross, D. A., 1348
 Ross, H., 1273
 Ross, R. A., 4978
 Ross, R. K., 1162
 Roth, J. A., 1676, 1743, 4129,
 4362, 5361
 Rothberg, J., 2118
 Rothnagel, J. A., 5071
 Roths, J. B., 1665
 Rotstein, S., 3707, 4356
 Rouanet, P., 2901
 Rougier, P., 1550
 Rousseau, F., 1037
 Rouyer, N., 165
 Rowinsky, E. K., 1794
 Rowlands, C., 1802
 Roy, D., 2256
 Roza, L., 609

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Rozengurt, E., 5208
 Ruan, S., 5395
 Rubin, A. S., 1565
 Rubin, J., 5654
 Rubinstein, D. B., 3139
 Rubio, M-P., 3465
 Rudoll, T. L., 3765
 Rudy, W., 1262, 1516
 Rughetti, A., 2457
 Rugstad, H. E., 4874
 Ruiter, D. J., 6061
 Ruka, W., 5012
 Ruppert, J. M., 4477, 5093,
 5620
 Rusch, V. W., 2379
 Rushfeldt, C., 658
 Russell, C., 4555
 Russell, E. K., 4169
 Russell, M., 3386
 Russo, A., 5908
 Rustagi, P., 2810
 Rustan, T. D., 509
 Rustum, Y. M., 1560
 Rutka, J. T., 3624
 Rutz, H-P., 957
 Ruven, H. J. T., 1642
 Ryan, A. J., 2012
 Ryberg, D., 5853

S
 Saba, V., 5429
 Sabzevari, H., 4933
 Safe, S., 1802
 Sagae, S., 1702, 3382
 Sage, R. E., 3455
 Sager, R., 5004
 Saito, N., 3302
 Saiki, R. K., 2472
 Saisho, H., 2472
 Saishoji, T., 464
 Saito, H., 2676
 Saito, H., 3382
 Saito, H., 4466
 Saito, H., 5624
 Saito, J., 3382
 Saito, S., 3382
 Saito, S., 5528
 Saka, M., 147
 Sakai, A., 1982
 Sakai, K., 1043
 Sakai, T., 1328
 Sakakura, C., 687
 Sakamoto, H., 1136
 Sakamoto, M., 2005
 Sakr, W., 2723
 Saksela, E., 5600
 Saksena, N. K., 6067
 Salavati, R., 1511
 Saldanha, J., 851
 Saleh, M. N., 4555
 Salgaller, M. L., 2154
 Salghetti, S. E., 985
 Salour, M., 833
 Salvatore, M., 3198
 Samejima, K., 3948
 Samet, J. M., 4817
 Samid, D., 4890
 Samrowski, W. E., 5507
 Sampson, K. E., 1354
 Samuel, J., 1484
 Sanchez, R., 937

Sandberg-Nordqvist, A-C., 2475
 Sanderson, N. D., 1719
 Sandlund, J. T., 127
 Sandvig, K., 1755
 Santelli, G., 5523
 Santen, R. J., 6042
 Santodonato, L., 1107
 Santos, O., 1091
 Santostefano, M., 1802
 Sara, V., 2475
 Sarasin, A., 1625
 Sarkaria, J. N., 4413
 Sartorelli, A. C., 4907, 5127,
 5487
 Sartorius, S. E., 1794
 Sasaki, H., 1136
 Sasaki, H., 1906
 Sasaki, K., 1982
 Sasaki, S., 687
 Sasaki, T., 1397
 Sasaki, Y., 3632
 Sato, H., 1397
 Sato, K., 851
 Sato, M., 2538
 Sato, M., 2944
 Sato, N., 1702, 3078
 Sato, S., 1085
 Satoh, M., 1829, 4767
 Satomi, Y., 1328
 Satomura, S., 5419
 Sattler, G. L., 3145
 Saucier, J-M., 5987
 Sausville, E. A., 2081
 Sauter, G., 2199
 Sauveur, C., 3536
 Savarese, D. M. F., 2587
 Sawada, H., 772
 Sawada, M., 5559
 Sawai, K., 687
 Sawaya, R., 2208, 4143
 Scambia, G., 1297, 2457
 Scamps, C., 3655
 Scanlon, M., 891, 5784
 Scardino, P. T., 4461
 Schaafsma, H. E., 3241
 Schaefer, D. I., 4946
 Schäfer, R., 4670
 Schalken, J. A., 1995, 3241,
 5512
 Schally, A. V., 5439
 Schantz, S. P., 2189
 Scheck, A. C., 5605
 Schechter, R. L., 4900
 Scheffer, G. L., 1475
 Schelling, M. E., 4075
 Schendel, D. J., 4020
 Schenker, T., 2840
 Scheper, R. J., 456, 1475
 Scheppeck, W., 3283
 Scheumann, G., 4987
 Schibler, M. J., 4701
 Schiff, P. B., 1388
 Schildberg, F. W., 1690
 Schiller, J. H., 1286
 Schilsky, R. L., 1293, 2304
 Schinkel, A., 310
 Schlachbach, L., 2810
 Schlager, J. J., 1338
 Schlaifer, D., 4850
 Schleicher, R., 3968
 Schlessinger, J., 3118, 4424

Schllichtholz, B., 5872
 Schlom, J., 600, 2154, 3355,
 3776, 4555
 Schlumberger, M., 5872
 Schlussel, R. N., 4971
 Schmid, F. A., 587
 Schmid, H., 3283
 Schmidt, E. E., 2736
 Schmidt, H., 5143
 Schmidt, L., 861
 Schmidt, W., 799
 Schmits, R., 4367
 Schmitt, E., 4134
 Schmocker, B. J., 271
 Schneiderman, M. H., 6017
 Schneller, H. E., 127
 Schofield, P. C., 3405
 Schomacker, K. T., 5954
 Schornagel, J. H., 5669
 Schreiber, G. J., 2560
 Schreiber, H., 840, 1978
 Schrijvers, A. H. G. J., 4383
 Schroeder, M. E., 968
 Schubiger, P. A., 5727
 Schuh, A. C., 615
 Schuhmann, A., 4189
 Schüller, H. M., 2498
 Schultz-Hector, S., 1444
 Schulz, K-D., 5439
 Schulze-Osthoff, K., 2623
 Schumaker, L. M., 3712
 Schuster, J. M., 2338
 Schuuring, E., 4148
 Schwab, M., 3327
 Schwade, J. G., 1091
 Schwander, J., 4680
 Schwartz, C. E., 2553
 Schwartz, D. R., 1461
 Schwartz, E. L., 1142, 3509
 Schwartz, M., 663, 668
 Schwartz, M. A., 1503
 Schwartz-Albiez, R., 1262
 Schwechheimer, K., 2386
 Schwonzen, M., 4367
 Schwy, W. E., 4582
 Scott, D. P., 1338
 Scott, L., 737
 Scott, R. E., 1338
 Sebers, S., 2081
 Sedlmayer, A., 1788
 Sedwick, W. D., 997
 Seed, T. M., 4518
 Seelen, C. M. J., 1642
 Seftor, E. A., 3411
 Seftor, R. E. B., 3411
 Segarini, P., 3386
 Seiki, M., 1397
 Seitz, G., 4035
 Sekhavat, M., 3139
 Sekido, Y., 1709
 Sekiguchi, K., 2005
 Sekiya, C., 5419
 Sela, M., 5251
 Seligman, P., 3968
 Sellers, T. A., 4230
 Selstam, G., 2309
 Selzer, M. G., 4493
 Senger, D. R., 2912, 4727
 Senter, P. D., 2123
 Seppo, A., 5600
 Sérée, E., 5121

Sergeev, I. N., 3935
 Serre, C-M., 4695
 Seruca, R., 5853
 Servidei, T., 304
 Seslar, S. P., 1233
 Setanoians, A., 523
 Sethi, T., 5208
 Setlow, R. B., 2249
 Setser, A., 4828
 Seung, S., 840
 Sexton, C. J., 5328
 Seyama, T., 2940
 Seynaeve, C. M., 2081
 Sgagias, M. K., 1538
 Shabahang, M., 3712
 Shaffer, D. W., 5929
 Shah, G., 38
 Shah, S. A., 1360
 Shani, A., 5962
 Shao, Z-M., 3226
 Shapiro, D. N., 5108, 5535
 Sharkey, F., 3369
 Sharkey, S. M., 4994
 Sharma, A., 5877
 Sharma, M., 2771
 Sharp, R., 4329
 Shaw, G. L., 5181
 Shaw, M. E., 1230
 Shay, J. W., 4772
 Shé, M. N., 944
 Shearer, M. H., 5734
 Sheehan, J., 4082
 Sheikh, M. S., 3226
 Shen, X., 968
 Shepherd, T. A., 3956
 Sher, E., 5566
 Sherman, J., 2410
 Sherman, M. P., 6067
 Sherr, C. J., 1986, 5535
 Sheth, A. R., 4855
 Sheu, J-C., 1653
 Shewach, D. S., 5219
 Shi, D., 5784
 Shi, F., 3986
 Shi, Y. E., 1409
 Shibagaki, I., 846
 Shields, P. G., 3486
 Shiku, H., 5395
 Shillitoe, E. J., 2189, 2330
 Shimada, H., 6051
 Shimada, S., 600
 Shimada, Y., 846
 Shimamoto, Y., 4004
 Shimazu, H., 1281
 Shimokata, K., 1, 1709
 Shimokawa, K., 5350
 Shimosato, Y., 5903
 Shimotsuma, M., 687
 Shin, D. M., 2874
 Shin, K-H., 4811
 Shiomi, T., 495
 Shiozaki, H., 1696, 3421
 Shipp, N. G., 550
 Shirahata, A., 3948
 Shiraishi, Y., 3427
 Shirakawa, F., 4643
 Shirasaka, T., 4004
 Shirasawa, H., 3179
 Shirasu, M., 687
 Shirasuna, K., 147
 Shively, J. E., 1612

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Shoup, T. M., 5867
 Shpitz, B., 271
 Shu, S., 1043, 4315
 Shu, W.-P., 4971
 Shubik, P., 6075
 Shultz, K. L., 1059, 3741
 Shultz, L. D., 3741
 Sica, D., 1380
 Siciliano, M., 3603
 Siddik, Z. H., 4567
 Siddiki, B., 884
 Sidman, C. L., 1665
 Sidransky, D., 2231, 4477, 5093,
 5620
 Siegal, G. P., 1906
 Siegall, C. B., 334
 Siegfried, J. M., 4349
 Siemens, H. J., 4268
 Siems, W. G., 5143
 Silber, J. R., 3416
 Silber, R., 5908
 Simi, B., 4182
 Simizu, B., 3179
 Simmons, A., 67
 Simons, J. W. I. M., 4797
 Singer, S., 810
 Singer, S., 5808
 Singh, G., 4994, 5452
 Sioussat, T. M., 2912
 Siracusa, L. D., 1498
 Sirica, A. E., 254
 Siriwardana, G., 3968
 Sirotnak, F. M., 587
 Sizemore, N., 4511
 Siziopikou, K. P., 3362
 Skinner, D. G., 4066
 Sklar, J., 4676
 Skoog, L., 3707, 4356
 Skrincosky, D. M., 2667
 Skroch-Angel, P., 4197
 Skunca, M., 2618
 Slamon, D. J., 4960
 Slaper, H., 53
 Slate, D. L., 4658
 Slawin, K., 4461
 Slayter, M. V., 1480
 Slobos, R. J., 4164
 Slichenmyer, W. J., 4164
 Sliwicki, M., 4960
 Slovak, M. L., 1475, 3221, 4866
 Sluiter, W., 2548
 Sly, L., 2287
 Smaaland, R., 3129
 Smedsrød, B., 658
 Smit, J. J. M., 1747
 Smith, A., 5727
 Smith, A. J., 1747
 Smith, C. D., 1343
 Smith, C. G., 4010
 Smith, G. J., 500
 Smith, G. K., 810
 Smith, I. E., 266
 Smith, J. A., 4627
 Smith, J. C., 5507
 Smith, J. M., 1480
 Smith, J. W., II, 2204
 Smith, K. J., 2728
 Smith, K. S., 1354
 Smith, L. S., 5929
 Smith, M. T., 1023
 Smith, S., 2231
 Smith, S. A., 1218
 Smith, S. G., 5697
 Smith, S. L., 3624
 Smith, T. J., 3276
 Smithers, D. A., 266
 Sninsky, J. J., 2472
 Snow, G. B., 3524, 4383
 Snyder, S. W., 766
 Snyderman, C., 5654
 Sobel, E., 3943
 Sobrero, A., 3677
 Sobrino-Simoes, M., 5494
 Soini, Y., 4817
 Solere, P., 3536
 Soloway, A. H., 3308
 Soma, H., 3427
 Somerville, J. E., 2123
 Sondak, V. K., 1043
 Sondel, P. M., 1286
 Song, C. W., 324, 1431, 1599,
 2076
 Sonnier, M., 235
 Soong, S.-j., 2816
 Sorensen, J. M., 4828
 Sothern, R. B., 3129
 Sotnik-Barkai, I., 1838, 5962
 Soule, H. D., 3394
 Soussi, T., 5872
 Soutter, A. D., 5297
 Sparano, J. A., 3509
 Sparkes, R. S., 212, 5083
 Sparks, R. L., 1770
 Spate, V., 795
 Speicher, D., 1450
 Spelsberg, F., 1590
 Spence, A., 5663
 Spengler, B. A., 4978
 Spicer, T. P., 6067
 Spillare, E. A., 1684
 Spirio, L., 5581
 Spitz, M. R., 2189
 Sporn, M. B., 1480, 4461
 Springer, B., 5439
 Spruck, C. H., III, 1162, 4066,
 5620
 Spyros, F., 5076
 Squartini, F., 2846
 Squires, S., 2012
 Sredni, B., 1838, 5962
 Srinivasan, R., 5361
 Srivastava, S., 1889, 4452
 Stables, J. N., 5328
 Stacewicz-Sapuntzakis, M., 3723
 Stack, M. S., 1998
 Stackhouse, T., 861
 Stafford, W. F., III, 4026
 Stahel, R. A., 2840
 Ståhlbom, P.-A., 2475
 Staib, L., 1113
 Stanbridge, E. J., 6011
 Stancovski, I., 5251
 Staniunas, R. J., 4048
 Stanley, J., 5613
 Stanners, C. P., 3817
 Stanton, P., 4161
 Stapleton, P., 2313
 Star, W. M., 2548
 Starling, J. J., 3956
 Starnes, H. F., Jr., 4010
 Stass, S. A., 4449
 Stastny, J. J., 5740
 Staubus, A. E., 3308
 Stearns, M. E., 878, 3073
 Steck, P. A., 2208, 5043
 Steeg, P. S., 1971
 Steele, C., 2330
 Steele, G. D., Jr., 1916, 4048
 Stefanski, S. A., 410
 Stegeman, J. J., 3700
 Stein, C. A., 2239
 Stein, G. S., 2399
 Stein, J. L., 2399
 Steinbach, G., 2745
 Steinberg, B. M., 910
 Steinberg, S. M., 67, 600, 4828,
 5181
 Steinbrueck, T., 2947
 Steiner, M. G., 681
 Steinmetz, K. A., 536, 4230
 Stelmack, G. L., 3530
 Stendahl, U., 2309
 Sterenborg, H. J. C. M., 53
 Sterling-Levis, K., 1222
 Stern, H. S., 271
 Stern, R., 5251
 Stetler-Stevenson, M., 2081
 Stetler-Stevenson, W. G., 2208,
 3159, 3411
 Steven, K., 1162, 5620
 Stevens, J. K., 5148
 Stevens, J. L., 4542
 Stevenson, D. K., 2700
 Stewart, A. J., 4156
 Stewart, B. W., 4287
 Stieglitz, K., 310
 Stöhrer, G., 4107
 Stolfi, R. L., 3518
 Stone, M. J., 1392
 Stoner, G., 1620
 Stoppacciaro, A., 5067
 Stopelli, M. P., 3198
 Storer, B., 1286
 Straubinger, R. M., 5877
 Strauss, E. E., 1770
 Strelein, J. W., 728
 Strife, A., 401
 Strutt, H. L., 2012
 Stuart, N. S. A., 5649
 Stubblefield, E., 5043
 Sturmans, F., 75, 4860
 Su, B., 1751
 Su, J. Q., 4456
 Su, L.-K., 2728
 Su, S. L., 3327
 Su, Z-Z., 1929
 Suarez, H., 1625
 Subbarao, V., 2790
 Suberville, A. M., 235
 Sublett, J. E., 5108
 Subrahmanyam, V. V., 1023
 Subramanian, R., 2368
 Subramanyam, B., 766
 Suchard, S. J., 378
 Suda, H., 490
 Sudo, K., 4262, 5233
 Suematsu, M., 2676
 Sugahara, H., 675
 Sugano, H., 953
 Suganuma, M., 239, 992, 1012,
 1982, 3462
 Sugawara, S., 6001
 Sugimachi, K., 1706, 2884, 5000
 Sugimoto, Y., 2538
 Sugimura, T., 1136, 2786
 Sugio, K., 5000
 Sugiura, M., 2484
 Sugiura, T., 147
 Sugiyama, H., 5589
 Sugiyama, T., 3795
 Sugiyama, T., 3899
 Suit, H. D., 5012, 5018
 Sulfarò, S., 5775
 Sumizawa, T., 5680
 Summerhayes, I. C., 5620
 Sundaresan, P., 3217
 Sundqvist, K.-G., 4376
 Sung, C., 2092, 3752
 Supko, J. G., 3062, 4843
 Surh, Y.-J., 1017
 Sussenbach, J. S., 5754
 Susumu, N., 3643
 Sutherland, R. L., 5940
 Sutherland, R. M., 2700
 Suttle, D. P., 1373
 Sutton, F., 2803
 Suyama, K., 5452
 Suyama, M., 1
 Suzui, M., 3908
 Suzuki, H., 1709
 Suzuki, M., 5528
 Svennerholm, L., 120
 Svensson, H. P., 2123
 Swenberg, J. A., 3895
 Switzer, B. R., 2750
 Symann, M. L., 3139
 Szallasi, Z., 2507
 Sze, L., 5244
 Szepesi, A., 3968
 Szinai, I., 1098
 Szwerdgold, B. S., 1751

T

Tada, A., 1906
 Tada, M., 2472
 Tada, S., 2676
 Taetle, R., 3386
 Taffe, B. G., 5377
 Taga, H., 5419
 Taga, S., 5314
 Taghian, A., 5012, 5018
 Taguchi, T., 4349
 Tahara, E., 4102
 Tahara, H., 1696, 3421
 Tai, M-S., 4026
 Tai, T., 5395
 Tainaka, K., 2326
 Takada, A., 354
 Takada, K., 4238
 Takagi, H., 4329
 Takagi, K., 1555
 Takahashi, H., 1612
 Takahashi, H., 1906
 Takahashi, H., 3179
 Takahashi, H., 5079
 Takahashi, M., 1709
 Takahashi, M., 2786
 Takahashi, M., 2830
 Takahashi, R., 3795
 Takahashi, S., 32
 Takahashi, S., 1702
 Takahashi, T., 1, 1709
 Takahashi, T., 1, 1709
 Takahashi, T., 687

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Takahashi, Y., 5350
 Takano, S., 464
 Takao, S., 1281
 Takashima, A., 4014
 Takatsuka, Y., 1696
 Takayama, H., 4329
 Takayama, S., 4701
 Takebe, H., 2944
 Takeda, K., 6001
 Takeda, R., 4218
 Takeda, Y., 3302
 Takeichi, M., 1696, 3421
 Takemoto, K., 4153
 Takeshima, Y., 4817
 Taketa, K., 2970, 5419
 Taketo, M., 5589
 Takeuchi, A., 1871
 Takeuchi, Y., 4218
 Takimoto, H., 106
 Takizawa, H., 4175
 Talpaz, M., 2118, 3289
 Tamai, S., 5038
 Tamargo, R. J., 329
 Tamatani, T., 1871
 Tamimi, Y., 5512
 Tamura, M., 2566
 Tanabe, M., 3179
 Tanaka, H., 32
 Tanaka, J., 5638
 Tanaka, K., 2566
 Tanaka, K., 5079
 Tanaka, S., 2884
 Tanaka, S., 4701, 4978
 Tanaka, T., 772, 2775, 3903,
 3908, 5350
 Tanda, S., 5528
 Tang, D. C., 4059
 Tang, H-Y., 5219
 Taniguchi, H., 687
 Taniguchi, N., 3207, 3899
 Tanikawa, K., 5419
 Tanimura, H., 1085
 Tanizawa, A., 4251
 Tanizawa, O., 1883
 Tannenbaum, S. R., 1017
 Taraboletti, G., 3812
 Tarone, R., 3694
 Tasimowicz-Alpini, A., 4652
 Taskinen, P. J., 4486
 Tateke, R. J., 4303
 Tateishi, M., 5000
 Taub, R., 3789
 Taupin, J.-L., 5610
 Taylor, A. M. R., 438
 Taylor, C. R., 3233
 Taylor, D. J., 5649
 Taylor, M. W., 3555
 Taylor, P. A., 4273
 Tedeschi, M., 544
 Teelmann, K., 2319
 Teh, S. J., 3700
 Teneriello, M. G., 3103
 Tennenbaum, T., 4803
 Tennent, B. J., 1059, 3741
 Tepper, R. I., 3125
 Terada, M., 1136
 Terada, N., 3968
 Terao, N., 4823
 Terasawa, M., 2051
 Terashima, Y., 1906
 Terheggen, P. M. A. B., 5669
 Termont, D. S. M. L., 248
 Tesch, H., 4310
 Testa, J. R., 3217, 4349, 4761
 Testa, U., 569, 1297
 Testi, A. M., 3800
 Tetenes, E., 1727
 Thakkar, N. S., 2057
 Thetter, O., 1027
 Theuer, C. P., 340
 Thiele, C. J., 926
 Thiessen, J. J., 4837
 Thijssen, J. H. H., 4563
 Thilly, W. G., 5808
 Thomas, D., 5365
 Thomas, D. C., 3270
 Thomas, P. E., 3276
 Thompson, A. M., 2947
 Thompson, C. H., 5649
 Thompson, E. A., 5447
 Thompson, E. W., 1416, 3229
 Thompson, T. C., 4461
 Thompson, W. D., 212, 5083
 Thomson, D., 3468
 Thorens, B., 4204
 Thorgeirsson, S. S., 1719
 Thorlacius, S., 1637
 Thorpe, P. E., 3000
 Thun, M. J., 1322
 Thusu, K., 5104
 Tibbels, S., 4619
 Tikhonov, Y. V., 5143
 Timmer, A., 5707
 Timmer-Bosscha, H., 5707
 Tishler, R. B., 2212
 Titani, K., 2005
 Titlestad, I., 5920
 Tiu, S. N., 170
 Tius, M. A., 3462
 Tjandra, N., 5386
 Tkeshelashvili, L. K., 4172
 Tlsty, T. D., 3098, 4946
 Tobe, T., 846
 Tobias, V., 1222
 Tobler, A., 921
 Toge, T., 5815
 Tognazzi, K., 4727
 Toguchida, J., 368, 846, 3795
 Toh, Y., 2884
 Tokino, K., 5093, 5620
 Tokino, T., 2231
 Tolleson, W. H., 905
 Tomassetti, A., 5791
 Tomasz, M., 5127
 Tomlinson, G., 4757
 Tomoda, Y., 2051
 Tong, A. W., 1392
 Tong, W. P., 3730
 Tong, Y., 1889
 Tong, Y. A., 4452
 Toniolo, A., 2957
 Toniolo, P., 460
 Topalian, S. L., 5
 Topham, J., 3919
 Torri, J. A., 873, 1409
 Torrisi, R., 4769
 Torti, F. M., 4010, 4658
 Torti, S. V., 4658
 Tortora, G., 868
 Tory, K., 861, 3118
 Toso, J. F., 1461
 Tosto, L. M., 6011
 Tounekti, O., 5462
 Toussaint, C., 3541, 4608
 Towle, M. J., 2553
 Tracey, P. A., 3771
 Trachtenberg, J., 1304
 Traganos, F., 3186, 4613, 5096
 Trail, P. A., 334
 Travis, W. D., 4817
 Trayzman, R. J., 1833
 Tréaniel, J., 5872
 Triadafilopoulos, G., 2374
 Trickett, A. E., 1222
 Triebel, F., 3569
 Tritarelli, E., 569
 Tritton, T. R., 5237
 Trogadis, J., 5148
 Troll, W., 4528
 Trucco, M., 4745
 Trump, B. F., 4817
 Trunet, P. F., 266
 Tsai, C-M., 1079
 Tsai, Y. C., 1162, 4066, 5620
 Tsao, S-W., 1489
 Tsao, Y-P., 5908
 Tsarfaty, I., 5355
 Tseng, H-J., 4691
 Tsiftsoglou, A. S., 1072
 Tsioulas, G. J., 2374
 Tsongalis, G. J., 3865
 Tsuoboi, C., 5382
 Tsuchida, Y., 5284
 Tsuchiya, M., 851
 Tsuchiya, M., 2676
 Tsuchiya, Y., 1397
 Tsujimoto, H., 687
 Tsujisaki, M., 4927
 Tsujiuchi, T., 5038
 Tsukada, Y., 4238
 Tsukaguchi, T., 2319
 Tsukahara, S., 2538
 Tsukamoto, T., 1709
 Tsukita, S., 3585
 Tsukui, T., 3257
 Tsuruo, T., 2538, 5022, 5475,
 5802
 Tsutsui, J-i., 1281
 Tsutsumi, M., 5038
 Tsuyama, N., 2940
 Tsuyuoka, K., 354
 Tu, C-P. D., 231
 Tuason, L., 1380
 Tubbs, R. R., 1380, 5613
 Tudor, E. G., 5954
 Tung, Y., 2796
 Turbide, C., 4938
 Turc-Carel, C., 3655
 Turchi, V., 2457
 Tursz, T., 5314
 Tuttle, T. M., 833
 Twardy, D. J., 3579
 Tyrrell, R. M., 4505

U

Überla, K., 714
 Uchida, E., 5289
 Uchiumi, T., 1085
 Uchiyama, A., 949
 Uckun, F. M., 447, 1431
 Udove, J. A., 4960
 Ueda, R., 1, 1709
 Uemura, D., 490

Ueno, M., 3046
 Uhlenbrück, G., 4367
 Ullmann, C. D., 600
 Ullrich, A., 4424, 5822
 Umbas, R., 3241, 5512
 Umezawa, K., 4896
 Untawale, S., 1630
 Unteregger, G., 4035
 Upadhyaya, P., 3719
 Upeslaci, J., 3336
 Urba, W. J., 2204
 Urban, J. L., 840
 Urmacher, C., 279
 Utterlinde, A. M., 4383

V

Vacca, A., 5067
 Vaden, S. L., 101
 Vähäkangas, K. H., 4817
 Vainio, H., 5643
 Valent, M., 2581
 Valentine, M., 5535
 Valinski, H., 3172
 Vallera, D. A., 4273
 Valteau-Couanet, D., 1534
 Valve, E. M., 5199
 Vambutas, A., 910
 van Acker, S. A. B. E., 4603
 Van Beneden, R. J., 2976
 Van Cong, N., 2888
 van de Loosdrecht, A. A., 4399
 van der Merbel-de Wit, L. E. A.,
 2548
 van den Berg, F. M., 4754
 van den Brandt, P. A., 75, 4860
 van den Broek, M., 2614
 van den Ent, F. M. I., 2399
 van der Leun, J. C., 53, 4212
 Van der Meer, R., 248, 784
 van der Poel, H. G., 5512
 van der Riet, E., 4477
 van der Valk, P., 1475
 Van Der Ven, L. T. M., 5754
 van der Vlijgh, W. J. F., 4603
 van der Wall, E., 4563
 Vande Woude, G. F., 5355
 van Dongen, G. A. M. S., 3524,
 4383
 Vanhaesebroeck, B., 2623
 Vanhamme, L., 615, 622
 van Heijningen, T. H. M., 1475
 van Kalken, C. K., 1475
 van Krieken, J. H. J. M., 4148
 Vánky, F., 2416
 van Laar, J. A. M., 1560
 Van Meir, E. G., 957, 5345
 van Muijen, G. N. P., 6061
 Van Rensburg, C. E. J., 318
 Van Roy, F., 2623
 van Solinge, W. W., 1823
 Van Staden, A. M., 318
 van Tellingen, O., 2061
 van't Veer, P., 75, 4860
 van Walsum, M., 3524, 4383
 van Weelden, H., 53
 van Wijnen, A. J., 2399
 van Zeeland, A. A., 1149, 1642
 Varban, M. L., 3172
 Varesco, L., 5581
 Varticovski, L., 3028
 Varvayanis, S., 3085

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Vassal, G., 1534
 Vaughan, A. T. M., 2300
 Vaysse, N., 1182
 Vecchio, G., 5523
 Végh, Z., 2416
 Veigh, M. L., 997
 Veissière, D., 2762
 Velasco, J. A., 4474
 Velicescu, M., 4138
 Vellucci, V. F., 899
 Vercellotti, G. M., 5308
 Vergely, C., 4595
 Vermorken, J. B., 456, 5413
 Verna, J.-M. G., 4715
 Veronesi, U., 6036
 Versantvoort, C. H. M., 1747
 Versnel, M. A., 388
 Vertino, P. M., 1684
 Vicentini, L. M., 5566
 Vichi, P. J., 5237
 Vidali, G., 741
 Viel, S., 3569
 Vierbuchen, M., 4367
 Vigneri, R., 3736
 Vihko, P., 1051
 Vile, R. G., 962, 3860
 Vincek, V., 728
 Vinci, J. M., 348
 Vindivich, D., 744
 Vinters, H. V., 170
 Vionnet, J. A., 242, 3694
 Vishwanatha, J. K., 6017
 Visser, G. W. M., 3524
 Vitetta, E. S., 1392
 Vitolo, D., 5654
 Vivier, E., 5610
 Vlamis, V., 3730
 Vlock, D. R., 5654
 Voest, E. E., 4603
 Vogan, K., 5269
 Vogel, C.-W., 592, 2368
 Vogelstein, B., 1986, 2231, 2728
 Vogelzang, N. J., 1293, 2304
 Vogt, P. K., 615
 Vokes, E., 3667
 Volant, A., 5745
 Vollmers, H. P., 4197
 Volovics, A., 75
 von Deimling, A., 3465
 von Eschenbach, A. C., 2852
 von Fliedner, V., 4310
 Von Hoff, D. D., 5929
 von Holst, H., 2475
 Voravud, N., 2874
 Vore, M., 5382
 Vreman, H. J., 2700
 Vrielinck, H., 1149
 Vuillequez, J. J., 393
 Vukanovic, J., 1833
 Vukosavljevic, T., 5775

W

Waalkes, M. P., 922
 Waber, P. G., 6028
 Wachter, H., 260
 Wacker, J., 1450
 Waddick, K., 1431
 Wadler, S., 3509
 Wagata, T., 846
 Wagner, B. A., 711
 Wagner, T., 4268

Waibel, R., 2840
 Wakeling, A. E., 3229
 Wakusawa, S., 1555
 Walbridge, S., 83, 3752
 Waldman, F., 2199
 Waldmann, T. A., 5683
 Walensky, L. D., 4720
 Walker, B. E., 1546
 Walker, S., 4837
 Wallace, D. M. A., 2300
 Wallace, L., 1727
 Wallace, M., 2947
 Wallace, P. K., 2358
 Wallace, R., 3336
 Walsh, J. H., 5208
 Walsh, P. C., 3869
 Walsh, T. E., 5181
 Walton, M. I., 1853
 Walz, T. M., 191
 Wan, M., 4138
 Wands, J. R., 3823
 Wang, B., 2272
 Wang, F.-S., 3677
 Wang, H. H., 2912
 Wang, J., 6006
 Wang, J. C., 3591, 4343
 Wang, J. M., 564
 Wang, L., 717
 Wang, L.-D., 1783
 Wang, M., 878, 3073
 Wang, P., 2416
 Wang, Q.-C., 4588
 Wang, R. C., 3314
 Wang, R. R. C., 4041
 Wang, S., 4452
 Wang, X., 1802
 Wang, Y., 1213
 Wang, Y., 1620
 Wang, Y., 2227
 Wang, Y., 5244
 Wang, Z., 2740
 Wang, Z., 3349, 4303
 Ward, J. M., 4329
 Wardlaw, S. A., 2965
 Warmoth, M. R., 1373
 Warren, R. C., 2937
 Wary, K. K., 1498
 Wasan, H., 5365
 Wasserman, R. A., 3591
 wasteson, A., 191
 Watabe, H., 5475
 Watanabe, H., 5297
 Watanabe, M., 1204, 3070
 Watanabe, T., 5244
 Waters, K., 810
 Waters, R., 1522
 Watson, G. J., 3000
 Watson, P., 5100
 Wattenberg, L. W., 5890
 Watts, P., 94
 Waugh, A. P. W., 609
 Waxman, D. J., 2490, 5629
 Waxman, J., 5365
 Waxman, S., 4109
 Wazer, D. E., 1952
 Weber, B. L., 627
 Weber, E., 2840
 Weber, G., 5982
 Weber, G. F., 5629
 Webster, L., 5004

Webster, M. K., 1808, 1816
 Wei, H., 1255
 Wei, M. X., 3125
 Wei, S.-J. C., 3294
 Wei, W., 1867
 Weichselbaum, R. R., 1978,
 3667, 5542
 Weidmann, E., 4745
 Weigel, R. J., 3472
 Weinberg, J., 4224
 Weinberg, J. B., 1939
 Weiner, A. K., 4803
 Weiner, L. M., 94, 3217, 4026
 Weisburger, J. H., 2422
 Weiss, C., 4268
 Weiss, G., 260
 Weiss, G. R., 5929
 Weiss, N. S., 2313
 Weiss, R., 5581
 Weitzman, S. A., 2644
 Weksler, B., 5483
 Welch, D. R., 5802
 Welch, W. R., 1489
 Wells, S. A., Jr., 2947
 Wellstein, A., 1409
 Welsch, C. W., 2272
 Welsh, J. A., 4817
 Wen, D., 5251
 Weng, C.-N., 4443
 Wennerberg, J., 2140
 Werelius, B., 4356
 Wernicke, D., 1102
 Wesley, O., 1286
 Westendorf, J. J., 5320
 Weston, A., 3486
 Westrick, L., 5176
 Weterman, M. A. J., 6061
 Whartenby, K. A., 5274
 Wheeler, R. H., 4555
 Whetton, A. D., 1735
 Whipple, J. A., 1761
 Whitaker, R. S., 1939
 Whitbread, J. A., 1142
 White, A. E., 3098, 4946
 White, E., 2313
 White, L., 1222
 White, R., 5581
 White, T., 5494
 Whiteside, T. L., 1461, 4745,
 5654, 5828
 Whitfield, D. M., 2906
 Whitlow, M., 3776
 Whitmore, W., 2987
 Whorton, A. R., 3765
 Whysong, D., 1853
 Wicek, D., 2762
 Wickstrom, E., 577
 Wiedemann, G. J., 4268
 Wielenga, V. J. M., 4754
 Wiels, J., 5314
 Wiener, J. R., 1939
 Wientjes, M. G., 3314
 Wiestler, O. D., 3465
 Wijnands, Y., 3611
 Wijnen, J., 2614
 Wikstrand, C. J., 120
 Wilander, E., 4550
 Wilbanks, G., 3362
 Wilder, R. B., 3022
 Wildrick, D. M., 1630
 Wilkinson, D. A., 4224

Willard, T. B., 1777
 Willemse, P. H. B., 5915
 Willey, J. C., 985
 Williams, A. T., 5328
 Williams, B. R. G., 2712
 Williams, D. E., 1565
 Williams, G., 5365
 Williams, G. M., 4534
 Williams, K. J., 2895
 Williams, S. S., 3964
 Williamson, M., 133
 Willis, S. M., 3723
 Willson, J. K. V., 1986
 Wilson, B. C., 4994
 Wilson, H. R., 810
 Wilson, P., 523
 Wilson, T., 3405
 Wiltrot, R. H., 5613
 Winawer, S. J., 279
 Winick, N. J., 2954
 Wink, D. A., 5845
 Winokur, T. S., 1480
 Winquist, R., 4486
 Winter, S. F., 3257
 Wiseman, R. W., 1218
 Wisniewski, D., 401
 Witt, P. L., 5176
 Witte, O. N., 485
 Wojcik, S. J., 3405
 Wolf, C., 165, 4096
 Wolf, G. T., 5113
 Wolf, J. K., 891
 Wolf, R. F., 5483
 Wolff, E. A., 2560
 Wong, A. J., 3217
 Wong, C.-Q., 3294
 Wong, G. Y., 2830
 Wong, J. M., 1916
 Wong, P. T. T., 762
 Wong, R. K. H., 3723
 Woo, A., 4900
 Wood, J. F., 3776
 Woodhouse, L. F., 5090
 Woodruff, L. S., 127
 Woods, V. L., Jr., 4890
 Woodworth, T., 3930
 Worland, P. J., 2081
 Wössmann, W., 4268
 Wright, M. A., 6006
 Wright, S. E., 4920
 Wu, C.-W., 2865
 Wu, G., 1724
 Wu, H.-C., 2852, 5300
 Wu, N. Z., 3765
 Wu, R., 2527
 Wu, S., 1939
 Wu, S., 5597
 Wu, S. V., 5208
 Wu, T.-C., 4720
 Wullich, B., 4035
 Wünsch, P. H., 5797
 Wyatt, J. I., 5090
 Wyllie, R., 3758
 Wynder, E. L., 2758
 Wynn, D. M., 5802

X

Xie, Y., 2906
 Xing, P.-X., 4082
 Xu, F., 1304

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 53

Xu, G-w., 1317
 Xu, Y-Y., 3823

Y

Yabkowitz, R., 378
 Yagi, H., 1273, 3294
 Yagi, T., 2944
 Yagita, M., 5600
 Yago, K., 5559
 Yagura, H., 675
 Yakushiji, M., 5225
 Yalowich, J. C., 3547
 Yamada, A., 490
 Yamada, H., 3795
 Yamada, K., 4238
 Yamada, M., 5284
 Yamada, T., 5759
 Yamada, Y., 1085
 Yamada, Y., 3459
 Yamagishi, M., 3046
 Yamaguchi, K., 2538
 Yamakawa, K., 1
 Yamamoto, K., 3427
 Yamamoto, K., 5284
 Yamamoto, M., 5172
 Yamamoto, S., 4218
 Yamamoto, T., 4262, 5233
 Yamamura, K., 423, 3459
 Yamanaka, Y., 2704, 4741, 5289
 Yamaoka, M., 4262, 5233
 Yamashiro, S., 5395
 Yamashita, J.-i., 464
 Yamashita, K., 2970
 Yamashita, N., 2786
 Yamashita, N., 4175
 Yamashita, S-i., 464
 Yamashita, U., 4102
 Yan, P. S., 641
 Yanagihara, K., 5815
 Yanagihara, R., 6067
 Yanagisawa, A., 953, 5087
 Yanase, T., 2566
 Yandell, D. W., 368, 846, 3465
 Yane, K., 4408
 Yang, A. S., 1162
 Yang, C. S., 1783, 3276
 Yang, D., 2020
 Yang, H., 112
 Yang, H-K., 3165
 Yang, J. C., 2358
 Yang, J-L., 2865
 Yang, L. Y., 1583

Yang, M. B., 329
 Yang, P., 4449
 Yang, S. Y., 4303
 Yang, Y-C., 3000
 Yanuck, M., 3257
 Yao, K-s., 3662
 Yao, M., 861
 Yarden, Y., 5251
 Yasui, A., 495
 Yasui, W., 4102
 Yasumura, S., 1461, 4745
 Yatsunami, J., 239, 992, 1012,
 1982
 Yazawa, K., 2786
 Ye, B. H., 2732
 Ye, J., 1255
 Ye, Y., 2712
 Yeh, G. C., 5977
 Yeh, Y., 3159
 Yen, A., 3085
 Yen, N., 1743
 Yeo, K-T., 2912
 Yeo, T-K., 2912
 Yeoh, G. C. T., 515
 Yeoman, L. C., 1630
 Yieh, L., 1409
 Yim, C-Y., 5507
 Yin, J., 1889
 Yokota, T., 3776
 Yokozaki, H., 868
 Yokozaki, H., 4102
 Yoneda, T., 354
 Yoneda, T., 737
 Yonehara, S., 2591
 Yonei, Y., 2676
 Yoo, J., 744
 Yoon, W-H., 1437
 Yorke, E. D., 2987
 Yoshiida, E., 490
 Yoshiida, M., 1328
 Yoshiida, O., 3795
 Yoshii, A., 3349, 4927
 Yoshikai, Y., 106
 Yoshikawa, T., 2326
 Yoshimi, N., 2775
 Yoshinari, T., 490
 Yoshioka, H., 147
 Yoshizawa, H., 1043
 Yoshizawa, S., 1012
 You, M., 1620
 You, W-c., 1317
 Youle, R. J., 2092, 3752

Young, C. W., 1226, 4109
 Young, M. R. I., 6006
 Yow, H., 1916
 Yu, C., 1332
 Yu, D., 891, 5784
 Yu, F., 5554
 Yu, J. S., 3125
 Yu, L., 4627
 Yu, M., 528
 Yu, M., 6031
 Yu, M. C., 1162, 4138
 Yu, M-W., 790
 Yu, Y. B., 6051
 Yuan, M., 884
 Yuan, S., 1304
 Yule, S. M., 3758
 Yun, C-H., 2028
 Yun, K., 5166
 Yung, W. K. A., 5043
 Yuspa, S. H., 992, 4803
 Yuzuki, D. H., 949

Z

Zadunaisky, J. A., 1255
 Zafferani, M., 3747
 Zaidi, S. I. A., 5897
 Zajchowski, D. A., 5004
 Zukut, R., 5
 Zalcman, G., 5872
 Zaman, G. J. R., 1747
 Zaman, M., 2379
 Zang, K. D., 4035
 Zangemeister-Wittke, U., 2840
 Zarrabi, M. H., 140
 Zasloff, M., 3052
 Zauli, G., 4481
 Zawadzki, V., 1516
 Zbar, B., 861, 3118
 Zea, A. H., 5613
 Zeff, R. A., 4303
 Zeiner, M., 3513
 Zeller, K-P., 5135
 Zelnick, C. R., 5251
 Zeng, X-r., 1317
 Zenita, K., 5559
 Zetter, B. R., 1971, 2661
 Zghal, M., 2944
 Zhai, Y-F., 2272
 Zhang, B-Q., 1392
 Zhang, H., 5714
 Zhang, H. B., 1128
 Zhang, K., 2950

Zhang, L., 1023
 Zhang, L., 1317
 Zhang, M. H., 5714
 Zhang, Q-H., 5528
 Zhang, Q-X., 5882
 Zhang, R., 2816, 5433
 Zhang, W., 4772
 Zhang, Y., 1743
 Zhang, Y., 2858
 Zhao, L., 1317
 Zhao, S., 1493
 Zhao, X-l., 2712
 Zhao, Y., 2901
 Zhao, Z., 1550
 Zhou, H. E., 5300
 Zhen, W., 2344
 Zheng, J., 4138
 Zheng, W., 795
 Zhirkovich, A., 460
 Zhou, H., 3817
 Zhou, W., 3925
 Zhou, X-J., 5121
 Zhou, Y., 2912
 Zhou, Z-l., 899
 Zhou-Pan, X-R., 5121
 Zhu, G-G., 5028
 Zia, F., 5214
 Zietman, A., 5012, 5018
 Zijlstra, J. G., 1064
 Zimbalist, E., 279
 Zimmer, S. G., 1516, 1929
 Zimmermann, A., 921
 Zimmermann, R., 3058
 Zimnicki, S. J., 2937
 Zindy, F., 235
 Zipf, T. F., 3289
 Zlatecki, R. A., 2466
 Zöller, M., 1262, 1516
 Zorbas, M. A., 1630
 Zordan-Nudo, T., 5994
 Zou, X., 3462
 Zou, Y., 3046
 Zou, Z-Q., 1889
 Zsebo, K. M., 1709
 Zucker, S., 140, 1195, 3154
 Zvibel, I., 652
 Zweig, S., 4138
 Zwelling, L. A., 1373
 Zwerger, T., 4035
 Zwiebel, J., 2168
 Zygmunt, A. I., 1770

* For title of article and coauthors, see listing in *Contents of Volume 53* beginning on page i at the end of this index issue.

SUBJECT INDEX

Volume 53

A

Abrin
entry of protein toxins
polarized epithelial cells, 1755

A121 cells
galactin-mediated adhesion
detection, cellular galactin-binding glycoproteins, 2667

A431 cells
xenografts
anti-epidermal growth factor receptor monoclonal antibody, cisplatin, 4637

Acetamide
alkylamides as inducers
human leukemia cell differentiation, structure-activity relationship, 766

2-Acetylaminofluorene
glucuronidation of carcinogen metabolites
complementary DNA-expressed uridine 5'-diphosphate glucuronosyltransferases, 1529
-induced lung and liver tumors
ras mutations, 1620

Acetylator
metabolic activation of *N*-hydroxy-2-aminoindole
colon cytosols, Syrian hamsters congenic at *NAT2* locus, 509

phenotype
ammonia dosing, Phase I study, 2304

Acetyldinaline
differential activity
leukemic cells and normal stem cells, rat leukemia, 3008

β 1,4-N-Acetylgalactosaminyltransferase
genetic and enzymatic basis
 G_{M2} and G_{D2} differential expression, human cancer cell lines, 5395

N-Acetylglucosaminyltransferase
III and V mRNA levels
hepatocarcinogenesis, LEC rats, 3899

N-Acetyltransferase
metabolic activation of *N*-hydroxy-2-aminoindole
colon cytosols, Syrian hamsters congenic at *NAT2* locus, 509

Acidification
intracellular
etoposide-induced apoptosis, HL-60 cells, 2349

Aclarubicin
aberrant functions
teniposide-resistant CEM cells, 5946

Acquired immunodeficiency syndrome
systemic expression of HIV-1 *tat* gene
endothelial proliferation, tumors of different histotypes, 5569

4'-(9-Acridinylamino)methanesulfon-m-aniside
topoisomerase II as a target
atypical multidrug resistance, small cell lung carcinoma cells, 1064

Acridonecarboxamide
derivative GF120918
reversal of multidrug resistance, 4595

Acrolein
modulation of rat hepatic cytochrome P450 2C11

cyclophosphamide, messenger RNA levels, 2490

Actin
E-cadherin-dependent cell-cell adhesion blockage of, stimulation of urokinase-type plasminogen activator expression, 3618

Adenocarcinoma
colonic
induction of TGF- α promoter activity and TGF- α secretion, TGF- β 1, 4041
local hyperthermia and SR 4233, enhanced radioimmunotherapy, 3022
neopterin and prognosis, 260
reduction of interstitial fluid pressure, dexamethasone, 4764

colonic and colorectal
gastrin gene expression, 2919

endometrial
p53 alterations, c-K-ras activation, 1883

gastric
poorly differentiated type, genetic instability in pancreatic cancer, 5087

gastrointestinal
5-fluorouracil and calcium leucovorin, *N*-(phosphonacetyl)-L-aspartate combination, 4828
vascular permeability factor, its receptors, 4727
“intestinal-type”
furan treatment, right/caudate liver lobes, 254

mammary
glucocorticoids, suppression of growth, 1808
isoglobotetraosylceramide, marker for highly metastatic cells, 2906
protective and curative potential of vaccination, IL-2 gene-transfected cells, 5067
spontaneous metastasis, serum and plasma M_r 92,000 progelatinase levels, 5802

ovarian
improved prediction of survival, immunocytochemistry and estrogen receptor, 5188

pancreatic
aberrant expression, type I fibroblast growth factor receptor, 4741
detection of *ras* gene mutations, pancreatic juice and peripheral blood, 2472

prostatic
metastatic potential, cell motility and glyceraldehyde-3-phosphate dehydrogenase expression, 1995
suppression of tumor growth, inhibin, 4855

Adenoma
chromosome 12 breakpoints
benign and malignant lipogenic tumors, 1670

rapid screening method
nonsense and frame-shift mutations, disease-causing *APC* alleles, 5581

sporadic
HLA class I antigens, histologically normal mucosa of colon, 2374

Adenomatous polyposis

familial
wild type and mutant *APC* gene products, 2728

Adenomatous polyposis
frequency of
strength of family history, epithelial cell proliferative compartment, 279

Adenosine monophosphate, cyclic
-dependent protein kinase
antisense oligodeoxynucleotide, depletion of $R1\alpha$ subunit, 868

growth factor-like properties
parathyroid hormone-related peptide, transfected rodent cell lines, 2980

Adenosine triphosphatase
 Ca^{2+} -transporting ATPase isoform 2
gene cloning, von Hippel-Lindau syndrome, 861

Adenosine triphosphate
inhibition of doxorubicin-induced apoptosis
2-deoxy-D-glucose, 2057
protein interaction of pRb110
 M_r 73,000 heat shock cognate protein, 1702

single-strand conformational polymorphism
 M_r 170,000 isozyme, DNA topoisomerase II, 1373

S-Adenosylhomocysteine hydrolase
inhibitor Z-4',5'-didehydro-5'-deoxy-5'-fluoroadenosine
suppression of proliferation, keratinocytes and squamous carcinoma cell lines, 6058

Adenovirus
E1A
counteraction of tumor suppression, *neu*-encoded oncoproteins, 5784
suppression of severe malignancy, *erbB/neu* in ovarian cancer cells, 891
wild-type type 5 transforming genes
transdominant suppressors of oncogenesis, transformed rat embryo fibroblast cells, 1929

Adhesion
E-cadherin expression and invasiveness esophageal cancer cell line, 3421

CEA-mediated
specificity, anti-CEA monoclonal antibodies, 3817

cell surface molecules
suppression of T-lymphoma cell apoptosis, monoclonal antibodies, 5022

galactin-mediated
detection, cellular galactin-binding glycoproteins, 2667

hepatocytes
integrin $\alpha_6\beta_4$, TA3/Ha mammary carcinoma cells, 3611

laminin peptides
malignant properties, melanoma, 423

Adhesion molecules
CD54/CD11a and CD58/CD2 differential expression, human melanoma cells, 3343

cellular recognition mechanisms, 2192

gap junction function and cancer, 3475

Adjuvants

carriers of immunogenicity in xenogeneic hosts
mouse anti-idiotypic monoclonal antibody MK2-23, 112
vaccinations with genetically engineered tumor cells
production of different cytokines, 714

Adozelesin
DNA alkylation
induction of CC-1065, *in vivo* mutagenesis, 5690
V79 cell resistance
multidrug resistance, 1354

Adrenal cortex
suramin
multiple potential mechanisms of action, 2239

Adriamycin
circumvention of multidrug resistance
direct binding to P-glycoprotein, thaliblastine, 2544
enhanced activity
W-77, human ovarian carcinoma cells, 2051
pharmacokinetic and pharmacodynamic advantages
pirarubicin, VX2 tumor model, 1550
protection from cytotoxicity
brefeldin A, L1210 cells, 5237
-resistant human tumor cells
M, 85,000 protein, complementary DNA, 2538
-resistant P388 leukemia
DNA topoisomerase II α gene rearrangement, 5885
temperature-sensitive liposomal hepatic artery, liver W256 carcinosarcoma, 3046

Aerodigestive tract
head and neck cancers and discordant *p53* gene mutations, 1676
neoplasms
chemoprevention strategies, 1469

Aflatoxin B₁
-DNA adducts
detection in human placenta and cord blood, 1278
-induced hepatic tumorigenesis
transient intervention, olitipraz, 3499
-induced rat hepatic hyperplastic nodules
no site-specific mutation, *p53* gene, 9
resistance
expression of aldo-keto reductase, 3887

Agaricus bisporus
lectin
reversible inhibition of proliferation, epithelial cell lines, 4627

Aging
formation of small-cell colonies
cultures, primary rat hepatocytes, 3145

AGM-1470: see TNP-470

AgSK1
carcinoma-associated antigen, 1122

Aldehyde reductase
expression of aldo-keto reductase
resistance to aflatoxin B₁, catalytic activity, 3887

Alkaline phosphatase
mechanism of protective effect
supplemental dietary calcium, cytolytic activity of fecal water, 248

Alkylamides
inducers of human leukemia cell differentiation
structure-activity relationship, 766

Alkylating agents
damage increased by folate deficiency
 γ -irradiation, Chinese hamster ovary cells, 5401
DNA damage induced by *N*-methyl-*N*-nitrosourea
fluorescence postlabeling assay, 2771

O⁶-Alkylguanine-DNA alkyltransferase
expression by transformed Chinese hamster ovary cell line
specificity, bischloroethylnitrosourea-induced mutation, 997
single amino acid change
inactivation by O⁶-benzylguanine, 4750

Alkyltransferase
repair of O⁶-methylguanine and O⁶-methylthymidine
1,2-dimethylhydrazine and O⁶-benzylguanine, rat liver, 3895

Allele
deletions in renal tumors
histopathological correlations, 5780
disease-causing *APC*
rapid screening method, nonsense and frame-shift mutations, 5581

Fv-1^b
lymphomagenesis, congenic mice, 3433

loss of heterozygosity
invasive low-grade and high-grade epithelial ovarian carcinoma, 4456

17p
loss in neural tumors, DNA hypermethylation, 2715

Allografts
renal
malignant transformation of cutaneous lesions, human papillomavirus, 5328

American Cancer Society
funding mechanisms for research, 2436s

American Cancer Society Research Workshop
cancer and nutrition, 2431s, 2432s

Group A report
cancer and nutrition, panel on human studies, 2449s

Group B report
cancer and nutrition, 2452s

Group C report
cancer and nutrition, cell and organ culture studies, 2455s

Amines
heterocyclic
cooked foods, possible human carcinogens, 2422

2-Amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline
intra- and interindividual variability
systemic exposure, cooked beef, 6075, 6076

Amino acids
glycine 363 change to cysteine
DNA topoisomerase I, camptothecin resistance, 4343
major CD44 proteins
different splice variants, metastatic rat tumor cell line, 1262

position 95
allelic variation in dihydrofolate reductase gene, antifolate resistance, 6031

single change
O⁶-alkylguanine-DNA alkyltransferase, inactivation by O⁶-benzylguanine, 4750

3-Amino-6-chloro-5-(1-homopiperidyl)-N-(diaminomethylene)-pyrazinecarboxamide
lowering of intracellular pH
increased thermosensitivity, tumor cells, 1599

3-Amino-1-hydroxypropylidene-1,1-bisphosphonate
-treated rats
increased growth rate and tumor burden, Walker 256 cells, 5452

2-Amino-3-methylimidazo[4,5-*f*]quinoline
inhibitory effect of *Bifidobacterium longum*
colon/mammary/liver carcinogenesis, 3914

2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]-pyridine
intra- and interindividual variability
systemic exposure, cooked beef, 6075, 6076

6-Aminonicotinamide
N-(phosphonacetyl)-L-aspartate and 6-methylmercaptopurine
potentiation, radiation, 3518

Aminopeptidase N
biochemical and functional characterization
human melanoma cells, 1450

Aminosugars
immunosuppressive
deacetylase activity, human tumor cells, 5600

Ammonia
intermediate biomarker of carcinogenesis
proliferation, human colonic mucosa, 3283

Ammonium trichloro(dioxyethylene-O'-O')tellurate: see AS101

Amonafide
dosing based on acetylator phenotype
Phase I study, 2304

Amphiregulin
epidermal growth factor receptor estrogen receptor expression and, primary breast cancer, 3597

Amphotericin B
modulation of cisplatin sensitivity
lung cancer cell lines, 3302

Amsacrine
drug resistance
temperature-sensitive topoisomerase II allele, 89

Androgen
induction of ovarian granulosa cell tumorigenesis
genetic susceptibility, SWXJ strains of mice, 1059
inhibition of cell proliferation
androgen receptor complementary DNA, PC-3 cells, 1304

ovaries from tumor-susceptible donors
granulosa cell tumorigenesis, genetically hypogonadal-immunodeficient

SUBJECT INDEX TO VOLUME 53

mice, 3741
 receptor status of neuroendocrine cells
 benign and malignant prostatic tissue, 1967
 -responsive Shionogi carcinoma cells
 growth, steroid hormones and opioid peptides, 4224

Androstenedione
 inhibition of *in vivo* conversion to estrone
 vorozole, healthy postmenopausal women, 4563

steroid production
 different parts, malignant and benign ovarian tumors, 2309

Anemia
 aplastic
 chronic radiation-induced alteration, hematopoietic repair, 4518

Angiogenesis
 antiangiogenic effects
 quinoline-3-carboxamide linomide, 1833
 inhibition by antiestrogens, 533

inhibitors
 heparin-steroid conjugates, antitumor activity, 3000
 inhibitor TNP-470
 inhibition of tumor growth, hormone-independent breast and prostate carcinoma, 5233
 inhibition of tumor growth and metastasis, rodent tumors, 4262
 tumor growth and metastasis, human cell lines, 2566

rat glioma model
 up-regulation of vascular endothelial growth factor, cognate receptors, 5822

relationship of endothelial cell proliferation
 tumor vascularity, human breast cancer, 4161

Angiotensin II
 induced hypertension
 tumor blood flow, interstitial fluid pressure, 2466
 mechanisms of change in tumor blood flow
 morphometry, 5528

Anion channels
 volume-regulated
 inwardly rectifying potassium channels, small cell lung cancer cells, 4156

Annamycin
in vitro cytotoxicity
 cellular pharmacology, DNA lesions, 1583

Annexin II
 expression
 regulation during mammalian cell cycle, 6017

Anthracycline
 apoptosis induced by antibiotics
 P388 parent and multidrug-resistant cells, 1845

Antibiotics
 anthracycline
 induction of apoptosis, P388 parent and multidrug-resistant cells, 1845
 antitumor

calicheamicins, monoclonal antibody conjugates, 3336

Antibodies
 bispecific
 cytolysis of leukemic B-cells, T-cells, 4310
 delivery of saporin, targeting via CD22 in B-cell lymphoma, 3015
 - β -lactamase conjugates
 site-specific prodrug activation, colon carcinoma xenograft models, 3956

Antibody-dependent cell-mediated cytotoxicity
 human carcinoma cells engineered with mAb genes
 self-reactive antibody expression, 3355

Anticancer drugs
 prevention of carcinogenicity
 metallothionein induction, 4767
 study of
 use of yeast, targeting of DNA topoisomerases, 3591

Antiestrogens
 inhibition of angiogenesis, 533
 steroid
 sensitivity to ICI 182,780, MCF7/LCC2 cells, 3229

Antifolates
 acquisition of resistance
 enhanced γ -glutamyl hydrolase activity, 2227
 inhibitors
 thymidylate and purine synthesis, WiDr colonic carcinoma cells, 5697

Antileukemic drugs
 biochemical consequences
 resistance to tiazofurin, K562 cells, 2344

Antineoplastic drugs
 mechanism of action
 anticancer drug-sensitive murine erythroleukemia clone, 1877

Antioxidants
 oxy radicals and cancer, 3207
 selenium status
 risk of lung cancer, 4860

Antisense oligodeoxynucleotide
 depletion of R10 subunit
 cyclic AMP-dependent protein kinase, growth inhibition in cancer cells, 868

Antisense oligonucleotides
 human papillomavirus type 18-specific transformed phenotype, human carcinoma cell lines, 2330

Antitumor agents
 induction of apoptosis
 susceptibility of HL-60 cells, cell cycle differences, 3186

Aorta
 endothelium-dependent relaxation
 photodynamic therapy, 2548

Apoptosis
 antiproliferative effects of isoflavones
 gastrointestinal tract, human cancer cell lines, 5815
 chemotherapy-induced
 specific proteolytic cleavage, poly(ADP-ribose) polymerase, 3976
 DNA strand breaks

terminal deoxynucleotidyl transferase, nick translation assays, 1945
 doxorubicin-induced
 inhibition by 2-deoxy-D-glucose, 2057
 effects of cisplatin on induction
 proliferating hepatoma cells, nonproliferating immature thymocytes, 2133
 etoposide-induced
 inhibition by bcl-2 protein, topoisomerase II-induced DNA strand breaks and their repair, 4251
 etoposide-induced cytotoxicity
 T-cell leukemic lines, 4287
 growth and
 transforming growth factor β 1, acute myelogenous leukemia, 3386
 induction by anthracycline antibiotics
 P388 parent and multidrug-resistant cells, 1845
 induction by anticancer drugs
 modulation by *bcl-2*, resistance to thymidylate stress, 3321
 induction by *N*-(4-hydroxy-phenyl)retinamide
 malignant hemopoietic cell lines, no response to retinoic acid, 6036
 induction by nitrogen mustard and camptothecin
 modulation by *bcl-2*, 1853
 induction in Burkitt's lymphoma cells
 Gb3/CD77 glycolipid antigen, 5314
 insight on biology of neuroectodermal tumors, 926
 loss of *p53*-associated G1 checkpoint
 cell survival after DNA damage, 4164
 -mimetic drug
 bleomycin, two types of cell death, 5462
 phospholipase activation
 photosensitized mouse lymphoma cells, 5897
 prevention by caffeine
 camptothecin or topotecan, HL-60 cells, 4613
 protection
 HIV-1 Tat protein, 4481
 retroviral wild-type *p53* expression vector
 penetration of human lung cancer spheroids, 4129
 suppression in hemopoietic cells
 activation, Abelson tyrosine kinase activity, 1735
 suppression of GRP78 induction
 elimination of resistance, cell-mediated cytotoxicity, 6001
 susceptibility of HL-60 cells
 cell cycle differences, induction by various antitumor agents, 3186
 T-lymphoma cell
 suppression, monoclonal antibodies against cell surface adhesion molecules, 5022

1- β -D-Arabinofuranosylcytosine
 prolongation of drug exposure
 encapsulation into DepoFoam, cerebrospinal fluid, 1596

Arachidonic acid
 growth signal
 murine P815 mastocytoma cells, 3405
 modulation of metabolism
 sensitivity of tumoricidal function,

SUBJECT INDEX TO VOLUME 53

macrophages, 3362

Arginine vasopressin
atrial natriuretic factor production and serum sodium, lung cancer cell lines, 67

Aromatase
inhibition of androstenedione conversion to estrone
vorazole, healthy postmenopausal women, 4563

inhibitor CGS 20267
Phase I study, postmenopausal advanced breast cancer, 266

Arotinoid
Ro 40-8757
all-trans- and 13-cis-retinoic acids, breast cancer, 2319

Aryl hydrocarbon responsiveness
aryl hydrocarbon receptor and, human ovarian carcinoma cell lines, 1802

AS101
protective role
combined with several cytotoxic drugs, mechanisms of action, 5962

protection of bone marrow stromal cells
toxic effects of cyclophosphamide, ASTA-Z 7557 and etoposide, 1838

A2780/S
cellular pharmacology
liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-platinum(II), 4913

Ascites
malignant
pathogenesis of formation, 2631

mice bearing human ovarian carcinoma xenografts
synthetic matrix metalloproteinase inhibitor, 2087

tumor and inflammatory effusions
vascular permeability factor, guinea pig and human, 2912

Ascorbate
free radicals
increased generation, L1210 cells exposed to edelfosine, 711

Ascorbic acid
oxy radicals and antioxidative responses in cancer, 3207

Aspirin
use
risk of fatal cancer, 1322, 6074

Assays
colorimetric *in situ* messenger RNA hybridization
epidermal growth factor receptor, colon carcinoma surgical specimens, 937

CYFRA 21-1
serum fragment of cytokeratin subunit 19, marker of lung cancer, 61

fluorescence postlabeling
DNA damage induced by N-methyl-N-nitrosourea, 2771

gel electrophoresis
quantification of hypoxic fraction, human breast cancer, 733

high-performance liquid chromatography plasma pharmacokinetics, vinblastine and N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate, 2061

histoculture drug-response
"patient-like" treatment model, pancreatic cancer, 3070

measurement in serum
polyclonal and monoclonal anti-taxol antibodies, 1388

presence of transforming genes
gonadal tumors, bivalve mollusk species, 2976

terminal deoxynucleotidyl transferase and nick translation
detection of DNA strand breaks, individual apoptotic cells, 1945

ASTA-Z 7557
toxic effects
protection of stromal cells, AS101, 1838

Astrocytoma
human
accumulation, wild type p53 protein, 3465

oligodendrocyte-associated genes
glioma and neuroblastoma, 170

transfection with glial fibrillary acidic protein complementary DNA expression, proliferation and tumorigenicity, 3624

Ataxia-telangiectasia
Fifth International Workshop, 438

gene in 64 families
premenopausal bilateral breast cancer, linkage analysis of DRD2, 5083

Atomic bomb survivors
in vitro irradiation
RET oncogene rearrangement, 2940

Atrial natriuretic factor
arginine vasopressin production and serum sodium, lung cancer cell lines, 67

Atrial natriuretic peptide
expression of functional receptors
human small cell lung cancer cell lines, 3165

Autoradiography
quantitative
spatial distribution of immunotoxins, solid tumors, 2092

urokinase receptor concentration, malignant and benign breast tumors, 3198

Azaserine
-induced preneoplastic lesions
cholecystokinin-A receptors, pancreas, 3925

Azoxymethane
carcinogenesis
chemopreventive effects of olipizaz, 2502

colon carcinogenesis
chemoprevention, organosulfur compounds, 3493

-induced biochemical changes
inhibitory effect, caffeic acid esters, 4182

B

B669
inhibition of cancer cell line proliferation phospholipase A₂-mediated mechanisms, 318

Bacillus Calmette-Guérin
vaccine

delayed-type hypersensitivity reactions, tumor-associated antigens, 456

Baculovirus
recombinants
expression, human carcinoembryonic antigen gene, 2154

BALB/3T3 cells
transformation
tumor necrosis factor as tumor promoter, 1982

Basement membrane
biochemical and functional characterization
aminopeptidase N, 1450

expression of thrombospondin and its receptors
normal, hyperplastic and neoplastic breast, 1421

BB-94
synthetic matrix metalloproteinase inhibitor
decreased tumor burden, mice bearing human ovarian carcinoma xeno-grafts, 2087

B-cells
cancer-defined epitopes
analysis of p53 antibodies, exposure on protein surface, 5872

control of HLA-DR antigen expression
γ-interferons, thyroid cells, 3943

immune response
polymorphic epithelial mucin, 2457

leukemic
cytology by T-cells, bispecific antibodies, 4310

Ly-1⁺ and IgH rearrangements
"normal" spleens and lymphomas, AKR/J and AKR Fv-1⁺ mice, 2147

production of growth-promoting factor wide target cell spectrum, THP-1 cells, 1871

bcl-2
modulation of apoptosis
induction by anticancer drugs, resistance to thymidine stress, 3321

BCL-2 protein
enhanced survival of mouse fibrosarcoma cells
tumor necrosis factor-mediated cytotoxicity, 1456

inhibition of etoposide-induced apoptosis topoisomerase II-induced DNA strand breaks, repair, 4251

Beef, cooked
intra- and interindividual variability systemic exposure, carcinogens, 6075, 6076

Benzene
phenolic metabolites and oxidative DNA damage, HL-60 cells and bone marrow, 1023

Benz(a)pyrene
glucuronidation of carcinogen metabolites
complementary DNA-expressed uridine 5'-diphosphate glucuronosyltransferases, 1529

Benz(a)pyrene diol-epoxide
DNA adduct in hepatocytes inactivation, plasmid reporter gene expression, 2279

Benz(b)thiophene-2-carboxamides

SUBJECT INDEX TO VOLUME 53

4-substituted
inhibition of urokinase, 2553

Benzol[c]phenanthrene dihydriodiol epoxides
stereoisomeric
sequence specificity, interaction with
supF gene, 1273

Benzophenoxazine
analogues
phototoxicity and pharmacokinetics,
EMT-6 cells, 2571

Benzoquinazoline
inhibitor 1843U89
biochemical and cellular pharmacology, 810

O⁶-Benzylguanine
1,2-dimethylhydrazine and
repair of O⁶-methylguanine and O⁴-
methylthymidine, rat liver, 3895
inactivation
single amino acid change, O⁶-alkyl-
guanine-DNA alkyltransferase, 4750
with or without streptozotocin
1,3-bis(2-chloroethyl)-1-nitrosourea
sensitivity, depletion of O⁶-methyl-
guanine DNA methyltransferase ac-
tivity, 4281

BIBW 22
bifunctional modulator on tumor cells
P-glycoprotein and nucleoside trans-
port, 1974

Bifidobacterium longum
inhibitory effect
induction by a food mutagen, colon/
mammary/liver carcinogenesis, 3914

Bile
glycoprotein
CEA-related gene, down-regulation in
malignant mouse tissues, 4938
differential regulation of carcinogen-
embryonic antigen, γ -interferon, 1612

Biochanin A
antiproliferative effects of isoflavones
gastrointestinal tract, human cancer
cell lines, 5815

Biochemistry
derivation of etiology from human-based
studies, 2437s

2,2'-Bipyridyl-6-carbothioamide
ferrous complex and
antitumor activity, inhibition of ribo-
nucleotide reductase R2 subunit, 19

Bis-aceto-ammine-dichloro-cyclohexylamine
platinum(IV)
preclinical antitumor evaluation, 2581

Bischloroethylnitrosourea
-induced mutation in Chinese hamster
ovary cells
O⁶-alkylguanine-DNA alkyltransferase
expression, 997

1,3-Bis(2-chloroethyl)-1-nitrosourea
resistance
contribution of glutathione transferase
M3-3, non-small cell lung cancer
cell line, 4257

sensitivity
depletion of O⁶-methylguanine DNA
methyltransferase activity, O⁶-ben-
zylguanine with or without strepto-
zotocin, 4281

Bis-diol-epoxide
metabolic activation of dibenz[a,h]an-
thracene

DNA-binding species, mouse skin, 944

**1,19-Bis(ethylamino)-5,10,15-triazanonade-
cane**
interaction with DNA and effect on
growth
human brain tumor cell lines, 3948

N¹,N²-Bis(ethyl)nor spermine
antitumor activity
human melanoma xenografts, possible
correlates of drug action, 581

N¹,N²-Bis(ethyl)spermine
growth inhibition
hormone-responsive and -resistant hu-
man breast cancer, 2071

Bismuth
-DOTA-conjugated anti-Tac antibody
 α -emitter therapy, 5683

cis-Bis-neodecanoato-trans-R,R-1,2-diamino-
cyclohexaneplatinum(II)
liposomal
cellular pharmacology, A2780/S and
A2780/PDD cells, 4913

Bisphosphonate
-treated rats
increased growth rate and tumor bur-
den, Walker 256 cells, 5452

Bladder
human
penetration of mitomycin C, 3314
urothelial cells
influence on cellular processes, altered
extracellular matrices, 4971

Bladder neoplasms
distinct pattern of p53 mutations
relationship to tobacco usage, 1162
heterogeneity
erbB-2 gene amplification, 2199
infrequency of H-ras mutation, 133
microsatellite instability, 5620
modulation of cisplatin nephrotoxicity
and drug resistance
control of metallothionein synthesis,
1829
poor survival
decreased E-cadherin immunoreactiv-
ity, 3241

preliminary mapping
deleted region of chromosome 9, 1230
role of chromosome 9, 4066

suppressor loci
human chromosome 9, 5093
tumor grade and invasion
levels of matrix metalloproteases,
5365

Blasts
primary clonogenic
radiation damage repair capacity,
acute lymphoblastic leukemia, 1431

Bleomycin
apoptosis-mimetic drug
two types of cell death, number of
molecules internalized, 5462

iodeoxyuridine and
Phase I clinical and pharmacological
study, advanced cancer, 1293

Blood
cord
detection, aflatoxin B₁-DNA adducts,
1278

Blood flow
heat-induced changes
influence of vascular thermotolerance,

cell survival in tumors, 2076
reduction in tumors
high-energy shock waves, 1590

tumor
microvascular mechanisms, morphom-
etry, 5528

Blood group A antigen
incompatible histo-
biosynthetic basis, gastric cancer tissue
of type O individuals, 5494

Bloom's syndrome
elevated production of active oxygen,
5104

malignantly transformed cells
mucinous ovarian cancer antigen,
3427

Bone
biological response
1,25-dihydroxyvitamin D₃ and two an-
alogues, 3935

metastasis
parathyroid hormone-like protein gene
expression, breast cancer, 5076

Bone marrow
chronic myelogenous leukemia
lineage-negative blast subpopulations,
c-kit ligand, 401

detection of *AML1/ETO* fusion tran-
script
t(8;21) masked translocation, acute
myelogenous leukemia, 4449

eradication of small cell lung cancer cells
immunotoxins, 3784

irradiated human
effect of stem cell factor, 3857

micrometastasis
immunocytochemical detection, operable
non-small cell lung cancer, 1027

oxidative DNA damage
benzene and phenolic metabolites,
1023

protection of stromal cells from toxic ef-
fects
AS101, 1838

removal of breast cancer cells
in vitro purging, ether lipids and cry-
opreservation, 3747

sequential impact on enzymic program
tiazofurin and ribavarin, 5982

transplantation
acceleration of granulocyte recovery,
G-CSF and metastatic breast cancer,
5424

transplantation and Phase I trial
carboplatin/etoposide/cyclophosphpha-
mide, refractory germ cell tumors,
3730

Boron neutron capture theory
intracerebral melanoma
boronophenylalanine as a capture
agent, 3308

Bovine serum albumin
-doxorubicin conjugate
multidrug resistance, rat hepatoma,
4238

Brain
drug delivery
controlled release polymers, interstitial
chemotherapy, 329

elevated levels
M, 92,000 type IV collagenases, 2208

experimental cerebral metastases

SUBJECT INDEX TO VOLUME 53

murine melanoma B16, protection with active immunization, 1113

fatal rat cells
migratory pattern, human glioma cells in adult rat brain, 5158

metastases
metastasis-related CD44 expression, not in glioblastomas, 5345

NCr/Sed-*nu/nu* nude and scid mice
transplantability, human and murine tumors, 5018

Brain neoplasms
associated cyst fluids
immunodetection, endogenous opioid peptides, 4715
characterization of insulin-like growth factor 1, 2475
disseminated tumor growth
quantitative analysis, *lacZ* reporter gene, 176
interaction of polyamine analogue and DNA, 3948

O⁶-methylguanine-DNA methyltransferase activity, 3416

pediatric
efficacy, transferrin receptor-targeted immunotoxins, 1348

retroviral-mediated gene transfer, 83

Breast
epithelial cells
protein tyrosine phosphatases, *neu* transformation, 2272

fibroadenoma and phyllodes tumor
clonal analysis, 4071

normal/hyperplastic/neoplastic expression, thrombospondin and its receptor, 1421

Breast neoplasms
advanced
cyclophosphamide/doxorubicin/5-fluorouracil, plus interferon- α 2b, 3509
postmenopausal patients, Phase I study of CGS 20267, 266
-associated mucin fusion protein *Escherichia coli*, tumor-specific epitope, 4920

breast/ovarian cancer locus
deletion unit on chromosome 17q, epithelial ovarian tumors, 1218

chemotherapy and bone marrow transplantation
acceleration of granulocyte recovery, granulocyte colony-stimulating factor, 5424

detailed deletion mapping
chromosome 17q, 3382

ductal carcinoma *in situ*
allelic loss, chromosome 17, 2947

estradiol induction
retinoic acid receptors, 5841

estrogen-negative cell line
constitutively active estrogen receptor variant, 5934

estrogen receptor expression
amphiregulin, epidermal growth factor receptor, 3597

estrogen-responsive
estrogen receptor variant messenger RNA lacking exon 4, 741

exon 5 deletion variant of estrogen receptor

coexpression, wild-type estrogen receptor, 5882

expression of E-cadherin cell adhesion molecules
relationship to metastasis, 1696

favorable prognosis
cell surface antigen LEA.135, 3233

growth and drug resistance
small heat shock protein hsp27, 4443

growth and lung metastasis
diets containing different linoleic acid levels, 4686

growth suppression of MCF-7 cells 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 3149

high proliferative capacity
c-myc amplification, 1956

hormone-dependent
matrix-degrading enzyme protease, 1409

hormone-responsive and -resistant
growth inhibition, *N¹,N¹²*-bis(ethyl) spermine, 2071

human primary
distinct regions, 1p deletion, 1990

increase in *M*, 92,000 type IV collagenase
plasma, 140

induction of *jun* gene family members not 17 β -estradiol, 291

inhibition of estrone sulfatase activity
estrone-3-methylthiophosphonate, 298

lowering of plasma insulin-like growth factor I levels
fenretinide, 4769

low risk
insulin-like growth factor-I, 3736

malignant and benign
urokinase receptor concentration, quantitative autoradiography, 3198

MCF7/LCC2 cells
sensitivity to ICI 182,780, 3229

multidrug-resistant
flavonol-stimulated efflux, 7,12-dimethylbenzanthracene, 5977

node-negative
HER-2/*neu* expression, 4960

normal cells and
nuclear matrix proteins, 3394

normal luminal mammary epithelial cells and
differential isolation, primary and metastatic sites, 627

parathyroid hormone-like protein gene expression
PCR analysis, 5076

peritumoral tissues and
main drug-metabolizing enzyme systems, 3541

postmenopausal
risk of, dietary fat, 75

premenopausal bilateral
linkage analysis of *DRD2*, ataxia-telangiectasia gene, 5083

linkage analysis of D17S74, thirty-five families, 212

production of immunoreactive endothelin 1
stimulation by interleukin 6, 464

putative tumor marker, 1751

quantification of hypoxic fraction
gel electrophoresis, individual cells,

733

refinement of regional loss of heterozygosity
chromosome 11p15.5, 4486

relationship of endothelial cell proliferation
tumor vascularity, 4161

removal of cells from bone marrow
in vitro purging, ether lipids and cryopreservation, 3747

role of cathepsin D in invasiveness, 873

suramin
multiple potential mechanisms of action, 2239

therapeutic effects
Ro 40-8757, all-trans- and 13-cis-retinoic acids, 2319

Brefeldin A
protection from Adriamycin cytotoxicity L1210 cells, 5237

Bromodeoxyuridine
labeling and flow cytometry
tamoxifen-induced increase in doubling time, MCF-7 xenografts, 4413

Bronchial epithelial cells
altered chromosomal methylation patterns
oncogene-induced transformation, 1684

immortalized human
biological consequences of overexpression, *c-erbB-2* gene, 2035
simian virus 40-immortalized development of tumorigenicity, 985

Bronchial neoplasia
early
p53 protein accumulation, 4817

BR96 sFV-PE40
selective killing of carcinoma cells, 334

Bryostatin 1
in vivo administration
platelet and neutrophil activation, modulation of protein kinase C activity, 2810

T-cell-induced tumor regression
 γ -interferon, 833

Buccal cells
cancer patients
carboplatin and cisplatin chemotherapy, drug-induced DNA modification, 5669

Busulfan
high-dose
chronopharmacology, children, 1534

Butanol
extraction and nuclelease P1 versions of ³²P postlabeling
tobacco smoking, DNA adducts in human oral tissue, 1522

Buthionine sulfoximine
variable baseline γ -glutamylcysteine synthetase mRNA expression
peripheral mononuclear cells, 3662

L-Buthionine sulfoximine
glutathione depletion
antagonism, taxol cytotoxicity, 2066

Butylated hydroxyanisole
3-methoxycatechol or
sodium nitrite and catechol, rat multigorgan carcinogenesis model, 32

styrene 7,8-oxide and
induction of cell proliferation, fore-

SUBJECT INDEX TO VOLUME 53

stomach, 3505
Butyrate
 intermediate marker of carcinogenesis
 proliferation, human colonic mucosa, 3283
BW12C79
 left-shifting agent
 mitomycin C and, skeletal muscle metabolism and magnetic resonance spectroscopy, 5649
Bystander effect
 tumor regression
 fraction of tumor mass genetically modified, 5274
C
CA 19-9
 urokinase-type plasminogen activator antigen
 clinical value of determination, colorectal cancer, 1788
Caco-2 cells
 insertion of human Ha-ras or polyoma virus middle T oncogenes
 increased protein kinase C α expression, 2762
E-Cadherin
 cell adhesion molecules
 expression in breast cancer tissues, relationship to metastasis, 1696
 correlation of expression with invasiveness
 esophageal cancer cell line, 3421
 decreased immunoreactivity
 poor survival, bladder tumors, 3241
 -dependent cell-cell adhesion
 blockage of, stimulation of urokinase-type plasminogen activator expression, 3618
 differentiation marker
 thyroid malignancies, 4987
 expression in primary and metastatic gastric cancer
 down-regulation, cellular dedifferentiation, 1690
 reduction of levels
 deletion of α -catenin gene, prostate cancer cells, 3585
Caffeic acid esters
 inhibitory effect
 azoxymethane-induced biochemical changes, aberrant crypt foci, 4182
Caffeic acid phenethyl ester
 induction of tumor promoter-mediated processes
 mouse skin, bovine lens, 1255
Caffeine
 induction by hyperthermia and hot mate infusion
 mutagenicity, *Saccharomyces cerevisiae*, 5750
 prevention of apoptosis and cell cycle effects
 camptothecin or topotecan, HL-60 cells, 4613
 release of radiation-induced S and G₂ phase arrest
 histone messenger RNA levels, V79 cells, 1507
Calcitriol
 TPA-induced tumorigenic transformation

osteopontin expression, mouse JB6 epidermal cells, 2217
Calcin
 control of HLA-DR antigen expression
 γ -interferons, thyroid cells, 3943
 dietary
 antiproliferative effect, colonic epithelium, 784
 mechanism of protective effect, cytolytic activity of fecal water, 248
 inhibition of multidrug resistance by NA-382, 1555
 intermediate biomarker of carcinogenesis proliferation, human colonic mucosa, 3283
 mobilization and clonal growth CCK_A and CCK_B, small cell lung cancer lines, 5208
 reversal of hypercalcemia
 neutralizing antibodies to interleukin 6, human squamous carcinoma, 737
 -transporting ATPase isoform 2 gene cloning, von Hippel-Lindau syndrome, 861
Calcium leucovorin
 5-fluorouracil and
 N-(phosphonacetyl)-L-aspartate combination, metastatic gastrointestinal adenocarcinoma, 4828
Calcyclin
 expression in melanocytic lesions, 6061
Calicheamicins
 preparation and characterization monoclonal antibody conjugates, 3336
Calmodulin
 control of HLA-DR antigen expression
 γ -interferons, thyroid cells, 3943
Camptothecin
 9-amino and 10,11-methylenedioxy derivatives
 pharmacokinetics, mice, 3062
 hypersensitivity of Cockayne's cells double strand breaks, nascent DNA, 2012
 induction of apoptosis and cell cycle effects
 caffeine, HL-60 cells, 4613
 modulation by *bcl-2*, 1853
 resistance from a single mutation glycine in DNA topoisomerase I to cysteine, 4343
Cancer
 -associated mucin epitope
 clinical evaluation, M43, 2803
 derivation of etiology from human-based studies, 2437s
 diet and nutrition
 development of hypotheses, evaluation in animal studies, 2442s
 elevated expression
 human mitochondrial hinge protein gene, 2460
 nutrition and
 American Cancer Society Research Workshop, 2431s, 2432s
 cell and organ culture studies, American Cancer Society Research Workshop, 2455s
 panel on animal studies, American Cancer Society Research Workshop, 2452s
 panel on human studies, American

Cancer Society Research Workshop, 2449s
problem
 prevention, therapy and basic science, 5890
Canventol
 inhibition of tumor promotion in CD-1 mouse skin
 inhibition of tumor necrosis factor α release, protein isoprenylation, 3462
Carbohydrate
 diet restrictions
 inhibition, skin tumor promotion, 27
 incompatible histocompatibility group A antigen expression
 biosynthetic basis, gastric cancer tissue of type O individuals, 5494
Carbohydrate antigens
 blood group Le^b
 subcellular localization, endometrial cancer cells, 3643
 sialyl Lewis A and X
 adhesion of human cancer cells, vascular epithelium, 354
Carbonic anhydrase
 -like domain of *Ptpgr* gene
 homozygous deletion, murine L-cells, 1498
Carboplatin
 cisplatin and
 drug-induced DNA modification, buccal cells of cancer patients, 5669
 etoposide and cyclophosphamide Phase I trial with autologous bone marrow transplantation, refractory germ cell tumors, 3730
1-Carboxymethyl-2-iminoimidazolidine
 inhibition of growth
 broad spectrum of cancer cells, solid tumors, 3172
Carcinoembryonic antigen
 biliary glycoprotein and differential regulation, γ -interferon, 1612
 gene expression
 baculovirus recombinants, 2154
 improved radioimmunotherapeutic efficacy
¹³¹I-CC49 and γ -interferon, 600
 monoclonal antibodies specificity, CEA-mediated adhesion, 3817
 -related gene
 biliary glycoprotein, down-regulation in malignant mouse tissues, 4938
 site-specific prodrug activation antibody- β -lactamase conjugates, colon carcinoma xenograft models, 3956
 urokinase-type plasminogen activator antigen
 clinical value of determination, colorectal cancer, 1788
Carcinogenesis
 accumulation of p53 protein
 human esophageal precancerous lesions, 1783
 colonic
 chemoprevention, organosulfur compounds, 3493
 chemoprevention, protocatechuic acid, 3908

SUBJECT INDEX TO VOLUME 53

colon/mammary/liver
inhibitory effect of *Bifidobacterium longum*, food mutagen, 3914

7,12-dimethylbenzanthracene
flavonol-stimulated efflux, multidrug-resistant breast cancer cells, 5977

early markers in head and neck cancer
transforming growth factor α , epidermal growth factor receptor messenger RNA, 3579

environmental
prevention of, head and neck cancer, 2189

expression of sulfated glycoprotein 2
induction by *N*-nitroso-*N*-methylurea, prostate and seminal vesicle, 1480

familial breast/ovarian cancer locus
deletion unit on chromosome 17q, epithelial ovarian tumors, 1218

fidelity of DNA replication
extracts, normal and malignant transformed human cells, 3270

genetic predisposition
transplacentally induced renal cell carcinoma, Eker rat, 5856

induction by azoxymethane
chemopreventive effects of olitipraz, 2502

liver
chromosome mapping, murine susceptibility loci, 209

modification of
identification and characterization of agents, cell and organ cultures, 2446s

mutated p53
tumor-distant epithelia, squamous cell carcinoma, 4189

nickel
induction of signature mutation, oxygen free radical damage, 4172

oral
chemoprevention with DL- α -difluoromethylornithine, tongue neoplasms, 772

HPV-16, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, 4811

oxy radicals and antioxidant responses in cancer, 3207

pancreatic
caloric restriction and intervention, 46

possible roles of metallothionein, 922

proliferation of human colonic mucosa intermediate biomarker, 3283

rat multiorgan model
sodium nitrite and catechol, 3-methoxycatechol or butylated hydroxyanisole, 32

reduction in formation and growth 1,2-dimethylhydrazine-induced aberrant crypt foci, 2786

skin
malignant progression, suprabasal expression of α 6 β 4 integrin, 4803

studying clonal heterogeneity in human cancers, 921

tamoxifen
Alderley Park Wistar-derived rats, 3919

tobacco
dietary fat, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanolone, 2758

UV-sensitive Chinese hamster ovary mutant cell line
identification of cellular defect, 495

Carcinogenicity
induction of renal carcinoma by phenacetin
hydronephrosis-bearing rats of SD/cShi strain, 4218

4-nitroquinoline-*N*-oxide
potent intracellular oxidative stress, 3250

prevention
anticancer drugs, metallothionein induction, 4767

transplacental
cisplatin, SENCAR mice, 3874

Carcinogens
chemical
different susceptibilities, cell lines from *grc* congenic rat strains, 4089

chemo干预 strategies
A/J mouse lung as a model, 410

chromatophromas and chromatophore hyperplasia
Pacific rockfish, 1761

clarification
scientific evidence and speculation, 4107

clonal analysis of multiple transformed phenotypes
tumorigenicity, 10T½ cells, 500

cooked beef
intra- and interindividual variability, systemic exposure, 6075, 6076

glucuronidation of metabolites
complementary DNA-expressed uridine 5'-diphosphate glucuronosyltransferases, 1529

heterocyclic amines in cooked foods, 2422

initiation of pancreatic cancer
DNA damage, repair and cell proliferation, 2790

*-*metabolizing enzyme systems
non-small cell lung cancer, peritoneal tissues, 4608

6-nitrochrysene
induction of mammary cancer, 3719

phenobarbital/3-methylcholanthrene/dithiolethiones
glutathione *S*-transferase class α transcripts, hepatocytes, 231

potentiation of genetic damage
folate deficiency, Chinese hamster ovary cells, 5401

transformation of Syrian hamster embryo fibroblasts
amplification potential, 3098

Carcinoid neoplasms
pulmonary
infrequent mutations, *p53* gene, 5797

Carcinoma
adenoid cystic cells
extracellular matrix production and degradation, plasminogen activator, 147

*-*associated antigen AgSK1, 1122

inhibition of skin tumor promotion
restriction, fat and carbohydrate calories, 27

motility
response to thrombospondin, met-

astatic potential, 378

neuroendocrine
stable expression of peripherin, 1175

rapid screening method
nonsense and frame-shift mutations, disease-causing *APC* alleles, 5581

selective cell killing
BR96 sFV-PE40, 334

Wilms' tumor and heparin-binding growth/differentiation factors, 1281

Carcinoma, breast
antibody response
c-erbB-2 oncoprotein, 5864

antitumor effect of 22-oxa-calcitriol synergism with tamoxifen, 2534

cell cycle arrest and growth inhibition UCN-01, 2081

cytosolic extracts
urokinase-type plasminogen activator, PAI-1, 2513

differential expression
p53-binding protein *MDM2* gene, 3226

ductal
receptor for urokinase, tumor-associated macrophages, 1911

estrogen receptor-negative
transcriptional control, estrogen receptor, 3472

expression of thrombospondin and its receptors, 1421

familial
deletions in chromosome 16, development of distant metastases, 3707

loss of heterozygosity, 4356

favorable prognosis
cell surface antigen LEA, 135, 3233

hormone-independent
inhibition of tumor growth, angiogenesis, 5233

human chromosome 14q32 expression
interferon- α -inducible gene, 4096

inhibition of cellular growth
O-phospho-L-tyrosine, activation of protein tyrosine phosphatases, 557

invasive
p53 mutations, histological type, 4665

metastatic
allelotyping and clonal analysis, limited genetic heterogeneity, 3804

primary
frequent deletion, three regions on chromosome 17q, 5617

regression
9-nitrocAMP-treated immunodeficient mice, 1577

regulation of fibroblast hepatocyte growth factor/scatter factor peptide growth factors, 1233

somatic *p53* mutations
Icelandic population, 1637

urokinase receptor concentration quantitative autoradiography, 3198

Carcinoma, colonic
antitumor activity
5-fluoro-2'-deoxyuridine \pm *N*-phosphonoacetyl-L-aspartate, 1560

*-*associated increase
mucin-bound sialyl-Lewis^x expression, altered glycosylation of MUC-1 protein core, 4082

SUBJECT INDEX TO VOLUME 53

-associated mucins
epitope on α 3/4-monofucosylated polylactosaminoglycans, monoclonal antibody FW6, 4367

cell line differentiation and growth inhibition
1,25-dihydroxyvitamin D₃ receptor as a marker, 3712

discrimination of MUC1 mucins
other sialyl-Le^a-carrying glycoproteins, monoclonal antibody, 755

locus of interaction
5-fluorouracil, leucovorin and interferon- α 2a, 4243

neopterin and prognosis, 260

paraffin-embedded surgical specimens
colorimetric *in situ* messenger RNA hybridization, epidermal growth factor receptor, 937

sensitivity of human cells
mild hyperthermia, 2740

WiDr cells
cytotoxicity of antifolate inhibitors, thymidylate and purine synthesis, 5697

xenograft models
site-specific prodrug activation, antibody- β -lactamase conjugates, 3956

Carcinoma, colorectal
antitumor activity of 5-fluorocytosine
expression of cytosine deaminase, 4619

cyclin gene amplification, 1986

early growth response gene
ubiquitin-ribosomal protein S27a gene, 1916

growth inhibition by interleukin 1
enhanced expression, γ -interferon receptors, 636

hereditary non-polyposis syndrome
microsatellite instability, 5853

increased expression
sialyl Lewis^x antigen, poor survival, 3632

signal-transducing ζ chains
tumor-infiltrating T-cells and NK cells, 5610

specific targeting and killing activities
anti-P-glycoprotein monoclonal antibody MRK16, 5475

suspected
tumor detection, ¹³¹I-labeled monoclonal antibody COU-1, 5920

TGF- α production and autoinduction
epidermal growth factor receptor gene, 1630

two tumor suppressor genes
chromosome 8p, 1172

Carcinoma, embryonal
cis-diamminedichloroplatinum(II)
resistance *in vitro* and *in vivo*, 5707

Carcinoma, endometrial
genetic instability of microsatellites, 5100
mutation of Ki-ras protooncogene, 1906

Carcinoma, epidermoid
xenografts
preclinical evaluation, ¹¹¹In-labeled B3 monoclonal antibody, 2834

Carcinoma, esophageal
altered messenger RNA
mutational profiles, p53 and Rb, 1889

Carcinoma, gastric
autocrine growth stimulator
interleukin 1 α , 4102
genetic changes at p53
base transitions, 2614

hepatocellular carcinoma and
ribosomal protein mRNAs, colonic carcinoma, 4048

intestinal and diffuse-type
differential expression, CD44 splice variants, 4197

Signet ring cell
T-cell receptor V region gene usage, CTL and TIL, 3078

Carcinoma, gastrointestinal
immunolectron microscopic localization transforming growth factor- β 1, binding protein, 183

Carcinoma, hepatocellular
aflatoxin B₁-induced hepatic hyperplastic nodules
no site-specific mutation, p53 gene, 9
carcinogenicity study
Alderley Park Wistar-derived rats, 3919

early detection
lectin-reactive α -fetoproteins, 5419

frequent multiplication
long arm of chromosome 8, 857

gastric carcinoma and
ribosomal protein mRNAs, colonic carcinoma, 4048

p53 expression
tumor growth, invasiveness, 4691

rejection of
immune reactions, hepatitis B viral antigens, 4648

risk of
elevated serum testosterone levels, 790

role and mutational heterogeneity
p53 gene, 368

splicing mutations of p53 gene, 1653

sugar chains
human cord serum α -fetoprotein, 2970

tumor progression
mediation by p53 mutation, 2884

Carcinoma, lung
marker for susceptibility
glutathione S-transferase μ polymorphism, 2313

sensitivity of human cells
mild hyperthermia, 2740

stimulation of proliferation
insulin-like growth factor-I, lung fibroblast-derived IGF-I, 3399

Carcinoma, mammary
alkylator-induced toxicity
glutathione S-transferase cDNA, 4900

suppressor gene *Mcs*
cloning of overexpressed genes, 5766

TA3/Ha cells
integrin $\alpha_6\beta_4$, adhesion to hepatocytes, 3611

Carcinoma, non-small cell lung
DT-diaphorase gene expression
cigarette smoking as determinant, 5458

mutated epidermal growth factor receptor, 3217

Carcinoma, ovarian
aryl hydrocarbon receptor
aryl hydrocarbon responsiveness, 1802

enhanced Adriamycin activity
bifunctional inhibitor W-77, 2051

galactin-mediated adhesion
cellular galactin-binding glycoproteins, 2667

high-grade
adjacency of benign or low-grade malignancies, molecular characteristics, 4138

invasive low-grade and high-grade epithelial comparison, loss of heterozygosity, 4456

kinetics and tissue distribution
radiolabeled chimeric monoclonal antibody MOv18 IgG, F(ab') fragments, 5413

p53 mutation
common genetic event, 2128

progressive
synthesis of types I and III procollagens, tumor tissue and peritoneal cavity, 5028

xenografts
decreased tumor burden, synthetic matrix metalloproteinase inhibitor, 2087

fenretinide effectiveness, potentiation of cisplatin activity, 5374

Carcinoma, prostate
genotypic characterization, 4035

growth factor regulation of gene expression, 1051

hormone-independent
inhibition of tumor growth, angiogenesis, 5233

loss of expression and heterozygosity suppressor gene *DCC*, 2723

Carcinoma, renal cell
chromosome 17p deletions
p53 mutations, 3092

estrogen-induced
increase, insulin-like growth factor 1 receptors, 2256

familial
genetic and physical map of chromosome 3p, translocation, 3118

glycolipid sulfotransferase activity levels regulation, involvement of protein kinase C, 2484

infiltration of T-cells
production, interleukin 2 and receptors, 5828

inhibition of cellular growth
O-phospho-L-tyrosine, activation of protein tyrosine phosphatases, 557

loss of T-cell receptor ζ chain
p56^{ck}, 5613

metastasis
oligoclonal T-cell response, vaccination with autologous tumor cells, 4745

pelvic
induction by phenacetin, hydronephrosis-bearing rats of SD/cShi strain, 4218

regulation of activity levels
glycolipid sulfotransferases, transforming growth factor α , 5638

T-cell infiltration
poor proliferative response, 1380

transplacentally induced

SUBJECT INDEX TO VOLUME 53

genetic predisposition, Eker rat, 5856
 tumor-specific lysis
 tumor-infiltrating lymphocytes, 4020

Carcinoma, skin
 basal cell
 distinct infrared spectroscopic patterns, 762

Carcinoma, small cell lung
 compensatory occurrence of IV²Fucα,
 II³NeuAcα-Gg,Cer
 human fetal antigen Lc,Cer, small cell lung carcinoma, 5903
 stimulation of serotonergic autocrine loop
 nicotine, 5566
 topoisomerase II as a drug target
 atypical multidrug resistance, 1064

Carcinoma, squamous cell
 adult
 infrequency of MDM2 gene amplification, pediatric solid tumors, 6028
 chromosome changes
 in vitro response to radiation, 5542
 esophageal
 loss of 17p, p53 gene mutation and p53 protein overexpression, 846
 TP53 gene mutation, 5745
 β-fibroblast growth factor expression
 regional endothelial cell proliferation, 1444

head and neck
 culture conditions, chromosome abnormalities, 2140
 E48 and IgG-mediated therapy, xenografts, 3524
 environmental carcinogenesis and its prevention, 2189
 immunotargeting, monoclonal antibody U36, 4383
 incidence, p53 mutations, 4477
 local invasiveness, increased stromelysin 3 gene expression, 165
 peritumoral IL-2 injections, local and systemic activation of immune cells, 564
 pharynx preservation, cancer chemoprevention, 5113
 p53 mutation, lack of correlation with radiosensitivity, 3667
 restricted specificity, human cytotoxic T-cell lines, 1461
 three discrete regions of deletion, 3p, 5775
 transforming growth factor α, epidermal growth factor receptor messenger RNA, 3579
 interaction between UVA and UVB hairless mice, 4212

lung
 serum fragment of cytoskeletal subunit 19, CYFRA 21-1, 61
 multicellular tumor spheroids
 enhancement, heme oxygenase expression, 2700
 protection against malignant conversion of benign papillomas
 polyphenolic fraction, green tea, 5409
 reversal of hypercalcemia
 neutralizing antibodies to human interleukin 6, 737
 suppression of proliferation
 Z-4',5'-dihydro-5'-deoxy-5'-fluoro-

adenosine, 6058
 tumor-distant epithelia
 mutated p53, 4189

Carcinoma, transitional cell
 bladder
 local control, differences in DNA supercoiling, 2300
 epidermal growth factor receptor
 autocrine and paracrine stimulation, 5300
 urinary bladder
 high-risk human papillomavirus infections, p53 overexpression, 4823

Carcinoma cells
 human papillomavirus type 18-specific antisense oligonucleotides
 transformed phenotype, 2330
 role of carrier ligand
 platinum resistance, 799
 self-reactive antibody
 monoclonal antibody genes, 3355
 Shionogi
 growth, steroid hormones and opioid peptides, 4224

Carcinosarcoma
 liver W256
 temperature-sensitive liposomal Adriamycin, hepatic artery, 3046

Cardiotoxicity
 mitoxantrone
 inhibition by ICRF-187, neonatal rat heart cells, 550

β-Carotene
 chemoprevention strategies
 lung and upper aerodigestive tract cancer, 1469
 inhibition of rectal mucosal ornithine decarboxylase
 colon cancer, 3723
 selenium status
 risk of lung cancer, 4860

Carotenoids
 serum micronutrients
 subsequent risk, oral and pharyngeal cancer, 795
 vegetables and fruit
 lung cancer, Iowa Women's Health Study, 536

Casein
 cloning of overexpressed genes
 mammary carcinoma suppressor gene, 5766

Cataract
 bovine lens and mouse skin
 inhibition of tumor promoter-mediated processes, caffic acid phenethyl ester, 1255

Catechol
 sodium nitrite and
 3-methoxycatechol or butylated hydroxyanisole, rat multiorgan carcinogenesis model, 32

α-Catenin
 deletion of gene
 reduction of E-cadherin levels, prostate cancer cells, 3585

Cathepsin D
 mannose-6-phosphate/IGFIII receptor and
 benign and malignant mammary tumors, 2901
 role in invasiveness

human breast cancer cells, 873
Cathepsin G
 mechanism of neutrophil-mediated lysis
 human neuroblastoma cells, 362

CC-1065
 induction of *in vivo* mutagenesis
 adozelesin DNA alkylation, 5690

CD4
 autoreactive and heat shock protein 60
 antitumor activity, syngeneic fibrosarcoma, 106
 -dependent mechanism
 development of tumor-reactive cytotoxic cells, interleukin 3, 2112

CD8
 peptide-induced
 target, mutant p53 tumor suppressor protein, 3257

CD11a
 binding of intestinal intraepithelial cells
 colon cancer cells, 1608

CD16
 c-erbB-2 and
 bispecific monoclonal antibody targeting, human tumor xenograft, 94

CD34
 effect of stem cell factor
 irradiated human bone marrow, 3857

CD36
 expression of thrombospondin and its receptors
 normal, hyperplastic and neoplastic breast, 1421
M, 85,000 protein
 complementary DNA, Adriamycin-resistant human tumor cells, 2538

CD44
 differential expression of splice variants
 intestinal- and diffuse-type gastric carcinoma, normal gastric mucosa, 4197
 major proteins from different splice variants
 metastatic rat tumor cell lines, 1262
 metastasis-related
 expression in human brain metastases, not in glioblastomas, 5345
 promoter activity
 link, ras and metastatic behavior of tumor cells, 1516

variant proteins
 tumor progression, human colorectal cancer, 4754

CD44H
 mediation
 binding of ovarian cancer cells, peritoneal mesothelium, 3830

CD51
 expression of thrombospondin and its receptors
 normal, hyperplastic and neoplastic breast, 1421

CD54/CD11a
CD58/CD2 and
 differential expression, human melanoma cells, 3343

CD59
 complement inhibitors
 messenger RNA expression, human tissues and tumors, 348

Cell culture
 differential isolation

SUBJECT INDEX TO VOLUME 53

normal luminal mammary epithelial cells, breast cancer cells, 627
identification and characterization of agents
modification, carcinogenesis, 2446s
physiological
normal and malignant mammary epithelial cells, discrimination of cell type, 2644
report of Group C
American Cancer Society Research Workshop, 2455s

Cell cycle
arrest and growth inhibition
UCN-01, human breast carcinoma cells, 2081
arrest and role of *p53*
radiosensitivity, Burkitt's lymphoma cell lines, 4776
association of origins of replication
nuclear matrix, normal human fibroblasts, 3865
cell-free SV40 DNA replication system
interaction between replication forks, topoisomerase I-DNA cleavable complexes, 5908
chromosomes 8/12/17 copy number
DNA ploidy, Astler-Coller stage C colon cancer, 681
circadian stage of cell sampling
DNA synthesis and ploidy, non-Hodgkin's lymphoma, 3129
cyclin A expression
cell proliferation marker, hematological malignancies, 235
cyclin A and cyclin B
differential effect of ionizing radiation, HeLa cells, 1128
cyclin A and cyclin E
candidates for restriction point protein, 1493
differences in susceptibility of HL-60 cells
apoptosis, induction by various antitumor agents, 3186
effect of stem cell factor
irradiated human bone marrow, 3857
glutathione depletion
L-buthionine sulfoximine, antagonism of taxol cytotoxicity, 2066
G₁ or late S phase
cisplatin at 41.5°C, cell killing and chromosomal aberrations, 1239
G₂-M
arrest of progression, genistein, 1328
growth inhibition by deferrroxamine
neuroblastoma sensitivity, 3968
hyperphosphorylation
retinoblastoma protein and p53, okadaic acid, 239
interactions and DNA repair
radiation sensitization, etoposide, 2105
kinetics
different DNA ploidy levels, DNA content and cyclin B, 5096
loss of *p53*-associated G1 checkpoint cell survival after DNA damage, 4164
mammalian
regulation, annexin II expression, 6017
methionine dependence

biochemical defect, fresh patient tumors in primary histoculture, 2479
normal and neoplastic growth and development, 929
overexpression of DNA binding activity distal CCAAT box, thymidine kinase promoter, 3253
quiescent state of yeast cells, 1867
radiation and oncogenic transformation taxol, 1368
radiation induced S and G₂ phase arrest caffeine release, histone messenger RNA levels, 1507
-specific effects of tumor necrosis factor α
monocyte-mediated leukemic cell death, role of β_2 -integrins, 4399
therapeutic tumor-specific block methionine starvation, 5676

Cell motility
glyceraldehyde-3-phosphate dehydrogenase expression
prostatic adenocarcinoma, 1995
inhibition
nm23 transfection, human and murine tumor cells, 1971

CEM cells
teniposide-resistant
non-complex-stabilizing inhibitors of enzyme, aberrant functions, 5946

CEM-C7 cells
cloning and expression
mutant glucocorticoid receptors, 4059

Central nervous system neoplasms
characterization of thread proteins
neuroectodermal tumors, 3823
lactotetraose series ganglioside 3',6'-isoL_D
tumors of other systems, 120
plasma and cerebrospinal fluid pharmacokinetic study
nonhuman primates, 725

c-erbB-2
CD16 and
bispecific monoclonal antibody targeting, human tumor xenograft, 94
c-myc amplification
high proliferative capacity, breast cancer, 1956
transfected gene
biological consequences of overexpression, immortalized human bronchial epithelial cells, 2035

c-erbB-2/neu
enhanced expression
severe malignancy, ovarian cancer cells, 891

Cerebrospinal fluid
pharmacokinetics and toxicology of immunotoxins
administration into the subarachnoid space, nonhuman primates and rodents, 3752
pharmacokinetic study of topotecan nonhuman primates, 725
prolongation of drug exposure encapsulation into DepoFoam, 1596

Cervical cells
human papillomavirus-transfected genetic analysis, *in vitro* progression, 1167

Cervix

epithelium
retinoid status, appearance of reserve cells and keratin expression, 2287

c-fos
mechanism of induction by ultraviolet B mouse JB6 epidermal cells, 38

CGS 20267
Phase I study
postmenopausal patients, advanced breast cancer, 266

Chains
signal-transducing
tumor-infiltrating T-cells and NK cells, colorectal carcinoma, 5610
single
anti-carcinoma antibody fused to β -lactamase, genetic construction, 2123

Chemoimmunotherapy
protective role of AS101
combined with several cytotoxic drugs, mechanisms of action, 5962

Chemointervention strategies
A/J mouse lung as a model, 410

Chemoprevention
agents
inhibition of oxidative stress, HeLa cells, 4528
caffein acid phenethyl ester
inhibition of tumor promoter-mediated processes, mouse skin and bovine lens, 1255
colon carcinogenesis
organosulfur compounds, 3493
protocatechuic acid, 3908
dietary DL- α -difluoromethylornithine initiation and postinitiation stages, hepatocarcinogenesis, 3903
diethylnitrosamine-induced hepatocarcinogenesis
protocatechuic acid, 2775
environmental carcinogenesis and its prevention
head and neck cancer, 2189
head and neck multistage tumorigenesis increased polysomes, chromosomes 7 and 17, 2874
inhibition of tumor promotion by canavanol
inhibition of tumor necrosis factor α release, CD-1 mouse skin, 3462
olitipraz
carcinogenesis induced by azoxymethane, 2502
oral carcinogenesis
DL- α -difluoromethylornithine, tongue neoplasms, 772

p53 protein accumulation
early bronchial neoplasia, 4817
strategies
lung and upper aerodigestive tract cancer, 1469
therapy and basic science
resolution of cancer problem, 5890

Chemotaxis
chemokinesis and
prostate stromal cell secretory proteins, prostate tumor cell lines, 1416
haptotaxis and
autocrine motility factor-like substance, human malignant mesothelioma cells, 4376

SUBJECT INDEX TO VOLUME 53

mediation by stem cell factor
c-kit, small cell lung cancer, 1709

Chemotherapy
acceleration of granulocyte recovery
granulocyte colony-stimulating factor,
metastatic breast cancer, 5424

amphibolic drug combinations
multienzyme systems, 3998

BIBW 22 as bifunctional modulator
P-glycoprotein and nucleoside transport, 1974

biological properties and growth in
SCID mice
cell line KBM-5, 3603

circadian-dependent toxicity
5-fluorouracil, pyrimidine enzymes, 2816

circadian stage of cell sampling
DNA synthesis and ploidy, non-Hodgkin's lymphoma, 3129

differences in activities and substrate specificity
pyrimidine nucleoside phosphorylases, 3687

DNA damaging agents and sequence-specific DNA binding, p53, 2212

evaluation of drug disposition
perfused tumor and skin preparation, 101

evasion by cancer cells, 747

5-fluorouracil
dihydropyrimidine dehydrogenase activity, human peripheral blood
mononuclear cells and liver, 5433

high-dose regimen for refractory lymphomas
plasma and cellular pharmacokinetics, mitoxantrone, 4850

Hoechst 33342
cytotoxicity and drug resistance, human cell cultures, 1332

individualized
neuroendocrine markers and drug sensitivity testing, non-small cell lung cancer, 5181

-induced apoptosis
specific proteolytic cleavage, poly(ADP-ribose) polymerase, 3976

interstitial
controlled release polymers, drug delivery in brain, 329

main drug-metabolizing enzyme systems
human breast tumors, peritumoral tissues, 3541

methylthioadenosine phosphorylase deficiency
non-small cell lung cancers, 1098

modeling of development of metastases
primary and locally recurrent tumors, clinical data base for prostatic cancer, 2987

modulation of cisplatin nephrotoxicity and drug resistance
control of metallothionein synthesis, bladder synthesis, 1829

pharmacokinetics and metabolism of ifosfamide
continuous infusion, children, 3758

pharmacokinetics of recombinant human interleukin 3
ovarian cancer, 5915

quiescent state of yeast cells
cell cycle, 1867

roles of metallothionein in carcinogenesis, 922

synergy of anti-Fas antibody
overcoming tumor necrosis factor and drug resistance, 2591

three drug
potentiation of regimen, radiation, 3518

tumor cell heme uptake
induction of ferritin synthesis, altered oxidant sensitivity, 5308

Chinese hamster cells
allelic variation in dihydrofolate reductase gene
amino acid position 95, antifolate resistance, 6031

Chinese hamster ovary cells
transformed to express human *O⁶-alkylguanine-DNA alkyltransferase* specificity, bischloroethylnitrosourea-induced mutation, 997

cell killing and chromosomal aberrations
cisplatin at 41.5°C, G₁ or late S phase, 1239

increased genetic damage
alkylating agents and γ -irradiation, folate deficiency, 5401

radiation yield of interphase chromosomes
mitosis-promoting factor activity, inducer mitotic cells, 5592

sensitivity to *ERCC-1* overexpression
DNA damaging agents, 3237

transfection with interleukin 10 prevention, tumor growth and macrophage infiltration, 4134

UV-sensitive mutant cell line
identification of cellular defect, UVS1, 495

O-(Chloroacetyl-carbamoyl)fumagillo: see TNP-470

8-Chloroadenosine
mediation of 8-chloro-cyclic AMP-induced down-regulation
cAMP-dependent protein kinase, neoplastic mouse lung epithelial cells, 393

Cholestasis
17 β -estradiol glucuronide as inducer multidrug resistance transporter, 5382

Cholic acid
prediction of colonic tumor incidence
aberrant crypt foci, 4499

Choriocarcinoma
cell line development
evaluation, drug disposition, 101

genesis of
successive activation, platelet-derived growth factor β receptor and growth factor B genes, 2927

c-H-ras
mRNA and nucleoside diphosphate kinase/nm23
lung metastasis, rat-transplantable osteosarcoma, 5038

Chromatin
modification of DNA bases
intact target human cells, activated polymorphonuclear leukocytes, 1269

regional DNA hypermethylation at

D17S5
progression of renal tumors, 2718

Chromatophoromas
chromatophore hyperplasia and Pacific rockfish, 1761

Chromosome 1p
deletion
distinct regions, human primary breast cancer, 1990

Chromosome 1p36
deletion as primary aberration intestinal tumorigenesis, 1895

Chromosome 3p
deletions and p53 mutations
prognostic significance, primary resected non-small cell lung cancer, 1 detailed genetic and physical map familial renal cell carcinoma translocation, 3118

three discrete regions of deletion head and neck cancers, 5775

Chromosome 6
human epithelial ovarian cancer allelotyping, 2393

Chromosome 7
17 and
increased polysomes, head and neck multistage tumorigenesis, 2874

Chromosome 8
complementation of radiosensitive phenotype
SCID mice, 6011
frequent multiplication of long arm hepatocellular carcinoma, 857

Chromosome 8p
two tumor suppressor genes colorectal carcinoma, 1172

Chromosome 8p22
homozygous deletion and frequent allelic loss of loci
human prostate cancer, 3869

Chromosome 9
bladder cancer suppressor loci, 5093
preliminary mapping of deleted region bladder cancer, 1230
role in human bladder cancer, 4066

Chromosome 9p
critical region deleted in lung cancer homozygous loss, interferon genes, 2410
localization of homozygous deletions continuous linkage group, glioma cell lines, 3674

Chromosome 10
loss in human glioblastoma functional role, 5043
loss of heterozygosity for loci morphologically malignant meningioma progression, 2386

Chromosome 11
disruption of *ALL-1* gene epipodophyllotoxin-related secondary AML, 2954

Chromosome 11p15.5
refinement of regional loss of heterozygosity
human breast tumors, 4486

Chromosome 11q23
Southern blot analysis of *ALL-1* rearrangements acute leukemia, 3800

Chromosome 12

breakpoints
benign and malignant lipogenic tumors, 1670

Chromosome 14q32
interferon- α -inducible gene expression in breast carcinoma, 4096

Chromosome 16
deletions in familial breast carcinoma development, distant metastases, 3707

Chromosome 17
7 and
increased polysomes, head and neck multistage tumorigenesis, 2874
allelic loss
ductal carcinoma *in situ*, breast, 2947

Chromosome 17p
allelic loss in neural tumors
DNA hypermethylation, 2715
deletions and *p53* mutations
renal cell carcinoma, 3092
loss
p53 gene mutation and protein overexpression, esophageal squamous cell carcinoma, 846

Chromosome 17q
deletion unit
epithelial ovarian tumors, 1218
detailed deletion mapping
ovarian and breast cancers, 3382
frequent deletion of three regions
primary human breast carcinomas, 5617
linkage analysis of D17S74
thirty-five families, premenopausal bilateral breast cancer, 212

Chromosomes
aberrations and cell killing
cisplatin at 41.5°C, Chinese hamster ovary cells, 1239
abnormalities and karyotypic patterns
culture conditions, head and neck squamous cell carcinoma, 2140
altered methylation patterns
oncogene-induced transformation, bronchial epithelial cells, 1684
changes characterizing *in vitro* response radiation, human squamous cell carcinoma lines, 5542
8/12/17 copy number
proliferative activity and DNA ploidy, Astler-Coller stage C colon cancer, 681
homozygous deletions within 9p21-p22 critical region of chromosome loss, malignant mesothelioma, 4761
loss of heterozygosity
invasive low-grade and high-grade epithelial ovarian carcinoma, 4456
mapping of murine susceptibility loci liver carcinogenesis, 209
proliferating cell nuclear antigen and myc
ultrastructural localization, synchronized neuroblastoma cells, 1899
radiation yield of interphase chromosome breaks
mitosis-promoting factor activity, inducer mitotic cells, 5592
recurrent deletions of specific sites 1p/3p/6q/9p, human malignant mesothelioma, 4349
sequential genetic alterations

allelotype analysis of skin tumors, polymorphic microsatellites, 6022
translocations affecting band 3q27 cloning of *bcl-6*, B-cell lymphoma, 2732
t(6;11) translocation
cloning of *ALL-1* fusion partner, *AF-6* gene, 5624
t(9;11) translocation
topoisomerase II DNA-binding sites, acute myeloid leukemia, 4489

Chromosome X
inactivation
formalin-fixed paraffin-embedded tissue, 4676

Chronopharmacology
high-dose busulfan in children, 1534

Chronotherapy
circadian stage of cell sampling
DNA synthesis and ploidy, non-Hodgkin's lymphoma, 3129

Cigarette smoking
detection of DNA adducts
human oral tissue, 1522
determinant of DT-diaphorase gene expression
non-small cell lung carcinoma, 5458
dose and susceptibility to lung cancer polymorphisms, *CYP1A1* and glutathione S-transferase, 2994
glutathione S-transferase μ polymorphism
marker for susceptibility, lung carcinoma, 2313
incidence of *p53* mutations progression, head and neck cancer, 4477
metabolites of tobacco-specific nitrosamine
smokers' urine, 721
schistosomiasis and
p53 gene mutation, urothelial cancer, 3795

Circadian rhythm
-dependent toxicity of 5-fluorodeoxyuridine
pyrimidine enzymes, relevance to chemotherapy, 2816
stage of cell sampling
DNA synthesis and ploidy, non-Hodgkin's lymphoma, 3129

Cirrhosis
early detection of hepatocellular carcinoma
lectin-reactive α -fetoproteins, 5419

Cisplatin: see also *cis*-Diamminedichloroplatinum(II)
anti-epidermal growth factor receptor monoclonal antibody and antitumor effect, A431 cell xenografts, 4637
carboplatin and
drug-induced DNA modification, buccal cells of cancer patients, 5669
41.5°C during G₁ or late S phase
cell killing and chromosomal aberrations, Chinese hamster ovary cells, 1239
-induced DNA cross-links
topoisomerase II inhibition, glioblastoma, 5663
-induced neurotoxicity

protection with reduced glutathione, rats, 544
induction of apoptosis
proliferating hepatoma cells, nonproliferating immature thymocytes, 2133
modulation of sensitivity
accumulation by amphotericin B, lung cancer cell lines, 3302
nephrotoxicity and drug resistance
metallothionein synthesis, bladder tumor, 1829
potentiation of activity
fenretinide effectiveness, ovarian carcinoma xenograft, 5374

primary resistance
cross-resistance to diverse drugs, ovarian cancer cell lines, 5225
-resistant ovarian cancer cells
-oraplatin sensitivity/resistance, 242
sensitivity
tamoxifen modulation, malignant melanoma cells, 1571
transformation, rat ovarian epithelial and Rat-1 fibroblast cell lines, 3771

tirapazamine and
tumor-dependent schedule-dependent interaction, 4633
transplacental carcinogenicity
SENCAR mice, 3874

c-kit
lineage-negative blast subpopulations
chronic myelogenous leukemia, 401

Clofazimine
inhibition of cancer cell line proliferation phospholipase A₂-mediated mechanisms, 318

c-myc
amplification
high proliferative capacity, breast cancer, 1956
correlation with suppression of *c-kit* expression
small cell lung cancer cell lines, 4337
deregulation
theophylline-induced differentiation, Burkitt's lymphoma, 127
drug-induced changes in gene expression synthesis of *M*, 72,000 constitutive heat shock protein, HL-60 cell differentiation, 3034

E_μ-myc transgenic mice
multiple mechanisms, tumorigenesis, 1665

neuclear oncogenes and growth factors
tumorigenesis, transgenic mouse model, 1719

Cockayne's cells
hypersensitivity to camptothecin double strand breaks, nascent DNA, 2012

Codon 248
p53 mutation and tumor suppressor function
enhancement of tumor growth, anti-sense *p53*, 4362

Collagen
type IV
chemotaxis and haptotaxis, human malignant mesothelioma cells, 4376

Collagenase
M, 72,000 matrix metalloproteinase binding and localization, cell surface

SUBJECT INDEX TO VOLUME 53

invadopodia, 3159
 tumor cell-derived stimulatory factor
 expression of interstitial collagenase, stromelysin and *M*, 72,000 gelatinase, 3154
 type IV
 benign and malignant prostate, 878
 type IV *M*, 72,000
 differential integrin expression, melanoma cell invasion, 3411
 type IV *M*, 92,000
 elevated levels, human brain tumors, 2208
 increase in plasma, colon and breast cancers, 140

Colon
 aberrant crypt foci
 azoxymethane-induced biochemical changes, inhibitory effect of caffeic acid esters, 4182
 aberrant crypts
 cell kinetic evaluation, 3726
 carcinogenesis
 chemoprevention, organosulfur compounds, 3493
 chemoprevention, protocatechuic acid, 3908
 inhibitory effect of *Bifidobacterium longum*, food mutagen, 3914
 1,2-dimethylhydrazine aberrant crypt foci
 reduction in formation, docosahexanoic acid, 2786
 epithelial cell proliferation
 caloric restriction, dietary fat, 2745
 histologically normal mucosa
 HLA class I antigens, 2374

Colonic mucosa
 proliferation as intermediate biomarker
 carcinogenesis, effects of various agents, 3283

Colonic neoplasms
 antiproliferative effect of dietary calcium
 colonic epithelium, 784
 Astler-Coller stage C
 proliferative activity and DNA ploidy, chromosomes 8/12/17 copy number, 681
 binding of intestinal intraepithelial cells
 HML-1 and CD11a, 1608
 cytolytic activity of fecal water
 mechanism of protective effect, supplemental dietary calcium, 248
 increase in *M*, 92,000 type IV collagenase
 plasma, 140
 inhibition of rectal mucosal ornithine decarboxylase activity
 β -carotene, 3723
 permanently labeled by lectin-mediated endocytosis
 trap label, distribution of, 658
 prediction of tumor incidence
 aberrant crypt foci, cholic acid, 4499
 proliferation of human colonic mucosa
 intermediate biomarker of carcinogenesis, 3283
 putative tumor marker, 1751
 quantitative differential effects
 magnetic resonance spectroscopy, 5808
 reduced risk

high intake of vitamin E, 4230
 risk of fatal cancer
 aspirin use, 1322

Colony-stimulating factor
 granulocyte
 acceleration of granulocyte recovery after chemotherapy and bone marrow transplantation, metastatic breast cancer, 5424
 pharmacokinetics of piroxantrone, Phase I trial, 2587
 granulocyte-macrophage
 block of lung tumor production, 1 α , 25-dihydroxyvitamin D₃ plus γ -interferon, 6006
 controlled release, biodegradable cytokine depots, 5841
 description of genes and lack of proliferation, nonhematopoietic human malignant cell lines, 3139
 high efficiency gene transfer, primary human tumor explants, 2221
 inhibition of binding to receptors, dimethyl sulfoxide, 1142
 Phase I trial of chronic oral etoposide, advanced malignancies, 5929
 macrophage
 cytokine regulation, human monocyte differentiation, 2603
 interleukin 2 and, protection from T-cell leukemia/lymphoma EL4, 4273

Colorectal neoplasms
 CD44 variant proteins
 tumor progression, 4754
 clinical value of determination
 urokinase-type plasminogen activator antigen, plasma, 1788
 comparative dual label study
 first and second generation TAG-72, 271
 cytokinetic effects of interferon
 design of interferon/5-fluorouracil combinations, 5429
 genomic instability
 clinicopathological variables, family history, 5849
 metabolic activation of N-hydroxy-2-aminofluorene
 colon cytosols, Syrian hamsters congenital at *NAT2* locus, 509
 metastasis
 mutation in *nm23* gene, 717
 strength of family history
 frequency of adenomatous polyps, epithelial cell proliferative compartment, 279

Comedocarcinoma
 expression of thrombospondin and its receptors
 normal, hyperplastic and neoplastic breast, 1421

Complements
 C3b
 paracrine migration-stimulating factor, hepatic sinusoidal endothelial cells, 4418
 inhibitors
 messenger RNA expression, human tissues and tumors, 348
 resistance
 molecular basis, melanoma cells exposed to C3-cleaving membrane pro-

tease p65, 592
Cortisol
 -heparin conjugates
 antitumor activity, 3000
Corynebacterium parvum
 cytokine production
 vaccinations, cytokine production by genetically engineered tumor cells, 714
Cryopreservation
 ether lipids and
 in vitro purging, removal of breast cancer cells from bone marrow, 3747

Crypts
 aberrant
 cell kinetic evaluation, 3726
 aberrant foci
 prediction of colonic tumor incidence, cholic acid, 4499
Cu,Zn-superoxide dismutase
 oxy radicals and antioxidant responses in cancer, 3207
3',5'-Cyclic nucleotide phosphodiesterase
 potential target for tumor growth inhibition
 tumor cells, 3058

Cyclin
 gene amplification
 colorectal carcinoma, 1986

Cyclin A
 cyclin B and
 differential effect of ionizing radiation, HeLa cells, 1128
 expression in human hematological malignancies
 marker of cell proliferation, 235

Cyclin B
 DNA content and
 different ploidy levels, cell cycle kinetics, 5096

Cyclin D1
 rearrangements of gene
 breakpoints within *BCL-1* locus, B-cell lymphoma, 4148

Cyclin E
 cyclin A and
 candidates for restriction point protein, 1493

Cyclobutane pyrimidine dimers
 ultraviolet-induced
 selective removal from epidermis, hairless mouse, 1642

Cyclocreatine
 inhibition of growth
 broad spectrum of cancer cells, solid tumors, 3172

Cyclopental[c,d]pyrene
 metabolites
 sulfotransferase-mediated activation, 1017

Cyclopentenylcytosine
 resistance in murine leukemia L1210 cells, 5714

Cyclophosphamide
 carboplatin and etoposide
 Phase I trial with autologous bone marrow transplantation, refractory germ cell tumors, 3730
 doxorubicin and 5-fluorouracil plus interferon- α 2b, advanced breast cancer, 3509
 ifosfamide and

SUBJECT INDEX TO VOLUME 53

differential activation by cytochromes P-450 2B and 3A, liver microsomes, 5629

-induced myelosuppression protection, combined interleukin 1 β /interleukin 2 treatment, 569

modulation of rat hepatic cytochrome P450 2C11 steroid 5 α -reductase activity and messenger RNA, acrolein and phosphoramidate mustard, 2490 protective role of AS101 combination with several cytotoxic drugs, mechanisms of action, 5962

Cyclosporin A doxorubicin and Phase I pharmacokinetic study, 4837

CYFRA 21-1 immunoradiometric assay serum fragment of cytokeratin subunit 19, marker of lung cancer, 61

Cystadenoma benign or low-grade malignancies adjacency to high-grade ovarian carcinoma, molecular characteristics, 4138

Cytochrome b₅ reductive activation of mitomycin C, 4907

Cytochrome c oxidase mitochondrial target site for daunomycin, K562 cells and heart tissue, 1072

Cytochrome P450 hepatic and pulmonary enzymes metabolism of 6-nitrochrysene, 2028 -induced cytotoxicity of mitoxantrone formation, electrophilic intermediates, 5135 oxidative catabolism of all-trans-retinoic acid lipid peroxides, human microsomes, 1226

Cytochrome P450 1A1 hepatic cellular distribution immunohistochemistry, rainbow trout, 3700

P450 EF and reversal of expression, MCA-C3H/10T½ cell-derived tumors, 968

Cytochrome P450 3A 2B and cyclophosphamide and ifosfamide, liver microsomes, 5629

liver vinblastine metabolism, drug interactions, 5121

Cytochrome P450 2C11 modulation by cyclophosphamide messenger RNA levels, acrolein and phosphoramidate mustard, 2490

Cytogenetics genotypic characterization prostatic carcinoma, 4035

Cytokeratins hyperphosphorylation okadaic acid class tumor promoters, primary keratinocytes, 992

subunit 19 serum fragment measured by CYFRA 21-1 assay, marker for lung cancer, 61

Cytokines autologous stem cell transplantation sequential production, granulocyte recovery, 1297 constitutive expression patterns footprinting, individual tumors and their variants, 1978 controlled release, biodegradable depots cancer vaccine design, 5841 engineered interleukin 4-secreting cells glioma treatment, 3125 interleukin 1 α and interleukin 6 inhibition of growth, MCF-7 cells, 1538 interleukin 2 and interferon- γ immunological and clinical effects, 1286 oncostatin M-induced growth inhibition increased resistance, melanoma cell lines derived from advanced-stage lesions, 2708 production by genetically engineered tumor cells vaccinations, 714 regulation human monocyte differentiation, 2603 secondary secretion human interleukin 2 analogues, immunotherapy, 2597

Cytolsin cytotoxic protein purification characterization, transformed fibroblasts, 1195

Cytoplasm elk-1 proteins phosphoproteins and activators, mitogen-activated protein kinase, 3449

Cytosine deaminase antitumor activity of 5-fluorocytosine colorectal carcinoma cells, 4619

Cytosol colonic metabolic activation of N-hydroxy-2-aminofluorene, Syrian hamsters congenic at *NAT2* locus, 509 extracts of breast carcinoma urokinase-type plasminogen activator, PAI-1, 2513

glutathione S-transferase chemical selectivity, drug-resistant L5178Y murine lymphoblasts, 3530

Cytostasis proliferation of A375 melanoma cells inhibition by nitric oxide/nucleophile complexes, 564

Cytotoxic cells tumor-reactive interleukin 3-enhanced development, CD4-dependent mechanism, 2112

Cytotoxic T-lymphocytes autoreactive and heat shock protein 60 antitumor activity, syngeneic fibrosarcoma, 106

DNA sequence analysis T-cell receptor genes, oligoclonal T-cell response, 840

human B-cell immune response polymorphic epithelial mucin, 2457

in situ amplification antitumor activity, human regressive melanoma, 3569

peptide-induced CD8 $^{+}$

target, mutant *p53* tumor suppressor protein, 3257

restricted specificity squamous cell carcinoma, head and neck, 1461

selective loss of HLA class I allospecificities staining of melanoma cells, monoclonal antibodies, 3349

suppression of growth spontaneous melanoma metastases, SCID/hu mice, 4933

suppression of stress protein GRP78 induction elimination of resistance, cell-mediated cytotoxicity, 6001

T-cell receptor V region gene usage autologous gastric Signet ring cell carcinoma, 3078

D

DAB₄₈₈IL-2 Phase I trial of 90-min infusion hematological cancers, 3930

Daunomycin -antibody immunoconjugates management, soft tissue sarcomas, 5740

mitochondrial cytochrome c oxidase as a target site K562 cells and heart tissue, 1072

Deacetylase activity of human tumor cells production, immunosuppressive aminosugars, 5600

N-(Deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate plasma pharmacokinetics of vinblastine and high-performance liquid chromatography, 2061

Decay-accelerating factor complement inhibitors messenger RNA expression, human tissues and tumors, 348

Deferoxioxamine growth inhibition neuroblastoma sensitivity, 3968

Deoxycholate intermediate biomarker of carcinogenesis proliferation, human colonic mucosa, 3283

2-Deoxy-D-glucose inhibition of doxorubicin-induced apoptosis, 2057

12-Deoxyporphol 13-esters inhibition phorbol 12-myristate 13-acetate induced tumor promotion, CD-1 mouse skin, 2507

Deoxyuridine triphosphatase elevation of activity failure to accumulate deoxyuridine triphosphate, fluorodeoxyuridine-induced DNA damage, 5219

DepoFoam prolongation of drug exposure cerebrospinal fluid, 1596

Dermis reticular calcyclin expression, melanocytic lesions, 6061

SUBJECT INDEX TO VOLUME 53

Desmoid neoplasms
familial adenomatous polyposis
somatic and germ-line mutations, *APC* gene, 5079

Desmoplasia
expression of thrombospondin and its receptors
normal, hyperplastic and neoplastic breast, 1421

Detergents
nonionic
P-glycoprotein drug binding, reversal of multidrug resistance, 5994

Dexamethasone
reduction of interstitial fluid pressure
human colon adenocarcinoma xenograft, 4764

1,2-Diaminocyclohexane platinum(IV) complexes
modulation of cytotoxicity
cellular pharmacology, axial and equatorial ligands, 4567

cis-Diamminedichloroplatinum(II): see also Cisplatin
5-fluorouracil and
with and without leucovorin, non-small cell lung cancer cell lines, 1079

interleukin 1 and
synergistic antitumor activity, solid tumors, 1091

resistance *in vitro* and *in vivo*
human embryonal carcinoma cells, 5707

Dibenzo[a,h]anthracene
metabolic activation
bis-diol-epoxide involvement, DNA-binding species in mouse skin, 944

Dicumarol
hypoxia and
adducts of mitomycin C and DNA, EMT6 mouse mammary tumor cells, 5127

reductive activation of mitomycin C NADH:cytochrome *b*₅ reductase, 4907

Z-4',5'-Didehydro-5'-deoxy-5'-fluoroadenosine
suppression of proliferation
keratinocytes, squamous carcinoma cell lines, 6058

Diet
calcium
antiproliferative effect, colonic epithelium, 784

caloric restriction and dietary fat
epithelial cell proliferation, rat colon, 2745

pancreatic carcinogenesis, rat, 46

calories/parity/prolactin
mammary tumor risk, epithelial kinetics and differentiation, 1188

derivation of etiology from human-based studies, 2437s

different levels of linoleic acid
breast cancer growth, lung metastasis, 4686

fenretinide
decreased tumor incidence, mouse prostate reconstitution model system, 4461

flavonol-stimulated efflux
7,12-dimethylbenzanthracene, multi-

drug resistance, 5977

food mutagen
inhibitory effect of *Bifidobacterium longum*, colon/mammary/liver carcinogenesis, 3914

intermediate biomarker of carcinogenesis
proliferation, human colonic mucosa, 3283

nutrition and cancer
development of hypotheses, evaluation in animal studies, 2442s

restriction-induced inhibition
mononuclear cell leukemia, insulin-like growth factor 1 axis, 2750

restriction of fat and carbohydrate calories
inhibition, skin tumor promotion, 27

vegetables and fruit
lung cancer, Iowa Women's Health Study, 536

Dietary fat
antiproliferative effect of dietary calcium
colonic epithelium, 784

caloric restriction and
epithelial cell proliferation, rat colon, 2745

risk of postmenopausal breast cancer, 75

tobacco carcinogenesis
4-(methylnitrosamo)-1-(3-pyridyl)-1-butanone, 2758

Diethylnitrosamine
-induced hepatocarcinogenesis
chemoprevention, protocatechuic acid, 2775

chemopreventive effects, dietary DL- α -difluoromethylornithine, 3903

Diethylstilbestrol
prenatal exposure
pituitary tumors, 1546

Differentiation factors
heparin-binding growth-new family of, Wilms' tumor and other human carcinomas, 1281

Differentiation therapy
cancer
laboratory and clinical investigations, 4109

2',2'-Difluorodeoxycytidine
template-located
kinetics and fidelity of base insertion, Klenow fragment, 4582

α -Difluoromethylornithine
development of resistance to hydroxyurea
treatment of K562 cells, 5262

DL- α -Difluoromethylornithine
chemoprevention of oral carcinogenesis
tongue neoplasms, rats, 772

chemopreventive effects
initiation and postinitiation stages, hepatocarcinogenesis, 3903

Digestive tract neoplasms
risk of fatal cancer
aspirin use, 1322

Dihydrofolate reductase
delivery of radionuclides
pretargeted monoclonal antibodies, affinity system, 2368

Dihydropyrimidine dehydrogenase
activity
human peripheral blood mononuclear cells, liver, 5433

Dihydrotestosterone
hormone regulation of human prostate organ culture, 5199

3,4-Dihydroxy-3,4-dihydrocyclopenta[c,d]-pyrene
sulfotransferase-mediated activation, 1017

7R,8S-Dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene
dose-dependent differences in profile of mutations
coding region of hypoxanthine phosphoribosyltransferase gene, Chinese hamster V-79 cells, 3294

1 α ,25-Dihydroxyvitamin D₃
 γ -interferon and
block of lung tumor production, GM-CSF and induction of immunosuppressor cells, 6006

receptor as marker
human colon carcinoma cell line differentiation and growth inhibition, 3712

TPA-induced tumorigenic transformation
osteopontin expression, mouse JB6 epidermal cells, 2217

two analogues and
biological response, target organs, 3935

Dilantin: see Phenytoin

7,12-Dimethylbenzanthracene
flavonol-stimulated efflux
7,12-dimethylbenzanthracene, multidrug-resistant breast cancer cells, 5977

1,2-Dimethylhydrazine
-induced aberrant crypt foci in colon
reduction in formation, docosahexanoic acid, 2786

Dimethyl sulfoxide
inhibition of binding of GM-CSF and insulin to receptors
human leukemia cells, 1142

Diphtheria toxin
fusion toxin DAB₄₈₀IL-2
Phase I trial of 90-min infusion, hematological cancers, 3930

Dipyridamole
analogue BIBW 22
P-glycoprotein and nucleoside transport, 1974

Dithiolethiones
glutathione S-transferase class α transcripts
hepatocytes, 231

DNA
adduct formation and hepatocarcinogenicity
toremifene and tamoxifen, 4534

alkylation
in vivo mutagenesis, induction by CC-1065 and adozelesin, 5690

antisense
inhibition of tumor growth, induction by c-Ha-ras, 577

association of origins of replication
nuclear matrix, normal human fibroblasts, 3865

binding activity
distal CCAAT box, human thymidine kinase promoter in human tumor

SUBJECT INDEX TO VOLUME 53

cell lines, 3253
 binding by p53
 chemotherapy and DNA damaging agents, 2212
 -binding species in mouse skin bis-diol-epoxide involvement, metabolic activation of dibenz[a,h]anthracene, 944
 bulk damage teniposide antiproliferative activity, MCF-7 cells, 3547
 complementation of radiosensitive phenotype chromosome 8, SCID mice, 6011
 damage cell survival, loss of *p53*-associated G1 checkpoint, 4164
 damaging agents sensitivity to *ERCC-1* overexpression, Chinese hamster ovary cells, 3237
 different ploidy levels and cell cycle kinetics DNA content, cyclin B, 5096
 digestion bleomycin, apoptosis-mimetic drug, 5462
 double strand break repair defect scid mice, 1244
 drug-induced modification buccal cells of cancer patients, carboplatin and cisplatin chemotherapy, 5669
elk-1 variant differential splicing, encoding of activators and repressors, 215
 fidelity of replication extracts, normal and malignantly transformed human cells, 3270
 fragmentation etoposide-induced cytotoxicity, T-cell leukemic lines, 4287
 frequent multiplication long arm of chromosome 8, hepatocellular carcinoma, 857
 hypermethylation D17S5, progression of renal tumors, 2719
 17p allelic loss, neural tumors, 2715
in situ hybridization genotypic characterization, prostatic carcinoma, 4035
 interaction of a polyamine analogue human brain tumor cell lines, 3948
 intracellular acidification etoposide-induced apoptosis, HL-60 cells, 2349
 intratumoral injection inhibition of melanoma growth, herpes simplex virus thymidine kinase gene, 3860
 introplicine and topoisomerase II molecular and cellular interactions, surface-enhanced Raman scattering spectroscopy, 4784
 lesions produced by annamycin *in vitro* cytotoxicity, cellular pharmacology, 1583
 melphalan-damaged binding, poly(ADP-ribose) polymerase, 5370
 modification of bases in chromatin intact target human cells, activated polymorphonuclear leukocytes, 1269
 mutagenicity in *Saccharomyces cerevisiae* induction by hyperthermia, hot mate infusion and hot caffeine, 5750
 nascent double strand breaks, Cockayne's syndrome cells and camptothecin hypersensitivity, 2012
 no detectable amplifications acquisition of hormone-independent growth, MSF-7 cells, 283
 nuclear oxidative damage in liver, rats exposed to psychological stress, 4153
p53 abnormalities different subtypes, human sarcomas, 468
 ploidy and proliferative activity chromosomes 8/12/17 copy number, Astler-Coller stage C colon cancer, 681
 ploidy and synthesis circadian stage of cell sampling, non-Hodgkin's lymphoma, 3129
 presence of point mutations *N-ras* gene, radiation-transformed rat embryo cells, 1511
 presence of transforming genes gonadal tumors, bivalve mollusk species, 2976
 -protein complexes induction in HeLa S3 cells, KW-2149, 4466
 -protein cross-links molecular implications, welders, 460
 sequence analysis of T-cell receptor genes oligoclonal T-cell response, tumor with multiple target antigens, 840
 sequence-specific binding redox modulation, *p53* conformation, 4469
 sequence-specific interaction conformational domain, *p53*, 5361
 strand bias repair of *p53* gene, normal and xeroderma pigmentosum group C fibroblasts, 5377
 strand breaks in individual apoptotic cells terminal deoxynucleotidyl transferase, nick translation assays, 1945
 studying clonal heterogeneity in human cancers, 921
 supercoiling local control, T2/3 transitional cell carcinoma of the bladder, 2300
 synthesis chronic radiation-induced alteration, aplastic anemia, 4518
 topoisomerase I-mediated cleavage induction by ED-110, 490
DNA, complementary
 basic fibroblast growth factor tumor necrosis, H-ras-transformed cells, 158
 -expressed uridine 5'-diphosphate glucuronosyltransferase glucuronidation, carcinogen metabolites, 1529
 glutathione S-transferase alkylator-induced toxicity, rat mammary carcinoma cells, 4900
 interleukin 2 tumor-specific lysis by tumor-infiltrating lymphocytes, renal cell carcinoma, 4020
 kidney down-expression in Wilms' tumor, subtractive hybridization approach, 2888
molecular cloning
 prostate-specific membrane antigen, 227
molecular cloning and characterization *M*, 85,000 protein, overexpression in Adriamycin-resistant human tumor cells, 2538
mouse heparin-binding growth factor receptor use of kinase insert sequence, 1136
DNA adducts
 aflatoxin B₁ detection in human placenta and cord blood, 1278
 benzo(a)pyrene diol-epoxide inactivation of plasmid reporter gene expression, hepatocytes, 2279
 detection in human oral tissue tobacco smoking, ³²P postlabeling, 1522
 hemoglobin 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, red blood cells, 777
 mitomycin C anil hypoxia and dicumarol, EMT6 mouse mammary tumor cells, 5127
 2-nitroimidazole detection of hypoxic cells, monoclonal antibody, 5721
 platinum resistance role of carrier ligand, human carcinoma cell lines, 799
 polycyclic aromatic hydrocarbons cancer susceptibility genes, human lung, 3486
 pyridyloxobutyl inhibition of repair, O⁶-methylguanine, 2780
DNA damage
 distinct pattern of *p53* mutations bladder cancer, relationship to tobacco usage, 1162
 fluorodeoxyuridine-induced elevation of deoxyuridine triphosphatase, failure to accumulate deoxyuridine triphosphate, 5219
N-methyl-*N*-nitrosourea fluorescence postlabeling assay, 2771
 oxidative benzene and phenolic metabolites, HL-60 cells and bone marrow, 1023
 oxy radicals and antioxidant responses in cancer, 3207
 repair and cell proliferation carcinogen treatment, initiation of pancreatic cancer, 2790
 ultraviolet radiation-induced photorepair in skin, platyfish *Xiphophorus*, 2249
DNA footprinting
 individual tumors and their variants constitutive cytokine expression patterns, 1978

SUBJECT INDEX TO VOLUME 53

DNA polymerase α
 interruption of progression of DNA synthesis
 codons 12 and 13, *H-ras*, 2895

DNA repair
 cell cycle interactions and
 radiation sensitization, topoisomerase II poison etoposide, 2105
 -deficient xeroderma pigmentosum patients
 high mutation frequency, *ras* genes, 1625
 identification of cellular defect
 UV-sensitive Chinese hamster ovary mutant cell line, 495
 role of carrier ligand
 platinum resistance, human carcinoma cell lines, 799

DNA synthesis
 persistent inhibition
H-ras and *v-myc* expression, rat embryo fibroblasts, 1213
 ploidy and
 circadian stage of cell sampling, non-Hodgkin's lymphoma, 3129

DNA topoisomerase I
 -DNA cleavable complexes
 interaction between replication forks, cell-free SV40 DNA replication system, 5908
 glycine 363 change to cysteine
 camptothecin resistance, 4343
 inhibitor
 therapeutic efficacy, human tumor xenografts, 2823
 mammalian poison Hoechst 33342
 cytotoxicity and drug resistance, human cell cultures, 1332
 -mediated DNA cleavage
 induction by ED-110, 490
 topoisomerase II activities and inhibition by introplicine, 5987

DNA topoisomerase II
 DNA-binding sites at breakpoints t(9;11) chromosome translocation, acute myeloid leukemia, 4489
 enhanced gene expression
 response to heat shock stress, KB cells, 1085
 etoposide
 radiation sensitization, DNA repair and cell cycle interactions, 2105
 -induced DNA strand breaks and their repair
 etoposide-induced apoptosis, inhibition by bcl-2 protein, 4251
 inhibition and altered kinetics
 nitrosourea and cisplatin-induced DNA cross-links, glioblastoma, 5663
 inhibitors
 aberrant functions, teniposide-resistant CEM cells, 5946
 introplicine and DNA
 molecular and cellular interactions, surface-enhanced Raman scattering spectroscopy, 4784
 protection from Adriamycin cytotoxicity
 breffelin A, L1210 cells, 5237
 single-strand conformational polymorphism
 M_r 170,000 isozyme, human tumor

cells, 1373
 target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside
 atypical multidrug resistance, small cell lung carcinoma cells, 1064
 temperature-sensitive allele
 drug resistance, amsacrine and etoposide, 89

DNA topoisomerase II α
 drug-resistant small cell lung cancer cell line
 VP-16, 4866
 gene rearrangement
 fusion mRNA transcript, Adriamycin-resistant P388 leukemia, 5885
 targeting
 study of anticancer drugs, use of yeast, 3591

Docosahexanoic acid
 1,2-dimethylhydrazine aberrant crypt foci
 reduction in formation, colon, 2786

Doxorubicin
 antibody-targeted delivery
 entrapment in liposomes, eradication of lung cancer, 1484
 -bovine serum albumin conjugate
 multidrug resistance, rat hepatoma, 4238
 cardiotoxicity
 effect of verapamil, altered muscle gene expression, 4658
 combined with liposome-encapsulated muramyl tripeptide
 canine monocyte activation, 3986
 cyclophosphamide and 5-fluorouracil plus interferon- α 2b, advanced breast cancer, 3509
 cyclosporin A and
 Phase I pharmacokinetic study, 4837
 encapsulated in liposomes
 initial clinical trial, 2796
 growth and drug resistance
 small heat shock protein hsp27, breast cancer cell lines, 4443
 -induced apoptosis
 inhibition by 2-deoxy-D-glucose, 2057
 -pretreated BALB/c mice
 cardioprotective properties, O -(β -hydroxyethyl)-rutosides, 4603
 resistance
 modulatory effects, tamoxifen and recombinant human α -interferon, 3040
 sterically stabilized liposomes
 arrest of growth, human lung tumor xenograft, 3964
 -treated normal and tumor-bearing mice
 protective effects, interleukin 1 α , 1565
 treatment of sarcoma-bearing rats
 preservation of lean body mass, growth hormone, 5483

Drug delivery
 controlled release polymers
 interstitial chemotherapy, 329

Drug resistance
 alternatively spliced glucocorticoid receptor mRNAs
 human multiple myeloma cells, 3877
 cross-resistance to diverse drugs
 primary cisplatin resistance, ovarian cancer cell lines, 5225

growth and
 small heat shock protein hsp27, breast cancer cell lines, 4443
L5178Y murine lymphoblasts
 chemical sensitivity, cytosolic glutathione S-transferases, 3530
mammalian DNA topoisomerase I poison
 Hoechst 33342, human cell cultures, 1332
nephrotoxicity and
 cisplatin and metallothionein synthesis, bladder tumor, 1829
temperature-sensitive topoisomerase II allele
 amsacrine and etoposide, 89

Drug screening
 amphibolic drug combinations multienzyme systems, 3998

D17S74
 linkage analysis in thirty-five families premenopausal bilateral breast cancer, 212

DT-diaphorase
 density-dependent growth inhibition normal but not transformed cells, 1338
gene expression
 cigarette smoking as determinant, non-small cell lung carcinoma, 5458

DU-145 cells
 invasive potential
 metalloproteinase matrilysin, 417

E

ED-110
 induction
 topoisomerase I-mediated DNA cleavage, 490

Edatrexate
 compared to methotrexate
 leucovorin rescue, metastatic murine solid tumors, 587

Edelfosine
 exposure of L1210 cells
 increased generation, lipid-derived and ascorbate free radicals, 711

Effector cells
 anti-CD3/IL-2
 cross-reactivity, lymph nodes draining heterologous clones of a murine tumor, 4315

Effusions
 tumor and inflammatory vascular permeability factor, guinea pig and human, 2912

Ehrlich ascites
 tumor-bearing mice
 purine nucleotide levels, host tissues, 5143

Eicosanoids
 modulation of arachidonic acid metabolism
 sensitivity of tumoricidal function, macrophages from different sites, 3362

ELAM-1
 adhesion of human cancer cells carbohydrate antigens, vascular endothelium, 354

Electron paramagnetic resonance
 membrane lipid free radicals

SUBJECT INDEX TO VOLUME 53

photofrin photosensitization, L1210
 murine leukemia cells, 3670

Electrophilic intermediates
 formation of
 cytochrome P-450-induced cytotoxicity, mitoxantrone, 5135

Elk-1 proteins
 phosphoproteins
 activators, mitogen-activated protein kinase, 3449

Elongation factor 2
 phosphorylation
 normal and malignant rat glial cells, 2260

Embryo cells
 radiation-transformed rat
 presence of point mutations, N-ras gene, 1511

rat fibroblast
 wild-type adenovirus type 5 transforming genes, transdominant suppressors of oncogenesis, 1929

Syrian hamster
 immortalization, 4797
 induction of neoplastic progression, protein phosphatase inhibitors, 1777

EMT6 cells
 adducts of mitomycin C and DNA
 hypoxia and dicumarol, 5127

 phototoxicity and pharmacokinetics benzophenoxazine analogues, 2571

Endometrial neoplasms
 subcellular localization
 blood group Le^b carbohydrate antigen, 3643

Endometrium
 hyperplasia and carcinoma
 mutation, Ki-ras protooncogene, 1906

 uterine
 p53 alterations, c-K-ras-2 activation, 1883

Endoplasmic reticulum
 subcellular distribution
 bcl-2 oncoprotein, 4701

Endothelial cells
 antiangiogenic effects
 quinoline-3-carboxamide linomide, 1833
 migration and invasiveness
 induction by soluble factor, polyoma virus-transformed middle T oncogene, 3812

 platelet-derived growth
 sensitivity of KB cells, pyrimidine antimetabolites, 5680

 proliferation
 relationship to tumor vascularity, human breast cancer, 4161

 regional proliferation
 β -fibroblast growth factor expression, squamous cell carcinoma, 1444

Endothelial growth factor
 vascular
 photosensitizer uptake, 153

Endothelin 1
 stimulation of production by interleukin 6
 human breast cancer cells, 464

Endothelioma
 soluble factor
 induction of endothelial cell migration and invasiveness, polyoma virus

 middle T oncogene, 3812

Endothelium
 - dependent relaxation
 photodynamic therapy, rat aorta, 2548

 proliferation
 tumors of different histotypes, systemic expression of HIV-1 tat gene, 5569

Enzymes
 drug- and carcinogen-metabolizing
 non-small cell lung cancer, peritumoral tissues, 4608

 main drug-metabolizing systems
 human breast tumors, peritumoral tissues, 3541

 multienzyme systems
 amphibolic drug combinations, 3998

 sequential impact of tiazofurin and ribavirin
 bone marrow, 5982

1,6-Epi-cyclophellitol
 inhibition of metastasis, 4896

Epidemiology
 derivation of etiology from human-based studies, 2437s

Epidermal growth factor
 blockade of receptor function
 bivalent and monovalent fragments, monoclonal antibodies, 4322

 inhibition of laryngeal papilloma differentiation
 epidermal growth factor receptor, 910

 - like growth factor secretion
 inhibition by vitamin A, tracheobronchial epithelial cells, 2527

 - mediated receptor-dependent events
 inhibitory effects, α -interferon, 5148

 receptor-mediated autocrine and paracrine stimulation
 transitional cell carcinoma, 5300

 regulation of fibroblast hepatocyte growth factor/scatter factor
 breast carcinoma cell lines, 1233

Epidermis
 mouse dendritic T-cells
 killing, skin-derived tumor cells, 4014

 transgenic
 cooperation between v-fos and v-ras
 Ha, papillomas, 5071

 ultraviolet-induced cyclobutane pyrimidine dimers
 hairless mouse, 1642

Epinephrine
 mechanisms of change in tumor blood flow
 morphometry, 5528

Epipodophyllotoxin
 - related secondary AML
 disruption, common region of ALL-1 gene, 2954

Epithelial cells
 ectocervical
 immortalization, human papillomavirus, 4511

 mammary
 estrogen receptor-negative, inhibition of growth by estrogen, 5004

 mechanism of protective effect
 supplemental dietary calcium, cytolytic activity of fecal water, 248

 polarized
 entry of protein toxins, 1755

 proliferation in rat colon
 caloric restriction, dietary fat, 2745

 proliferative compartment
 frequency of adenomatous polyps, strength of family history, 279

 rat kidney
 HPV16 transformation, glucocorticoid requirement for growth, 4432

 reversible inhibition of proliferation
 Agaricus bisporus lectin, 4627

Epithelial neoplasms
 mucin synthesis and secretion
 MUC-1 mucin gene, 1437

Epithelium
 cervical
 retinoid status, appearance of reserve cells and keratin expression, 2287

 colonic
 antiproliferative effect, dietary calcium, 784

 small intestinal
 inhibition of doxorubicin-induced apoptosis, 2-deoxy-D-glucose, 2057

 tumor-distant
 mutated p53, head and neck cancer, 4189

 vascular
 adhesion of human cancer cells, carbohydrate antigens, 354

Epitopes
 cancer-defined B-cell
 analysis of p53 antibodies, exposure on protein surface, 5872

 cross-reactivity of anti-CD3/IL-2 activated effector cells
 lymph nodes draining heterologous clones, murine tumor, 4315

 tumor-specific
 Escherichia coli, breast tumor-associated mucin fusion protein, 4920

erbB-2
 gene amplification
 heterogeneity, bladder cancer, 2199

 overexpressing rat thyroid cells
 loss of thyrotropin regulation, TGF- β
 induced growth arrest, 5548

 overexpression in breast tumors
 high-level of expression, ribosomal protein L19, 1403

Erythroleukemia
 anticancer drug-sensitive clone
 mechanism of antineoplastic drugs, 1877

 induced differentiation
 different modulation, protein kinase C isoforms, 5554

Esophageal neoplasms
 correlation
 E-cadherin expression, invasiveness, 3421

 risk of fatal cancer
 aspirin use, 1322

Esophagus
 normal/dysplastic/squamous cell carcinoma
 expression of sialyl-Tn antigens, 1706

 precancerous lesions
 accumulation of p53 protein, carcinogenesis, 1783

 squamous cell carcinoma
 TP53 gene mutation, 5745

Estradiol

SUBJECT INDEX TO VOLUME 53

hormone regulation of human prostate
organ culture, 5199

-induced renal tumors
localization of estrogen receptors, interstitial cells, 5447

induction of retinoic acid receptors
human breast cancer cells, 5940

17 β -Estradiol
induction of *jun* gene family members
breast cancer cells, 291

17 β -Estradiol glucuronide
inducer of cholestasis
physiological substrate, multidrug resistance transporter, 5382

Estramustine
depolymerization of microtubules
binding to tubulin, 4573

Estrogen
antiestrogen modulation and
insulin-like growth factor-binding proteins, MCF-7 cells, 5193

antiestrogens
inhibition of angiogenesis, 533

-induced kidney tumors
increase, insulin-like growth factor 1 receptors, 2256

inhibition of estrone sulfatase activity
estrone-3-methylthiophosphonate,
breast cancer, 298

inhibition of growth
estrogen receptor-negative mammary epithelial cells, 5004

localization of receptors in interstitial cells
estradiol-induced renal tumors, interstitial cells, 5447

receptor
exon 5 deletion variant, wild-type estrogen receptor in breast cancer, 5882

receptor-negative BT-20 breast cancer cell line
constitutively active estrogen receptor variant, 5934

receptor-positive transplantable rat thyroid tumor cell lines
establishment of, 4408

-regulated genes
acquisition of hormone-independent growth, MCF-7 cells, 283

-responsive breast cancer cell lines
estrogen receptor variant messenger RNA lacking exon 4, 741

type II binding sites
dysplastic dorsolateral prostate, Noble rat, 528

Estrone
inhibition of *in vivo* conversion of androstanedione
vorozole, healthy postmenopausal women, 4563

Estrone sulfatase
inhibition by estrone-3-methylthiophosphonate
breast cancer therapy, 298

Ethanol
transplacental induction
pancreas tumors in hamsters, 2498

Ether lipid
analogues
inhibition of phosphatidylinositol-3-kinase, 4297

cryopreservation and
in vitro purging, removal of breast cancer cells from bone marrow, 3747

edelfosine
lipid-derived and ascorbate free radicals, L1210 cells, 711

N-Ethyl-N'-nitro-N-nitrosoguanidine
mutagenic processing of ethylation damage
mammalian cells, 1149

7-Ethyl-10-[4-(1-piperidino)-1-piperidino]-carboxyloxy-camptothecin
therapeutic efficacy
human tumor xenografts, 2823

Etiology
derivation from human-based studies, 2437s

ET-18-OCH₃
inhibition of phosphatidylinositol-3-kinase, 4297

Etoposide
carboplatin and cyclophosphamide
Phase I trial with autologous bone marrow transplantation, refractory germ cell tumors, 3730

drug resistance
temperature-sensitive topoisomerase II allele, 89

-induced apoptosis
inhibition by bcl-2 protein, topoisomerase II-induced DNA strand breaks and their repair, 4251

-induced apoptosis in HL-60 cells
intracellular acidification, 2349

-induced cytotoxicity
human T-cell leukemic lines, 4287

pharmacokinetics in children
dosing equation, 4881

radiation sensitization
DNA repair and cell cycle interactions, 2105

randomized Phase I trial
granulocyte-macrophage colony-stimulating factor, advanced malignancies, 5929

reversal of resistance by novobiocin
non-P-glycoprotein expressing multi-drug-resistant tumor cell lines, 5487

toxic effects
protection of stromal cells, AS101, 1838

Ewing's tumor
chimeric EWS-FL11 transcript complex t(11;22;14) translocation, 3655

EWS/Fli-1
chimeric protein
transcriptional activator, 5859

Exon 7
lack of
APC gene messenger RNA, novel isoforms, 5589

Extracellular matrix
altered
influence on cellular processes, bladder urothelial cells, 4971

M, 72,000 matrix metalloproteinase binding and localization, cell surface invadopodia, 3159

melanoma-mediated dissolution proteolytic pathways, 693

metalloproteases

tumor grade and invasion, bladder cancer, 5365

production and degradation
plasminogen activator, adenoid cystic carcinoma cells, 147

reorganization
radiation-induced transforming growth factor β , murine mammary gland, 3880

type II transforming growth factor β receptor
enhanced expression, human pancreatic cancer cells, 2704

F

F(ab')₂ fragments
⁶⁷Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35
preclinical evaluation, 5727

radiolabeled chimeric monoclonal antibody MOv18 IgG and kinetics and tissue distribution, ovarian carcinoma, 5413

Farallon Island Radioactive Waste Dump
chromatophoromas and chromatophore hyperplasia
Pacific rockfish, 1761

Fas antigen
antibody and drugs or toxins
overcoming tumor necrosis factor and drug resistance, 2591

Fenretinide
dietary
decreased tumor incidence, mouse prostate reconstitution model system, 4461

effectiveness against human ovarian carcinoma xenograft
potentiation, cisplatin activity, 5374

lowering of plasma insulin-like growth factor I levels
breast cancer, 4769

treatment of prostate cancer, 224

Ferritin
induction of synthesis
tumor cell heme uptake, altered oxidant sensitivity, 5308

FET cells
induction of TGF- α promoter activity
TGF- α secretion, colon adenocarcinoma, 4041

α -Fetoprotein
human cord serum
sugar chains, human liver and hepatocellular carcinoma, 2970

lectin-reactive
early detection, hepatocellular carcinoma, 5419

Fetus
prenatal exposure to diethylstilbestrol
pituitary tumors, 1546

rat brain cells
migratory pattern, human glioma cells in adult rat brain, 5158

Fibroadenoma
phyllodes tumor and
clonal analysis, breast, 4071

Fibroblast growth factor
 β -regional endothelial cell proliferation, squamous cell carcinoma, 1444

SUBJECT INDEX TO VOLUME 53

acidic and basic
overexpression, advanced stage pancreatic cancer, 5289

basic
overexpression of complementary DNA, H-ras-transformed cells, 158
secretion by an animal tumor, detection in urine, 5297
unscheduled expression, pancreatic acinar cancer cell line, 1182

differential growth factor production
high and low metastatic variants, B16BL6 melanoma, 4075

type I receptor
aberrant expression, pancreatic adenocarcinoma, 4741

Fibroblast growth factor 4
LacZ and
cotransfection of MCF-7 cells, spontaneous metastasis, 2178
transfection of MCF-7 cells
tumorigenicity, tamoxifen-treated athymic nude mice, 2168

Fibroblasts
activation protein
regulation and heteromeric structure, cells of mesenchymal and neuroectodermal origin, 3327

amphiregulin and epidermal growth factor receptor
estrogen receptor expression, human primary breast cancer, 3597

diploid human
factors that stimulate production of hyaluron
human mesothelioma cells, 388

H-ras-transformed
spontaneous revertants, up-regulation of lysyl oxidase, 4670

human diploid
production of morphological transformants, transforming growth factor- α , 2162

hypersensitivity of human lymphocytes UV-B and solar irradiation, 609

lung
insulin-like growth factor-I, lung carcinoma cells, 3399

neoplastic transformation and tumorigenic conversion
 $\alpha\beta$ integrin, 2950

normal and group C
DNA strand bias, repair of *p53* gene, 5377

normal human
association of origins of replication, nuclear matrix, 3865

preneoplastic and neoplastic Syrian hamster embryo
transformation by carcinogens, amplification potential, 3098

presence of transforming genes
gonadal tumors, bivalve mollusk species, 2976

production of growth-promoting factor wide target cell spectrum, THP-1 cells, 1871

rat embryo cells
inhibition of DNA synthesis, H-ras and *v-myc*, 1213
wild-type adenovirus type 5 transforming genes, transdominant suppression

sors of oncogenesis, 1929
regulation of hepatocyte growth factor/scatter factor expression
peptide growth factors, breast carcinoma cell lines, 1233

SV40-infected precrisis
multiple mechanisms, N-(phosphonacetyl)-L-aspartate drug resistance, 4946

transformed
purification and characterization, cytotoxic protein, 1195

Fibronectin
adhesion of metastatic ras-transformed NIH 3T3 cells, 701
chemotaxis and haptotaxis
autocrine motility factor-like substance, human malignant mesothelioma cells, 4376

pre-messenger RNA alternative splicing coordinate oncodevelopmental modulation, liver tumor, 2005

Fibrosarcomatous cells
enhanced survival
BCL-2 protein expression, tumor necrosis factor-mediated cytotoxicity, 1456

Fibrosarcoma
syngeneic
autoactive and heat shock protein 60, antitumor activity, 106

Flavonoids
arrest of cell cycle progression G₂-M, genistein, 1328

Flavonol
stimulated efflux
7,12-dimethylbenzanthracene, multidrug-resistant breast cancer cells, 5977

Fli-1 protein
EWS/Fli-1 chimeric protein transcriptional activator, 5859

Flow cytometry
bromodeoxyuridine labeling and tamoxifen-induced increase in doubling time, MCF-7 xenografts, 4413

genotypic characterization
prostatic carcinoma, 4035

Fluid
accumulation
pathogenesis, malignant ascites formation, 2631

interstitial pressure and tumor blood flow, angiotensin II-induced hypertension, 2466

Fluorescence
laser-induced
pharmacokinetics, fluorescent drug, 5954

5-Fluorocytosine
antitumor activity
colorectal carcinoma cells, cytosine deaminase expression, 4619

Fluorodeoxyuridine
-induced DNA damage and cytotoxicity elevation of deoxyuridine triphosphate, failure to accumulate deoxyuridine triphosphate, 5219

5-Fluorodeoxyuridine
circadian-dependent toxicity
cytidine deaminase, relevance to pyrimidine enzymes, 2816

5-Fluoro-2'-deoxyuridine
± N-phosphonacetyl-L-aspartate antitumor activity, colon carcinoma 26, 1560

5-Fluoropyrimidines
differences in activities and substrate specificity
pyrimidine nucleoside phosphorylases, chemotherapy, 3687

5-Fluorouracil
calcium leucovorin and N-(phosphonacetyl)-L-aspartate combination, metastatic gastrointestinal adenocarcinoma, 4828

chemotherapy-induced myocardial ischemia
protein kinase C-mediated vasoconstriction, vascular smooth muscle, 3028

clinical implication for chemotherapy dihydropyrimidine dehydrogenase activity, human peripheral blood mononuclear cells and liver, 5433

cyclophosphamide and doxorubicin plus interferon- α 2b, advanced breast cancer, 3509

cis-diamminedichloroplatinum(II) and with and without leucovorin, non-small cell lung cancer cell lines, 1079

inhibition of gastrointestinal toxicity oxonic acid, no loss of antitumor activity, 4004

-interferon combinations
cytokinetic effects of interferon, colorectal cancer, 5429

leucovorin and interferon- α 2a locus of interaction, colon carcinoma cells, 4243

novel mechanism of resistance decreased folylpolyglutamate synthetase expression, 3677

protective role of AS101 combination with several cytotoxic drugs, mechanisms of action, 5962

FO-1 cells
induction and antigenic profile HLA-A and -B antigens, β_2 -microglobulin, 4303

Folate
deficiency
damage by alkylating agents and γ -irradiation, Chinese hamster ovary cells, 5401

Folate binding protein
gene transfection and expression NIH/3T3 cells, 5791

Folylpolyglutamate synthetase
decreased expression novel mechanism, fluorouracil resistance, 3677

Forestomach
induction of cell proliferation styrene 7,8-oxide, butylated hydroxyanisole, 3505

Formalin
-fixed paraffin-embedded tissue X chromosome inactivation, 4676

Fostriecin
aberrant functions
teniposide-resistant CEM cells, 5946

Fourier transform infrared spectroscopy

SUBJECT INDEX TO VOLUME 53

ultrastructural appraisal
multidrug resistance, K562 and LR73
cell lines, 3681

Free radicals
membrane lipid
photofrin photosensitization, L1210
murine leukemia cells, 3670

Friend erythroleukemia
anticancer drug-sensitive murine clone
mechanism of action, antineoplastic
drugs, 1877

Friend leukemia cells
metastatic
 α_1 -interferon gene transfer, abrogation
of tumorigenicity, 1107

Fruit
vegetables and
lung cancer, Iowa Women's Health
Study, 536

α -1,3-Fucosyltransferases
synthesis of sialyl Le^a and sialyl Le^b
human malignant cell lines, 5559

Funding
mechanisms
research through the American Cancer
Society, 2436s
research through the National Cancer
Institute, 2434s

Furan
preferential induction in right/caudate
liver lobes
"intestinal-type" adenocarcinoma, 254

Fusion proteins
breast tumor-associated
Escherichia coli, tumor-specific epi-
tope, 4920

BR96 sFV-PE40
selective killing, carcinoma cells, 334

single chain anti-carcinoma antibody
fused to β -lactamase
genetic construction, expression and
characterization, 2123

Fusion toxins
DAB₄₈₈IL-2
Phase I trial, hematological cancers,
3930

Fv molecules
741F8 anti-c-erbB-2 single-chain Fv
monovalent and divalent forms, *in vivo*
tumor targeting, 4026

G

Galactoside
-binding lectin
regulation of expression, monocytic
differentiation, 5033

Galaptin
-mediated adhesion
A121 cells, detection of cellular galap-
tin-binding glycoproteins, 2667

Gallium nitrate
inhibition of protein tyrosine phosphatase, 1862

Gangliosides
 G_{M2} and G_{D2}
genetic and enzymatic basis, human
cancer cell lines, 5395

G_{M3}
molecular cloning of monoclonal anti-
body, human cancers, 5244

lactotetraose series
3',6'-isomeric, tumors of central nervous
system, 120

Gap junction
function and cancer, 3475

Gastric neoplasms
base transitions
genetic changes at p53, 2614
high affinity binding sites
gastrin-releasing peptide, Ménétrier's
mucosa, 5090

human cell line in chick embryo
TIMP-1, negative regulator of met-
astatic ability, 1397

monoclonal antibody 2B5
truncated mucin glycan, 4791

poorly differentiated type
genetic instability, pancreatic cancer,
5087

primary and metastatic
E-cadherin expression, 1690

tissue of type O individuals
biosynthetic basis, incompatible histo-
blood group A antigen, 5494

Gastrin
expression and processing of progastrin
ovarian cancer, 1823

gene expression
normal human colon and colorectal
adenocarcinoma, 2919

Gastrin-releasing peptide
high affinity binding sites
human gastric cancer, Ménétrier's mu-
cosa, 5090

Gastritis
precancerous gastric lesions
high risk population, stomach cancer,
1317

Gastrointestinal neoplasms
Phase I clinical trial
monoclonal antibody D612, metastatic
gastrointestinal cancer, 4555

Gastrointestinal tract
adenocarcinoma
vascular permeability factor, its recep-
tors, 4727

human cancer cell lines
antiproliferative effects, isoflavones,
5815

inhibition of oxonic acid
5-fluorouracil, no loss of antitumor ac-
tivity, 4004

Glutaminase
72-kDa
interstitial collagenase and stromely-
sin, tumor cell-derived collagenase-
stimulatory factor, 3154

Gel electrophoresis
individual cells
quantification of hypoxic fraction, hu-
man breast cancers, 733

Gene
AF-6
cloning of *ALL-1* fusion partner, acute
myeloid leukemia, 5624

ALL-1
disruption in common region, epipo-
dophyllotoxin-related secondary
AML, 2954

rearrangements analyzed by Southern
blot, chromosome 11q23 in acute
leukemia, 3800

altered expression
oxy radicals and antioxidant re-

sponses, cancer, 3207

AML1/ETO fusion transcript
t(8;21) masked translocation, acute
myelogenous leukemia, 4449

analysis of *in vitro* progression
human papillomavirus-transfected cer-
vical cells, 1167

APC
messenger RNA, novel isoforms that
lack exon 7, 5589

somatic and germ-line mutations, des-
moid tumors, 5079

wild type and mutant gene products,
2728

ataxia-telangiectasia
Fifth International Workshop, 438

bcl-2
modulation, nitrogen mustard and
camptothecin induced apoptosis,
1853

regulation of oncoprotein, human
neuroblastoma cells, 4978

tumor necrosis factor-mediated cyto-
toxicity, survival of mouse fibrosar-
coid cells, 1456

BCL-ABL
role in human leukemia, 485

bcl-2 oncogene
subcellular distribution, 4701

bulk damage to DNA
teniposide antiproliferative activity,
MCF-7 cells, 3547

E-cadherin
differentiation marker, thyroid malig-
nancies, 4987

cancer susceptibility
polycyclic aromatic hydrocarbon-DNA
adducts, human lung, 3486

carinoembryonic antigen
baculovirus recombinants, 2154

α -catenin
reduction of E-cadherin levels, pros-
tate cancer cells, 3585

Ca^{2+} -transporting ATPase isoform
cloning, von Hippel-Lindau syndrome,
861

CDK4
coamplification with *MDM2* and *GLI*,
human sarcomas, 5535

CEA-related
biliary glycoprotein, down-regulation
in malignant mouse tissues, 4938

cell density inhibition of proliferation
multiple histone promoter factors, os-
teosarcoma cells, 2399

chimeric EWS-FL11 transcript
Ewing cell line, complex t(11;22;14)
translocation, 3655

chromosome mapping of murine suscep-
tibility loci
liver carcinogenesis, 209

complementary DNA
heparin-binding growth factor recep-
tor, use of kinase insert sequence,
1136

cyclin
amplification, colorectal carcinoma,
1986

cyclin D1
breakpoints within *BCL-1* locus, B-cell
lymphoma, 4148

CYP1A1 and glutathione S-transferase

polymorphisms, lung cancer susceptibility and cigarette dose, 2994
DCC
 expression in human gliomas, 5606
 loss of expression and heterozygosity, prostatic carcinoma, 2723
 deleted region of chromosome 9
 preliminary mapping, bladder cancer, 1230
 detection and intervention
 early ovarian cancer, 3839
 dihydrofolate reductase
 allelic variation at amino acid position 95, antifolate resistance in Chinese hamster cells, 6031
 disease-causing *APC* alleles
 rapid screening method, nonsense and frame-shift mutations, 5581
 DNA topoisomerase II
 response to heat shock stress, KB cells, 1085
 DT-diaphorase
 cigarette smoking as determinant, non-small cell lung carcinoma, 5458
elk-1 variant
 differential splicing, encoding of activators and repressors, 215
 epidermal growth factor receptor
 TGF- α production and autoinduction, colorectal carcinoma cell line, 1630
erbB-2: see *erbB2*
ERCC-1
 sensitivity of Chinese hamster ovary cells, DNA damaging agents, 3237
 erythropoietin
 down-modulation, induced megakaryocytic maturation, 1156
 estrogen receptor
 transcriptional control, estrogen receptor-negative breast carcinoma, 3472
 EWS/Fli-1 chimeric protein
 transcriptional activator, 5859
 expression and cell proliferation in liver 2,3,7,8-tetrachlorodibenzo-*p*-dioxin exposure, 2265
 familial breast/ovarian cancer locus
 deletion unit on chromosome 17q, epithelial ovarian tumors, 1218
 fibronectin pre-mRNA alternative splicing
 coordinate oncodevelopmental modulation, liver tumor, 2005
 fusion of *PAX3*
 transcription factors, alveolar rhabdomyosarcoma, 5108
 gastrin
 expression, normal human colon and colorectal adenocarcinoma, 2919
 genetic and enzymatic basis
 G_{M2} and G_{D2} differential expression, human cancer cell lines, 5395
 genetic modification of fraction of tumor mass
 bystander effect, tumor regression, 5274
 glutathione S-transferase μ polymorphism
 marker for susceptibility, lung carcinoma, 2313
grc congenic strains of rats
 different susceptibilities, chemical carcinogens, 4089

growth factor B
 platelet-derived growth factor β receptor and, genesis of choriocarcinoma, 2927
 growth factor dependency
 preneoplastic mouse mammary epithelial cells, 668
 growth factor regulation of expression human prostatic carcinoma cell line, 1051
 heme oxygenase
 singlet oxygen, UVA/near-visible light, 4505
 heterogeneity in MLL/AF-4 fusion mRNA
 polymerase chain reaction, t(4;11) acute leukemia, 3853
 high efficiency transfer
 primary human tumor explants, no cell selection, 2221
 high mobility group protein I(Y)
 increased expression, high grade prostate cancer, 5512
 progressive transformation, mouse mammary epithelial cells, 2655
hinge
 human mitochondria, elevated expression in cancer, 2460
HIV-1 tat
 endothelial proliferation, tumors of different histotypes, 5569
HNPPC
 genetic instability of microsatellites, endometrial carcinoma, 5100
 homeobox *HB24*
 ability to form tumors in nude mice, human T-cell line, 373
hprt
 profile of mutations, 7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo(*a*)pyrene, 3294
IGF2
 maintenance of genomic imprinting, locus in hepatoblastoma, 4781
 instability
 clinicopathological variables and family history, colorectal cancer, 5849
 instability in pancreatic cancer
 poorly differentiated type, gastric cancer, 5087
 insulin-like growth factor II
Avall restriction fragment length polymorphism, occurrence of smooth muscle tumors, 5754
 inhibition of expression, tamoxifen, 1727
int-2
 growth-stimulating activity of IL-6, mammary epithelial cells, 2957
 interferon
 homozygous loss, critical region on 9p deleted in lung cancer, 2410
 α -interferon-inducible
 human chromosome 14q32 expression, breast carcinoma, 4096
 α -interferon transfer
 metastatic Friend leukemia cells, abrogation of tumorigenicity, 1107
 γ -interferon
 enhanced HLA molecule expression, human tumor infiltrating lymphocytes, 3561
 interleukin 2
 protective and curative potential of vaccination, mouse mammary adenocarcinoma, 5067
 transfection into melanoma cells, cellular immune response, 949
in vitro and *in vivo* targeting of expression melanoma cells, 962
Ki-ras expression
 production of transgenic mice, thyroglobulin promoter, 5523
LacZ
 cotransfection of MCF-7 cells with fibroblast growth factor 4, spontaneous metastasis, 2178
lacZ reporter
 quantitative analysis, disseminated tumor growth within brain, 176
 limited molecular heterogeneity
 allelotyping and clonal analysis, metastatic breast carcinoma, 3804
 linkage analysis of *DRD2*
 ataxia-telangiectasia gene, premenopausal bilateral breast cancer, 5083
 loss of heterozygosity
 invasive low-grade and high-grade epithelial ovarian carcinoma, 4456
M, 170,000 isozyme
 single-strand conformational polymorphism, DNA topoisomerase II, 1373
MAGE-1/MAGE-2/MAGE-3
 messenger RNA expression, transformed and normal human cell lines, 5
MDM2
 amplification, metastatic osteosarcoma, 16
 amplification and overexpression, glioma without *p53* mutation, 2736
 amplification in pediatric solid tumors, lack of association with *p53* in adult squamous cell carcinoma, 6028
MDM2 amplification
p53 mutation, human soft tissue sarcoma, 2231
mdr1
 P-glycoprotein external epitope, monoclonal antibody, 310
mdr3
 transcriptional activation, multidrug-resistant P388 tumor cells, 1657
 mechanisms of drug-induced changes
 heat shock proteins, differentiation, 3034
 monoclonal antibody
 self-reactive antibody expression, human carcinoma cells, 3355
 monomorphic *NAT1* and polymorphic *NAT2*
 metabolic activation of N-hydroxy-2-aminofluorene, colon cytosols, 509
MRP
 non-P-glycoprotein multidrug resistance, 190-kDa membrane bound glycoprotein, 3658
 transmembrane drug transporter, multidrug-resistance lung cancer cell lines, 1747
MUC-1
 mucin synthesis and secretion, epithelial cancer cell lines, 1437

SUBJECT INDEX TO VOLUME 53

mucin
heterogeneity of expression, normal and neoplastic tissues, 641

multidrug resistance-associated localization, HT1080/DR4 and H69AR human tumor cell lines, 3221

mutated *WT1*
altered trans-activational properties, WAGR-associated Wilms' tumor, 4757

nm23
mutation associated with metastasis, colorectal cancer, 717

transfection and inhibition of cell motility, human and murine tumor cells, 1971

N-ras
presence of point mutations, radiation-transformed rat embryo cells, 1511

oligodendrocyte-associated
human glioma and neuroblastoma cell lines, 170

ornithine decarboxylase and ribonucleotide reductase R2 subunit
resistance to hydroxyurea, K562 cells, 5262

overexpressed
cloning, mammary carcinoma suppressor, 5766

parathyroid hormone-related protein
PCR analysis, breast cancer and bone metastases, 5076

p53-binding protein *MDM2*
differential expression, human breast carcinoma, 3226

plasmid reporter
inactivation of expression, one benzo(a)pyrene diol-epoxide DNA adduct in hepatocytes, 2279

predisposition
transplacentally induced renal cell carcinoma, Eker rat, 5856

progesterin
ovarian cancer, 1823

prostatic nerve growth factor inducible A
binding of novel element, retinoblastoma gene promoter, 5597

Ptpg
carbonic anhydrase-like domain, homozygous deletion in L-cells, 1498

***ras* mutations**
detection in pancreatic juice and peripheral blood, pancreatic adenocarcinoma, 2472

rearrangement in Adriamycin-resistant P388 leukemia
DNA topoisomerase II α , 5885

retroviral-mediated transfer
treatment of brain tumors, rats, 83

scid
complementation of radiosensitive phenotype, chromosome 8, 6011

stromelysin 3
local invasiveness, head and neck squamous cell carcinoma, 165

supF
sequence specificity, stereoisomeric benzo[c]phenanthrene dihydrodiol epoxides, 1273

susceptibility in SWXJ strains of mice

C19 androgen induction, ovarian granulosa cell tumorigenesis, 1059

T-cell receptor
DNA sequence analysis, oligoclonal T-cell response, 840

therapy
cytokine-modified renal carcinoma cells, 4020

three regions on chromosome 17q frequent deletion, primary human breast carcinomas, 5617

thymidine kinase
herpes simplex virus, inhibition of melanoma growth by intratumoral DNA injection, 3860

***TP53* mutations**
esophageal squamous cell carcinoma, 5745

transcriptional activity
inactive *p53* mutants, wild-type *p53*, 4772

selective removal from epidermis, ultraviolet-induced cyclobutane pyrimidine dimers, 1642

transfection and expression
folate binding protein, NIH/3T3 cells, 5791

transforming
presence in gonadal tumors, bivalve mollusk species, 2976

ubiquitin-ribosomal protein S27a
early growth response gene, human colorectal carcinoma, 1916

WT1
granulosa cell and other sex cord-stromal tumors, 2712

Genistein
antiproliferative effects of isoflavones gastrointestinal tract, human cancer cell lines, 5815

arrest of cell cycle progression G₂-M, 1328

Genomic imprinting
maintenance of IGF2 locus, hepatoblastoma, 4781

Genotoxicity
benzene and phenolic metabolites oxidative DNA damage, HL-60 cells and bone marrow, 1023

DNA-protein cross-links
molecular implications, welders, 460

induction of cell proliferation in fore-stomach
styrene 7,8-oxide, butylated hydroxyanisole, 3505

Germ cell neoplasms
Phase I trial with autologous bone marrow transplantation carboplatin, etoposide and cyclophosphamide, 3730

GF120918
reversal of multidrug resistance, 4595

Glia
normal and malignant phosphorylation of elongation factor 2, 2260

Glia fibrillary acidic protein
transfection of human astrocytoma cells expression, proliferation and tumorigenicity, 3624

Glioblastoma
chromosome 10 loss

functional role, 5043

elevated levels
M, 92,000 type IV collagenases, brain, 2208

human brain metastases
metastasis-related CD44 expression, 5345

modulation of *in vitro* invasion
urokinase-type plasminogen activator receptor antibody, 4143

retroviral-mediated gene transfer
brain tumors in rats, 83

topoisomerase II inhibition and altered kinetics

nitrosourea and cisplatin-induced DNA cross-links, cytotoxicity, 5663

Glioma
elevated levels
M, 92,000 type IV collagenases, brain, 2208

expression of tumor suppressor gene *DCC*, 5605

human cells in adult rat brain migratory pattern, fetal rat brain cells, 5158

localization of chromosome 9p homozygous deletions
continuous linkage group, 3674

model of tumor angiogenesis
up-regulation of vascular endothelial growth factor, cognate receptors, 5822

oligodendrocyte-associated genes, 170

sensitivity of human cells
mild hyperthermia, 2740

treatment by engineered interleukin 4-secreting cells, 3125

Turcot's syndrome
absence of germ line mutations, *p53* gene, 957

without *p53* mutation
amplification and overexpression, *MDM2* gene, 2736

Xenografts
intrarterial therapy, 4-hydroperoxyclophosphamide, 2338

Glucocorticoids
alternatively spliced glucocorticoid receptor mRNAs
human multiple myeloma cells, 3877

disruption of transforming growth factor α autocrine loop
suppression of growth, rat mammary adenocarcinoma cells, 1808

-mediated suppression of mammary tumor growth
overexpression, transforming growth factor α , 1816

requirement for growth
HPV16-transformed rat kidney epithelial cells, 4432

-sensitive and -resistant leukemic cells
cloning and expression, mutant glucocorticoid receptors, 4059

Glucose
transporter protein GLUT 2
reduction in expression, preneoplastic and neoplastic hepatic lesions, 4204

α -Glucosidase
inhibition of metastasis
1,6-epi-cyclophellitol, 4896

γ -Glutamylcysteine synthetase

SUBJECT INDEX TO VOLUME 53

variable messenger RNA expression
peripheral mononuclear cells, buthionine sulfoximine treatment, 3662

γ -Glutamyl hydrolase
enhanced activity
acquisition of resistance to antifolates, 2227

Glutathione
depletion by L-buthionine sulfoximine antagonism, taxol cytotoxicity, 2066
oxy radicals and antioxidative responses in cancer, 3207
reduced
cisplatin-induced neurotoxicity, rats, 544

Glutathione S-reductase
expression of aldo-keto reductase
resistance to aflatoxin B₁, catalytic activity, 3887

Glutathione S-transferase
bifunctional inhibitor W-77
enhanced Adriamycin activity, human ovarian carcinoma, 2051
class α transcripts
carcinogen exposure, hepatocytes, 231
complementary DNA
alkylator-induced toxicity, rat mammary carcinoma cells, 4900
cytosolic
chemical sensitivity, drug-resistant
L5178Y murine lymphoblasts, 3530
immunohistochemical localization
human lung, 5643
polymorphisms
lung cancer susceptibility, cigarette dose, 2994

Glutathione S-transferase μ
cancer susceptibility genes
polycyclic aromatic hydrocarbon-DNA adducts, human lung, 3486
isoenzymes
genotype and phenotype, lung cancer, 1004
polymorphism
marker for susceptibility, lung carcinoma, 2313

Glutathione transferase M3-3
1,3-bis(2-chloroethyl)-1-nitrosourea resistance
non-small cell lung cancer cell line, 4257

Glycan
truncated mucin
monoclonal antibody 2B5, gastric and duodenal glands, 4791

Glyceraldehyde-3-phosphate dehydrogenase
association with cell motility
metastatic potential, prostatic adenocarcinoma, 1995

Glycolipid sulfotransferase
involvement of protein kinase C
activity levels, renal cell carcinoma cells, 2484
regulation of activity levels
transforming growth factor α , renal cell carcinoma cells, 5638

Glycolipids
Gb3/CD77 antigen
induction of apoptosis, Burkitt's lymphoma, 5314

Glycoprotein 2
sulfated

carcinogenesis induced by *N*-nitroso-N-methylurea, prostate and seminal vesicle, 1480

Glycoproteins
biliary
CEA-related gene, down-regulation in malignant mouse tissues, 4938
differential regulation of carcinoembryonic antigen, γ -interferon, 1612
IIB/IIIA binding to fibrinogen inhibition, tumor cell membrane proteins, 221
M, 190,000 membrane bound
MRP gene, non-P-glycoprotein multidrug resistance, 3658

platelet membrane Ib/IX and IIb/IIIa platelet α -granule proteins, aggregation induced by osteosarcoma cells, 4695

sialyl-Le^a-carrying
discrimination of MUC1 mucins, colon carcinoma, 755

Glycosaminoglycan
suramin
multiple potential mechanisms of action, 2239

Glycosphingolipids
compensatory occurrence of IV²Fuc α , II³NeuAc α -Gg α Cer
human fetal antigen Lc α Cer and, small cell lung carcinoma, 5903

Glycosyltransferases
blood group Le^b carbohydrate antigen subcellular localization, endometrial cancer cells, 3643

G nucleotides
incidence of *p53* mutations
progression, head and neck cancer, 4477

Golgi apparatus
blood group Le^b carbohydrate antigen subcellular localization, endometrial cancer cells, 3643

Gonadal neoplasms
presence of transforming genes bivalve mollusk species, 2976

gp46
immunogenic and neutralizing domain sequence analysis, HTLV-I, 6067

gp110
tumor rejection antigen
BALB/c Meth A sarcoma, 1602

Grants
trends in program project grant funding National Cancer Institute, 477

Granulocytes
differentiating HL-60 cells
transforming growth factor- α proto-oncogene, 191

recovery
sequential production, autologous stem cell transplantation, 1297

Granulosa cell neoplasms
WT1 analysis, 2712

Granulosa cells
ovarian
tumorigenesis, androgen induction and genetic susceptibility, 1059

tumorigenesis
genetically hypogonadal-immunodeficient mice grafted with ovaries from tumor-susceptible donors, 3741

Growth factors
dependency and gene expression preneoplastic mouse mammary epithelial cells, 668

differential production
high and low metastatic variants, B16BL6 melanoma, 4075

diverse chemical carcinogens and hepatocarcinogenesis, TGF- α transgenic mice, 4329

epidermal growth factor-like
inhibition of secretion by vitamin A, tracheobronchial epithelial cells, 2527

heparin-binding growth/differentiation factors
new family of, Wilms' tumor and other human carcinomas, 1281

lack of latent transforming growth factor β binding protein malignant prostatic tissue, 3193

-like properties
parathyroid hormone-related peptide, transfected rodent cell lines, 2980

nuclear oncogenes and tumorigenesis, transgenic mouse model, 1719

peptide
regulation of fibroblast growth factor/scatter factor, breast carcinoma cell lines, 1233

platelet-derived
prognostic significance, epithelial ovarian neoplasms, 4550

regulation of gene expression human prostatic carcinoma cell line, 1051

suramin
multiple potential mechanisms of action, 2239

Growth hormone
insulin-like growth factor 1 axis
diet restriction-induced inhibition, mononuclear cell leukemia, 2750
preservation of lean body mass doxorubicin treatment, sarcoma-bearing rats, 5483

GRP78
suppression of induction in B/C10ME tumor
elimination of resistance, cell-mediated cytotoxicity, 6001

H

Haptotaxis
chemotaxis and
autocrine motility factor-like substance, human malignant mesothelioma cells, 4376

H69AR cells
localization
multidrug resistance-associated gene, 3221

H-2 complex
H-2D δ
radiation-enhanced expression, B16 melanoma cells, 1952

Head and neck cancer
discordant *p53* gene mutations, 1676
multistage tumorigenesis
increased polysomes, chromosomes 7 and 17, 2874

SUBJECT INDEX TO VOLUME 53

pharynx preservation
cancer chemoprevention, 5113

Heart
cardioprotective properties
O-(β -hydroxyethyl)-rutosides, doxorubicin-pretreated BALB/c mice, 4603

mitochondrial cytochrome *c* oxidase
target site for daunomycin, 1072

neonatal rat cells
mitoxantrone cardiotoxicity, protection with ICRF-187, 550

Heat
-induced changes in blood flow and cell survival
influence, vascular thermotolerance, 2076

Heat shock proteins
failure to increase levels
oxidative injury, activation of heat shock transcription factor, 12

hsp27
growth and drug resistance, breast cancer cell lines, 4443

hsp60
recognition of CD4⁺ T-cells, syngeneic fibrosarcoma, 106

mechanisms of drug-induced changes gene expression, HL-60 cell differentiation, 3034

M, 73,000
protein interaction, retinoblastoma gene product pRb110, 1702

Heat shock stress
enhanced expression of DNA topoisomerase II gene
KB cells, 1085

HeLa cells
differential effect of ionizing radiation cyclin A and cyclin B, 1128
extracts from normal and malignant transformed human cells fidelity, DNA replication, 3270
inhibition of oxidative stress chemopreventive agents, 4528
radiation yield of interphase chromosomes breaks
mitosis-promoting factor activity, inducer mitotic cells, 5592

HeLa S3 cells
induction of protein-DNA complexes KW-2149, 4466

Hematological neoplasms
cell proliferation marker cyclin A expression, 235

Phase I trial of 90-minute infusion fusion toxin DAB₄₈₆IL-2, 3930

Hematopoiesis
autologous stem cell transplantation sequential production, granulocyte recovery, 1297
differentiating HL-60 cells transforming growth factor- α protooncogene, 191
normal and neoplastic growth and development, 929

Hematopoietic cells
malignant cell lines unresponsive to retinoic acid
N-(4-hydroxyphenyl)retinamide, induction of apoptosis, 6036
suppression of apoptosis

activation, Abelson tyrosine kinase activity, 1735

Hematopoietic growth factor
induced megakaryocytic maturation down-modulation, erythropoietin gene expression, 1156

Hematopoietic progenitors
heterogeneity of lineage derivation Philadelphia-positive acute lymphoblastic leukemia, 3289

Heme
tumor cell uptake
induction of ferritin synthesis, altered oxidant sensitivity, 5308

Heme oxygenase
enhancement of expression and activity A431 squamous carcinoma multicellular tumor spheroids, 2700
gene induction
singlet oxygen, UVA/near-visible light, 4505

Hemoglobin
4-(methylnitrosamino)-1-(pyridyl)-1-butanone adducts red blood cells, 777

Hemostasis
platelet glycoprotein IIb/IIIa binding to fibrinogen inhibition, tumor cell membrane proteins, 221

Heparin
-binding growth/differentiation factors new family of, Wilms' tumor and other human carcinomas, 1281
-binding growth factor receptor complementary DNA, use of kinase insert sequence, 1136
-steroid conjugates angiogenesis inhibitors, antitumor activity, 3000
suramin multiple potential mechanisms of action, 2239

Hepatitis
early detection of hepatocellular carcinoma lectin-reactive α -fetoproteins, 5419

Hepatitis B
viral antigens immune reactions, rejection of hepatocellular carcinoma, 4648

Hepatitis virus, woodchuck
precancerous altered hepatic foci N-myc 2 and insulin-like growth factor II, 2020

Hepatoblastoma
IGF2 locus maintenance, genomic imprinting, 4781

Hepatocarcinogenesis
N-acetylglucosaminyltransferase III and V
LEC rats, 3899
diethylnitrosamine-induced chemoprevention, protocatechuic acid, 2775
growth factors and diverse chemical carcinogens
TGF- α transgenic mice, 4329
initiation and postinitiation stages chemopreventive effects, dietary DL- α -difluoromethylornithine, 3903

reduction in expression glucose transporter protein GLUT 2, reexpression of GLUT 1, 4204

Hepatocarcinogenicity
DNA adduct formation and tamoxifen and tamoxifen, 4534

Hepatocyte growth factor
-scatter factor regulation peptide growth factors, breast carcinoma cell lines, 1233

Hepatocytes
adhesion integrin $\alpha_6\beta_4$, TA3/Ha mammary carcinoma cells, 3611
fetal rat transformation-induced alterations, tyrosine aminotransferase expression, 515
glutathione S-transferase class α transcripts carcinogen exposure, 231
human cord serum α -fetoprotein sugar chains, hepatocellular carcinoma, 2970
inactivation of plasmid reporter gene expression one benzo(a)pyrene diol-epoxide DNA adduct, 2279
primary rat cell cultures effect of age, formation of small-cell colonies, 3145

Hepatoma
multidrug resistance bovine serum albumin-doxorubicin conjugate, 4238

Hepatoma cells
Kupffer cell-induced reduction of mitochondrial energization mediation by nitric oxide, 2676
proliferating effects of cisplatin, induction of apoptosis, 2133

Hepatotoxicity
4-ipomeanol Phase I and pharmacological study, lung cancer, 1794

HepG2 cells
insulin-like growth factor II expression promotion by suramin, inhibition of growth, 652

Heregulin
induction of ICAM-1 implications, mammary tumors, 5251

Her-2/neu
expression in node-negative breast cancer, 4960

Herpes simplex virus
thymidine kinase gene inhibition of murine melanoma growth, intratumoral injection of DNA, 3860

Heterotransplantation
solubilized attachment matrix early B-lineage acute lymphoblastic leukemia, 1222

Hexamethylene bisacetamide
differential modulation protein kinase C isoforms, erythroleukemia during induced differentiation, 5554

Hexosamines
production of immunosuppressive ami-

SUBJECT INDEX TO VOLUME 53

nosugars
deacetylase activity, human tumor cells, 5600

High mobility group protein I(Y)
elevated gene expression
progressive transformation, mammary epithelial cells, 2655
increased expression
high grade prostatic cancer, 5512

Histone
messenger RNA levels and p34^{cdc2} activation
caffeine release, radiation-induced S and G₂ phase arrest, 1507
promoter factors
cell density inhibition of proliferation, osteosarcoma cells, 2399

Histopathology
correlations
allelic deletions, renal tumors, 5780

HLA complex
-A and -B antigens
induction and antigenic profile, differential effect of β_2 -microglobulin in FO-1 melanoma cells, 4303

class I
sporadic adenomas, histologically normal mucosa of colon, 2374

differential expression of *MAGE-1/MAGE-2/MAGE-3*
messenger RNA, transformed and normal human cell lines, 5

DR antigen expression
signal transduction, malignant and nonmalignant human thyroid cells, 3943

enhanced expression of molecules
stimulation of tumor infiltrating lymphocytes, transduction of melanoma cells, 3561

human epithelial ovarian cancer allele-type, 2393

loss of class I allo specificities
staining of melanoma cells, melanoma cells, 3349

HL-60 cells
differentiation
drug-induced changes in gene expression, constitutive heat shock protein, 3034
transforming growth factor- α protooncogene expression, 191

etoposide-induced apoptosis
intracellular acidification, 2349

induction of apoptosis and cell cycle effects
prevention by caffeine, camptothecin or topotecan, 4613

oxidative DNA damage
benzene and phenolic metabolites, 1023

susceptibility to apoptosis
cell cycle differences, induction by various antitumor agents, 3186

HML-1
binding of intestinal intraepithelial cells
colon cancer cells, 1608

Hodgkin's disease
advanced
serum interleukin 6 levels, correlation with survival, 2118

Hoechst 33342

mammalian DNA topoisomerase I poison
cytotoxicity and drug resistance, human cell cultures, 1332

Hormones
regulation of human prostate organ culture, 5199

H-ras
codons 12 and 13
DNA synthesis interruption, DNA polymerase α , 2895
infrequency of mutation
bladder cancer, 133
insertion in human colonic Caco-2 cells
increased protein kinase C α expression, 2762
-transformed cells
basic fibroblast growth factor complementary DNA, 158

HT1080 cells
inhibition of invasion
recombinant plasminogen activator inhibitor, 6051

HT1080/DR4 cells
localization
multidrug resistance-associated gene, 3221

HTLV-I
sequence analysis
immunogenic and neutralizing domain, gp46 surface membrane protein, 6067

Human immunodeficiency virus-1
systemic expression of *tat* gene
endothelial proliferation, tumors of different histotypes, 5569

Tat protein
protection from apoptosis, 4481

Human papillomavirus
high-risk infections
overexpression of p53 protein, transitional cell carcinoma of the urinary bladder, 4823

malignant transformation of cutaneous lesions
renal allografts, 5328

-transfected human cervical cells
genetic analysis, *in vitro* progression, 1167

type 16
immortalization, normal human ectocervical epithelial cells, 4511

N-methyl-*N'*-nitro-*N*-nitrosoguanidine, oral carcinogenesis, 4811

retinoic acid inhibition, transformation of keratinocytes, 905

type 16 transformed rat kidney epithelial cells
glucocorticoid requirement for growth, 4432

type 18-specific antisense oligonucleotides
transformed phenotype, human carcinoma cell lines, 2330

Hyaluron
factors to stimulate production
human mesothelioma cells, fibroblasts, 388

Hydrocarbons, aromatic
major metabolites of cyclopenta[*c,d*]pyrene
sulfotransferase-mediated activation,

1017

Hydrocarbons, polycyclic aromatic
-DNA adducts
cancer susceptibility genes, human lung, 3486
hepatic cellular distribution
cytochrome P-450 1A1, rainbow trout, 3700

Hydrolyzed benzoquinone mustard
chemical sensitivity
cytosolic glutathione S-transferases, drug-resistant L5178Y murine lymphoblasts, 3530

Hydroxephosphos
-bearing rats of SD/cShi strain
induction of renal pelvic carcinoma, phenacetin, 4218

Hydroperoxides
lipid
oxidative catabolism of all-*trans*-retinoic acid, human microsomes, 1226

4-Hydroperoxycyclophosphamide
intrarterial therapy
human glioma xenografts, 2338
-purged marrow in women with metastatic breast cancer
acceleration of granulocyte recovery, granulocyte colony-stimulating factor, 5424

4-Hydroxy-3,4-dihydrocyclohexa[*c,d*]pyrene
sulfotransferase-mediated activation, 1017

N-Hydroxy-2-acetylaminofluorene
metabolic activation by NAT1 and NAT2
colon cytosols, Syrian hamsters congenic at *NAT2* locus, 509

O-(β -Hydroxyethyl)-rutosides
cardioprotective properties
doxorubicin-pretreated BALB/c mice, 4603

N-(4-Hydroxyphenyl)retinamide
induction of apoptosis
malignant hematopoietic cell lines, no response to retinoic acid, 6036

Hydroxyurea
development of resistance
 α -difluoromethylornithine, treatment of K562 cells, 5262

Hypercalcemia
reversal of
neutralizing antibodies to interleukin 6, human squamous carcinoma, 737

Hypersensitivity, delayed-type
reactions to tumor-associated antigens
autologous tumor cell/*Bacillus Calmette-Guérin* vaccine, colon carcinoma, 456

Hypertension
angiotensin II-induced
tumor blood flow, interstitial fluid pressure, 2466

Hyperthermia
antitumor effects
role of active oxygen species, lipid peroxidation, 2326

cisplatin at 41.5°C during G₁ or late S phase
cell killing and chromosomal aberrations, Chinese hamster ovary cells, 1239

effects of temperature

SUBJECT INDEX TO VOLUME 53

therapeutic efficacy, ifosfamide pharmacokinetics, 4268
induction of resistance to UVB primary and immortalized epidermal keratinocytes, 4952
influence of vascular thermotolerance heat-induced changes, cell survival in tumors, 2076
interleukin 1 α and antitumor effect, 324
mild sensitivity of human cells, 2740
SR 4233 and antitumor effects of radioimmunotherapy, nude mice with human colonic adenocarcinoma xenografts, 3022

Hypothalamus
prenatal exposure to diethylstilbestrol pituitary tumors, 1546

Hypoxanthine phosphoribosyltransferase gene in V-79 cells profile of mutations, 7R, 8S-dihydroxy-9S, 10R-epoxy-7, 8, 9, 10-tetrahydrobenzo(a)pyrene, 3294

Hypoxia
dicumarol and adducts of mitomycin C and DNA, EMT6 mouse mammary tumor cells, 5127
mammalian cell radiosensitization nitric oxide, 5845
quantification of hypoxic fraction gel electrophoresis of individual cells, human breast cancer, 733
unusual oxygen concentration toxicity of SR-4233, 3992

Hypoxic cells detection by monoclonal antibody recognition, 2-nitroimidazole adducts, 5721

I

IA-1 marker for neuroendocrine differentiation human lung cancer cell lines, 4169

ICAM-1 clinical relevance of expression primary lesions, serum of patients with malignant melanoma, 4927
induction by heregulin implications, mammary tumors, 5251
 γ -interferon-induced bifunctional antibody-mediated lysis, LFA-1-dependent mechanism, 4652 transduction of retinoic acid and γ -interferon human tumor cell lines, 826

Iceland somatic *p53* mutations human breast carcinoma, 1637

ICI 182,780 inhibition insulin-like growth factor I gene expression, stimulation by tamoxifen, 5585 sensitivity of MCF7/LCC2 cells, 3229

ICRF-187 protection from mitoxantrone cardiotoxicity neonatal rat heart cells, 550

Ifosfamide

cyclophosphamide and differential activation by cytochromes P-450 2B and 3A, liver microsomes, 5629
pharmacokinetics effects of temperature, therapeutic efficacy, 4268
pharmacokinetics and metabolism continuous infusion, children, 3758

Image analysis computerized HER-2/neu expression, node-negative breast cancer, 4960

Imiquimod oral immunomodulator and interferon inducer Phase I trial, 5176

Immortalization Syrian hamster embryo cells, 4797

Immune cells local and systemic activation peritumoral IL-2 injections, advanced squamous cell carcinoma of the head and neck, 5654

Immune response humoral tumor immunity, recombinant SV40 large tumor antigen and monoclonal anti-idiotype, 5734

Immunization active protection, cerebral metastases of melanoma B16, 1113

Immunoassays radio- and enzyme monoclonal antibody, pharmacokinetics of S 12363, 3536

Immunobead-polymerase chain reaction detection of circulating tumor cells, 3455

Immunochemotherapy site-specific prodrug activation antibody- β -lactamase conjugates, colon carcinoma xenograft models, 3956

Immunocomplexes daunomycin-antibody management, soft tissue sarcomas, 5740

Immunocytochemistry estrogen receptor levels and improved prediction of survival, advanced ovarian adenocarcinoma, 5188

Immunoelectron microscopy localization of transforming growth factor- β TGF- β 1 binding protein, gastrointestinal carcinoma, 183

Immunogen immunotargeting of head and neck cancer monoclonal antibody U36, 4383

Immunoglobulin G -mediated therapy 186 Re-labeled E48, human head and neck squamous cell carcinoma xenografts, 3524
monoclonal antibody homodimers enhanced antitumor activity, nude mice, 2560

Immunoglobulin H rearrangements and Ly-1 $^{+}$

"normal" spleens and lymphomas, AKR/J and AKR Fv-1 b mice, 2147

Immunoglobulins clonal gene rearrangement coexistence of aneuploid subclones, 5320
DNA double strand break repair defect scid mice, 1244
theophylline-induced differentiation deregulation of c-myc, Burkitt's lymphoma, 127

Immunohistochemistry hepatic cellular distribution cytochrome P-450 IA1, rainbow trout, 3700
HER-2/neu expression node-negative breast cancer, 4960
localization parathyroid hormone-related protein, human prostate cancer, 1724
localization of glutathione S-transferases human lung, 5643

Immunomodulator oral interferon inducer and, Phase I trial, 5176

Immunoscintigraphy 131 I-labeled monoclonal antibody COU-1 suspected colorectal carcinoma, 5920

Immunosuppression enhanced activity metastatic lymphoma cells, 1921

Immunotherapy adoptive tracking of tumor-infiltrating lymphocytes, LAK cells, 2358
vaccine-primed T-cells, secondary sensitization to tumor, 1043
differential expression of *MAGE-1/MAGE-2/MAGE-3* messenger RNA, transformed and normal human cell lines, 5
human carcinoma cells engineered with mAb genes self-reactive antibody expression, 3355
human interleukin 2 analogues reduced secondary cytokine secretion, 2597
imaging of activated natural killer cells positron emission tomography, preferential uptake in tumors, 5867
mouse anti-idiotypic monoclonal antibody MK2-23 modulation by adjuvants, carriers of immunogenicity, 112
quantitative analysis of *lacZ* reporter gene disseminated tumor growth within brain, 176
src-specific immune regression Rous sarcoma virus-induced tumors, 915
target for peptide-induced CD8 $^{+}$ cytotoxic T-cells mutant *p53* tumor suppressor protein, 3257

Immunotoxins anti-B4-blocked ricin therapeutic efficacy, different SCID mouse tumor models, 1360
BR96 sFV-PE40 selective killing, carcinoma cells, 334

SUBJECT INDEX TO VOLUME 53

entry of protein toxins
polarized epithelial cells, 1755
eradication of small cell lung cancer cells
bone marrow, 3784
no proteolysis required for activity
recombinant form, *Pseudomonas exotoxin A*, 340
pharmacokinetics and toxicology
administration into the subarachnoid space, nonhuman primates and rodents, 3752
Pseudomonas exotoxin-based
antibody LL2 or LL2-Fab⁺, regression of B-cell lymphoma, 819
spatial distribution in solid tumors
quantitative autoradiography, 2092
transferrin receptor-targeted efficacy, pediatric brain tumors, 1348

Inflammation
lipopolysaccharide-induced rat urinary bladder tumorigenesis, 5172

Infrared spectroscopy
distinct patterns
human basal cell carcinoma, skin, 762

Inhibin
prostatic
suppression of tumor growth, Dunning R3327G rat tumor, 4855

Insulin
inhibition of binding to receptors
dimethyl sulfoxide, human leukemia cells, 1142

Insulin-like growth factor
-binding protein-2
regulation of insulin-like growth factor action, lung tumors, 4680
-binding proteins
estrogen and antiestrogen modulation, MCF7 cells, 5193
receptor inhibition
human melanoma, athymic mice, 2522

Insulin-like growth factor I
axis
diet restriction-induced inhibition, mononuclear cell leukemia, 2750
gene expression in uterus
stimulation by tamoxifen, inhibition by ICI 182780, 5585
human lung fibroblast-derived IGF-I and stimulation of proliferation, lung carcinoma cells, 3399
human primary brain tumors, 2475
inhibition of gene expression
tamoxifen, 1727
normal human mesothelial cells
mesothelial cell lines, 2858
peptide analogues
inhibition of growth, prostatic cancer cell lines, 1102

plasma
lowering of level by fenretinide, breast cancer, 4769
receptor increase
estrogen-induced kidney tumors, 2256
receptor overexpression
low risk, human breast cancer, 3736

Insulin-like growth factor II
gene
Aval1 restriction fragment length polymorphism, occurrence of smooth muscle tumors, 5754

N-myc-2 and
precancerous altered hepatic foci, woodchuck hepatitis virus carriers, 2020
promotion of expression by suramin
inhibition of growth, HepG2 cells, 652

WT1 transcript localization and human fetal kidney, Wilms' tumor, 5166

Integrins
 α_6
neoplastic transformation and tumorigenic conversion, fibroblasts, 2950
regulation by laminin, tumor cell chemotaxis receptor, 2661

$\alpha_6\beta_4$
suprabasal expression, malignant progression in skin carcinogenesis, 4803

TA3/Ha mammary carcinoma cells, adhesion to hepatocytes, 3611

$\alpha_5\beta_1$ and $\alpha_5\beta_1$
72 kDa type IV collagenase, melanoma cell invasion, 3411

β_2
monocyte-mediated leukemic cell death, tumor necrosis factor α , 4399
gap junction function and cancer, 3475
signaling
implications for tumorigenesis, 1503

Interferon
cytokinetic effects
colorectal cancer, 5429
genes
homozygous loss, critical region on 9p deleted in lung cancer, 2410
inducer
oral immunomodulator, Phase I trial, 5176

α -**Interferon**
-inducible gene on chromosome 14q32
expression in breast carcinoma, 4096
inhibitory effects
epidermal growth factor-mediated receptor-dependent events, 5148
localization of chromosome 9p homozygous deletions
continuous linkage group, glioma cell lines, 3674
tamoxifen and
modulatory effects, doxorubicin resistance, 3040
tumor-specific lysis by tumor-infiltrating lymphocytes
renal cell carcinoma, 4020
with and without
immunological and clinical effects, interleukin 2, 1286

$\alpha 1$ -**Interferon**
gene transfer into Friend leukemia cells
abrogation of tumorigenicity, immunocompetent mice, 1107

$\alpha 2a$ -**Interferon**
5-fluorouracil and leucovorin
locus of interaction, colon carcinoma cells, 4243

$\alpha 2b$ -**Interferon**
cyclophosphamide/doxorubicin/5-fluorouracil
Phase I trial, advanced breast cancer, 3509

γ -**Interferon**

cytokine regulation
human monocyte differentiation, 2603

differential regulation
carcinoembryonic antigen, biliary glycoprotein, 1612

1 α ,25-dihydroxyvitamin D₃ and
block of lung tumor production, GM-CSF and induction of immunosuppressor cells, 6006

gene
enhanced HLA molecule expression, human tumor infiltrating lymphocytes, 3561

¹³¹I-CC49 and
improved radioimmunotherapeutic efficacy, 600

-induced ICAM-1
bifunctional antibody-mediated lysis, LFA-1-dependent mechanism, 4652

retinoic acid and
ICAM-1 expression, human tumor cell lines, 826

role in T-cell-induced tumor regression, 833

Interleukin 1
cis-diamminedichloroplatinum(II) and synergistic antitumor activity, solid tumors, 1091
growth inhibition by interleukin 1
enhanced expression, γ -interferon receptors, 636
receptor antagonist
inhibition of metastasis augmentation, melanoma-nude mouse system, 5051

Interleukin 1 α
autocrine growth stimulator
human gastric carcinoma cells, 4102
hyperthermia and
antitumor effect, 324
interleukin 6 and
inhibition of growth, MCF-7 cells, 1538
protective effects
doxorubicin-treated normal and tumor-bearing mice, 1565
tumor necrosis factor- α and
induction of anchorage independence, *v-jun* transgenic murine cells, 615

Interleukin 1 β
induction of interleukin 1 receptor antagonist
tumor necrosis factor binding protein, humans, 4010
interleukin 2 treatment and protection, cyclophosphamide-induced myelosuppression, 569

Interleukin 2
analogues
reduced secondary cytokine secretion, 2597
complementary DNA
tumor-specific lysis by tumor-infiltrating lymphocytes, renal cell carcinoma, 4020
development of tumor-reactive cytotoxic cells
CD4-dependent mechanism, interleukin 3, 2112
functional expression of receptor
human factor-dependent megakaryoblastic leukemia cell line, 675
gene-transfected cells

SUBJECT INDEX TO VOLUME 53

vaccination, mouse mammary adenocarcinoma, 5067

gene transfection
cellular immune response augmentation, melanoma cells, 949

immunological and clinical effects
with and without interferon- α , 1286

interleukin 1 β treatment and
protection, cyclophosphamide-induced myelosuppression, 569

macrophage-colony stimulating factor and
antitumor protection, T-cell leukemia/lymphoma EL4, 4273

peritumoral injections
local and systemic activation of immune cells, advanced squamous cell carcinoma of the head and neck, 5654

poor proliferative response
infiltration of renal cell carcinoma, T-cells, 1380

protection of hairy leukemic cells
LAK-mediated cytotoxicity, 3555

receptors and
T-cells infiltrating renal cell carcinoma, 5828

Interleukin 3
description of genes
lack of proliferation, nonhematopoietic human malignant cell lines, 3139

development of tumor-reactive cytotoxic cells
CD4-dependent mechanism, 2112

pharmacokinetics
after chemotherapy for ovarian cancer, 5915

Interleukin 4
inhibitory effect on production of IL-6
adult T-cell leukemia cells, 4643

-secreting engineered cells
glioma treatment, 3125

Interleukin 6
-dependent tumor cell growth
inhibition, reshaping of human antibody, 851

description of genes
lack of proliferation, nonhematopoietic human malignant cell lines, 3139

growth inhibition
human lung cancer cell lines, 4175

growth-stimulating activity
transfection with *int-2* gene, mammary epithelial cells, 2957

inhibitory effect of IL-4
adult T-cell leukemia cells, 4643

interleukin 1 α and
inhibition of growth, MCF-7 cells, 1538

neutralizing antibodies
reversal of hypercalcemia, human squamous carcinoma, 737

oncostatin M-induced growth inhibition
increased resistance, melanoma cell lines derived from advanced-stage lesions, 2708

production of immunoreactive endothelin 1
human breast cancer cells, 464

serum levels

lymphoma patients, survival in advanced Hodgkin's disease, 2118

Interleukin 10
transfection into CHO cells
prevention, tumor growth and macrophage infiltration, 4134

Interstitial cells
localization of estrogen receptors
kidney, estradiol-induced renal tumors, 5447

Interstitial fluid
pressure
reduction by dexamethasone, human colon adenocarcinoma xenograft, 4764

Intestine
biological response
1,25-dihydroxyvitamin D₃ and two analogues, 3935

intraepithelial lymphocytes
binding to colon cancer cells, HML-1 and CD11a, 1608

pharmacological retinoids
vitamin A-metabolizing enzymes, 2965

tumorigenesis
deletion of 1p36, primary chromosomal aberration, 1895

Intestine, small
epithelium
inhibition of doxorubicin-induced apoptosis, 2-deoxy-D-glucose, 2057

Introplicine
DNA and topoisomerase II
molecular and cellular interactions, surface-enhanced Raman scattering spectroscopy, 4784

inhibition of both topoisomerase I and II activities, 5987

Invasopodia
cell surface
binding and localization, M, 72,000

matrix metalloproteinase, 3159

Invasion
metalloproteinase matrixlysin
DU-145 cells, 417

m-Iodobenzylguanidine
uptake and storage
frequent neuronal functions, neuroblastoma cell lines, 304

Iododeoxyuridine
bleomycin and
Phase I clinical and pharmacological study, advanced cancer, 1293

Iowa Women's Health Study
lung cancer
vegetables and fruit, 536

4-Ipomeanol
Phase I and pharmacological study
lung cancer, 1794

Iron
2,2'-bipyridyl-6-carbothioamide and its ferrous complex
antitumor activity, inhibition of ribonucleotide reductase R2 subunit, 19

Irradiation
differences in DNA supercoiling
local control, T2/3 transitional cell carcinoma of the bladder, 2300

in vitro
RET oncogene rearrangement, 2940

solar
UVB and, hypersensitivity of human lymphocytes, 609

γ -Irradiation
alkylating agents and
folate deficiency, genetic damage in Chinese hamster ovary cells, 5401

Isoflavones
antiproliferative effects
gastrointestinal tract, human cancer cell lines, 5815

Isoglobotetraosylceramide
marker for highly metastatic cells
rat mammary adenocarcinoma, 2906

J

JB6 cells
mechanism of induction of *c-fos* ultraviolet B, 38

jun
induction by transforming growth factor- α
not 17 β -estradiol, breast cancer cells, 291

JunB
promoter-specific *trans*-activation and inhibition, 3789

Jurkat cells
protection from apoptosis
HIV-1 Tat protein, 4481

K

KB cells
enhanced expression of DNA topoisomerase II gene
response to heat shock stress, 1085

expression of platelet-derived endothelial cell growth factor
sensitivity, pyrimidine antimetabolites, 5680

KBM-5 cells
biological properties and growth
SCID mice, 3603

K562 cells
biochemical consequences
resistance to tiazofurin, 2344

development of resistance to hydroxyurea
 α -difluoromethylorainthine, 5262

merocyanine 540-mediated phototherapy enhancement by salicylate, 806

mitochondrial cytochrome c oxidase target site for daunomycin, 1072

ultrastructural appraisal
multidrug resistance, Fourier transform infrared spectroscopy, 3681

Keratin
expression in mouse cervical epithelium
retinoid status, 2287

Keratinocytes
human papillomavirus type 16-mediated transformation
inhibition by retinoic acid, 905

hyperphosphorylation of cytokeratins
okadaic acid class tumor promoters, 992

oral carcinogenesis
HPV-16, N-methyl-N'-nitro-N-nitrosoguanidine, 4811

primary and immortalized
induction of resistance to UVB, hyperthermia, 4952

resistance to transforming growth factor- β_1

SUBJECT INDEX TO VOLUME 53

mutant *p53*, 899
 suppression of proliferation
Z'-4',5'-didehydro-5'-deoxy-5'-fluoro-adenosine, 6058

Kidney
 allograft
 malignant transformation of cutaneous lesions, human papillomavirus, 5328
 biological response
 1,25-dihydroxyvitamin D₃ and two analogues, 3935
 complementary DNAs down-expressed in Wilms' tumor
 subtractive hybridization approach, 2888
⁶⁷Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35
 preclinical evaluation, 5727

epithelial cells
 HPV16 transformation, glucocorticoid requirement for growth, 4432

genetic predisposition
 transplacentally induced renal cell carcinoma, Eker rat, 5856

human fetal
 Wilms' tumor and, insulin-like growth factor II and WT1 transcript, 5166

localization of estrogen receptors
 interstitial cells, 5447

progression of neoplasms
 regional DNA hypermethylation, D17S5, 2719

regeneration
 regulation, protein kinase C isozymes, 4542

Kinase
 role of *BCR-ABL* oncogene
 human leukemia, 485

Klenow fragment
 kinetics and fidelity of base insertion
 template-located 2',2'-difluorodeoxycytidine, 4582

K1000 neoplasms
 secretion by an animal tumor
 detection of basic fibroblast growth factor, urine, 5297

K-ras
 antisense retroviral construct
 intratracheal instillation, prevention of orthotopic lung cancer growth, 1743

p53 gene mutations and
 epithelial ovarian neoplasms, 3103

Kupffer cells
 -induced reduction of mitochondrial energization
 nitric oxide, hepatoma cells, 2676

KW-2149
 induction of protein-DNA complexes
 HeLa S3 cells, 4466

L

β -Lactamase
 -antibody conjugates
 site-specific prodrug activation, colon carcinoma xenograft models, 3956

fusion with single chain anti-carcinoma antibody
 genetic construction, expression and characterization, 2123

Lactone ring
 9-amino and 10,11-methylene derivatives

camptothecin, pharmacokinetics in mice, 3062

Lactotetraose series
 ganglioside 3',6'-isoL_{D1}
 tumors of central nervous system, other systems, 120

LAK cells
 mechanisms of adoptive immunotherapy
 tracking of tumor-infiltrating lymphocytes, 2358
 -mediated cytotoxicity
 protection by interleukin 2, hairy leukemic cells, 3555

Laminin
 A chain
 plasminogen activator production, B16F10 melanoma, 1998

adhesion of metastatic *ras*-transformed NIH 3T3 cells, 701

chemotaxis and haptotaxis
 autocrine motility factor-like substance, human malignant mesothelioma cells, 4376

peptides
 adhesion and malignant properties, melanoma, 423

regulation
 tumor cell chemotaxis receptor, laminin-binding integrin subunit α_6 , 2661

Laser
 -induced fluorescence
 pharmacokinetics, fluorescent drug, 5954

Lc,Cer
 human fetal antigen
 compensatory occurrence of IV²Fuc α , II³NeuAc α -Gg,Cer, small cell lung carcinoma, 5903

L-cells
 homozygous deletion
 carbonic anhydrase-like domain, *Ptpgr* gene, 1498

L1210 cells
 exposure to edelfosine
 increased generation, lipid-derived and ascorbate free radicals, 711

membrane lipid free radicals
 photofrin photosensitization, electron paramagnetic resonance spin trapping, 3670

protection from Adriamycin cytotoxicity
 brefeldin A, 5237

resistance to cyclopentenylcytosine, 5714

LEA.135
 identification of cell surface antigen
 favorable prognosis, human breast cancer, 3233

Lectin
Agaricus bisporus
 reversible inhibition of proliferation, epithelial cell lines, 4627

galactoside-binding
 regulation of expression, monocytic differentiation, 5033

-mediated endocytosis of a trap label
 permanently labeled colon cancer cells, distribution of, 658

-reactive α -fetoproteins
 early detection, hepatocellular carcinoma, 5419

Leiomyoma

chromosome 12 breakpoints
 benign and malignant lipogenic tumors, 1670

Lens
 inhibition of tumor promoter-mediated processes
 cafeic acid phenethyl ester, 1255

Leucovorin
cis-diamminedichloroplatinum(II) and 5-fluorouracil
 non-small cell lung cancer cell lines, 1079

5-fluorouracil and
 N-(phosphonacetyl)-L-aspartate combination, metastatic gastrointestinal adenocarcinoma, 4828

5-fluorouracil and α 2a-interferon
 locus of interaction, colon carcinoma cells, 4243

rescue
 edatrexate compared to methotrexate, metastatic murine solid tumors, 587

Leukemia
 ability to form tumors in nude mice
 homeobox gene *HB24*, human T-cell line, 373

benzene and phenolic metabolites
 oxidative DNA damage, HL-60 cells and bone marrow, 1023

cell differentiation
 alkylamides as inducers, structure-activity relationship, 766

human factor-dependent megakaryoblastic
 functional expression, interleukin 2 receptor, 675

inhibition of binding of GM-CSF and insulin to receptors
 dimethyl sulfoxide, 1142

monocyte-mediated leukemic cell death
 role of β_2 -integrins, cell cycle-specific effects of TNF- α , 4399

mononuclear cell
 diet restriction-induced inhibition, insulin-like growth factor 1 axis, 2750

role of *BCR-ABL* oncogene, 485

t(4;11) acute
 heterogeneity in MLL/AF-4 fusion mRNA, polymerase chain reaction, 3853

Leukemia, acute
 Southern blot analysis
 ALL-1 rearrangements, chromosome 11q23, 3800

Leukemia, lymphoblastic
 acute
 primary clonaligenic blasts, radiation damage repair capacity, 1431

early B-lineage acute
 heterotransplantation, solubilized attachment matrix, 1222

Philadelphia-positive acute
 heterogeneity, lineage derivation, 3289

Leukemia, lymphocytic
 chronic
 binding of melphalan-damaged DNA, poly(ADP-ribose) polymerase, 5370

Leukemia, myeloblastic
 acute
 modulation, p145^{c-kit} function in cells, 4424

Leukemia, myelocytic

SUBJECT INDEX TO VOLUME 53

acute
 differential activity of acetyldinaline, rat, 3008

Leukemia, myelogenous

acute
 growth and apoptosis, transforming growth factor $\beta 1$, 3386
 $t(8;21)$ masked translocation, *AML1/ETO* fusion transcript, 4449

blasts
 transforming growth factor- $\beta 1$ and stem cell factor, *c-kit*, 3638

chronic
 derivation of cell line KBM-5, biological properties and growth in *SCID* mice, 3603
 lineage-negative blast subpopulations, *c-kit* ligand responsiveness, 401

Leukemia, myeloid

acute
 cloning of *ALL-1* fusion partner, *AF-6* gene, 5624
 epipodophyllotoxin, disruption of *ALL-1* gene, 2954
 topoisomerase II DNA-binding sites, $t(9;11)$ chromosome translocation, 4489
 induction of differentiation
 liposomal all-*trans*-retinoic acid, 2100

Leukemia, P388

Adriamycin-resistant
 DNA topoisomerase II α gene rearrangement, 5885
 milky spots as implantation site for malignant cells
 peritoneal dissemination, mice, 687

Leukemia, promyelocytic

acute
 induction of differentiation, liposomal all-*trans*-retinoic acid, 2100

Leukemia, T-cell

adult
 HTLV-I-associated myopathy, sequence analysis of an immunogenic and neutralizing domain, 6067
 inhibitory effect of IL-4, production of IL-6, 4643
 etoposide-induced cytotoxicity, 4287
 -lymphoma EL4
 antitumor protection, macrophage-colony stimulating factor and interleukin 2, 4273

Leukemia cells

differential activity of acetyldinaline
 rat leukemia, 3008
 glucocorticoid-sensitive and -resistant
 cloning and expression, mutant glucocorticoid receptors, 4059
 hairy
 protection by interleukin 2, LAK-mediated cytotoxicity, 3555
 induced megakaryocytic maturation
 down-modulation, erythropoietin gene expression, 1156
 megakaryocytic differentiation
 TPA and staurosporine, retinoblastoma tumor suppressor gene expression, 3085
 promyelocytic
 differentiation, glucocorticoid receptors, 3513

Leukemia virus

bovine
 lymphosarcoma, phenotype and ontogeny of cells carrying tumor-associated antigen, 429

Leukocytes

activated polymorphonuclear
 modification of DNA bases in chromatin, intact target human cells, 1269

DNA

platinum-DNA adduct, different types of malignancies, 3694

Lewis antigens

sialyl Le α and sialyl Le β
 α -(1,3)-fucosyltransferases, human malignant cell lines, 5559

LFA-1

-dependent mechanism
 bifunctional antibody-mediated lysis, interferon- γ -induced ICAM-1, 4652

Liarozole

13-*cis*-retinoic acid and anti-prostatic tumor activity, 3073

Li-Fraumeni syndrome

malignant tumors and family history of cancer
 screening, germ line *p53* mutations, 452

Ligands

axial and equatorial
 modulation of cytotoxicity and cellular pharmacology, 1,2-diaminocyclohexane platinum(IV) complexes, 4567

cis-diammine and 1,2-diaminocyclohexane
 platinum resistance, human carcinoma cell lines, 799

Light

near-visible/UVA
 singlet oxygen, induction of heme oxygenase gene, 4505

Linoleic acid

diets containing different levels
 breast cancer growth, lung metastasis, 4686

Linomide

antiangiogenic effects, 1833

Lipid peroxidation

active oxygen species and antitumor effects, hyperthermia, 2326

Lipids

-derived and ascorbate free radicals
 L1210 cells exposed to edelfosine, 711
 effects of nonionic detergents
 P-glycoprotein drug binding, multidrug resistance, 5994

ether lipid analogues
 inhibition of phosphatidylinositol-3-kinase, 4297

free radicals
 photofrin photosensitization, L1210 murine leukemia cells, 3670

hydroperoxides
 oxidative catabolism of all-*trans*-retinoic acid, human microsomes, 1226

in vitro cytotoxicity
 cellular pharmacology, annamycin, 1583

Lipogenic neoplasms

benign and malignant
 chromosome 12 breakpoints, 1670

Lipopolysaccharide

-induced inflammation
 rat urinary bladder tumorigenesis, 5172

Liposomes

Adriamycin
 hepatic artery, liver W256 carcinosarcoma, 3046

all-*trans*-retinoic acid
 induction of differentiation, myeloid leukemia cell lines, acute promyelocytic leukemia cells, 2100

cis-bis-neodecanoato-*trans-R,R-1,2*-diaminocyclohexaneplatinum(II)
 cellular pharmacology, A2780/S and A2780/PDD cells, 4913

DepoFoam

prolongation of drug exposure, cerebrospinal fluid, 1596

-encapsulated doxorubicin
 eradication of lung cancer, 1484
 initial clinical trial, 2796

-encapsulated muramyl tripeptide doxorubicin and, canine monocyte activation, 3986

Stealth

preferential accumulation in tumor tissue, increased microvascular permeability, 3765

sterically stabilized
 doxorubicin, arrest of growth in human lung tumor xenograft, 3964

taxol-containing

antitumor effect, taxol-resistant murine tumor model, 5877

Liver

aflatoxin B₁-induced hepatic hyperplastic nodules
 no site-specific mutation, *p53* gene, 9

carcinogenesis
 chromosome mapping, murine susceptibility loci, 209
 inhibitory effect of *Bifidobacterium longum*, food mutagen, 3914

cellular distribution of cytochrome P-450 1A1
 immunohistochemistry, rainbow trout, 3700

cytochrome P450 3A
 vinblastine metabolism, drug interactions, 5121

cytochrome P450 enzymes
 metabolism of 6-nitrochrysene, 2028

gene expression and cell proliferation
 2,3,7,8-tetrachlorobenzene-*p*-dioxin exposure, 2265

metastases
 clinical relevance of ICAM-1 expression, serum of patients with malignant melanoma, 4927

mouse sinusoidal endothelial cells
 paracrine migration-stimulating factor, metastatic tumor cells, 4418

oxidative damage of nuclear DNA
 rats exposed to psychological stress, 4153

peripheral blood mononuclear cells and dihydropyrimidine dehydrogenase activity, 5433

pharmacological retinoids
 vitamin A-metabolizing enzymes, 2965

Phase I and pharmacological study
 4-ipomeanol, lung cancer, 1794

SUBJECT INDEX TO VOLUME 53

precancerous altered hepatic foci
N-myc 2 and insulin-like growth factor II, woodchuck hepatitis virus carriers, 2020

promoter-specific *trans*-activation and inhibition
JunB, 3789

rats treated with 1,2-dimethylhydrazine and *O⁶*-benzylguanine repair, *O⁶*-methylguanine and *O⁴*-methylthymidine, 3895

right/caudate lobes furan treatment, "intestinal-type" adenocarcinoma, 254

Liver microsomes
differential activation of cyclophosphamide and ifosfamide cytochromes P-450 2B and 3A, 5629

Liver neoplasms
2-acetylaminofluorene-induced *ras* mutations, 1620

aflatoxin-induced tumorigenesis transient intervention, olitipraz, 3499

coordinate oncodemotional modulation fibronectin pre-mRNA alternative splicing, 2005

W256 carcinosarcoma temperature-sensitive liposomal Adriamycin, hepatic artery, 3046

LNCaP cells
autocrine regulation prostate-specific antigen gene expression, 2852

Locus
bladder cancer suppressor chromosome 9, 5093

L19 protein
high-level of expression *erbB-2* overexpression, breast tumors, 1403

LR73 cells
ultrastructural appraisal multidrug resistance, Fourier transform infrared spectroscopy, 3681

Lung
A/J mouse model, chemointervention strategies, 410

cancer susceptibility genes polycyclic aromatic hydrocarbon-DNA adducts, 3486

carcinoïd tumors infrequent mutations, *p53* gene, 5797

cytochrome P450 enzymes metabolism of 6-nitrochrysene, 2028

fibroblast-derived IGF-I and insulin-like growth factor-I stimulation of proliferation, lung carcinoma cells, 3399

immunohistochemical localization glutathione S-transferases, 5643

metastasis and breast cancer growth diets containing different linoleic acid levels, 4686

metastasis from rat-transplantable osteosarcoma nucleoside diphosphate kinase/*nm23* and c-Ha-ras mRNA, 5038

Lung epithelial cells
mediation of 8-chloro-cyclic AMP-induced down-regulation

cyclic AMP-dependent protein kinase, 393

Lung neoplasms
2-acetylaminofluorene-induced *ras* mutations, 1620

antibody-targeted delivery doxorubicin entrapped in liposomes, 1484

atrial natriuretic factor arginine vasopressin production, serum sodium, 67

block of production of GM-CSF 1 α ,25-dihydroxyvitamin D₃ plus γ -interferon, 6006

chemoprevention strategies, 1469

critical region of 9p homozygous loss, interferon genes, 2410

genotype and phenotype glutathione S-transferase class μ isoenzymes, 1004

growth inhibition by IL-6 autocrine mechanism, 4175

human xenograft arrest of growth, doxorubicin encapsulated in sterically stabilized liposomes, 3964

marker for neuroendocrine differentiation IA-1, 4169

modulation of cisplatin sensitivity accumulation of amphotericin B, 3302

non-small cell cisplatin and 5-fluorouracil, with and without leucovorin, 1079

down-regulation of growth, thymosin α_1 , 5214

immunocytopological detection, bone marrow micrometastasis, 1027

individualized chemotherapy, neuroendocrine markers and drug sensitivity testing, 5181

main drug- and carcinogen-metabolizing enzyme systems, peritumoral tissues, 4608

methylthioadenosine phosphorylase deficiency, 1098

p53 alterations, metastatic involvement, 2846

prognostic significance, *p53* mutations and 3p deletions, 1

penetration of spheroids retroviral wild-type *p53* expression vector, induction of apoptosis, 4129

Phase I and pharmacological study 4-ipomeanol, 1794

prevention of growth intratracheal instillation, retroviral antisense K-ras construct, 1743

primary non-small cell preferential expression, epidermal growth factor receptor, 2379

regulation of insulin-like growth factor action membrane and secreted insulin-like growth factor-binding protein-2, 4680

selenium status and, 4860

serum fragment of cytokeratin subunit 19

CYFRA 21-1 immunoradiometric assay, 61

small cell altered topoisomerase II α , VP-16, 4866

CCK_A and CCK_B receptors, Ca²⁺ mobilization, 5208

c-myc expression, correlation with *c-kit* expression, 4337

eradication of cells from bone marrow, immunotoxins, 3784

expression, functional atrial natriuretic peptide receptors, 3165

inwardly rectifying K⁺ channels, volume-regulated anion channels, 4156

mediation of chemotaxis by stem cell factor, *c-kit*, 1709

monoclonal antibody SEN7, epitope on NCAM, 2840

surgically treated patients
proliferating cell nuclear antigen, argyrophilic nucleolar organizer regions, 5000

susceptibility and cigarette dose polymorphisms, *CYP1A1* and glutathione S-transferase, 2994

vegetables and fruit Iowa Women's Health Study, 536

Luteinizing hormone releasing hormone analogues in ovarian cancer cell lines high affinity binding, antiproliferative effects, 5439

Ly-1
B cell populations and IgH rearrangements "normal" spleens and lymphomas, AKR/J and AKR Fv-1^b mice, 2147

Lymph node
hilar and mediastinal metastasis and *p53* alterations, non-small cell lung cancer, 2846

micrometastatic prostate cancer cells reverse transcriptase-polymerase chain reaction, 5350

tumor-draining T-cell-induced tumor regression, γ -interferon, 833

Lymphoblasts
drug-resistant L5178Y murine chemical sensitivity, glutathione S-transferase, 3530

Lymphocytes
DNA double strand break repair defect scid mice, 1244

hypersensitivity to UVB and solar irradiation, 609

intestinal intraepithelial binding to colon cancer cells, HML-1 and CD11a, 1608

in vitro-sensitized vaccine-draining lymph node oligoclonal T-cell response, metastasis of renal cell carcinoma, 4745

tumor-infiltrating adoptive immunotherapy and improved tracking, LAK cells, 2358

enhanced HLA molecule expression, transduction of melanoma cells, 3561

poor proliferative response, renal cell carcinoma, 1380

T-cell receptor V region gene usage, autologous gastric Signet ring cell carcinoma, 3078

SUBJECT INDEX TO VOLUME 53

tumor-specific lysis, renal cell carcinoma, 4020

Lymphohematopoietic precursors
role of tyrosine phosphorylation activation of *c-jun*, 447

Lymphoma
Burkitt's
deregulation of *c-myc*, theophylline-induced differentiation, 127
induction of apoptosis, Gb3/CD77 glycolipid antigen, 5314
radiosensitivity, role of *p53* in cell cycle arrest, 4776
interstitial pressure of subcutaneous nodules
changes during treatment, 2204
metastatic
enhanced immunosuppressive activity, 1921
non-Hodgkin's
agricultural risk factors, 2421
circadian stage of cell sampling, DNA synthesis and ploidy, 3129
photosensitized mouse cells
phospholipase activation, apoptosis, 5897
refractory
high-dose regimen, mitoxantrone, 4850
serum interleukin 6 levels
survival, advanced Hodgkin's disease with B symptoms, 2118
suramin
multiple potential mechanisms of action, 2239
T-cell
suppression of apoptosis, monoclonal antibodies against cell surface adhesion molecules, 5022
-T-cell leukemia
antitumor protection, macrophage-colony stimulating factor and interleukin 2, 4273

Lymphoma, B-cell
cloning of *bcl-6*
chromosome translocations, 2732
delivery of saporin using bispecific antibody
targeting via CD22, 3015
multiple breakpoints within *BCL-1* locus rearrangements, cyclin D1 gene, 4148
regression
Pseudomonas exotoxin-based immunotoxins, antibody LL2 or LL2-Fab', 819

Lymphomagenesis
AKR.Fv^{1b} congenic mice, 3433

Lymphosarcoma
bovine leukemia virus
phenotype and ontogeny, cells carrying tumor-associated antigen, 429

Lysophospholipid
phospholipase A₂-mediated mechanisms inhibition of cancer cell line proliferation, riminophenazine agents, 318

Lysyl oxidase
up-regulation
spontaneous revertants, H-ras-transformed fibroblasts, 4670

M

clinical evaluation, 2803

Macrophages
control of HLA-DR antigen expression
γ-interferons, thyroid cells, 3943
differentiation of human promyelocytic leukemia cells
glucocorticoid receptor expression, 3513
infiltration
prevention of tumor growth, IL-10 transfected into CHO cells, 4134
nitric oxide synthesis
delay of progression, UV light-induced skin cancers, 5507
sensitivity of tumoricidal function
modulation of arachidonic acid metabolism, different anatomical sites, 3362
tumor-associated
receptor for urokinase, ductal breast carcinoma, 1911

Magainin2
analogue peptides and anticancer efficacy, 3052

Magnetic resonance spectroscopy
quantitative differential effects
rhodamine 123, normal and human colon cancer cells, 5808

skeletal muscle metabolism
left-shifting agent BW12C79, mitomycin C, 5649

Major histocompatibility complex
cell lines from *grc* congenic strains of rats
different susceptibilities, chemical carcinogens, 4089

class I alleles
selectively down-regulated expression, human solid tumors, 2416

class I antigen H-2D^d
radiation-enhanced expression, B16 melanoma cells, 1952

Malignancy
advanced
chronic oral etoposide, granulocyte-macrophage colony-stimulating factor, 5929
antitumor effect
anti-epidermal growth factor receptor monoclonal antibody, cisplatin, 4637

ascites formation
pathogenesis, 2631

benign and low-grade
adjacency to high-grade ovarian carcinoma, molecular characteristics, 4138

borderline
mutation of *K-ras* protooncogene, ovarian epithelial tumors, 1489

carcinoma-associated antigen AgSK1, 1122

different types
platinum-DNA adduct, leukocyte DNA, 3694

environmental carcinogenesis and its prevention
head and neck cancer, 2189

expression of α-(1,3)-fucosyltransferases synthesis, sialyl Le^x and sialyl Le^a, 5559

expression of tumor suppressor gene

DCC
human gliomas, 5605
family history of cancer and screening, germ line *p53* mutations, 452

hematological
cell proliferation marker, cyclin A expression, 235

hemopoietic cell lines
N-(4-hydroxyphenyl)retinamide, induction of apoptosis, 6036

high mobility group protein I(Y)
increased expression, high grade prostatic cancer, 5512

human basal cell carcinoma of skin
distinct infrared spectroscopic patterns, 762

increased polysomes
chromosomes 7 and 17, head and neck multistage tumorigenesis, 2874

increased sialyl Lewis^x antigen expression
poor survival, colorectal carcinoma, 3632

individual tumors and their variants
footprinting, constitutive cytokine expression patterns, 1978

milky spots as implantation site for malignant cells
peritoneal dissemination, mice, 687

morphologically malignant meningioma progression
loss of heterozygosity, loci on chromosome 10, 2386

mouse tissues
biliary glycoprotein, CEA-related gene, 4938

multiple mechanisms of tumorigenesis
Eμ-myc transgenic mice, 1665

nonhematopoietic human cell lines
lack of proliferation, GM-CSF/IL-3/IL-6 receptors, 3139

normal and malignant mammary epithelial cells
physiological culture, discrimination of cell type, 2644

normal human mesothelial cells and cell lines
insulin-like growth factor I, 2858

ovarian cancer cells
enhanced *c-erbB/neu* expression, 891

pediatric brain tumors
efficacy, transferrin receptor-targeted immunotoxins, 1348

progression in oral carcinogenesis
HPV-16, N-methyl-N'-nitro-N-nitrosoguanidine, 4811

progression of skin carcinogenesis
suprabasal expression, α6β4 integrin, 4803

prostate
benign tissue and, type IV collagenase, 878

rat glial cells
phosphorylation of elongation factor 2, 2260

risk of fatal cancer
aspirin use, 6074

suppression by antisense oligonucleotide, 868

therapeutic efficacy
anti-B4-blocked ricin immunotoxin,

SUBJECT INDEX TO VOLUME 53

different SCID mouse tumor models, 1360

thyroid differentiation marker, E-cadherin, 4987

Malignant potential

p53 and *Ki-ras* gene mutations epithelial ovarian neoplasms, 3103

Malignant transformation

early markers of carcinogenesis in head and neck cancer transforming growth factor α , epidermal growth factor receptor messenger RNA, 3579

Mammalian cells

hypoxic radiosensitization by nitric oxide, 5845

mitogenic processing of ethylation damage methoxyamine, site-directed mutagenesis, 1149

Mammary cells

formation of hyperplastic outgrowths *p53* mutations, 1646

Mammary epithelial cells

growth-stimulating activity of IL-6 transfection with *int-2* gene, 2957

kinetics and differentiation calories, parity and prolactin, 1188

normal and malignant physiological culture, discrimination of cell type, 2644

normal luminal cell and breast cancer differential isolation, primary and metastatic sites, 627

Pneumatoplastic

growth factor dependency, gene expression, 668

progressive transformation elevated high mobility group-I(Y) gene expression, 2655

TM pneumatoplastic outgrowths morphological and functional properties, 663

Mammary gland

carcinogenesis inhibitory effect of *Bifidobacterium longum*, food mutagen, 3914

radiation-induced transforming growth factor β extracellular matrix reorganization, 3880

Mammary neoplasms

benign and malignant *in situ* hybridization, mannose-6-phosphate/IGFIII receptor and cathepsin D, 2901

development preneoplastic stage, *p53* mutations, 3374

glucocorticoid-mediated suppression of growth overexpression, transforming growth factor α , 1816

induction tamoxifen dependency, 2937

induction by 6-nitrochrysene (rats), 3719

induction of ICAM-1 neu differentiation factor, 5251

monoterpene-induced regression mannose 6-phosphate/insulin-like growth factor receptor II, transform-

ing growth factor- β 1 levels, 3849

ovary-independent systematic *H-ras* amplification, progressively anaplastic phenotypes, 5339

Risk of

calories/parity/prolactin, epithelial kinetics and differentiation, 1188

Mannose-6-phosphate

-IGFII receptor and cathepsin D RNA levels

in situ hybridization, benign and malignant mammary tumors, 2901

IGFII receptor

transforming growth factor- β 1, monoterpene-induced regression of mammary tumors, 3849

Mastocytoma

arachidonic acid as growth signal, 3405 production of growth-promoting factor wide target cell spectrum, THP-1 cells, 1871

Mathematical model

development of metastases primary and locally recurrent tumors, clinical data base for prostatic cancer, 2987

Matrigel

heterotransplantation early B-lineage acute lymphoblastic leukemia, 1222

Matrix

-degrading enzyme protease hormone-dependent breast cancer cells, 1409

invasion overexpression of urokinase receptor, cell migration in osteosarcoma cell line, 3109

Matrix metalloproteinase

increase in *M*, 92,000 type IV collagenase plasma, colon and breast cancers, 140

inhibitor decreased tumor burden, mice bearing human ovarian carcinoma xenografts, 2087

secretion by human prostate explant cultures, inhibitors, 4493

TIMP-1 as negative regulator human gastric cancer cell line, chick embryo, 1397

MCA-C3H/10T $^{1/2}$ cells

reversal of cytochrome P-4501A1 and P-450-EF expression, 968

MCF-7 cells

acquisition of hormone-independent growth estrogen-regulated genes, no detectable DNA amplifications, 283

cotransfection with fibroblast growth factor 4

LacZ, spontaneous metastasis, 2178

3',5'-cyclic nucleotide phosphodiesterase potential target, tumor growth inhibition, 3058

dissociation bulk damage to DNA, teniposide anti-proliferative activity, 3547

estrogen and antiestrogen modulation insulin-like growth factor-binding proteins, 5193

growth suppression 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 3149

inhibition of growth interleukin 1 α and interleukin 6, 1538

transfection fibroblast growth factor 4, tumorigenicity, 2168

Xenografts

tamoxifen-induced increase in doubling time, bromodeoxyuridine labeling and flow cytometry, 4413

MCF-10 cells

nuclear matrix proteins, 3394

MCF7/LCC2 cells

sensitivity to ICI 182,780, 3229

MDL 28,842

suppression of proliferation keratinocytes and squamous carcinoma cell lines, 6058

Megakaryocytes

induced maturation of leukemia cell line UT-7

down-modulation, erythropoietin gene expression, 1156

Melanocytic neoplasms

calcyclin expression, 6061

Melanoma

adhesion to laminin peptides differences, malignant properties, 423

-associated antigen expression high molecular weight, primary acral lentiginous lesions with poor prognosis, 2830

biochemical and functional characterization

aminopeptidase N, 1450

blood flow reduction in tumors high-energy shock waves, 1590

cell invasion 72 kDa type IV collagenase, differential integrin expression, 3411

cell lines derived from advanced-stage lesions increased resistance, oncostatin M-induced growth inhibition, 2708

cells exposed to C3-cleaving membrane protease *p65* molecular basis, complement resistance, 592

differential expression of *MAGE-1*/*MAGE-2/MAGE-3* messenger RNA, transformed and normal human cell lines, 5

differential expression CD54/CD11a and CD58/CD2, 3343

environmental skin cancer mechanisms, models and human relevance, 3439

human culture insulin-like growth factor receptor inhibition, 2522

human xenografts antitumor activity, *N,N'*-bis(ethyl)norspermine, 581

induction and antigenic profile HLA-A and -B antigens, β_2 -microglobulin, 4303

inhibition of growth by intratumoral DNA injection herpes simplex virus thymidine kinase gene, 3860

SUBJECT INDEX TO VOLUME 53

insight on biology of neuroectodermal tumors, 926
 interstitial pressure of subcutaneous nodules
 changes during treatment, 2204
 intracerebral
 boron neutron capture theory, 3308
 malignant
 clinical relevance of ICAM-1 expression, primary lesions, 4927
 development of, p53 overexpression as late event, 2235
 -mediated dissolution of extracellular matrix
 proteolytic pathways, 693
 molecular cloning of monoclonal antibody
 reactivity to ganglioside G_{M3}, human cancers, 5244
 mouse anti-idiotypic monoclonal antibody MK2-23
 modulation by adjuvants, carriers of immunogenicity, 112
 -nude mouse system
 interleukin 1 receptor antagonist, inhibition of metastasis augmentation, 5051
 production of growth-promoting factor
 wide target cell spectrum, THP-1 cells, 1871
 proliferation of A375 cells
 inhibition by nitric oxide/nucleophile complexes, 564
 regressive
 antitumor activity, *in situ* amplification of cytotoxic T-lymphocytes, 3569
 replicative senescence and melanogenesis
 specific tyrosinases, 2469
 spontaneous metastases
 suppression of growth by CTL, SCID/hu mice, 4933
 staining with monoclonal antibodies
 selective loss, HLA class I allospecificities, 3349
 tamoxifen modulation
 cisplatin sensitivity (humans), 1571
 targeting of gene expression, 962
 transduction
 enhanced HLA molecule expression, human tumor infiltrating lymphocytes, 3561
 transfection of interleukin 2 gene
 augmentation, cellular immune response, 949
Melanoma, B16
 cerebral metastases
 protection, active immunization, 1113
 3',5'-cyclic nucleotide phosphodiesterase potential target, tumor growth inhibition, 3058
 radiation-enhanced expression
 MHC class I antigen H-2D^b, 1952
Melanoma, B16BL6
 high and low metastatic variants
 differential growth factor production, secretion, 4075
Melanoma, B16F10
 plasminogen activator production
 modulation by synthetic peptide, laminin A chain, 1998
Melphalan

damaged DNA
 binding, poly(ADP-ribose) polymerase, 5370
 DNA damaging agents
 sensitivity to *ERCC-1* overexpression, Chinese hamster ovary cells, 3237
Membrane
 permeability
 etoposide-induced cytotoxicity, T-cell leukemia lines, 4287
Ménétrier's mucosa
 high affinity binding sites
 gastrin-releasing peptide, gastric cancer, 5090
Meningioma
 morphologically malignant
 progression of, loss of heterozygosity for loci on chromosome 10, 2386
 progesterone receptor expression, 1312
Merbarone
 aberrant functions
 teniposide-resistant CEM cells, 5946
Merocyanine 540
 -mediated phototherapy
 enhancement by salicylate, 806
Mesenchyme
 regulation and heteromeric structure
 fibroblast activation protein, 3327
Mesothelial cells
 normal human cells and cell lines
 insulin-like growth factor I, associated molecules, 2858
Mesothelioma
 factors that stimulate production of hyaluron
 mesothelial cells, fibroblasts, 388
 human malignant
 chemotaxis and haptotaxis, autocrine motility factor-like substance, 4376
 recurrent deletions of specific chromosomal sites, 1p/3p/6q/9p, 4349
 malignant
 critical region of chromosome loss, 9p21-p22, 4761
Mesothelium
 peritoneal
 binding of ovarian cancer cells, mediation by CD44H, 3830
Metal ions
 structural role
 “wild-type” conformation, p53, 1739
Metalloproteases
 matrix
 tumor grade and invasion, bladder cancer, 5365
Metalloproteinase
 -dependent proteolytic pathways
 melanoma-mediated dissolution, extracellular matrix, 693
 elevated levels
 M, 92,000 type IV collagenases, brain, 2208
 M, 72,000
 binding and localization, cell surface invadopodia, 3159
 matriptisin
 invasive potential, expression in DU-145 cells, 417
Metallothionein
 control of synthesis
 modulation of cisplatin nephrotoxicity and drug resistance, bladder tumor,

1829
 induction
 prevention of carcinogenicity, anticancer drugs, 4767
 possible roles in carcinogenesis, 922
 resistance *in vitro* to tumor necrosis factor, 4874
Metastasis
 adhesion to hepatocytes
 integrin $\alpha_4\beta_1$, TA3/Ha mammary carcinoma cells, 3611
 amphiregulin and epidermal growth factor receptor
 estrogen receptor expression, human primary breast cancer, 3597
 augmentation induced by IL-1 or LPS
 interleukin 1 receptor antagonist, human melanoma/nude mouse system, 5051
 behavior of tumor cells
 ras, CD44 promoter activity, 1516
 bone
 parathyroid hormone-like protein gene expression, breast cancer, 5076
 breast cancer
 acceleration of granulocyte recovery, granulocyte colony-stimulating factor, 5424
 allelotyping and clonal analysis, limited genetic heterogeneity, 3804
 E-cadherin cell adhesion molecule expression
 breast cancer, 1696
 cerebral
 murine melanoma B16, protection with active immunization, 1113
 colorectal cancer
 mutation in *nm23* gene, 717
 distant
 development in primary familial breast carcinoma, deletions on chromosome 16, 3707
 distribution of permanently labeled colon cancer cells
 lectin-mediated endocytosis, trap label, 658
 fibroblast growth factor 4 transfection
 MCF-7 cells, tumorigenicity, 2168
 Friend leukemia cells
 α_1 -interferon gene transfer, abrogation of tumorigenicity, 1107
 gastric cancer
 E-cadherin expression, 1690
 high and low metastatic variants
 B16BL6 melanoma, differential growth factor production, 4075
 inhibition by 1,6-epi-cyclophilitol, 4896
 inhibition of tumor growth and multimeric forms, Tyr-Ile-Gly-Ser-Arg peptide, 3459
 inhibition of tumor growth
 O-(chloroacetyl-carbamoyl)fumagillool, 4262
 isoglobotetraosylceramide as marker
 rat mammary adenocarcinoma, 2906
 lung
 breast cancer growth, dietary linoleic acid, 4686
 nucleoside diphosphate kinase/*nm23* and c-Ha-ras mRNA, rat-transplantable osteosarcoma, 5038
 lymphoma cells

SUBJECT INDEX TO VOLUME 53

enhanced immunosuppressive activity, 1921

melanoma
suppression of growth by CTL, SCID/hu mice, 4933

milky spots as implantation site for malignant cells
peritoneal dissemination, mice, 687

modeling of development
primary and locally recurrent tumors, clinical data base for prostatic cancer, 2987

nude mouse models
human stomach cancer, 1204

osteosarcoma
MDM2 gene amplification, 16

p53 alterations
non-small cell lung cancer, 2846

paracrine migration-stimulating factor
mouse hepatic sinusoidal endothelial cells, 4418

rat tumor cell lines
major CD44 proteins, different splice variants, 1262

-related variant CD44
expression in human brain metastases, not in glioblastomas, 5345

renal cell carcinoma
oligoclonal T-cell response, vaccination with autologous tumor cells, 4745

solid tumors
edatrexate compared to methotrexate, leucovorin rescue, 587

spontaneous
cotransfection with fibroblast growth factor 4 and *LacZ*, MCF-7 cells, 2178

development of model, human osteosarcoma transplanted orthotopically into bone of athymic mice, 4890

serum and plasma *M*, 92,000 progelatinase, 5802

-suppressing function of *EIA*
counteraction of tumor suppression, reexpression of *neu*-encoded oncoprotein, 5784

suramin
multiple potential mechanisms of action, 2239

TIMP-1 as negative regulator
human gastric cancer cell line, chick embryo, 1397

tumor growth and
inhibitory effect of TNP-470, human cell lines, 2566

Metastatic potential
cell motility and glyceraldehyde-3-phosphate dehydrogenase expression
prostatic adenocarcinoma, 1995

motility of human carcinoma cells
response to thrombospondin, 378

Methionine
dependence
biochemical defect, fresh patient tumors in primary histoculture, 2479

starvation
therapeutic tumor-specific cell cycle block, 5676

Methotrexate
compared to edatrexate
leucovorin rescue, metastatic murine solid tumors, 587

delivery of radionuclides
pretargeted monoclonal antibodies, affinity system, 2368

Methoxamine
mechanisms of change in tumor blood flow
morphometry, 5528

Methoxyamine
mutagenic processing of ethylation damage
mammalian cells, 1149

3-Methoxycatechol
butylated hydroxyanisole or sodium nitrite and catechol, rat multigeneration carcinogenesis model, 32

3-Methylcholanthrene
glutathione *S*-transferase class α transcripts
hepatocytes, 231

N-Methylformamide
-induced changes
synthesis of *M*, 72,000 constitutive heat shock protein, HL-60 cell differentiation, 3034

O⁶-Methylguanine
inhibition of repair
pyridyloxobutyl DNA adducts, 2780

O⁶-methylthymidine and
repair of, rats treated with 1,2-dimethylhydrazine and *O⁶-benzylguanine*, 3895

O⁶-Methylguanine-DNA methyltransferase
activity
brain tumors and adjacent normal brain, 3416

prolonged depletion of activity
O⁶-benzylguanine with or without streptozotocin, 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity, 4281

ribozyme-mediated modulation, 1731

6-Methylmercaptopurine
N-(phosphonacetyl)-L-aspartate and 6-aminonicotinamide
potentiation, radiation, 3518

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone
bioactivation
mechanisms of inhibition, dietary phenethyl isothiocyanate, 3276

hemoglobin adducts
red blood cells, 777

metabolites in smokers' urine, 721

tobacco carcinogenesis
dietary fat, 2758

transplacental induction
pancreas tumors in hamsters, 2498

N-Methyl-*N'*-nitro-*N*-nitrosoguanidine
hprt gene
mutagenicity, mutational spectrum, 2865

HPV-16 and
oral carcinogenesis, 4811

Methylthioadenosine phosphorylase
deficiency in human non-small cell lung cancers, 1098

Microautoradiography
normal organ distribution
radioiodinated single-chain Fv and other immunoglobulin forms, 3776

Microcirculation
blood flow reduction in tumors

high-energy shock waves, 1590

Microfilament
-depolarizing agents
scytophycins, circumvention of P-glycoprotein-mediated multidrug resistance, 1343

β_2 -Microglobulin
induction and antigenic profile of HLA-A and -B antigens
FO-1 melanoma cells, 4303

Micrometastasis
bone marrow
immunocytological detection, operable non-small cell lung cancer, 1027

Microsatellite
genetic instability
endometrial carcinoma, 5100

genomic instability in colorectal cancer
clinicopathological variables, family history, 5849

instability
bladder cancer, 5620

hereditary non-polyposis colorectal carcinoma syndrome, 5853

polymorphic
allelotype analysis of skin tumors, chromosome alterations, 6022

Microsomes
oxidative catabolism of all-*trans*-retinoic acid
lipid peroxides, 1226

Microtubules
depolymerization of estramustine binding to tubulin, 4573

Microvasculature
increased permeability
preferential accumulation of Stealth liposomes, tumor tissue, 3765

mechanisms of change in tumor blood flow
morphometry, 5528

Migration-stimulating factor
paracrine
metastatic tumor cells, mouse hepatic sinusoidal endothelial cells, 4418

Milky spots
implantation site for malignant cells
peritoneal dissemination, mice, 687

Misonidazole
unusual oxygen concentration
toxicity of SR-4233, 3992

Mitochondria
alterations
photodynamic therapy-resistant cells, 4994

cytochrome c oxidase as a target site
daunomycin, K562 cells and heart tissue, 1072

energization
Kupffer cell-induced reduction, mediation by nitric oxide, 2676

hinge protein gene
elevated expression, cancer, 2460

subcellular distribution
bcl-2 oncogene, 4701

Mitogen
-activated protein kinase
elk-1 proteins, phosphoproteins and activators, 3449

Mitomycin C
bioactivation by xanthine dehydrogenase kinetics and mechanism, aerobic and

SUBJECT INDEX TO VOLUME 53

hypoxic conditions, 5470
 DNA adducts and
 hypoxia and dicumarol, EMT6 mouse mammary tumor cells, 5127
 induction of protein-DNA complexes
 KW-2149, HeLa S3 cells, 4466
 left-shifting agent BW12C79 and
 skeletal muscle metabolism, magnetic resonance spectroscopy, 5649
 penetration in human bladder, 3314
 reductive activation
 NADH:cytochrome *b*₅ reductase, 4907

Mitosis
 -promoting factor activity
 inducer mitotic cells, radiation yield of interphase chromosome breaks, 5592
 ultrastructural localization
 proliferating cell nuclear antigen, myc oncogene, 1899

Mitoxantrone
 cardiotoxicity
 inhibition by ICRF-187, neonatal rat heart cells, 550
 cytochrome P-450-induced cytotoxicity formation, electrophilic intermediates, 5135
 plasma and cellular pharmacokinetics
 high-dose chemotherapeutic regimen, refractory lymphomas, 4850

Molecular biology
 derivation of etiology from human-based studies, 2437s

Mollusk
 bivalve species
 presence of transforming genes, gonadal tumors, 2976

Monoclonal antibodies
 anti-B4-blocked ricin immunotoxin therapeutic efficacy, SCID mouse tumor models, 1360
 anti-carcinoembryonic antigen specificity, CEA-mediated adhesion, 3817
 anti-colon MAb35
 ⁶⁷Ca labeling, preclinical evaluation, 5727
 anti-idiotype
 SV40 large tumor antigen, tumor immunity, 5734
 anti-idiotypic MK2-23 modulation of adjuvants, immunogenicity, 112
 anti-P-glycoprotein MRK16 targeting and killing, colorectal carcinoma cell lines, 5475
 anti-taxol measurement in serum, 1388
 2B5
 truncated mucin glycan, gastric and duodenal glands, 4791
 -based radio- or enzyme immunoassay pharmacokinetics, S 12363, 3536
 biophysical characterization tandem repeats, human mucin protein core, 5386
 bispecific
 c-erbB-2 and CD16, human tumor xenograft model, 94
 bivalent and monovalent blockade, epidermal growth factor receptor function, 4322

cell surface molecules suppression, T-lymphoma cell apoptosis, 5022
 cisplatin and
 antitumor effect, anti-epidermal growth factor receptor monoclonal antibodies, 4637
 conjugate preparation and characterization calicheamicins, 3336
 CYFRA 21-1 immunoradiometric assay serum fragment of cytokeratin subunit 19, marker of lung cancer, 61
 D612
 Phase I clinical trial, metastatic gastrointestinal cancer, 4555
 discrimination of MUC1 mucins other sialyl-Le^a-carrying glycoproteins, colon carcinoma, 755
 expression of sialyl-Tn antigens esophageal carcinoma, 1706
 external epitope of *mdrl* P-glycoprotein, 310
 741F8 anti-*c-erbB-2* single-chain Fv monovalent and divalent forms, *in vivo* tumor targeting, 4026
 first and second generation TAG-72 comparative dual label study, colorectal cancer, 271
 FW6
 epitope on α 3/4-monofucosylated polylactosaminoglycans, fetal and colon carcinoma-associated mucins, 4367
 gene engineering of human carcinoma cells self-reactive antibody expression, 3355
 high molecular weight melanoma-associated antigen primary acral lentiginous melanoma lesions, poor prognosis, 2830
 homodimers enhanced antitumor activity, nude mice, 2560
¹³¹I-CC49 combined with γ -interferon, improved radioimmunotherapeutic efficacy, 600
¹³¹I-labeled COU-1 tumor detection, suspected colorectal carcinoma, 5920
 immunobead-PCR detection of circulating tumor cells, 3455
¹¹¹In-labeled preclinical evaluation, nude mice bearing human epidermoid carcinoma xenografts, 2834
 intracellular and secreted mucins multiple forms, pancreatic cancer cell line, 884
 lactotetraose series ganglioside 3',6'-isoL_{D1}
 tumors of central nervous system, other systems, 120
 M43
 clinical evaluation, 2803
 molecular cloning reactivity to ganglioside G_{M3} antigen, human cancers, 5244
 MSN-1-reactive antigen subcellular localization, endometrial

cancer cells, 3643
 pretargeted delivery of radionuclides, dihydrofolate reductase and methotrexate, 2368
 radioiodinated single-chain Fv and other immunoglobulin forms microautoradiography, normal organ distribution, 3776
 radiolabeled chimeric MOv18 IgG and F(ab')₂ fragments kinetics and tissue distribution, ovarian carcinoma, 5413
 recognition of 2-nitroimidazole adducts detection of hypoxic cells, 5721
¹⁸F-labeled E48 IgG-mediated therapy, human head and neck squamous cell carcinoma xenografts, 3524
 response against c-erbB-2 oncogene breast carcinoma, 5864
 SEN7
 epitope on neural cell adhesion molecule, small cell lung cancer, 2840
 single chain anti-carcinoma antibody fused to β -lactamase genetic construction, expression and characterization, 2123
 staining of melanoma cells selective loss, HLA class I allospecificities, 3349
 -targeted delivery doxorubicin entrapped in liposomes, eradication of lung cancer, 1484
 U36
 immunotargeting, head and neck squamous cell carcinoma, 4383

Monocytes activation
 doxorubicin combined with liposome-encapsulated muramyl tripeptide, 3986
 autocrine and paracrine growth factor tumor necrosis factor α , ovarian cancer, 1939
 control of HLA-DR antigen expression γ -interferons, thyroid cells, 3943
 differentiation cytokine regulation, 2603
 regulation of expression, galactoside-binding lectin, 5033
 -mediated leukemic cell death role of β -integrins, cell cycle-specific effects of TNF- α , 4399

Mononuclear cells peripheral blood
 liver and, dihydropyrimidine dehydrogenase activity, 5433
 variable baseline γ -glutamylcysteine synthetase mRNA expression, buthionine sulfoximine treatment, 3662

Monoterpene
 -induced regression of mammary tumors mannose 6-phosphate/insulin-like growth factor receptor II, transforming growth factor- β 1 levels, 3849

Motility factor
 autocrine
 chemotaxis and haptotaxis, human malignant mesothelioma cells, 4376

MSI-238
 magainin2 and analogue peptides anticancer efficacy, 3052

SUBJECT INDEX TO VOLUME 53

Mucin

- breast tumor-associated fusion protein
- Escherichia coli*, tumor-specific epitope, 4920
- cancer-associated epitope
- clinical evaluation, M43, 2803
- gene expression
- heterogeneity, normal and neoplastic tissues, 641
- polymorphic epithelial
- human B-cell immune response, 2457
- synthesis and secretion
- MUC-1 mucin gene expression, epithelial cancer cell lines, 1437

Mucinous antigen

- ovarian cancer
- malignantly transformed Bloom's syndrome cells, 3427

Mucin protein core

- tandem repeats
- biophysical characterization, 5386

Mucins

- discrimination of MUC1 with novel monoclonal antibody
- sialyl-Le^a-carrying glycoproteins, colon carcinoma, 755
- fetal and colon carcinoma-associated epitope on α 3/4-monofucosylated polylactosaminoglycans, monoclonal antibody FW6, 4367
- intracellular and secreted
- multiple forms, pancreatic cell line, 884
- truncated glycan defined by monoclonal antibody 2B5
- gastric and duodenal glands, 4791

Mucosa

- gastric
- differential expression, CD44 splice variants, 4197
- histologically normal
- HLA class I antigens, colon, 2374
- Ménétrier's
- high affinity binding sites, gastrin-releasing peptide in gastric cancer, 5090
- rectal
- inhibition of ornithine decarboxylase, β -carotene, 3723

Mucous cells

- hyperplasia of pancreas with chronic inflammation
- frequent c-Ki-ras activation, 953

MUC-1 protein

- altered glycosylation
- colon carcinoma-associated increase, mucin-bound sialyl-Lewis^x expression, 4082

Multidrug resistance

- associated gene
- localization, HT1080/DR4 and H69AR human tumor cell lines, 3221
- atypical
- topoisomerase II as a drug target, small cell lung carcinoma cells, 1064
- bovine serum albumin-doxorubicin conjugate
- rat hepatoma, 4238
- breast cancer cells
- flavonol-stimulated efflux, 7,12-dimethylbenzanthracene, 5977

circumvention by thaliblastine

- direct binding to P-glycoprotein, 2544
- colorectal carcinoma cell lines
- targeting and killing, anti-P-glycoprotein monoclonal antibody MRK16, 5475
- component of V79 cell resistance
- adozelesin, 1354
- cytostatic
- second international symposium, 2683
- how cancer cells evade chemotherapy, 747
- inhibition by NA-382, 1555
- lung cancer cell lines
- MRP* gene, transmembrane drug transporter, 1747
- non-P-glycoprotein
- MRP* gene, 190-kDa membrane bound glycoprotein, 3658
- overexpression, M_r 110,000 vesicular protein, 1475
- non-P-glycoprotein expressing tumor cell lines
- reversal of etoposide, novobiocin, 5487

P388 cells

- induction of apoptosis, anthracycline antibiotics, 1845

P-glycoprotein

- circumvention by scytovphycins, 1343
- functional imaging, organotechnetium complex, 977
- P-glycoprotein and nucleoside transport
- BIBW 22 as bifunctional modulator, 1974
- P-glycoprotein drug binding
- nonionic detergents, 5994

P388 tumor cells

- transcriptional activation, *mdr3* gene, 1657
- reversal by GF120918, 4595
- small cell lung cancer cells
- inwardly rectifying K⁺ channels, volume-regulated anion channels, 4156

transporter

- 17 β -estradiol glucuronide as inducer, cholestasis, 5382

tumor cells

- enhancement of vincristine cytotoxicity, phenytoin, 3262
- ultrastructural appraisal
- Fourier transform infrared spectroscopy, K562 and LR73 cell lines, 3681

Muramyl tripeptide

- liposome-encapsulated
- doxorubicin and, canine monocyte activation, 3986

Muscle

- gene expression
- effect of verapamil, doxorubicin cardiotoxicity, 4658

Muscle, skeletal

- metabolism
- BW12C79 and mitomycin C, magnetic resonance spectroscopy, 5649

Muscle, smooth

- occurrence of tumors
- insulin-like growth factor II gene, *AvalI* restriction fragment length polymorphism, 5754
- vascular
- 5-fluorouracil chemotherapy and myo-

cardial ischemia, protein kinase C-mediated vasoconstriction, 3028

Mutagenesis

- induction by CC-1065
- adozelesin DNA alkylation, transgenic mouse model, 5690
- oxy radicals and antioxidant responses in cancer, 3207
- site-directed
- mutagenic processing of ethylation damage, mammalian cells, 1149

Mutagenicity

- induction by hyperthermia
- hot mate infusion and hot caffeine, *Saccharomyces cerevisiae*
- modification of DNA bases in chromatin intact target human cells, activated polymorphonuclear leukocytes, 1269
- mutagenicity
- induction by hyperthermia, hot mate infusion and hot caffeine, 5750
- mutational spectrum and
- N-methyl-N'-nitro-N-nitrosoguanidine, *hprt* gene, 2865

Mutagens

- potentiation of genetic damage
- folate deficiency, Chinese hamster ovary cells, 5401

Mutations

- clonal heterogeneity in human cancers, 921
- interruption of progression of DNA synthesis
- DNA polymerase α , codons 12 and 13 of H-ras, 2895
- nonsense and frame-shift
- rapid screening method, disease-causing APC alleles, 5581
- somatic and germ-line
- APC gene, desmoid tumors from patients with familial adenomatous polyposis, 5079
- stereospecific benzo[c]phenanthrene dihydrodiol epoxides
- sequence specificity, interaction with *supF* gene, 1273

myc

- proliferating cell nuclear antigen and oncogenes
- ultrastructural localization, synchronized neuroblastoma cells, 1899

Myeloid cells

- production of growth-promoting factor wide target cell spectrum, THP-1 cells, 1871

Myeloma

- coexistence of aneuploid subclones
- clonal immunoglobulin gene rearrangement, 5320

Myeloma, multiple

- alternatively spliced glucocorticoid receptor mRNAs, 3877
- disseminated growth
- SCID mice, 1392
- interleukin 6-dependent tumor cell growth
- inhibition, reshaping of antibody, 851

Myopathy

- human T-cell lymphoma/leukemia virus type I
- sequence analysis, immunogenic and neutralizing domain, 6067

SUBJECT INDEX TO VOLUME 53

Myelopoiesis
 acceleration of granulocyte recovery
 granulocyte colony-stimulating factor,
 metastatic breast cancer, 5424

human factor-dependent megakaryoblastic leukemia
 functional expression, interleukin 2 receptor, 675

Myeloproliferative disease
 chronic radiation-induced alteration
 aplastic anemia, DNA synthesis, 4518

Myelosuppression
 cyclophosphamide-induced protection, combined interleukin 1 β /interleukin 2 treatment, 569

Myelotoxicity
 benzene and phenolic metabolites
 oxidative DNA damage, HL-60 cells and bone marrow, 1023

Myocardial ischemia
 5-fluorouracil chemotherapy
 protein kinase C-mediated vasoconstriction, vascular smooth muscle, 3028

N

NA-382
 inhibition of multidrug resistance, 1555

NAD
 kinetics and mechanism of mitomycin C bioactivation
 aerobic and hypoxic conditions, 5470

NADH:cytochrome b₅ reductase
 reductive activation of mitomycin C, 4907

NAD(P)H:(quinone-acceptor)oxidoreductase
 density-dependent growth inhibition normal but not transformed cells, 1338

National Cancer Institute
 funding mechanisms for research, 2434s trends in program project grant funding, 477

Natural killer cells
 activated imaging by positron emission tomography, preferential uptake in tumors, 5867

production of immunosuppressive amino-sugars deacetylase activity, human tumor cells, 5600

transdominant suppressors of oncogenesis wild-type adenovirus type 5 transforming genes, rat embryo fibroblast cells, 1929

tumor-infiltrating T-cells and signal-transducing ζ chains, colorectal carcinoma, 5610

NCAM epitope recognition by monoclonal antibody SEN7 small cell lung cancer, 2840

Neoplasia elevated production of active oxygen Bloom's syndrome, 5104

Neoplastic progression induction in Syrian hamster embryo cells protein phosphatase inhibitors, 1777 transformation of Syrian hamster embryo fibroblasts

amplification potential, various carcinogens, 3098

Neoplastic transformation normal and neoplastic tissues heterogeneity, mucin gene expression, 641 tumorogenic conversion of fibroblasts $\alpha 6$ integrin, 2950

Neopterin prognosis colonic adenocarcinoma, 260

Nephrotoxicity drug resistance and cisplatin and metallothionein synthesis, bladder tumor, 1829

Nerve growth factor -like protein chemotaxis and chemokinesis, prostate tumor cell lines, 1416 prostatic inducible A gene, binding of novel element in retinoblastoma gene promoter, 5597

TRK protooncogene messenger RNA and coexpression in neuroblastoma, favorable prognosis, 2044

Neu differentiation factor induction of ICAM-1 implications, mammary tumors, 5251

Neural neoplasms 17p allelic loss DNA hypermethylation, 2715

Neuroblastoma cell differentiation regulation, Bcl-2 oncogene, 4978 frequent neuronal functions uptake and storage, *m*-iodobenzylguanidine, 304 mechanism neutrophil-mediated lysis, 362 messenger RNA for TRK protooncogene low affinity nerve growth factor receptor, favorable prognosis, 2044 neuronal differentiation alternatively spliced *src* mRNAs, 3179 oligodendrocyte-associated genes, 170 *p53* gene relationship, N-myc amplification, 4053 *p53* mutations in Ewing's sarcomas, 5284 primary absence of *p53* mutations, 5269 sensitivity to growth inhibition deferrioxamine, 3968 ultrastructural localization proliferating cell nuclear antigen, myc oncogenes, 1899

Neuroectodermal neoplasms characterization of thread proteins, 3823 chimeric EWS-FL11 transcript Ewing cell line, complex t(11;22;14) translocation, 3655 insight on biology of, 926

Neuroendocrine cells androgen receptor status benign and malignant prostatic tissue, 1967

Neuroendocrine markers drug sensitivity testing and individualized chemotherapy, individu-

alized chemotherapy, 5181

Neurofilaments oligodendrocyte-associated genes glioma and neuroblastoma, 170

Neurotoxicity cisplatin-induced protection with reduced glutathione, rats, 544

Neutrophils activation *in vivo* administration, bryostatin 1, 2810 -mediated lysis mechanism, human neuroblastoma cells, 362

Nickel induction of signature mutation oxygen free radical damage, 4172

Nicotine stimulation of serotonergic autocrine loop human small cell lung carcinoma, 5566

Nicotinic acid mononucleotide aspirin use risk of fatal cancer, 6074

NIH/3T3 cells folate binding protein gene transfection and expression, 5791 metastatic *ras*-transformed adhesion to osteopontin, fibronectin and laminin, 701 presence of transforming genes gonadal tumors, bivalve mollusk species, 2976 transformation ornithine decarboxylase overexpression, 2618

Nitric oxide hypoxic mammalian cell radiosensitization, 5845 macrophage synthesis delay of progression, UV light-induced skin cancers, 5507 mediation of Kupffer cell-induced reduction mitochondrial energization, hepatoma cells, 2676 -nucleophile complexes inhibition, proliferation of A375 melanoma cells, 564 oxy radicals and antioxidant responses in cancer, 3207

9-Nitrocampothecin -treated immunodeficient mice regression of breast carcinoma tumors, 1577

6-Nitrochrysene induction of mammary cancer, 3719 metabolism hepatic and pulmonary cytochrome P450 enzymes, 2028

Nitrogen mustard induction of apoptosis modulation by *bcl-2*, 1853

Nitroglycerin protein kinase C-mediated vasoconstriction 5-fluorouracil chemotherapy, myocardial ischemia, 3028

4-Nitroquinoline-*N*-oxide potent intracellular oxidative stress,

SUBJECT INDEX TO VOLUME 53

3250

4-Nitroquinoline 1-oxide
-induced tongue neoplasms in rats
chemoprevention of oral carcinogenesis, DL- α -difluoromethylornithine, 772

Nitrosamine
tobacco-specific
smokers' urine, 721

N-Nitrosodimethylamine
chronic ingestion and effects on rats, 4107

N-Nitroso-N-methylurea
induction of carcinogenesis
expression of sulfated glycoprotein 2, prostate and seminal vesicle, 1480

Nitrosourea
cisplatin-induced DNA cross-links and topoisomerase II inhibition and altered kinetics, glioblastoma, 5663

N-myc
amplification
mutation of *p53* gene, neuroblastoma, 4053

N-myc 2
insulin-like growth factor II and precancerous altered hepatic foci, woodchuck hepatitis virus carriers, 2020

Nodules
subcutaneous
interstitial pressure, melanoma and lymphoma, 2204

Nonidet P-40
effects of nonionic detergents
P-glycoprotein drug binding, multidrug resistance, 5994

Nonsteroidal antiinflammatory drugs
aspirin
use and risk of fatal cancer, 1322

Novobiocin
reversal of etoposide resistance
non-*P*-glycoprotein expressing multidrug-resistant tumor cell lines, 5487

Nuclear matrix
association of origins of replication
normal human fibroblasts, 3865
differences in DNA supercoiling
local control, T2/3 transitional cell carcinoma of the bladder, 2300

Nuclear matrix proteins
normal and breast cancer cells, 3394
patterns in human benign prostatic hyperplasia
prostate cancer, 744

Nucleolar organizer
argyrophilic
proliferating cell nuclear antigen and, prognosis in lung cancer, 5000

Nucleoside diphosphate kinase
-nm23
c-Ha-ras mRNA and lung metastasis in osteosarcoma, 5038

Nucleosides
transport and *P*-glycoprotein
BIBW 22 as bifunctional modulator, 1974

Nucleotides
purine
levels in host tissues, Ehrlich ascites tumor-bearing mice, 5143

Nutrition

cancer and
American Cancer Society Research Workshop, 2431s, 2432s
cell and organ culture studies, American Cancer Society Research Workshop, 2455s
panel on animal studies, American Cancer Society Research Workshop, 2452s
panel on human studies, American Cancer Society Research Workshop, 2449s
diet and cancer
development of hypotheses, evaluation in animal studies, 2442s

O

Occupational risks
agricultural
non-Hodgkin's lymphoma, 2421
welders
DNA-protein cross-links, 460

Okadaic acid
class tumor promoters
hyperphosphorylation of cytokeratins, primary keratinocytes, 992
hyperphosphorylation
retinoblastoma protein and *p53*, 239
induction of neoplastic progression
protein phosphatase inhibitors, Syrian hamster embryo cells, 1777
teleocidin and
absence of syngeneic effects, tumor promotion in CD-1 mouse skin, 1012

Oligodendrocyte
-associated genes
human glioma and neuroblastoma cell lines, 170

Oligonucleotides
human papillomavirus type 18-specific antisense
transformed phenotype, human carcinoma cell lines, 2330

Oltipraz
chemopreventive effect
carcinogenesis induced by azoxymethane, 2502
transient intervention
aflatoxin-induced hepatic tumorigenesis, 3499

Oncogenes
BCR-ABL
role in human leukemia, 485
c-Ha-ras
inhibition of tumor growth, antisense DNA, 577
c-Ki-ras
activation in mucous cell hyperplasias, pancreas, 953
c-myc: *see c-myc*
elk-1 variant
differential splicing, encoding of activators and repressors, 215
environmental skin cancer mechanisms, models and human relevance, 3439

H-ras
spontaneous revertants of rat fibroblasts, up-regulation of lysyl oxidase, 4670

H-ras and v-myc

inhibition of DNA synthesis, rat embryo fibroblasts, 1213
-induced transformation
altered chromosomal methylation patterns, bronchial epithelial cells, 1684

Ki-ras
expression by transgenic mice, control of thyroglobulin promoter, 5523
loss of heterozygosity
invasive low-grade and high-grade epithelial ovarian carcinoma, 4456

met expression
sarcoma tumorigenicity, 5355

middle T
induction by soluble factor, endothelial cell migration and invasiveness, 3812

neu
increased protein tyrosine phosphatases, human breast epithelial cells, 2272

normal and neoplastic growth and development, 929

nuclear
transgenic mouse for synergistic effects, tumorigenesis, 1719

ras: *see ras*
regulation and heteromeric structure
fibroblast activation protein, 3327

RET
rearrangement, *in vitro* irradiation, 2940

src-specific immune regression
Rous sarcoma virus-induced tumors, 915

systematic H-ras amplification
ovary-independent mammary tumors, progressively anaplastic phenotypes, 5339

transformation
radiation, taxol, 1368

v-fos and v-ras Ha
induction of autonomous papillomas, transgenic epidermis, 5071

v-jun transgenic mice
characterization of sarcoma cell lines, 622

v-jun transgenic murine cells
induction of anchorage independence, tumor necrosis factor- α and interleukin 1 α , 615

Oncogenesis
coamplification of *CDK4* gene
MDM2 and *GLI*, human sarcomas, 5535

functional role
chromosome 10 loss, human glioblastomas, 5043

growth inhibition of lung cancer cell lines
interleukin 6, 4175

transdominant suppressors
wild-type adenovirus type 5 transforming genes transformed rat embryo fibroblast cells, 1929

Oncoproteins
bcl-2
differentiation, human neuroblastoma cells, 4978
subcellular distribution, 4701

c-erbB-2
antibody response, breast carcinoma,

SUBJECT INDEX TO VOLUME 53

5864
***neu*-encoded**
 counteraction of tumor suppression,
EIA, 5784

Oncostatin M
 -induced growth inhibition
 increased resistance, melanoma cell
 lines derived from advanced-stage le-
 sions, 2708

Opioids
 endogenous peptides
 human brain tumors, associated cyst
 fluids, 4715

peptides and steroid hormones
 growth, androgen-responsive Shionogi
 carcinoma cells, 4224

Oral neoplasms
 subsequent risk
 serum micronutrients, 795

Oral tissue
 detection of DNA adducts
 tobacco smoking, ^{32}P postlabeling,
 1522

Organ culture
 hormone regulation of human prostate,
 5199

identification and characterization of
 agents
 modification, carcinogenesis, 2446s

report of Group C
 American Cancer Society Research
 Workshop, 2455s

Organosulfur compounds
 chemoprevention
 colon carcinogenesis, 3493

Organotechnetium complex
 functional imaging
 multidrug-resistant P-glycoprotein,
 977

Ormaplatin
 sensitivity/resistance
 cisplatin-resistant ovarian cancer cells,
 242

Ornithine decarboxylase
 development of resistance to hydroxyu-
 rea
 α -difluoromethylornithine, K562 cells,
 5262

inhibition of activity in rectal mucosa
 β -carotene, colon cancer, 3723

overexpression
 transformation of NIH/3T3 cells,
 2618

Osteopontin
 adhesion of metastatic *ras*-transformed
 NIH 3T3 cells, 701

TPA-induced tumorigenic transforma-
 tion and
 $1\alpha,25$ -dihydroxyvitamin D₃, mouse
 JB6 epidermal cells, 2217

Osteosarcoma
 cell migration
 overexpression of urokinase receptor,
 matrix invasion, 3109

metastatic
MDM2 gene amplification, 16

rat-transplantable
 lung metastasis, nucleoside diphos-
 phate kinase/*nm23* and c-Ha-*ras*
 mRNA, 5038

transplanted orthotopically into bone of
 athymic mice

development, spontaneous metastasis
 model, 4890

Osteosarcoma cells
 aggregation
 platelet α -granule proteins, platelet
 membrane glycoproteins Ib/IX and
 IIb/IIIa, 4695

cell density inhibition of proliferation
 concerted control, multiple histone
 promoter factors, 2399

Ovarian neoplasms
 anticancer efficacy
 magainin2 and analogue peptides,
 3052

anti-p53 antibody response, 3468

autocrine and paracrine growth factor
 tumor necrosis factor α , 1939

binding to peritoneal mesothelium
 mediation by CD44H, 3930

cisplatin-resistant
 ormaplatin sensitivity/resistance, 242

cross-resistance to diverse drugs
 primary cisplatin resistance, 5225

detailed deletion mapping
 chromosome 17q, 3382

detection and intervention
 National Cancer Institute Conference,
 investigational strategies, 3839

epithelial
 alleleotype, 2393

deletion unit on chromosome 17q,
 1218

mutation of *K-ras* protooncogene, bor-
 derline malignancy, 1489

p53 and *Ki-ras* gene mutations, 3103

prognostic significance, platelet-de-
 rived growth factor, 4550

expression and processing of progastrin,
 1823

high efficiency gene transfer
 no cell selection, primary human tu-
 mor explants, 2221

LHRH analogues
 high affinity binding, direct antiprolif-
 erative effects, 5439

malignant and benign
 steroid production in different parts,
 2309

mucinous antigen
 malignantly transformed Bloom's syn-
 drome cells, 3427

pharmacokinetics of recombinant human
 interleukin 3
 chemotherapy, 5915

Ovary
 granulosa cell tumorigenesis, 3741

C19 androgen induction, genetic sus-
 ceptibility, 1059

-independent mammary tumors
 systematic H-*ras* amplification, pro-
 gressively anaplastic phenotypes,
 5339

transformation of epithelial cell lines
RAST24, no influence on cisplatin
 sensitivity, 3771

22-Oxa-calcitriol
 antitumor effect
 synergism with tamoxifen, athymic
 mice implanted with human breast
 carcinoma, 2534

Oxaliplatin
 cytotoxicity and protein binding

red blood cell partitioning, 5970

Oxidants
 altered sensitivity
 tumor cell heme uptake, induction of
 ferritin synthesis, 5308

Oxidative stress
 intracellular
 4-nitroquinoline-N-oxide, 3250

lipid-derived and ascorbate free radicals
 exposure to edelfosine, L1210 cells,
 711

Oxonic acid
 inhibition of gastrointestinal toxicity
 5-fluorouracil, no loss of antitumor ac-
 tivity, 4004

Oxygen
 active
 elevated production, Bloom's syn-
 drome, 5104

active species and lipid peroxidation
 antimutagen effects, hyperthermia, 2326

damage of nuclear DNA
 liver, rats exposed to psychological
 stress, 4153

fluence rate effects
 photodynamic therapy, multicell tu-
 mor spheroids, 1249

free radical damage
 nickel, induction of signature muta-
 tion, 4172

inhibition of oxidative stress
 chemopreventive agents, HeLa cells,
 4528

oxidative injury
 activation of heat shock transcription
 factor, heat shock protein levels, 12

singlet
 induction of human heme oxygenase
 gene, UVA/near-visible light, 4505

unusual concentration
 toxicity of SR-4233, 3992

Oxy radicals
 antioxidant responses and
 cancer, 3207

P

p34^{cdc2}
 activation
 caffeine release, radiation-induced S
 and G₂ phase arrest, 1507

p53
 abnormalities in different subtypes
 human sarcomas, 468

absence of germ line mutations of exons
 5 to 9

Turcot's syndrome, glioma and poly-
 posis, 957

absence of mutations
 primary neuroblastomas, 5269

accumulation in esophageal precancer-
 ous lesions

early biomarker for carcinogenesis,
 1783

accumulation of wild type protein
 human astrocytoma, 3465

alterations
 metastatic involvement, non-small cell
 lung cancer, 2846

analysis of antibodies
 cancer-defined B-cell epitopes, expo-
 sure on protein surface, 5872

anti-p53 antibody response in cancer pa-

SUBJECT INDEX TO VOLUME 53

tients, 3468
 antisense
 codon 248 *p53* mutations, retention of tumor suppressor function, 4362
 base transitions
 gastric cancer, 2614
 -binding protein *MDM2* gene
 differential expression, human breast carcinoma, 3226
 conformation
 redox modulation, sequence-specific DNA binding, 4469
 conformational domain
 sequence-specific interaction, DNA, 5361
 discordant gene mutations
 primary head and neck cancers, upper aerodigestive tract, 1676
 distinct pattern of mutations
 bladder cancer, relationship to tobacco usage, 1162
 gene alterations
 activation of c-K-ras-2, uterine endometrium, 1883
 gene expression
 hepatocellular carcinoma, tumor growth and invasiveness, 4691
 gene mutation and protein overexpression
 loss of 17p, esophageal squamous cell carcinoma, 846
 gene mutations
 cigarette smoking and schistosomiasis, urothelial cancer, 3795
 lack of occurrence, testis cancer, 3574
 germ line mutant
 dominant negative effect, tumorigenesis, 4452
 germ line mutation screening
 malignant tumors, family history of cancer, 452
 high frequency of mutations
 strand bias and tumor heterogeneity, ultraviolet radiation-induced skin tumors, 2961
 inactive mutants
 transcriptional activity, wild-type *p53*, 4772
 incidence of mutations
 progression, head and neck cancer, 4477
 induction
 wavelength specific patterns in skin, exposure to UV radiation, 2697
 infrequent mutations
 pulmonary carcinoid tumors, 5797
 Ki-ras gene mutations and epithelial ovarian neoplasms, 3103
 loss of associated G1 checkpoint cell survival after DNA damage, 4164
 mutant
 resistance to transforming growth factor- β_1 , murine keratinocytes, 899
 mutant suppressor protein target, peptide-induced CD8⁺ cytotoxic T-cells, 3257
 mutation
 chromosome 17p deletions, renal cell carcinoma, 3092
 common genetic event, ovarian carcinoma, 2128
 Ewing's sarcomas but not neuroblastoma, 5284
 formation of hyperplastic outgrowths, mouse mammary cells, 1646
 histological type, invasive breast carcinoma, 4665
 lack of correlation, radiosensitivity in head and neck cancer cell lines, 3667
MDM2 amplification, human soft tissue sarcoma, 2231
 preneoplastic stage, mouse mammary tumor development, 3374
 profiles, altered mRNA in esophageal carcinoma, 1889
 relationship to N-myc amplification, neuroblastoma, 4053
 subset, advanced stage prostate cancer, 3369
 tumor-distant epithelia, head and neck cancer, 4189
 tumor progression, hepatocellular carcinoma, 2884
 mutations and 3p deletions
 prognostic significance, primary resected non-small cell lung cancer, 1 mutations in adult squamous cell carcinoma
 infrequency of *MDM2* gene amplification, pediatric solid tumors, 6028
 no site-specific mutation
 aflatoxin B₁-induced hepatic hyperplastic nodules, 9
 overexpression
 high-risk human papillomavirus infections, transitional cell carcinoma of the urinary bladder, 4823
 late event, development of malignant melanoma, 2235
 protein accumulation
 early bronchial neoplasia, 4817
 repair and DNA strand bias
 normal and xeroderma pigmentosum group C fibroblasts, 5377
 retinoblastoma protein and hyperproliferation, okadaic acid, 239
 retroviral wild-type
 vector penetration of lung cancer spheroids, induction of apoptosis, 4129
 role and mutational heterogeneity
 hepatocellular carcinoma, 368
 role in cell cycle arrest
 radiosensitivity, Burkitt's lymphoma cell lines, 4776
 sequence-specific DNA binding chemotherapy and DNA damaging agents, 2212
 somatic mutations
 breast carcinoma, Icelandic population, 1637
 splicing mutations
 human hepatocellular carcinoma, 1653
 subset of human malignant gliomas amplification and overexpression, *MDM2* gene, 2736
 ultraviolet-specific mutations in gene skin tumors, xeroderma pigmentosum, 2944
 "wild-type" conformation structural role, metal ions, 1739
 p56^{ck}
 loss of T-cell receptor ζ chain
 T-cells, human renal cell carcinoma, 5613
 p65
 exposed melanoma cells
 molecular basis, complement resistance, 592
 p110
 overexpression of vesicular protein non-P-glycoprotein-mediated multidrug resistance, 1475
 p145^{ck}
 modulation of function in cells acute myeloblastic leukemia, 4424
 P185
neu transformation
 protein tyrosine phosphatases, human breast epithelial cells, 2272
 p190^{BCR-ABL}
 p210^{BCR-ABL}/ or heterogeneity of lineage derivation, Philadelphia-positive acute lymphoblastic leukemia, 3289
 PAI-1
 urokinase-type plasminogen activator and cytosolic extracts, breast carcinoma, 2513
 Pancreas
 cholecystokinin-A receptors azaserine-induced preneoplastic lesions, 3925
 juice and peripheral blood detection of *ras* gene mutations, pancreatic adenocarcinoma, 2472
 mucous cell hyperplasias chronic inflammation, c-Ki-ras activation, 953
 Pancreatic neoplasms
 acinar cell line unscheduled expression, basic fibroblast growth factors, 1182
 advanced stage overexpression, acidic and basic fibroblast growth factors, 5289
 carcinogenesis caloric restriction and intervention, 46
 carcinogen treatment in initiation DNA damage, repair and cell proliferation, 2790
 enhanced expression type II transforming growth factor β receptor, 2704
 genetic instability poorly differentiated type, gastric cancer, 5087
 high efficiency gene transfer no cell selection, primary human tumor explants, 2221
 multiple forms intracellular and secreted mucins, 884
 "patient-like" treatment model orthotopic transplantation, human tumor tissue in nude mice, 3070
 transplacental induction ethanol, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 2498
 Papilloma
 autonomous cooperation between *v-fos* and *v-ras* Ha, transgenic epidermis, 5071
 chemically induced benign protection against malignant conver-

SUBJECT INDEX TO VOLUME 53

sion, polyphenolic fraction from green tea, 5409

Laryngeal
epidermal growth factor receptor, decreased epithelial differentiation, 910

Paraffin
-embedded colon carcinoma specimens colorimetric *in situ* messenger RNA hybridization, epidermal growth factor receptor, 937
-embedded tissue formalin, X chromosome inactivation, 4676

Parathyroid hormone
-related peptide growth factor-like properties, transfected rodent cell lines, 2980
-related protein gene expression PCR analysis, breast cancer and bone metastases, 5076
-related protein in human prostate cancer immunohistochemical localization, 1724

α -Particles
extremely low doses induction of sister chromatid exchange, 2188

PC-3 cells
inhibition of cell proliferation androgen receptor complementary DNA, 1304

PC-12 cells
protection from apoptosis HIV-1 Tat protein, 4481

P388 cells
induction of apoptosis anthracycline antibiotics, 1845

P815 cells
arachidonic acid as growth signal, 3405

Pelvis
induction of renal carcinoma by phenacetin hydronephrosis-bearing rats of SD/cShi strain, 4218

Peptides
endogenous opioid human brain tumors, associated cyst fluids, 4715
growth factors fibroblast hepatocyte growth factor/scatter factor, breast carcinoma cell lines, 1233
-induced CD8⁺ cytotoxic T-cells target, mutant *p53* tumor suppressor protein, 3257
magainin2 and analogues anticancer efficacy, 3052
synthetic human B-cell immune response, polymorphic epithelial mucin, 2457 laminin A chain, plasminogen activator production of B16F10 melanoma, 1998

Tyr-Ile-Gly-Ser-Arg
multimeric forms, inhibition of tumor growth and metastasis, 3459

Peripherin
stable expression by neuroendocrine carcinomas skin, xenograft on nude mice and pri-

mary cultures, 1175

Peritoneal cavity
tumor tissue and progressive ovarian carcinoma, procolagens types I and III, 5028

Peritoneum
dissemination milky spots as implantation site for malignant cells, 687

Perspectives in Cancer Research
competing influences concomitant tumor resistance, 3266 gap junction function and cancer, 3475 signaling by integrins tumorigenesis, 1502 suramin multiple potential mechanisms of action, 2239

Pesticides
agricultural risk factors non-Hodgkin's lymphoma, 2421

P-glycoprotein
direct binding circumvention of multidrug resistance, thaliblastine, 2544
drug binding and reversal of multidrug resistance nonionic detergents, 5994
enhanced Adriamycin activity bifunctional inhibitor W-77, human ovarian carcinoma, 2051
inhibition of multidrug resistance by NA-382, 1555

mdrl
external epitope, monoclonal antibody, 310
-mediated multidrug resistance circumvention by scytophyccins, 1343
monoclonal antibody MRK16 targeting and killing, multidrug-resistant colorectal carcinoma cell lines, 5475
multidrug-resistant functional imaging, organotechnetium complex, 977
nucleoside transport and BIBW 22 as bifunctional modulator, 1974

pH
intermediate biomarker of carcinogenesis proliferation, human colonic mucosa, 3283
intracellular lowering of, thermosensitivity of tumor cells, 1599
intracellular acidification etoposide-induced apoptosis, HL-60 cells, 2349

Phagocytosis
distribution of permanently labeled colon cancer cells lectin-mediated endocytosis, trap label, 658

Pharyngeal neoplasms
subsequent risk serum micronutrients, 795

Pharynx
preservation cancer chemoprevention, head and neck cancer, 5113

Phenacetin
induction of renal pelvic carcinoma hydronephrosis-bearing rats of SD/cShi strain, 4218

1,10-Phenanthroline
structural role of metal ions "wild-type" conformation, p53, 1799

Phenethyl isothiocyanate
dietary mechanisms of inhibition, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone bioactivation, 3276

Phenobarbital
glutathione S-transferase class α transcripts hepatocytes, 231

Phenytoin
enhancement of vincristine cytotoxicity multidrug-resistant tumor cells, 3262

Phorbol 12-myristate 13-acetate
induced tumor promotion in CD-1 mouse skin inhibition by 12-deoxyphorbol 13-esters, 2507

12-Phorbol-13-myristic acid
retinoic acid and γ -interferon ICAM-1 expression, human tumor cell lines, 826

Phosphatidylcholine
putative tumor marker breast and colon cancer, 1751

Phosphatidylinositol-3-kinase
inhibition by antitumor ether lipid analogues, 4297

Phospholipase
activation-triggered apoptosis photosensitized mouse lymphoma cells, 5897

Phospholipase A₂
-mediated oxidative and nonoxidative mechanisms inhibition of cancer cell line proliferation, riminophenazine agents, 318

Phospholipase D
activation signal transduction pathways, response to γ -radiation, 4474

N-(Phosphonacetyl)-L-aspartate
 \pm 5-fluoro-2'-deoxyuridine antitumor activity, colon carcinoma 26, 1560

6-methylmercaptopurine and 6-aminonicotinamide
potentiation, radiation, 3518
multiple mechanisms of drug resistance SV40-infected precrisis human fibroblasts, 4946

Phosphoproteins
elk-1 proteins activators, mitogen-activated protein kinase, 3449

M, 32,000
selective expression, competency for self-renewal, 4720

Phosphoramido mustard
modulation of rat hepatic cytochrome P450 2C11 cyclophosphoramido, messenger RNA levels, 2490

O-Phospho-L-tyrosine
inhibition of cellular growth activation, protein tyrosine phosphatases, 557

Photochemotherapeutic agents

SUBJECT INDEX TO VOLUME 53

benzophenoxazine analogues, 2571

Photochemotherapy
pharmacokinetics of fluorescent drug
laser-induced fluorescence, 5954

Photodynamic therapy
endothelium-dependent relaxation
rat aorta, 2548

fluence rate effects
multicell tumor spheroids, 1249

-resistant cells
mitochondrial alterations, 4994

Photofrin
photosensitization
membrane lipid free radicals, L1210
murine leukemia cells, 3670

Photorepair
skin
ultraviolet radiation-induced DNA
damage, platyfish *Xiphophorus*,
2249

Photosensitization
mouse lymphoma cells
triggering of apoptosis, phospholipase
activation, 5897

Photosensitizer
uptake
tumor-secreted vascular permeability
factor/vascular endothelial growth
factor, 153

Phototherapy
merocyanine 540-mediated
enhancement by salicylate, 806

Phyllodes neoplasms
breast
clonal analysis, comparison to fibroad-
enoma, 4071

Pirarubicin
pharmacokinetic and pharmacodynamic
advantages over Adriamycin
intraarterial hepatic administration,
VX2 tumor model, 1550

Piroxanthrone
pharmacokinetics
Phase I trial with granulocyte-colony
stimulating factor, 2587

Pituitary neoplasms
prenatal exposure to diethylstilbestrol,
1546

Placenta
detection of aflatoxin B₁-DNA adducts,
1278

transplacental carcinogenicity of cisplat-
in
SENCAR mice, 3874

Plasma
pharmacokinetics of vinblastine
N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl
isoleucinate, high-performance li-
quid chromatography, 2061

pharmacokinetic study of topotecan
nonhuman primates, 725

Plasma membrane
cytotoxic protein purification
characterization, transformed fibro-
blasts, 1195

Plasmid
reporter gene inactivation
one benzo(a)pyrene diol-epoxide DNA
adduct, hepatocytes, 2279

Plasminogen activator
extracellular matrix production and deg-
radation

adenoid cystic carcinoma cells, 147

inhibitor
inhibition, invasion of HT1080 sar-
coma cells, 6051

modulation of production
synthetic peptide from laminin A
chain, B16F10 melanoma, 1998

urokinase-type
receptor antibody, modulation of inva-
sion in human glioblastoma cells,
4143

stimulation, blockage of E-cadherin-
dependent cell-cell adhesion, 3618

urokinase-type and PAI-1
cytosolic extracts, breast carcinoma,
2513

urokinase-type antigen in plasma
clinical value, detection of colorectal
cancer, 1788

Platelet-derived growth factor
 β receptor
successive activation, genesis of human
choriocarcinoma, 2927

Platelets
activation
in vivo administration, bryostatin 1,
2810

-derived endothelial cell growth
sensitivity of KB cells, pyrimidine anti-
metabolites, 5680

-derived growth factor and its receptor
prognostic significance, epithelial
ovarian neoplasms, 4550

glycoprotein IIb/IIIa binding to fibrino-
gen

inhibition, tumor cell membrane pro-
teins, 221

membrane glycoproteins Ib/IX and IIb/
IIIa

platelet α -granule proteins, aggrega-
tion induced by osteosarcoma cells,
4695

Platinum
-DNA adduct in leukocyte DNA
different types of malignancies, 3694

resistance
cytostatic multidrug resistance, second
international symposium, 2683

role of carrier ligand, human carci-
noma cell lines, 799

Platinum complexes
bis(anti-amine-dichloro-cyclohexyl-
amine platinum(IV)
preclinical antitumor evaluation, 2581

Pleiotropin
heparin-binding growth/differentiation
factors
midline expression, Wilms' tumor and
other human carcinomas, 1281

PM-1 antibody
reshaping of
inhibition, interleukin 6-dependent tu-
mor cell growth, 851

Poly(ADP-ribose) polymerase
binding of melphalan-damaged DNA,
5370

specific proteolytic cleavage
early marker, chemotherapy-induced
apoptosis, 3976

Polyamine analogues
*N*¹,*N*¹²-bis(ethyl)spermine
growth inhibition, hormone-responsive

and -resistant human breast cancer,
2071

DNA interaction
human brain tumor cell lines, 3948

Polyamines
antitumor activity of *N*¹,*N*¹²-
bis(ethyl)spermine
human melanoma xenografts, 581

cancer
international symposium, 2689

Polyclonal antibodies
anti-taxol
measurement in serum, 1388

Polyethylene glycol
-modified chimeric toxin
transforming growth factor α , *Pseudo-*
monas exotoxin, 4588

Poly lactosaminoglycans
 α 3/4-monofucosylated
monoclonal antibody FW6, fetal and
colon carcinoma-associated mucins,
4367

Polymerase chain reaction
heterogeneity in MLL/AF-4 fusion
mRNA
t(4;11) acute leukemia, 3853

immunobead-PCR
detection of circulating tumor cells,
3455

parathyroid hormone-like protein gene
expression
breast cancer, bone metastases, 5076

Polymers
controlled release for drug delivery in
brain
interstitial chemotherapy, 329

Polymorphism
Aval restriction fragment length
insulin-like growth factor II gene, oc-
currence of smooth muscle tumors,
5754

Polyoma virus
middle T oncogene insertion in Caco-2
cells
increased protein kinase C α expres-
sion, 2762

-transformed middle T oncogene
induction by soluble factor, endothelial
cell migration and invasiveness,
3812

Polyposis
Turcot's syndrome
absence of germ line mutations, *p53*
gene, 957

Proline
biophysical characterization of tandem
repeats
human mucin protein core, 5386

Positron emission tomography
imaging of activated natural killer cells
preferential uptake in tumors, 5867

Potassium channel
inwardly rectifying
volume-regulated anion channels,
small cell lung cancer cells, 4156

³²P postlabeling
detection of DNA adducts in human oral
tissue
tobacco smoking, 1522

Pregnancy
transplacental carcinogenicity of cispla-
tin

SUBJECT INDEX TO VOLUME 53

SENCAR mice, 3874

Preneoplasia

- mouse mammary epithelial cells
- growth factor dependency, gene expression, 668
- TM preneoplastic mammary outgrowths morphological and functional properties, 663

Pressure

- interstitial
 - subcutaneous nodules, melanoma and lymphoma, 2204

Prevention

- therapy and basic science
 - resolution of cancer problem, 5890

Proadipocytes

- 3T3 T
 - loss of differentiation control, 1770

Procollagens

- types I and III
 - progressive ovarian carcinoma, tumor tissue and peritoneal cavity, 5028

Progastatin

- expression and processing by ovarian cancer, 1823

Progelatinase

- serum and plasma *M*, 92,000
 - spontaneous metastasis, mammary adenocarcinoma, 5802

Progesterone

- receptor expression in meningiomas, 1312
- steroid production
 - different parts, malignant and benign ovarian tumors, 2309

Program project

- grant funding trends
 - National Cancer Institute, 477

Prolactin

- calories and parity
 - mammary tumor risk, epithelial kinetics and differentiation, 1188

Proliferating cell nuclear antigen

- expression and argyrophilic nucleolar organizer regions
 - prognosis, surgically treated lung cancer patients, 5000
- myc oncogenes and ultrastructural localization, synchronized neuroblastoma cells, 1899

Prostate

- benign and malignant tissue
 - androgen receptor status, neuroendocrine cells, 1967
- dysplastic dorsolateral
 - type II estrogen-binding sites, Noble rat, 528
- expression of sulfated glycoprotein 2 induction of carcinogenesis, *N*-nitroso-N-methylurea, 1480
- hormone regulation
 - organ culture, 5199
- nerve growth factor inducible A gene binding
 - novel element, retinoblastoma gene promoter, 5597
- secretion of matrix metalloproteinases inhibitors, explant cultures, 4493
- specific antigen gene expression
 - autocrine regulation, LNCaP cells, 2852

-specific membrane antigen

- molecular cloning, complementary DNA, 227

Prostatic neoplasms

- advanced stage
 - subset, *p53* mutation, 3369
- anti-prostatic tumor activity
 - liaoazole and 13-cis-retinoic acid, 3073
- benign prostatic hyperplasia and nuclear matrix protein patterns, 744
- benign tissue and type IV collagenase, 878
- clinical data base
 - primary and locally recurrent tumors, modeling of metastases development, 2987
- DU-145 cells
 - invasive potential, metalloprotein matrixlysin, 417
- high grade
 - increased expression, high mobility group protein I(Y), 5512
- homozygous deletion and frequent allelic loss
 - chromosome 8p22 loci, 3869
- inhibition of cell proliferation
 - androgen receptor complementary DNA, 1304
- inhibition of growth
 - peptide analogues of insulin-like growth factor-1, 1102
- lack of latent transforming growth factor β binding protein, 3193
- micrometastatic
 - detection in lymph nodes, reverse transcriptase-polymerase chain reaction, 5350
- parathyroid hormone-related protein immunohistochemical localization, 1724
- prostate stromal cell secretory proteins chemotaxis and chemokinesis, 1416
- reduction of E-cadherin levels
 - deletion, α -catenin gene, 3585
- suppression of tumor growth
 - inhibin, Dunning R3327G rat tumor, 4855
- suramin
 - multiple potential mechanisms of action, 2239
- treatment with synthetic retinoid fenretinide, 224

Protease

- matrix-degrading enzyme
 - hormone-dependent breast cancer cells, 1409

Protein kinase

- cyclic AMP-dependent
 - antisense oligodeoxynucleotide, depletion of RI α subunit, 868
 - 8-chloroadenosine, mediation of 8-chloro-cyclic AMP-induced down-regulation, 393
 - mitogen-activated
 - elk-1 proteins, phosphoproteins and activators, 3449

Protein kinase A

- control of HLA-DR antigen expression
 - γ -interferons, thyroid cells, 3943

Protein kinase C

- differential modulation of isoforms
 - erythroleukemia, induced differentiation, 5554

-mediated vasoconstriction of vascular smooth muscle

5-fluorouracil chemotherapy, myocardial ischemia, 3028

modulation of activity

- in vivo* administration, bryostatin 1, 2810

regulation of glycolipid sulfotransferase activity levels, renal cell carcinoma cells, 2484

regulation of isozymes

- kidney regeneration, 4542

Protein kinase C α

- insertion of human *Ha-ras* or polyoma virus middle T oncogenes
 - human colonic Caco-2 cells, 2762

Protein tyrosine phosphatase γ

- Ptpg* gene in murine L-cells
 - carbonic anhydrase-like domain, homozygous deletion in L-cells, 1498

Protein tyrosine phosphatases

- activation
 - inhibition of cellular growth, O-phospho-L-tyrosine, 557
- increased expression
 - neu* transformation, human breast epithelial cells, 2272
- inhibition by gallium nitrate, 1862

Proteolysis

- not required for activity
 - immunotoxins made with recombinant form, *Pseudomonas* exotoxin A, 340
- specific cleavage of poly(ADP-ribose) polymerase
 - chemotherapy-induced apoptosis, 3976
- tumor-associated macrophages
 - receptor for urokinase, ductal breast carcinoma, 1911

Protocatechuic acid

- chemoprevention
 - colon carcinogenesis, 3908
 - diethylnitrosamine-induced hepatocarcinogenesis, 2775

Protooncogenes

- bcl-2*
 - induction of apoptosis, nitrogen mustard and camptothecin, 1853
- bcl-6*
 - cloning of, B-cell lymphoma, 2732
- c-fos* versus *c-jun*
 - preferential induction, early response to γ -rays in pig skin, 3246
- c-jun*
 - tyrosine phosphorylation, lymphohematopoietic precursor cells, 447
- c-kit*
 - c-myb* expression, small cell lung cancer cell lines, 4337
 - mediation of chemotaxis by stem cell factor, small cell lung cancer, 1709
 - transforming growth factor- β 1 and stem cell factor, myelogenous leukemia blasts, 3638
- c-K-ras-2* activation
 - p53* alterations, uterine endometrium, 1883
- c-src*
 - messenger RNAs, neuronal differentiation of neuroblastoma, 3179
- induction of *jun* gene family members

SUBJECT INDEX TO VOLUME 53

not 17 β -estradiol, breast cancer cells, 291

K-ras
mutation, endometrial hyperplasia and carcinoma, 1906
mutation in ovarian epithelial tumors, borderline malignancy, 1489

transforming growth factor- α
differentiating HL-60 cells, 191

TRK
nerve growth factor receptor coexpression, coexpression of messenger RNA in neuroblastoma, 2044

Pseudomonas aeruginosa
entry of protein toxins
polarized epithelial cells, 1755

Pseudomonas exotoxin
-based immunotoxins
antibody LL2 or LL2-Fab', regression of B-cell lymphoma, 819

transforming growth factor α and polyethylene glycol-modified chimeric toxin, 4588

Pseudomonas exotoxin A
recombinant form
immunotoxins, no proteolysis required for activity, 340

Purine
nucleotide levels in host tissues
Ehrlich ascites tumor-bearing mice, different growth phases of tumor, 5143

thymidylate and cytotoxicity of antifolate inhibitors, WiDr colonic carcinoma cells, 5697

Pyrazine-2-diazohydroxide
single bolus intravenous injection
Phase I study, advanced solid tumors, 4843

Pyridyloxobutyl
DNA adducts
inhibition of repair, O 6 -methylguanine, 2780

Pyrimidine
antimetabolites
sensitivity of KB cells, platelet-derived endothelial cell growth, 5680

enzymes
circadian-dependent toxicity, 5-fluorouracil, 2816

Pyrimidine nucleoside phosphorylases
differences in activities and substrate specificity
implications for chemotherapy, 5-fluoropyrimidines, 3687

Q

Quinoline-3-carboxamide
linomide
antiangiogenic effects, 1833

Quinone reductase
colon carcinogenesis
chemoprevention, organosulfur compounds, 3493

oxy radicals and antioxidant responses in cancer, 3207

R

Radiation
chromosome changes characterizing *in vitro* response
human squamous cell carcinoma lines, 5542

damage repair capacity
primary clonogenic blasts, acute lymphoblastic leukemia, 1431

-enhanced expression of H-2D b
B16 melanoma cells, 1952

-induced alteration
hematopoietic repair, preclinical phases of aplastic anemia and myeloproliferative disease, 4518

-induced S and G₂ phase arrest
caffeine release, histone messenger RNA levels, 1507

-induced transforming growth factor β
extracellular matrix reorganization, murine mammary gland, 3880

ionizing
DNA double strand break repair defect, scid mice, 1244

expression of cyclin A and cyclin B, HeLa cells, 1128

inhibition of DNA synthesis in fibroblasts, H-ras and v-myc, 1213

modeling of development of metastases primary and locally recurrent tumors, clinical data base for prostatic cancer, 2987

oncogenic transformation and taxol, 1368

potentiation
three-drug chemotherapy regimen, 3518

sensitization by etoposide
DNA repair, cell cycle interactions, 2105

-transformed rat embryo cells
presence of point mutations, N-ras gene, 1511

yield of interphase chromosome breaks mitosis-promoting factor activity, inducer mitotic cells, 5592

γ -Radiation
activation of phospholipase D signal transduction pathways, 4474

Radioimmunoassay
pharmacokinetics of S 12363, 3536

Radioimmunotherapy
enhanced effects with local hyperthermia and SR 4233
nude mice with human colonic adenocarcinoma xenografts, 3022

improved efficacy
¹³¹I-CC49 and γ -interferon, 600

¹⁸⁶Re-labeled E48 IgG-mediated therapy, human head and neck squamous cell carcinoma xenografts, 3524

Radionuclides
delivery to pretargeted monoclonal antibodies
dihydrofolate reductase and methotrexate, affinity system, 2368

Radiosensitivity
head and neck cancer cell lines
lack of correlation, p53 mutation, 3667

hypoxic mammalian cell nitric oxide, 5845

role of p53 in cell cycle arrest Burkitt's lymphoma cell lines, 4776

Raman scattering spectroscopy
surface-enhanced

introplicine, DNA and topoisomerase II, 4784

ras
gene mutations
detection in pancreatic juice and peripheral blood, pancreatic adenocarcinoma, 2472

high mutation frequency
DNA repair-deficient xeroderma pigmentosum patients, 1625

metastatic behavior of tumor cells and CD44 promoter activity, 1516

mutations
2-acetylaminofluorene-induced lung and liver tumors, 1620

transformation by R4ST24 ovarian epithelial and Rat-1 fibroblast cell lines, 3771

-transformed NIH 3T3 cells adhesion to osteopontin, fibronectin and laminin, 701

Rat-1 cells
transformation by R4ST24
no influence on cisplatin sensitivity, 3771

γ -Rays
early response in pig skin
preferential induction, c-fos versus c-jun, 3246

Receptors
Ah
growth suppression of MCF-7 cells, 2, 3,7,8-tetrachlorodibenzo-p-dioxin, 3149

androgen
inhibition of cell proliferation, PC-3 cells, 1304

status of neuroendocrine cells, benign and malignant prostatic tissue, 1967

anti-epidermal growth factor monoclonal antibodies plus cisplatin, A431 cell xenografts, 4637

aryl hydrocarbon
human ovarian carcinoma cell lines, 1802

atrial natriuretic peptide
human small cell lung cancer cell lines, 3165

basic fibroblast growth factor unscheduled expression, pancreatic acinar cancer cell line, 1182

CCK_A and CCK_B
Ca²⁺ mobilization and clonal growth, small cell lung cancer lines, 5208

chemotaxis
regulation by laminin, laminin-binding integrin subunit α_6 , 2661

cholecystokinin-A azaserine-induced preneoplastic lesions, 3925

cognate
up-regulation of vascular endothelial growth factor, glioma model of angiogenesis, 5822

1,25-dihydroxyvitamin D₃
marker, human colon carcinoma cell line differentiation and growth inhibition, 3712

1,25-dihydroxyvitamin D₃ and two analogues
biological response, target organs, 3935

SUBJECT INDEX TO VOLUME 53

elk-1 proteins
 phosphoproteins and activators, mitogen-activated protein kinase, 3449
 entry of protein toxins
 polarized epithelial cells, 1755
 epidermal growth factor
 amphiregulin and estrogen receptor expression, primary breast cancer, 3597
 autocrine and paracrine stimulation, transitional cell carcinoma, 5300
 blockade of function, bivalent and monovalent monoclonal antibodies, 4322
 colorimetric *in situ* messenger RNA hybridization, colon carcinoma surgical specimens, 937
 decreased epithelial differentiation, laryngeal papilloma, 910
 immortalization of normal human ectocervical epithelial cells, human papillomavirus, 4511
 inhibitory effects, α -interferon, 5148
 messenger RNA and transforming growth factor α , head and neck cancer, 3579
 mutation, non-small cell lung carcinoma, 3217
 preferential expression, primary non-small cell lung cancers and adjacent benign lung, 2379
 TGF- α production and autoinduction, colorectal carcinoma cell line, 1630

estrogen
 amphiregulin and epidermal growth factor receptor, human primary breast cancer, 3597
 establishment, transplantable rat thyroid tumor cell lines, 4408
 exon 5 deletion variant, wild-type estrogen receptor in breast cancer, 5882
 expression of variant, ER-negative breast cancer cell line, 5934
 improved prediction of survival, advanced ovarian adenocarcinoma, 5188
 inhibition of receptor-negative mammary epithelial cells by estrogen, 5004
 interstitial cells, kidney and estradiol-induced renal tumors, 5447
 transcriptional control, estrogen receptor-negative breast carcinoma, 3472
 variant messenger RNA lacking exon 4, estrogen-responsive breast cancer cell lines, 741

fibroblast growth factor type I
 aberrant expression, pancreatic adenocarcinoma, 4741

glucocorticoid
 differentiation, human promyelocytic leukemia cells, 3513
 messenger RNA, human multiple myeloma cells, 3877
 mutants, human leukemic cells, 4059

GM-CSF
 lack of proliferation, nonhematopoietic human malignant cell lines, 3139

GM-CSF and insulin
 inhibition of binding, dimethyl sulfox-

ide, 1142
 growth factor
 suramin, multiple potential mechanisms of action, 2239
 heparin-binding growth factor
 complementary DNA, use of kinase insert sequence, 1136
 insulin-like growth factor 1
 estrogen-induced kidney tumors, 2256
 inhibition, human melanoma culture and athymic mice, 2522
 inhibition of growth by peptide analogues, prostatic cancer cell lines, 1102
 low risk, human breast cancer, 3736

γ -interferon
 growth inhibition by interleukin 1, colorectal carcinoma, 636

interleukin 1
 antagonist, inhibition of metastasis augmentation, 5051
 antagonist induced by interleukin 1 β , tumor necrosis factor binding protein, 4010

interleukin 2
 human factor-dependent megakaryoblastic leukemia cell line, 675
 human interleukin 2 analogues, reduced secondary cytokine secretion, 2597
 T-cell infiltration, renal cell carcinoma, 1380

interleukin 3
 lack of proliferation, nonhematopoietic human malignant cell lines, 3139

interleukin 6
 lack of proliferation, nonhematopoietic human malignant cell lines, 3139

mannose-6-phosphate/IGFII
 transforming growth factor- β 1, monoterpene-induced regression of mammary tumors, 3849

mannose-6-phosphate/IGFIII
 cathepsin D, benign and malignant mammary tumors, 2901

nerve growth factor
 TRK protooncogene coexpression, neuroblastoma, 2044

platelet-derived growth factor β
 successive activation, genesis of choriocarcinoma, 2927

progesterone
 expression in meningiomas, 1312

retinoic acid
 induction by estradiol, human breast cancer cells, 5841

T-cell
 DNA double strand break repair defect, scid mice, 1244
 DNA sequence analysis of genes, oligoclonal T-cell response, 840

T-cell ζ chain
 p56 $^{\text{ICL}}$ in T-cells, human renal cell carcinoma, 5613

T-cell V region
 gene usage of CTL and TIL, autologous gastric Signet ring cell carcinoma, 3078

thrombospondin
 normal, hyperplastic and neoplastic

breast, 1421
 thymosin α 1
 down-regulation of growth, non-small cell lung cancer cells, 5214

transferrin
 efficacy of targeted immunotoxins, brain pediatric neoplasms, 1348
 pharmacokinetics and toxicology of immunotoxins, nonhuman primates and rodents, 3752

transforming growth factor type II
 human pancreatic cancer cells, 2704

tumor necrosis factor α
 autocrine and paracrine growth factor, ovarian cancer, 1939

urokinase
 concentration in malignant and benign breast tumors, quantitative autoradiography, 3198
 overexpression and matrix invasion, cell migration in osteosarcoma cell line, 3109
 tumor-associated macrophages, ductal breast carcinoma, 1911

urokinase-type plasminogen activator antibody, modulation of invasion in glioblastoma cells, 4143

vascular permeability factor
 adenocarcinomas, gastrointestinal tract, 4727

Rectal neoplasms
 risk of fatal cancer
 aspirin use, 1322

Red blood cells
 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone hemoglobin adducts, 777
 partitioning
 cytotoxicity and protein binding, oxaliplatin, 5970

Renal cell neoplasms
 allelic deletions
 histopathological correlations, 5780
 estradiol-induced
 localization of estrogen receptors, interstitial cells, 5447
 high efficiency gene transfer
 no cell selection, primary human tumor explants, 2221

Reserve cells
 appearance in mouse cervical epithelium
 retinoid status, 2287

Restriction point protein
 cyclin E and cyclin A, 1493

Retinoblastoma
 gene product pRb110
 protein interaction with M , 73,000
 heat shock cognate protein, 1702
 gene promoter
 binding of novel element, prostatic nerve growth factor inducible A gene, 5597
 mutational profiles of p53 and altered messenger RNA, esophageal carcinoma, 1889
 tumor suppressor gene expression
 megakaryocytic differentiation of leukemic cells, TPA and staurosporine, 3085

Retinoblastoma protein
 p53 and
 hyperphosphorylation, okadaic acid, 239

SUBJECT INDEX TO VOLUME 53

Retinoic acid
 immortalization of normal human ectocervical epithelial cells
 human papillomavirus, 4511
 inhibition of human papillomavirus type 16
 transformation, human keratinocytes, 905
 γ -interferon and
 ICAM-1 expression, human tumor cell lines, 826
 receptor induction by estradiol
 human breast cancer cells, 5841
unresponsive malignant hemopoietic cell lines
 N-(4-hydroxyphenyl)retinamide, induction of apoptosis, 6036
13-cis-Retinoic acid
 liarozole and
 anti-prostatic tumor activity, 3073
Ro 40-8757 and
 breast cancer, 2319
all-trans-Retinoic acid
 liposomal
 induction of differentiation, myeloid leukemia cell lines, acute promyelocytic leukemia cells, 2100
Ro 40-8757 and
 breast cancer, 2319
 oxidative catabolism
 lipid hydroperoxides, human microsomes, 1226
 time course of induction of metabolism up-regulation, cellular retinoic acid-binding protein, 472
Retinoic acid-binding protein
 cellular
 up-regulation, all-trans-retinoic acid metabolism, 472
Retinoids
 fenretinide effectiveness
 potentiation of cisplatin activity, ovarian carcinoma xenograft, 5374
 pharmacological
 vitamin A-metabolizing enzymes, 2965
 status
 appearance of reserve cells and keratin expression, mouse cervical epithelium, 2287
 synthetic fenretinide
 treatment of prostate cancer, 224
Retrovirus
 antisense K-ras construct
 intratracheal instillation, prevention of orthotopic lung cancer growth, 1743
 -mediated gene transfer
 treatment of brain tumors, rats, 83
Reverse transcription-polymerase chain reaction
 detection in lymph nodes
 micrometastatic prostate cancer cells, 5350
Rhabdomyosarcoma
 alveolar
 fusion of PAX3, transcription factors, 5108
 refinement of regional loss of heterozygosity
 chromosome 11p15.5, human breast tumors, 4486
Rhodamine 123
 quantitative differential effects
 normal cells and colon cancer cells, magnetic resonance spectroscopy, 5808
Ribavirin
 tiazofurin and
 sequential impact on enzymic program, bone marrow, 5982
Ribonucleotide reductase
 inhibition of R2 subunit
 antitumor activity, 2,2'-bipyridyl-6-carbothioamide and its ferrous complex, 19
Ribosomal protein
 high-level of L19 expression
 overexpression or erbB-2, breast tumors, 1403
Ribosome
 protein mRNAs of colonic carcinoma gastrointestinal malignancies, 4048
Ribozyme
 -mediated modulation
 human O⁶-methylguanine-DNA methyltransferase expression, 1731
Ricin
 anti-B4-blocked
 therapeutic efficacy, different SCID mouse tumor models, 1360
 entry of protein toxins
 polarized epithelial cells, 1755
Ricin A chain
 pharmacokinetics and toxicology of immunotoxins
 administration into the subarachnoid space, nonhuman primates and rodents, 3752
RIF-8A cells
 mitochondrial alterations
 photodynamic therapy-resistant cells, 4994
Riminothenazine agents
 clofazimine and B669
 inhibition of cancer cell line proliferation, phospholipase A₂-mediated mechanisms, 318
Risk assessment
 clarification
 scientific evidence and speculation, 4107
RNA
 HPV16-transformed rat kidney epithelial cells
 glucocorticoid requirement for growth, 4432
 human mitochondrial hinge protein gene elevated expression, cancer, 2460
RNA, messenger
 N-acetylglucosaminyltransferase III and V
 hepatocarcinogenesis, LEC rats, 3899
 alteration
 mutational profiles of p53 and Rb, esophageal carcinoma, 1889
 alternatively spliced glucocorticoid receptor
 human multiple myeloma cells, 3877
 alternatively spliced src
 neuronal differentiation, human neuroblastoma, 3179
 annexin II expression
 regulation, mammalian cell cycle, 6017
APC gene
 novel isoforms that lack exon 7, 5589
 carcinoembryonic antigen and biliary glycoprotein
 differential regulation, γ -interferon, 1612
 characterization of insulin-like growth factor 1, 2475
 colorimetric *in situ* hybridization technique
 epidermal growth factor receptor, colon carcinoma surgical specimens, 937
complementary DNA
 heparin-binding growth factor receptor, use of kinase insert sequence, 1136
complement inhibitors
 human tissues and tumors, 348
epidermal growth factor
 transforming growth factor α and, head and neck cancer, 3579
estrogen receptor variant
 lack of exon 4, estrogen-responsive breast cancer cell lines, 741
fibronectin pre-mRNA alternative splicing
 coordinate oncodevelopmental modulation, liver tumor, 2005
genetic and enzymatic basis
 G_{M2} and G_{D2} differential expression, human cancer cell lines, 5395
glucocorticoid receptor expression
 differentiation, human promyelocytic leukemia cells, 3513
glutathione S-transferase class α transcripts
 carcinogen exposure, hepatocytes, 231
 high-level of L19 expression
 erbB-2 overexpression, breast tumors, 1403
histone
 caffeine release, radiation induced S and G₂ phase arrest, 1507
MAGE-1/MAGE-2/MAGE-3
 differential gene expression, transformed and normal human cell lines, 5
MLL-AF-4 fusion
 heterogeneity, polymerase chain reaction in t(4;11) acute leukemia, 3853
 modulation of cytochrome P450 2C11 by cyclophosphoramide
 messenger RNA levels, acrolein and phosphoramide mustard, 2490
p53 abnormalities
 different subtypes, human sarcomas, 468
plasmid reporter gene inactivation
 one benzo(a)pyrene diol-epoxide DNA adduct, hepatocytes, 2279
progesterone receptor expression
 meningioma, 1312
prostate-specific antigen gene expression
 autocrine regulation, LNCaP cells, 2852
radiation-enhanced expression
 MHC class I antigen H-2D^b, B16 melanoma cells, 1952
ribosomal protein
 colonic carcinoma, gastrointestinal carcinoma, 4048
ribozyme-mediated modulation

SUBJECT INDEX TO VOLUME 53

human *O⁶-methylguanine-DNA methyltransferase* expression, 1731
transcriptional activation
mouse *mdr3* gene, multidrug-resistant P388 tumor cells, 1657
TRK protooncogene and low affinity nerve growth factor receptor coexpression in neuroblastoma, favorable prognosis, 2044
variable baseline γ -glutamylcysteine synthetase expression peripheral mononuclear cells, buthionine sulfoximine treatment, 3662
Rosenthal Foundation Award
how cancer cells evade chemotherapy, 747
role of *BCR-ABL* oncogene human leukemia, 485
Rous sarcoma virus
-induced tumors
src-specific immune regression, 915
RP60475
inhibition topoisomerase I and II activities, 5987
RP60475F
aberrant functions teniposide-resistant CEM cells, 5946

S

S 12363
pharmacokinetics monoclonal antibody-based radio- or enzyme immunoassay, 3536
Salicylate enhancement of merocyanine 540-mediated phototherapy, 806
Saporin delivery using bispecific antibody targeting via CD22, human B-cell lymphoma, 3015
Sarcoma
BALB/c Meth A *M*, 110,000 tumor rejection antigen, 1602
-bearing rats doxorubicin treatment, growth hormone and preservation of lean body mass, 5483
cell lines from *v-jun* transgenic mice, 622 coamplification of *CDK4* gene *MDM2* and *GLI*, 5535
different subtypes *p53* abnormalities, 468
Ewing's *p53* mutations, not neuroblastomas, 5284
HT1080 cells inhibition of invasion, plasminogen activator inhibitor, 6051
Kaposi's HIV-1 *tat* gene expression, endothelial proliferation and histotypes, 5569
Meth A tumorigenicity and tumor growth, increased TGF- β expression, 4391
soft tissue management of, daunomycin-antibody immunoconjugates, 5740
p53 mutation, *MDM2* amplification, 2231
tumorigenicity *met* expression, 5355

Scatter factor
regulation of fibroblast hepatocyte growth factor peptide growth factors, breast carcinoma cell lines, 1233
Schistosoma mansoni cigarette smoking and *p53* gene mutations, urothelial cancer, 3795
Scytovitamins circumvention *P-glycoprotein-mediated multidrug resistance*, 1343
Selenium status and risk of lung cancer, 4860
Self-renewal competency selective expression, *M*, 32,000, 4720
Seminal vesicle expression of sulfated glycoprotein 2 induction of carcinogenesis, *N-nitroso-N-methylurea*, 1480
Seric inhibitors concomitant tumor resistance competing influences, 3266
Serotonin autocrine loop stimulation by nicotine, small cell lung carcinoma, 5566
Serum response factor *elk-1* variant differential splicing, encoding of activators and repressors, 215
Severe combined immunodeficiency arrest of growth human lung tumor xenograft, doxorubicin encapsulated in sterically stabilized liposomes, 3964
mice complementation of radiosensitive phenotype, human chromosome 8, 6011
disseminated growth, multiple myeloma, 1392
NCr/Sed-*nu/nu* nude mice and transplantability into s.c. tissue, human and murine tumors, 5012
Sex cord-stromal neoplasms *WT1* analysis, 2712
Shigella toxin entry of protein toxins polarized epithelial cells, 1755
Shock waves high-energy blood flow reduction in tumors, 1590
Sialyl Lewis^x antigen increased expression with poor survival colorectal carcinoma, 3632
mucin-bound altered glycosylation of MUC-1 protein core, colon carcinoma-associated increase, 4082
Sialyl-Tn antigens normal squamous epithelium dysplasia and squamous cell carcinoma, esophagus, 1706
Signal transduction glycolipid antigen Gb3/CD77 induction of apoptosis, Burkitt's lymphoma, 5314
HLA-DR antigen expression γ -interferons, malignant and nonma-

ignant human thyroid cells, 3943
retinoic acid and γ -interferon ICAM-1 expression, human tumor cell lines, 826
Simian virus 40
DNA replication system interaction between replication forks, topoisomerase I-DNA cleavable complexes, 5908
-immortalized human bronchial epithelial cell lines development of tumorigenicity, 985
-infected precrisis human fibroblasts multiple mechanisms, *N*-(phosphonacetyl)-L-aspartate drug resistance, 4946
large tumor antigen and monoclonal anti-idiotype humoral immune responses, tumor immunity, 5734
Sister chromatid exchange induction extremely low doses of α -particles, 2188
Skeleton bisphosphonate-treated rats increased growth rate and tumor burden, Walker 256 cells, 5452
Skin carcinogenesis malignant progression, suprabasal expression of α 6 β 4 integrin, 4803
-derived tumor cells killing by mouse dendritic epidermal T-cells, 4014
DNA-binding species bis-diol-epoxide involvement, metabolic activation of dibenz[a,h]anthracene, 944
early response to γ -rays preferential induction, *c-fos* versus *c-jun*, 3246
exposure to UV radiation wavelength-specific patterns, *p53* induction, 2697
inhibition of tumor promoter-mediated processes caffeic acid phenethyl ester, 1255
inhibition of tumor necrosis factor α release, protein isoprenylation, 3462
neuroendocrine carcinomas stable expression of peripherin, 1175
phorbol 12-myristate 13-acetate induced tumor promotion inhibition by 12-deoxyphorbol 13-esters, 2507
photorepair ultraviolet radiation-induced DNA damage, platyfish *Xiphophorus*, 2249
preparation for evaluation of drug disposition development and characterization, 101
TPA-induced hyperplasia transforming growth factor β_1 induction, TGF- β_2 and β_3 , 5517
tumor promotion in CD-1 mice absence of syngeneic effects, okadaic acid and teleocidin, 1012
Skin neoplasms allelotype analysis polymorphic microsatellites, chromo-

SUBJECT INDEX TO VOLUME 53

some alterations, 6022
deleterious effects of UVB light on cutaneous immunity
tumor necrosis factor- α polymorphism, 728
DNA repair-deficient xeroderma pigmentosum patients
high mutation frequency, *ras* genes, 1625
environmental mechanisms, models and human relevance, 3439
hypersensitivity of human lymphocytes
UVB and solar irradiation, 609
induction by ultraviolet irradiation
wavelength dependence, albino hairless mice, 53
inhibition of tumor promotion
restriction of fat and carbohydrate calories, 27
interaction between UVA and UVB
hairless mice, 4212
mechanism of induction of *c-fos*
ultraviolet B, mouse JB6 epidermal cells, 38
transplacental carcinogenicity of cisplatin
SENCAR mice, 3874
ultraviolet radiation-induced strand bias and tumor heterogeneity, *p53* mutations, 2961
ultraviolet-specific mutations
p53 gene, xeroderma pigmentosum, 2944
UV light-induced delay of progression, macrophage nitric oxide synthesis, 5507
SN22995
aberrant functions
teniposide-resistant CEM cells, 5946
Sodium
atrial natriuretic factor
arginine vasopressin production, lung cancer cell lines, 67
Sodium nitrite
catechol and
3-methoxycatechol or butylated hydroxyanisole, rat multiorgan carcinogenesis model, 32
Sodium orthovanadate
induction of neoplastic progression protein phosphatase inhibitors, Syrian hamster embryo cells, 1777
Sodium-proton exchange
lowering of intracellular pH increased thermosensitivity, tumor cells, 1599
Spheroids
human lung cancer
penetration by retroviral wild-type *p53* expression vector, induction of apoptosis, 4129
multicellular tumor
fluence rate effects, photodynamic therapy, 1249
heme oxygenase expression, squamous carcinoma, 2700
SR4233
cisplatin and
tumor-dependent and schedule-dependent interaction, 4633
local hyperthermia and
antitumor effects of radioimmunotherapy, nude mice with human colonic adenocarcinoma xenografts, 3022
toxicity
unusual oxygen concentration, 3992
Statistical analysis
in vivo tumor growth experiments, 6042
Staurosporine
derivative NA-382
inhibition of multidrug resistance, 1555
inhibition of DNA synthesis
H-ras and *v-myc*, rat embryo fibroblasts, 1213
sensitization of tumor cells
tumor necrosis factor action, 2623
12-O-tetradecanoylphorbol-13-acetate and
increased retinoblastoma tumor suppressor gene expression, megakaryocytic differentiation of leukemic cells, 3085
Stem cell factor
interference with proliferation-inducing activity
transforming growth factor- β 1, myelogenous leukemia blasts, 3638
irradiated human bone marrow, 3857
mediation of chemotaxis
c-kit, small cell lung cancer, 1709
Stem cells
autologous transplantation
sequential production, granulocyte recovery, 1297
differential activity of acetyl-dinaline acute myelocytic leukemia, rat, 3008
3T3 T proadipocytes loss of differentiation control, 1770
Steroid
-heparin conjugates
angiogenesis inhibitors, antitumor activity, 3000
production
different parts, malignant and benign ovarian tumors, 2309
Steroid hormones
opioid peptides and growth, androgen-responsive Shionogi carcinoma cells, 4224
Steroid α -reductase
modulation of rat hepatic cytochrome P450 2C11 cyclophosphamide, messenger RNA levels, 2490
Stomach neoplasms
high risk population
precancerous gastric lesions, 1317
human
nude mouse metastatic models, 1204
risk of fatal cancer aspirin use, 1322
Streptozotocin
 O^6 -benzylguanine depletion of O^6 -methylguanine DNA methyltransferase, 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity, 4281
Stress
psychological
oxidative damage of nuclear DNA, liver of rats, 4153
Stress protein
suppression of GRP78 induction
elimination of resistance, cell-mediated cytotoxicity, 6001
Stroma
amphiregulin and epidermal growth factor receptor
estrogen receptor expression, human primary breast cancer, 3597
Stromal cells
fibroadenoma and phyllodes tumor clonal analysis, breast, 4071
immunolectron microscopic localization transforming growth factor- β 1 and binding protein, gastrointestinal carcinoma, 183
production of growth-promoting factor wide target cell spectrum, THP-1 cells, 1871
protection from toxic effects by AS101 cyclophosphamide, ASTA-Z 7557 and etoposide, 1838
secretory protein chemotaxis and chemokinesis, prostate tumor cell lines, 1416
Stromelysin
interstitial collagenase and 72-kDa gelatinase tumor cell-derived collagenase-stimulatory factor, 3154
Stromelysin 3
increased gene expression local invasiveness, head and neck squamous cell carcinoma, 165
Styrene 7,8-oxide
butylated hydroxyanisole and induction of cell proliferation, fore-stomach, 3505
Sugar
chains of human cord serum α -fetoprotein human liver, hepatocellular carcinoma, 2970
Styrene
7,8-oxide butylated hydroxyanisole and induction of cell proliferation, fore-stomach, 3505
Sulfotransferase
-mediated activation cyclopentadienylpyrene metabolites, 1017
Suramin
inhibition of growth promotion of insulin-like growth factor II, HepG2 cells, 652 multiple potential mechanisms of action, 2239
Surgery
modeling of development of metastases primary and locally recurrent tumors, clinical data base for prostatic cancer, 2987
Syndrome of inappropriate antidiuretic hormone
atrial natriuretic factor arginine vasopressin production, lung cancer cell lines, 67

T

Tac antibody
DOTA-bismuth-conjugated pharmacokinetics, α -emitter therapy, 5683
TAG-72
comparative dual label study of monoclonal antibodies colorectal cancer, 271 improved radioimmunotherapeutic effi-

SUBJECT INDEX TO VOLUME 53

cacy
¹³¹I-CC49 and γ -interferon, 600

site-specific prodrug activation
 antibody- β -lactamase conjugates, colon carcinoma xenograft models, 3956

Tamoxifen
 antitumor effect of 22-oxa-calcitriol
 athymic mice implanted with human breast carcinoma, 2534

carcinogenicity study
 Alderley Park Wistar-derived rats, 3919

-dependent rat mammary tumors, 2937

-induced increase
 doubling time of MCF-7 xenografts, bromodeoxyuridine labeling and flow cytometry, 4413

inhibition
 insulin-like growth factor I gene expression, 1727

inhibition by ICI 182,780
 insulin-like growth factor I gene expression, 5585

modulation of cisplatin sensitivity
 malignant melanoma cells, 1571

recombinant human α -interferon and modulatory effects, doxorubicin resistance, 3040

sensitivity to ICI 182,780
 MCF7/LCC2 cells, 3229

toremifene and
 hepatocarcinogenicity, DNA adduct formation, 4534

-treated athymic nude mice
 fibroblast growth factor 4 production, MCF-7 cells, 2168

Tat protein
 HIV-1
 protection from apoptosis, 4481

Taxol
 -containing liposomes
 antitumor effect, taxol-resistant murine tumor model, 5877

cytotoxicity
 glutathione depletion, L-buthionine sulfoximine, 2066

polyclonal and monoclonal antibodies measurement in serum, 1388

radiation and oncogenic transformation, 1368

Taxotere
 Phase I and pharmacokinetic study
 administration as 24-hour infusion, 523

short intravenous infusion
 Phase I and pharmacokinetic study, 1037

Tea, green
 polyphenolic fraction
 protection against malignant conversion, chemically induced benign skin papillomas, 5409

T-cells
 ability to form tumors in nude mice
 homeobox gene *HB24*, 373

cytolysis of leukemic B-cells
 bispecific antibodies, 4310

cytotoxic T-lymphocytes
in situ amplification, human regressive melanoma, 3569

-induced tumor regression

γ -interferon, 833

infiltration of renal cell carcinoma
 poor proliferative response, 1380

production, interleukin 2 and receptors, 5828

loss of T-cell receptor ζ chain p56^{ck}, human renal cell carcinoma, 5613

mouse dendritic epidermal killing, skin-derived tumor cells, 4014

oligoclonal metastasis of renal cell carcinoma, vaccination with autologous tumor cells, 4745

production of growth-promoting factor wide target cell spectrum, THP-1 cells, 1871

receptor V region gene usage
 CTL and TIL, autologous gastric Signet ring cell carcinoma, 3078

tumor-infiltrating signals-transducing ζ chains, colorectal carcinoma, 5610

vaccine-primed adoptive immunotherapy, secondary sensitization to tumor, 1043

10T½ cells
 clonal analysis
 multiple transformed phenotypes, tumorigenicity, 500

Teleocidin
 okadaic acid and
 absence of syngeneic effects, tumor promotion in CD-1 mouse skin, 1012

Temperature
 -sensitive liposomal Adriamycin
 hepatic artery, liver W256 carcinosarcoma, 3046

therapeutic efficacy
 pharmacokinetics of ifosfamide, 4268

Teniposide
 antiproliferative activity and bulk damage to DNA
 MCF-7 cells, 3547

-resistant CEM cells
 non-complex-stabilizing inhibitors of enzyme, aberrant functions, 5946

topoisomerase II as a target
 atypical multidrug resistance, small cell lung carcinoma cells, 1064

Testis neoplasms
 lack of occurrence
 $p53$ gene mutations, 3574

Testosterone
 elevated serum levels
 risk of hepatocellular carcinoma, 790

type II estrogen-binding sites
 dysplastic dorsolateral prostate, Noble rat, 528

1,4,7,10-Tetra-azacyclododecane-*N,N',N'',N'''*-tetraacetic acid
 -bismuth-conjugated anti-Tac antibody α -emitter therapy, 5683

2,3,7,8-Tetrachlorodibenzo-p-dioxin
 aryl hydrocarbon receptor
 aryl hydrocarbon responsiveness, human ovarian carcinoma cell lines, 1802

exposure
 gene expression and cell proliferation, liver, 2265

growth suppression of MCF-7 cells, 3149

12-O-Tetradecanoylphorbol 13-acetate
 -induced skin hyperplasia
 transforming growth factor β_1 induction, TGF- β_2 and β_3 down-modulation, 5517

-induced tumorigenic transformation
 osteopontin expression, 1 α ,25-dihydroxyvitamin D₃, 2217

inhibition of tumor promoter-mediated processes
 caffeoic acid phenethyl ether, mouse skin and bovine lens, 1255

staurosporine and
 increased retinoblastoma tumor suppressor gene expression, megakaryocytic differentiation of leukemic cells, 3085

Tetraplatin
 oxaliplatin
 red blood cell partitioning, biotransformation of oxaliplatin, 5970

Thaliblastine
 circumvention of multidrug resistance direct binding to P-glycoprotein, 2544

Theophylline
 -induced differentiation
 deregulation of *c-myc*, Burkitt's lymphoma, 127

Thermotolerance
 vascular
 heat-induced changes, blood flow and cell survival, 2076

THP-1
 production of growth-promoting factor wide target cell spectrum, 1871

Thread proteins
 characterization
 expression in neuroectodermal tumors, 3823

Thrombospondin
 its receptor and
 normal, hyperplastic and neoplastic human breast, 1421

motility of human carcinoma cells
 metastatic potential, structural domains, 378

Thymidine kinase
 gene
 herpes simplex virus, inhibition of melanoma growth in intratumoral DNA injection, 3860

promoter
 overexpression of DNA binding activity, distal CCAAT box, 3253

Thymidylate
 purine synthesis and
 cytotoxicity of antifolate inhibitors, WiDr colonic carcinoma cells, 5697

stress resistance
 induction to apoptosis, modulation by *bcl-2*, 3321

Thymidylate synthase
 benzoquinazoline inhibitor 1843U89
 biochemical and cellular pharmacology, 810

decreased folylpolyglutamate synthetase novel mechanism, fluorouracil resistance, 3677

Thymocytes
 nonproliferating immature

SUBJECT INDEX TO VOLUME 53

effects of cisplatin, induction of apoptosis, 2133

Thymosin α 1
down-regulation of growth
human non-small cell lung cancer cells, 5214

Thyroglobulin
promoter
Ki-ras expression, production of transgenic mice, 5523

Thyroid
establishment of transplantable tumor cell lines
estrogen receptor, 4408

malignancies
differentiation marker, E-cadherin, 4987

malignant and nonmalignant cells
control of HLA-DR antigen expression, γ -interferons, 3943

Thyroid neoplasms
in vitro irradiation
RET oncogene rearrangement, 2940

Thyrotropin
loss of regulation
transforming growth factor β -induced growth arrest, *erbB-2* overexpressing rat thyroid cells, 5548

Tiazofurin
biochemical consequences of resistance
K562 cells, 2344

ribavirin and
sequential impact on enzymic program, bone marrow, 5982

TIMP-1
negative regulator of metastatic ability
human gastric cancer cell line, chick embryo, 1397

Tirapazamine
cisplatin and
tumor-dependent schedule-dependent interaction, 4633

TLC D-99
initial clinical trial, 2796

TNP-470
inhibition of tumor growth
hormone-independent breast and prostate carcinoma, 5233

inhibition of tumor growth and metastasis
rodent tumors, 4262

inhibitory effect of angiogenesis
tumor growth and metastasis, human cell lines, 2566

Tobacco
carcinogenesis
dietary fat, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butane, 2758

oral carcinogenesis
HPV-16, *N*-methyl-*N'*-nitro-*N'*-nitrosoguanidine, 4811

smoking
detection of DNA adducts, human oral tissue, 1522

-specific nitrosamine
smokers' urine, 721

usage
distinct pattern of p53 mutations, bladder cancer, 1162

α -Tocopherol
serum micronutrients
subsequent risk, oral and pharyngeal cancer, 795

Tolytoxin
scytophycins
circumvention, P-glycoprotein-mediated multidrug resistance, 1343

Tongue neoplasms
chemoprevention of oral carcinogenesis
 $DL-\alpha$ -difluoromethylornithine, 772

Topotecan
24-hour continuous infusion
pediatric Phase I trial, pharmacokinetic study, 1032

induction of apoptosis and cell cycle effects
prevention by caffeine, HL-60 cells, 4613

plasma and cerebrospinal fluid pharmacokinetic study
nonhuman primates, 725

Toremifene
tamoxifen and
hepatocarcinogenicity, DNA adduct formation, 4534

Toxins
delivery of saporin using bispecific antibody
targeting via CD22, human B-cell lymphoma, 3015

protein
entry in polarized epithelial cells, 1755

synergy of anti-Fas antibody
overcoming tumor necrosis factor and drug resistance, 2591

Tracheobronchial epithelial cells
inhibition of epidermal growth factor-like growth factor
vitamin A, 2527

Transcription factors
fusion of *PAX3*
alveolar rhabdomyosarcoma, 5108

heat shock
oxidative injury, failure to increase levels of heat shock proteins, 12

normal and neoplastic growth and development, 929

Transferrin
receptor-targeted immunotoxins
efficacy, pediatric brain tumors, 1348

Transforming growth factor- α
disruption of autocrine loop
glucocorticoids, rat mammary adenocarcinoma cells, 1808

epidermal growth factor receptor messenger RNA and
early markers of carcinogenesis, head and neck cancer, 3579

induction of *c-jun* gene family members
not 17 β -estradiol, breast cancer cells, 291

nuclear oncogenes and growth factors
tumorigenesis, transgenic mouse model, 1719

overexpression
glucocorticoids, mammary tumor cell growth, 1816

production and autoinduction
epidermal growth factor receptor gene, colorectal carcinoma cell line, 1630

production of morphological transforms
diploid human fibroblasts, 2162

protooncogene expression

differentiating HL-60 cells, 191

***Pseudomonas* exotoxin and polyethylene glycol-modified chimeric toxin**, 4588

regulation of activity levels
glycolipid sulfotransferases, renal cell carcinoma, 5638

regulation of fibroblast hepatocyte growth factor/scatter factor
breast carcinoma cell lines, 1233

transgenic mice
growth factors and diverse chemical carcinogens, hepatocarcinogenesis, 4329

Transforming growth factor- β
differentiated growth factor production
high and low metastatic variants, B16BL6 melanoma, 4075

increased expression
inhibition of cell proliferation *in vitro*, tumor growth in Meth A sarcoma cells, 4391

-induced growth arrest
loss of thyrotropin regulation, *erbB-2* overexpressing rat thyroid cells, 5548

interleukin 1 α and interleukin 6 inhibition of growth, MCF-7 cells, 1538

latent binding protein
lack in malignant prostatic tissue, 3193

radiation-induced
extracellular matrix reorganization, murine mammary gland, 3880

regulation of fibroblast hepatocyte growth factor/scatter factor
breast carcinoma cell lines, 1233

Transforming growth factor- δ
growth and apoptosis
human acute myelogenous leukemia cells, 3386

immunolectron microscopic localization
TGF- β 1 binding protein, gastrointestinal carcinoma, 183

induction of TGF- α promoter activity
TGF- α secretion, human colon adenocarcinoma cell line, 4041

interference with proliferation-inducing activity
stem cell factor, myelogenous leukemia blasts, 3638

mannose-6-phosphate/IGFII receptor monoterpane-induced regression, mammary tumors, 3849

resistance in murine keratinocytes mutant p53, 899

TGF- β_2 and - β_3 down-regulation
TPA-induced skin hyperplasia, 5517

Transplantation
acceleration of granulocyte recovery
granulocyte colony-stimulating factor, metastatic breast cancer, 5424

autologous stem cell
sequential production, granulocyte recovery, 1297

bone marrow
radiation damage repair capacity, acute lymphoblastic leukemia, 1431

brain of NCr/Sed-*nu/nu* nude and scid mice
human and murine tumors, 5018

SUBJECT INDEX TO VOLUME 53

orthotopic
“patient-like” treatment model, pancreatic cancer, 3070
s.c. tissue of NCr/Sed-*nu/nu* nude and scid mice
human and murine tumors, 5012

Triton X-100
effects of nonionic detergents
P-glycoprotein drug binding, multidrug resistance, 5994

3T3 T cells
proadipocytes
loss of differentiation control, 1770

Tubulin
binding
depolymerization of microtubules, estramustine, 4573

Tumor-associated antigens
delayed-type hypersensitivity reactions
autologous tumor cell/*Bacillus Calmette-Guérin* vaccine, colon carcinoma, 456
phenotype and ontogeny
bovine leukemia virus-induced lymphosarcoma, 429
quantitative analysis of *lacZ* reporter gene
disseminated tumor growth within brain, 176

Tumor cells
autologous
oligoclonal T-cell response, metastasis of renal cell carcinoma, 4745

Tumor grade
invasion and
levels of matrix metalloproteases, bladder cancer, 5365

Tumorigenesis
aflatoxin-induced hepatic
transient intervention, oltipraz, 3499
clonal immunoglobulin gene rearrangement
coexistence, aneuploid subclones within a myeloma cell line, 5320
dominant negative effect
germ-line mutant *p53*, 4452
formation of hyperplastic outgrowths
p53 mutations, mammary cell lines, 1646
granulosa cell
genetically hypogonadal-immunodeficient mice grafted with ovaries from tumor-susceptible donors, 3741
inhibition of tumor growth by antisense DNA
c-Ha-ras oncogene, nude mice, 577
intestinal
deletion of 1p36, primary chromosomal aberration, 1895
O⁶-methylguanine-DNA methyltransferase activity
brain tumors, adjacent normal brain, 3416
microsatellite instability
bladder cancer, 5620
multiple mechanisms
Eμ-myc transgenic mice, 1665
nuclear oncogenes and growth factors
transgenic mouse model, synergistic effects, 1719
ovarian granulosa cell
C19 androgen induction, genetic sus-

ceptibility in mice, 1059
promoter-specific *trans*-activation and inhibition
JunB, 3789
signaling by integrins, 1503
ultraviolet-specific mutations in *p53* gene
skin tumors, xeroderma pigmentosum, 2944
urinary bladder
lipopolysaccharide-induced inflammation, 5172

Tumorigenicity
abrogation
α₁-interferon gene transfer, metastatic Friend leukemia cells, 1107
biological consequences of overexpression
transfected *c-erbB-2* gene, immortalized human bronchial epithelial cells, 2035
clonal analysis
multiple transformed phenotypes, 10T½ cells, 500
development
simian virus 40-immortalized human bronchial epithelial cell lines, 985
fibroblast growth factor 4 transfection
MCF-7 cells, tumorigenicity, 2168
transfection of human astrocytoma cells
glial fibrillary acidic protein complementary DNA, 3624

Tumor necrosis factor
binding protein
induction by interleukin 1 β , humans, 4010
drug resistance and
combination treatment, anti-Fas antibody and drugs or toxins, 2591
growth inhibition by interleukin 1
 γ -interferon receptors, colorectal carcinoma, 636
-mediated cytotoxicity
BCL-2 protein expression, survival of mouse fibrosarcoma cells, 1456
resistance *in vitro*
metallothionein, 4874
sensitization of tumor cells
staurosporine, 2623
tumor promoter in BALB/3T3 cell transformation, 1982

Tumor necrosis factor- α
autocrine and paracrine growth factor
ovarian cancer, 1939
cell cycle-specific effects
monocyte-mediated leukemic cell death, role of β_2 -integrins, 4399
inhibition of release and protein isoprenylation
inhibition of tumor promotion by canaventol, CD-1 mouse skin, 3462
interleukin 1 α and
induction of anchorage independence, *v-jun* transgenic murine cells, 615
polymorphism
deleterious effects of UVB, cutaneous immunity, 728

Tumor progression
benign or low-grade malignancies
adjacency to high-grade ovarian carcinoma, molecular characteristics, 4138
CD44 variant proteins

human colorectal cancer, 4754
development and
molecular mechanisms, 5055
environmental skin cancer
mechanisms, models and human relevance, 3439
expression of tumor suppressor gene
DCC
human gliomas, 5605
hepatocarcinogenesis in TGF- α transgenic mice
collaboration, growth factors and diverse chemical carcinogens, 4329
hepatocellular carcinoma
mediation by *p53* mutation, 2884
Ly-1 $^+$ B-cell populations and IgH rearrangements
“normal” spleens and lymphomas, AKR/J and AKR Fv-1 b mice, 2147
MDM2 gene amplification
metastatic osteosarcoma, 16
neoplastic transformation and conversion of fibroblasts
 $\alpha 6$ integrin, 2950
p53 overexpression as late event
development of malignant melanoma, 2235
renal cell carcinoma
chromosome 17p deletions, *p53* mutations, 3092

Tumor promoter
-mediated processes
inhibition by caffeic acid phenethyl ester, mouse skin and bovine lens, 1255
okadaic acid
hyperphosphorylation of cytokeratins, primary keratinocytes, 992
tumor necrosis factor
BALB/3T3 cell transformation, 1982

Tumor resistance
concomitant
competing influences, 3266

Tumors
in vivo growth experiments
statistical analysis, 6042
solid
basic fibroblast growth factor complementary DNA, H-ras-transformed cells, 158
edatrexate compared to methotrexate, leucovorin rescue, 587
infrequency of *MDM2* gene amplification, children, 6028
inhibition of growth, cyclocreatine, 3172
localization, multidrug resistance-associated gene, 3221
Phase I study, pyrazine-2-diazohydride, 4843
selectively down-regulated expression, MHC class I alleles, 2416
synergistic antitumor activity, cisplatin and interleukin 1, 1091
targeting of gene expression, melanoma cells, 962

Tumor suppressor genes
chromosome 8p
colorectal carcinoma, 1172
distinct regions involved in 1p deletion
human primary breast cancer, 1990
morphologically malignant meningioma

SUBJECT INDEX TO VOLUME 53

progression
loss of heterozygosity, loci on chromosome 10, 2386

Turcot's syndrome
glioma and polyposis
absence of germ line mutations, *p53* gene, 957

Tyr-Ile-Gly-Ser-Arg peptide
multimeric forms
inhibition, tumor growth and metastasis, 3459

Tyrosinases
association with melanoma replicative senescence
melanogenesis, 2469

Tyrosine
phosphorylation
activation of *c-jun*, lymphohematopoietic precursor cells, 447

Tyrosine aminotransferase
regulation of expression
transformation-induced alterations, fetal rat hepatocytes, 515

Tyrosine kinase
Abelson
suppression of apoptosis, hematopoietic cells, 1735

U

1843U89
biochemical and cellular pharmacology, 810

Ubiquitin
-ribosomal protein S27a gene
early growth response gene, human colorectal carcinoma, 1916

U1810 cells
contribution of glutathione transferase M3-3
1,3-bis(2-chloroethyl)-1-nitrosourea resistance, 4257

UCN-01
cell cycle arrest and growth inhibition
human breast carcinoma cells, 2081

UDP-glucuronosyltransferase
colon carcinogenesis
chemoprevention, organosulfur compounds, 3493

Ultraviolet
environmental skin cancer
mechanisms, models and human relevance, 3439

hypersensitivity of Cockayne's cells to camptothecin
double strand breaks, nascent DNA, 2012

-induced cyclobutane pyrimidine dimers
selective removal from epidermis, hairless mouse, 1642

-induced DNA damage
photorepair in skin, platyfish *Xiphophorus*, 2249

-induced skin cancers
delay of progression, macrophage nitric oxide synthesis, 5507

strand bias and tumor heterogeneity, *p53* mutations, 2961

-sensitive mutant cell line
cellular defect in UVSI, 495

-specific mutations in *p53* gene
skin tumors, xeroderma pigmentosum, 2944

wavelength dependence of skin cancer induction
albino hairless mice, 53

wavelength specific patterns of *p53* induction
human skin, 2697

Ultraviolet A
interaction with ultraviolet B
skin cancer induction, hairless mice, 4212

-near-visible light
singlet oxygen, induction of heme oxygenase gene, 4505

Ultraviolet B
deleterious effects on cutaneous immunity
tumor necrosis factor- α polymorphism, 728

induction of resistance by hyperthermia
primary and immortalized epidermal keratinocytes, 4952

mechanism of induction of *c-fos*
mouse JB6 epidermal cells, 38

solar irradiation and hypersensitivity of human lymphocytes, 609

Uridine 5'-diphosphate glucuronosyltransferase
complementary DNA-expressed glucuronidation, carcinogen metabolites, 1529

Urinary bladder
transitional cell carcinoma
high-risk human papillomavirus infections, *p53* overexpression, 4823

tumorigenesis
lipopolysaccharide-induced inflammation, 5172

Urine
detection of basic fibroblast growth factor
secretion by an animal tumor, 5297

Urokinase
-dependent proteolytic pathways
melanoma-mediated dissolution, extracellular matrix, 693

inhibition by 4-substituted benzo[*b*]thiophene-2-carboxamides, 2553

receptor concentration
quantitative autoradiography, malignant and benign breast tumors, 3198

-type plasminogen activator and PAI-1 cytosolic extracts, breast carcinoma, 2513

-type plasminogen activator receptor antibody
modulation *in vitro* invasion, human glioblastoma cells, 4143

plasma, clinical value and detection of colorectal cancer, 1788

Urothelial cells
bladder
influence on cellular processes, altered extracellular matrices, 4971

Urothelial neoplasms
cigarette smoking and schistosomiasis
p53 gene mutations, 3795

Uterus
endometrium
p53 alterations, c-K-ras activation, 1883

insulin-like growth factor I gene expression

sion
stimulation by tamoxifen, inhibition by ICI 182780, 5585

V

Vaccine
augmentation of cellular immune response
transfection of interleukin 2 gene, melanoma cells, 949

autologous tumor cell/*Bacillus Calmette-Guérin*
delayed-type hypersensitivity reactions, tumor-associated antigens, 456

autologous tumor cells
oligoclonal T-cell response, renal cell carcinoma, 4745

design for cancer
controlled release, biodegradable cytokine depots, 5841

human B-cell immune response
polymorphic epithelial mucin, 2457

-primed T-cells
adoptive immunotherapy, secondary sensitization to tumor, 1043

protective and curative potential
interleukin 2 gene-transfected cells, mouse mammary adenocarcinoma, 5067

tumor cells genetically engineered production of different cytokines, 714

Vascular endothelial growth factor
up-regulation
cognate receptors, glioma model of angiogenesis, 5822

Vascular permeability factor
its receptors and adenocarcinomas, gastrointestinal tract, 4727

tumor and inflammatory effusions guinea pig and human, 2912

tumor-secreted photosensitizer uptake, 153

Vasculature
influence of thermotolerance
heat-induced changes, cell survival in tumors, 2076

Tumor vascularity
relationship of endothelial cell proliferation, human breast cancer, 4161

Vasoconstriction
protein kinase C-mediated 5-fluorouracil chemotherapy, myocardial ischemia, 3028

V79 cells
caffeine release
radiation-induced S and G₂ phase arrest, 1507

coding region of hypoxanthine phosphoribosyltransferase gene profile of mutations, 7R, 8S-dihydroxy-9S, 10R-epoxy-7, 8, 9, 10-tetrahydrobenzo(*a*)pyrene, 3294

resistance to adozelesin
multidrug resistance, 1354

Vegetables
fruit and
lung cancer, Iowa Women's Health Study, 536

Verapamil
doxorubicin cardiotoxicity
altered muscle gene expression, neonatal

SUBJECT INDEX TO VOLUME 53

tal rat cardiomyocytes, 4658

Vesicular protein
M_r, 110,000
overexpression, non-P-glycoprotein-mediated multidrug resistance, 1475

Vinblastine
metabolism and drug interactions
liver cytochrome P450 3A, 5121

plasma pharmacokinetics
N-(deacetyl-*O*-4-vinblastoyl-23)-L-ethyl isoleucinate, high-performance liquid chromatography, 2061

Vinca alkaloids
pharmacokinetics of S 12363
monoclonal antibody-based radio- or enzyme immunoassay, 3536

Vincristine
selective enhancement of cytotoxicity
phenytoin, multidrug-resistant tumor cells, 3262

Vitamin A
inhibition of epidermal growth factor-like growth factor
tracheobronchial epithelial cells, 2527

-metabolizing enzymes
pharmacological retinoids, 2965

synthetic retinoid fenretinide
treatment of prostate cancer, 224

Vitamin C
selenium status
risk of lung cancer, 4860

vegetables and fruit
lung cancer, Iowa Women's Health Study, 536

Vitamin D
marker
human colon carcinoma cell line differentiation and growth, 3712

molecular mechanisms
tumor development and progression, 5055

Vitamin E
high intake
reduced risk of colon cancer, 4230

VM-26: see Teniposide

von Hippel-Lindau syndrome
positioning of Ca-ATPase gene, 861

Vorozole
inhibition of *in vivo* conversion of androstanedione
estrone, healthy postmenopausal women, 4563

VP-16
altered topoisomerase II α
small cell lung cancer cell lines, 4866

VX2 tumor model
pharmacokinetic and pharmacodynamic advantages
pirarubicin, Adriamycin, 1550

W

W-77
bifunctional inhibitor
enhanced Adriamycin activity, human ovarian carcinoma cells, 2051

WAGR syndrome
associated Wilms' tumor
altered *trans*-activational properties, mutated *WT1* gene product, 4757

Walker 256 cells
spontaneously metastatic
increased growth rate and tumor burden, skeleton of bisphosphonate-treated rats, 5452

Welders
DNA-protein cross-links
molecular implications, 460

Wilms' tumor
analysis of *WT1*
granulosa cell and other sex cord-stromal tumors, 2712

human fetal kidney
insulin-like growth factor II and *WT1* transcript, 5166

kidney complementary DNAs
subtractive hybridization approach, 2888

new family
heparin-binding growth/differentiation factors, 1281

WAGR-associated
altered *trans*-activational properties, mutated *WT1* gene product, 4757

Wound healing
tumor necrosis factor- α and interleukin 1 α
induction of anchorage independence, *v-jun* transgenic murine cells, 615

X

Xanthine dehydrogenase
bioactivation of mitomycin C
kinetics and mechanism, aerobic and hypoxic conditions, 5470

Xenografts
anti-epidermal growth factor receptor monoclonal antibody
cisplatin and, antitumor effect, 4637

colon carcinoma models
site-specific prodrug activation, antibody- β -lactamase conjugates, 3956

effects of temperature
therapeutic efficacy, ifosfamide pharmacokinetics, 4268

glioma
intraarterial therapy, 4-hydroperoxycephlophosphamide, 2338

heterotransplantation
Matrigel, early B-lineage acute lymphoblastic leukemia, 1222

human colon adenocarcinoma
reduction of interstitial fluid pressure, dexamethasone, 4764

human and murine tumors
transplantability into s.c. tissue, NCr/Sed-*nu/nu* nude and scid mice, 5012

human colonic adenocarcinoma
local hyperthermia and SR 4233, enhanced radioimmunotherapy, 3022

human epidermoid carcinoma

preclinical evaluation, ¹¹¹In-labeled B3 monoclonal antibody, 2834

human head and neck squamous cell carcinoma
¹⁸⁶Re-labeled E48, IgG-mediated therapy, 3524

human lung tumor
arrest of growth, doxorubicin encapsulated in sterically stabilized liposomes, 3964

human melanoma
antitumor activity, *N*¹,*N*²-bis(ethyl)norspermine, 581

human tumor
bispecific monoclonal antibody targeting *c-erbB-2* and CD16, 94
therapeutic efficacy, 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin, 2823

MCF-7
tamoxifen-induced increase in doubling time, bromodeoxyuridine labeling and flow cytometry, 4413

mice bearing human ovarian carcinoma decreased tumor burden, synthetic matrix metalloproteinase inhibitor, 2087

nude mouse model
management of soft tissue sarcomas, daunomycin-antibody immunoconjugates, 5740

ovarian carcinoma
fenretinide effectiveness, potentiation of cisplatin activity, 5374

stable expression of peripherin neuroendocrine carcinomas, 1175

Keroderma pigmentosum
DNA repair deficiency
high mutation frequency, *ras* genes, 1625

group C fibroblasts
DNA strand bias, repair of *p53* gene, 5377

ultraviolet-specific mutations *p53* gene, skin tumors, 2944

X-rays
cytostatic multidrug resistance second international symposium, 2683

radiation-transformed rat embryo cells presence of point mutations, *N-ras* gene, 1511

Y

Yeast
anticancer drugs
targeting of DNA topoisomerases, 3591

quiescent state
cell cycle phase, 1867

Z

Zinc
roles of metallothionein in carcinogenesis, 922
structural role of metal ions "wild-type" conformation, p53, 1739

